Molecule Name,Smiles,Standard Type,Standard Value,Standard Units,pChEMBL Value,Target Name,Comment,Action Type,Assay Description,Document Year
TANDUTINIB,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cccc2c1Nc1nnc(Cl)cc1C(=O)N2,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC1=NN(c2cccc(Br)c2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1ccc2[nH]ncc2c1)c1cccc(F)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cnccn1)Nc1ccnc2c(F)cc(F)cc12,Ki,25.12,nM,7.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cc2c(-c3ccc(Br)c(F)c3F)cncc2s1,Ki,6.31,nM,8.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1n[nH]c2cc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)ccc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCCC5)cnc(N)c34)cc2)c1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(O)c1cc2c(-c3cccc(F)c3)cncc2s1,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCC#N)c2)n1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=O)NC1CCN(c2nc3[nH]cc(C(=O)O)c(=O)c3c(C)c2F)C1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,OCC(CO)Nc1ncnc2[nH]cc(-c3ccccc3)c12,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(N)COc1cnc(Cl)c(C=Cc2ccncc2)c1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCOCC2)n1,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
SOTRASTAURIN,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c(=O)n(C)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2ccc(-c3cncc(OCCN)c3)cc12,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNCCOc1cncc(-c2ccc3[nH]nc(C)c3c2)c1,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCN1CCN(CCCC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1,Ki,25.12,nM,7.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,IC50,660.0,nM,6.18,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta in human U87MG cells by ELISA,2008.0
,Clc1cccc(CSc2nnc(-c3ccncc3)o2)c1,IC50,820.0,nM,6.09,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against human Glycogen synthase kinase-3,2002.0
,Cc1ccc(N2CCN(CCCNC(=O)c3nc(-c4cccnc4)no3)CC2)cc1C,IC50,350.0,nM,6.46,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,O=C(NCCCN1CCN(c2cccc(Cl)c2)CC1)c1nc(-c2ccncc2)no1,IC50,4000.0,nM,5.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,Cc1ccc(N2CCN(CCCNC(=O)c3nc(-c4cncnc4)no3)CC2)c(C)c1,IC50,3000.0,nM,5.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,Cc1cccc(N2CCN(CCCNC(=O)c3nc(-c4cccnc4)no3)CC2)c1C,IC50,630.0,nM,6.2,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,COc1ccccc1C1=C(N2CCc3ccccc32)C(=O)NC1=O,IC50,187.0,nM,6.73,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CSc1ccc(NC2=C(c3cccc([N+](=O)[O-])c3)C(=O)NC2=O)cc1,IC50,152.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1cccc(O)c1,IC50,1478.0,nM,5.83,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccccc2[N+](=O)[O-])=C1Nc1cccc(Cl)c1,IC50,104.0,nM,6.98,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1ccccc1C1=C(Nc2ccc(SC)cc2)C(=O)NC1=O,IC50,110.0,nM,6.96,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,Cc1cc(-c2cc(-c3ccccc3)[nH]c(=O)n2)ccc1O,IC50,5280.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in CHO AA8 cells co-expressing human tau protein after 2 hrs,2011.0
,COCCOc1cnn2ncc(-c3ccnc(Nc4cccc(OC)c4)n3)c2c1,Ki,80.0,nM,7.1,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12,Ki,19.95,nM,7.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)C1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)Oc1cc(-c2ccncc2)cc2[nH]nc(N)c12,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NC(CO)c1cc(Cl)cc(Cl)c1)c1ccc(-c2ccncc2)cc1,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1c(NCc2ccc(Cl)cc2)c(Nc2ccncc2)c1=O,Ki,316.23,nM,6.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)n1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)cc21,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(C)c(C)c(OCCCc2c(C(=O)O)[nH]c3c(-c4ccccc4C)cccc23)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC1CCN(C(=O)CO)CC1N(C)c1ncnc2[nH]ccc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C)c1,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC1CSc2c(C(=O)O)c(=O)c3cc(F)c(N4CCC(N)C4)cc3n21,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CS(=O)(=O)c1cccc(-c2cnn3c(C(N)=O)cc(-c4ccccc4)nc23)c1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(-n2c(=O)sn(C)c2=O)cc1,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibitory activity against recombinant rabbit Glycogen synthase kinase-3 beta,2002.0
,CCCCNc1nc(N)c(C(=O)c2ccccc2)s1,Ki,158.49,nM,6.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(Nc1cncc(-n2cnc3ccc(C#N)cc32)n1)c1ccccc1F,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=O)Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1ccccc1,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC1(N)CCN(c2cccnc2NC(=O)c2nc(-c3nc(N4CCOCC4)cc4ccccc34)cnc2N)CC1,IC50,3100.0,nM,5.51,Glycogen synthase kinase-3 beta,438374,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,Nc1ncc(-c2ncnc3c2CCCC3)nc1C(=O)Nc1ncccc1N1CCC(N)CC1,IC50,1500.0,nM,5.82,Glycogen synthase kinase-3 beta,438382,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,Cn1sc(=O)n(-c2ccccc2)c1=O,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibitory activity against recombinant rabbit Glycogen synthase kinase-3 beta,2002.0
,COc1cccc(C(C)NC(=O)c2cc(C)c(-c3ccc4[nH]nc(C)c4c3)s2)c1,Ki,50.12,nM,7.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1ccc(-c2ccc(=O)[nH]n2)cc1)Nc1cccc(C(F)(F)F)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(O)CNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1,Ki,316.23,nM,6.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(F)ccc1-c1c[nH]c(=O)c2cc(-c3ccncc3)sc12,IC50,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,,,Inhibition of human flag-tagged GSK3-beta expressed in HEK-MSRII cells assessed as CRMP-2 phosphorylation by alphaLISA assay,2011.0
,N#Cc1sc(NCCNc2nc(-c3ccc(Cl)cc3Cl)cn3ccnc23)nc1N,IC50,16.0,nM,7.8,Glycogen synthase kinase-3 beta,213534,,"Biochemical Assay: The ingredients required for this purpose are mixed in a black 384-well microtiter plate with transparent base (from Greiner, catalog number 781092). The requirements in this connection for each well of the 384-well microtiter plate are 5 nM GSK3β (from Upstate, catalog number xy), 40 μM GSK3β substrate GSM (sequence H-RRRPASVPPSPSLSRHS-(pS)-HQRR, from Upstate, catalog number 2-533), 30 μM nicotinamide adenine dinucleotide NADH (Roche Diagnostics, catalog number 10107735), 50 μM adenosine triphosphate ATP (from Sigma, catalog number A7966) and 2 mM phosphoenolpyruvate (from Roche, catalog number 128112). The required reaction buffer in which the biochemical reaction takes place consists of 50 mM Trizma hydrochloride Tris-HCl pH: 7.5 (from Sigma, catalog number T3253), 5 mM magnesium chloride MgCl2 (from Sigma, catalog number M8266), 0.2 mM DL-dithiothreitol DTT (from Sigma, catalog number D9779), 2 mM ethylenediaminetetraacetic acid EDTA (from Sigma, catalog number E6758), 0.01% Triton X-100 (from Sigma, catalog number T8787) and 0.05% bovine serum albumin BSA (from Sigma, catalog number B4287). Active substances are dissolved in dimethyl sulfoxide DMSO (from Sigma, catalog number D8418) in a concentration of 10 mM. Active substances are added in serial concentrations of 10 μM, 1 μM, 0.1 μM, 0.01 μM, 0.001 μM, 0.0001 μM, 0.00001 μM, 0.000001 μM to the mixtures of the biochemical reaction. As control, dimethyl sulfoxide is added instead of substance in a final concentration of 0.1%. The reaction is incubated at 30° C. for 2 hours and then the resulting fluorescence is measured in a Tecan Safire-XFLUOR4 instrument, version V4.50 (serial number 12901300283) with the specifications: measurement mode−fluorescence measured from below, extinction wavelength 340 nm, emission wavelength 465 nm, slit width extinction 5 nm, slit width emission 5 nm, gain mode 120, delay 0 μs, number of light flashes per measurement 3, and an integration time of 40 μs.",2013.0
,N#Cc1sc(NC2CCCN(c3nc(-c4ccc(Cl)cc4Cl)cn4nc(C(=O)O)cc34)C2)nc1N,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,213539,,"Biochemical Assay: The ingredients required for this purpose are mixed in a black 384-well microtiter plate with transparent base (from Greiner, catalog number 781092). The requirements in this connection for each well of the 384-well microtiter plate are 5 nM GSK3β (from Upstate, catalog number xy), 40 μM GSK3β substrate GSM (sequence H-RRRPASVPPSPSLSRHS-(pS)-HQRR, from Upstate, catalog number 2-533), 30 μM nicotinamide adenine dinucleotide NADH (Roche Diagnostics, catalog number 10107735), 50 μM adenosine triphosphate ATP (from Sigma, catalog number A7966) and 2 mM phosphoenolpyruvate (from Roche, catalog number 128112). The required reaction buffer in which the biochemical reaction takes place consists of 50 mM Trizma hydrochloride Tris-HCl pH: 7.5 (from Sigma, catalog number T3253), 5 mM magnesium chloride MgCl2 (from Sigma, catalog number M8266), 0.2 mM DL-dithiothreitol DTT (from Sigma, catalog number D9779), 2 mM ethylenediaminetetraacetic acid EDTA (from Sigma, catalog number E6758), 0.01% Triton X-100 (from Sigma, catalog number T8787) and 0.05% bovine serum albumin BSA (from Sigma, catalog number B4287). Active substances are dissolved in dimethyl sulfoxide DMSO (from Sigma, catalog number D8418) in a concentration of 10 mM. Active substances are added in serial concentrations of 10 μM, 1 μM, 0.1 μM, 0.01 μM, 0.001 μM, 0.0001 μM, 0.00001 μM, 0.000001 μM to the mixtures of the biochemical reaction. As control, dimethyl sulfoxide is added instead of substance in a final concentration of 0.1%. The reaction is incubated at 30° C. for 2 hours and then the resulting fluorescence is measured in a Tecan Safire-XFLUOR4 instrument, version V4.50 (serial number 12901300283) with the specifications: measurement mode−fluorescence measured from below, extinction wavelength 340 nm, emission wavelength 465 nm, slit width extinction 5 nm, slit width emission 5 nm, gain mode 120, delay 0 μs, number of light flashes per measurement 3, and an integration time of 40 μs.",2013.0
,COc1ccc(-c2ccnc(N[C@H]3CO[C@H]4[C@@H]3OC[C@@H]4NC(=O)Nc3cccc(C(F)(F)F)c3)n2)cc1,IC50,9750.0,nM,5.01,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using phosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O,IC50,216.0,nM,6.67,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CSc1ccc(NC2=C(c3ccccc3Cl)C(=O)NC2=O)cc1,IC50,161.0,nM,6.79,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(NCCCN1CCN(c2ccccc2)CC1)c1nc(-c2ccncc2)no1,IC50,5000.0,nM,5.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,Cc1ccc(Cl)cc1N1CCN(CCCNC(=O)c2nc(-c3cccnc3)no2)CC1,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCC#Cc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,O=C1Cc2c([nH]c3c(Br)cccc23)-c2ccccc2N1,IC50,599.79,nM,6.22,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,Cc1ccc(NC(=O)c2ccnc3[nH]c(-c4ccc(F)cc4)nc23)cn1,IC50,8.0,nM,8.1,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,O=C(NCCc1cccnc1Cl)c1ccnc2[nH]c(-c3ccoc3)nc12,IC50,9.0,nM,8.05,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCc1cn(CCNc2c3c(nc4cc(Cl)ccc24)CCCC3)nn1,IC50,26.3,nM,7.58,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCc1cn(CCNc2c3c(nc4ccc(OC)cc24)CCCC3)nn1,IC50,31.0,nM,7.51,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)CNCCNc3c4c(nc5ccccc35)CCCC4)c2)nc1OCC1CC1,IC50,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,Cc1ccc(-c2nnc(Nc3ccc(Cl)cc3)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,CN(C)c1ccc(-c2nnc(Nc3ccc(Cl)cc3)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,O=[N+]([O-])c1ccc(-c2nnc(Nc3ccc(Cl)cc3)o2)cc1,IC50,811.0,nM,6.09,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,COc1ccc(Nc2nnc(-c3ccc(N(C)C)cc3)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,CN(C)CCCn1nc(C2=C(c3cn(-c4csc5ccccc45)c4ccccc34)C(=O)NC2=O)c2ccccc21,IC50,4800.0,nM,5.32,Glycogen synthase kinase-3 beta,,,Inhibition of rabbit Glycogen synthase kinase-3 beta,2005.0
HYMENIALDISINE,NC1=NC(=O)/C(=C2\CCNC(=O)c3[nH]c(Br)cc32)N1,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta in human ReNcell VM cells after 3 hrs by immunoblotting technique,2012.0
,CC(C)OC(=O)N1CCn2cc(C3=C(c4cnc5ccccn45)C(=O)NC3=O)c3cccc(c32)C1,IC50,15.0,nM,7.82,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta dependent Tau protein serine-396 phosphorylation in human SY5Y cells,2004.0
,CC(C)n1c(=O)n(-c2ccccc2)c2nc(Nc3ccccc3)ncc21,IC50,2900.0,nM,5.54,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
ALSTERPAULLONE,O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1,Ki,15.85,nM,7.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
DORAMAPIMOD,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,C(=N/Nc1ncnc2c1cnn2-c1cccc(NCC2CC2)c1)\c1ccncc1,IC50,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
GW784752X,COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1,IC50,6.31,nM,8.2,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12,IC50,80.0,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta by kinetic assay,2010.0
INDOLYLYLMALEIMIDE 2,O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCOCCOCCn1cc2c2ccccc21,IC50,220.0,nM,6.66,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3beta (GSK3-beta),2003.0
,O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cccc2ccccc12,IC50,31.0,nM,7.51,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,O=C(Nc1ncnc2oc(-c3ccccc3)cc12)C1CC1,IC50,170.0,nM,6.77,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,CS(=O)(=O)c1ccc(Nc2cc(-c3ccccc3Cl)nc3c(Br)cnn23)cc1,IC50,450.0,nM,6.35,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,Brc1cnn2c(NCc3cccnc3)cc(C3CCNCC3)nc12,IC50,410.0,nM,6.39,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,Cc1cc(NCc2cccnc2)n2ncc(Br)c2n1,IC50,3530.0,nM,5.45,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,O[C@H]1CC[C@H](Nc2ccc3nnc(-c4cccc(C(F)(F)F)c4)n3n2)CC1,Ki,230.0,nM,6.64,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(Nc1n[nH]c2cc(-c3ccc(O)cc3)ccc12)C1CC1,IC50,15.0,nM,7.82,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)c1,IC50,125.0,nM,6.9,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCCC(=O)Nc1n[nH]c2ncc(-c3cccc4ccccc34)cc12,IC50,241.0,nM,6.62,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12,IC50,11.0,nM,7.96,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1,IC50,9.0,nM,8.05,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1ccc(C2=C(Nc3ccccc3)C(=O)NC2=O)cc1,IC50,390.0,nM,6.41,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CN(C)CCCn1nc(C2=C(c3cn(-c4cccnc4)c4ccccc34)C(=O)NC2=O)c2ccccc21,IC50,150.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Inhibition of rabbit Glycogen synthase kinase-3 beta,2005.0
,CN(C)CCCn1nc(C2=C(c3cn(-c4cnc5ccccc5c4)c4ccccc34)C(=O)NC2=O)c2ccccc21,IC50,3900.0,nM,5.41,Glycogen synthase kinase-3 beta,,,Inhibition of rabbit Glycogen synthase kinase-3 beta,2005.0
,Cc1sc(C(=O)CCl)cc1C(=O)CCl,IC50,5000.0,nM,5.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by liquid scintillation counting,2009.0
,CCCCCC(=O)Nc1ncnc2oc(-c3ccc(OC)cc3)cc12,IC50,437.0,nM,6.36,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,COc1ccc(-c2cc3c(NC(=O)CC4CCCC4)ncnc3o2)cc1,IC50,320.0,nM,6.5,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,CCCC(=O)Nc1n[nH]c2ncc(-c3ccccc3F)cc12,IC50,18.0,nM,7.75,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCNC(=O)Nc1n[nH]c2ncc(-c3ccccc3)cc12,IC50,2810.0,nM,5.55,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(Nc1n[nH]c2nc(-c3nccs3)c(Br)cc12)C1CCCC1,IC50,16.0,nM,7.8,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,Cn1nc(C(N)=O)c2c1-c1nc(NC3CCN(C(=O)c4ccccc4)CC3)ncc1CC2,IC50,48.0,nM,7.32,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2010.0
,CCN(CC)c1ccc(/C=C2\NC(=O)NC2=O)cc1,IC50,4200.0,nM,5.38,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta by ELISA,2009.0
,CCc1cc(NCc2cccnc2)n2ncc(Br)c2n1,IC50,920.0,nM,6.04,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,COc1ccc(-c2ccc(/C=C3\SC(=S)NC3=O)o2)c([N+](=O)[O-])c1,IC50,5560.0,nM,5.25,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2008.0
,COCCn1cc(-c2ccnc(Nc3ccccc3)n2)c2cccnc21,IC50,1050.0,nM,5.98,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,CC(=O)c1csc(C(=O)CCl)c1,IC50,8000.0,nM,5.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by liquid scintillation counting,2009.0
,O=C(CBr)c1ccc(Br)s1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by liquid scintillation counting,2009.0
,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1,IC50,560.0,nM,6.25,Glycogen synthase kinase-3 beta,,,Inhibition of GSK2beta phosphorylation in human BT474 cells,2010.0
LY-294002,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,IC50,8100.0,nM,5.09,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta in human U87MG cells by ELISA,2008.0
,CCOC(=O)Cn1sc(=O)n(CC(=O)N2CCCCC2)c1=O,IC50,539.0,nM,6.27,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by Z'-LYTE kinase assay,2009.0
,CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21,Kd,126.0,nM,6.9,Glycogen synthase kinase-3 beta,,,Binding affinity to GSK3-beta,2007.0
,COc1ccc(CSc2nnc(-c3ccc4c(c3)OCO4)o2)cc1F,IC50,65.0,nM,7.19,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,O=[N+]([O-])c1ccc(NCCNc2ncc(-c3ncc[nH]3)c(-c3ccc(Cl)cc3Cl)n2)nc1,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,COc1ccc(CSc2nnc(-c3ccc4c(c3)CCO4)o2)cc1C#N,IC50,28.0,nM,7.55,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
SB-216763,Cn1cc(C2=C(c3ccc(Cl)cc3Cl)C(=O)NC2=O)c2ccccc21,IC50,48.0,nM,7.32,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2010.0
,CS(=O)(=O)Nc1ccc(CCNC(=O)c2ccc(O)c3[nH]c(-c4ccc(Cl)cc4)nc23)cc1,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,CN1CCN(S(=O)(=O)c2ccc(-c3cnc(N)c(C(=O)Nc4cccnc4)n3)cc2)CC1,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2021.0
,COc1ccc(-c2oc3ncnc(N)c3c2-c2cccnc2)cc1,IC50,80.0,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,COc1ccc(NC2=C(c3ccccc3)C(=O)N(c3ccccc3)C2=O)cc1,IC50,5000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2005.0
,Cc1ccc2c(-c3ccnc(Nc4ccc(F)c(F)c4)n3)c(-c3ccccc3)nn2n1,Ki,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,C1=CC2C(c3ccnc(Nc4ccccc4)n3)=C(c3ccccc3)NN2C=C1,IC50,60.0,nM,7.22,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
GW441756X,Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
AST-487,CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
PD-0166285,CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COC(=O)c1cccc2c3c(c(CC(C)C)cc12)C(=O)NC3=O,IC50,486.0,nM,6.31,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2010.0
,O=C1NC(N[C@@H](CO)CC2CCCCC2)=N/C1=C\c1ccc2ncsc2c1,IC50,3308.0,nM,5.48,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC[C@@H](O)c2ccccc2)=N/C1=C\c1ccc2ncsc2c1,IC50,2604.0,nM,5.58,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CO[C@@H]1Cc2ccccc2[C@H]1NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,1267.0,nM,5.9,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C(Nc1cnccc1N1CCC(F)(F)CC1)c1ccnc(Nc2ccccc2)n1,IC50,0.2,nM,9.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
STAUROSPORINE,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,IC50,50.0,nM,7.3,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using CFFKNIVTPRTPPPSQGK-amide substrate after 90 mins incubation by LANCE method,2014.0
,N#Cc1ccc2nc(N)n(-c3nc4c(s3)CCCC4)c2c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1c(F)cccc1F,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1ccc(-c2n[nH]cc2-c2ccncc2)cc1,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc2c(c1)NC(=O)c1ccccc1N2,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(c1ncnc2[nH]c3ccccc3c12)C1CCCN(CCC#N)C1,IC50,480.0,nM,6.32,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,N#CCCN1CCC2CCN(c3ncnc4[nH]c5cc(F)ccc5c34)C2C1,IC50,2668.0,nM,5.57,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,O=C1c2ccccc2-c2onc3c(N4CCN(c5ccc(O)cc5)CC4)cc(NCCP(=O)(O)O)c1c23,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) using biotin-labelled IRS-1 peptide as substrate incubated for 15 mins by ELISA based assay,2022.0
,O=c1[nH]cc(-c2ccc(N3CCOCC3)cc2)c2sc(-c3ccncc3)cc12,IC50,63.1,nM,7.2,Glycogen synthase kinase-3 beta,,,Inhibition of human full length His-tagged GSK3-beta expressed in baculovirus by alphaLISA assay,2011.0
,O=c1[nH]cc(Br)c2sc(-c3ccncc3)cc12,IC50,158.49,nM,6.8,Glycogen synthase kinase-3 beta,,,Inhibition of human full length His-tagged GSK3-beta expressed in baculovirus by alphaLISA assay,2011.0
,O=c1[nH]cc(-c2ccc(N3CCOCC3)cc2)c2sc(-c3cn[nH]c3)cc12,IC50,12.59,nM,7.9,Glycogen synthase kinase-3 beta,,,Inhibition of human full length His-tagged GSK3-beta expressed in baculovirus by alphaLISA assay,2011.0
,O=c1[nH]cc(-c2ccc3c(c2)OCCO3)c2sc(-c3ccncc3)cc12,IC50,630.96,nM,6.2,Glycogen synthase kinase-3 beta,,,Inhibition of human flag-tagged GSK3-beta expressed in HEK-MSRII cells assessed as CRMP-2 phosphorylation by alphaLISA assay,2011.0
,Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(OC(F)(F)F)c4)c3)cc12,Ki,19.95,nM,7.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#Cc5cccnc5)cnc(N)c34)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCCOc1cc(-c2ccncc2)cc2[nH]nc(N)c12,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)NC1=NNC(=O)C1=Cc1cc2ccccc2[nH]1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,OCCCNc1ncnc2[nH]cc(-c3ccccc3)c12,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)=C(C)c1cccc2c(CCCOc3cccc(Cl)c3Cl)c(C(=O)O)[nH]c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(OC)c(CNC(=O)c2cc(N)c(C#N)c(OC(C)C)n2)c1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1nc(N2CCNCC2)nc2ccccc12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12,Ki,3162.28,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2c1C(c1ccccc1F)C1=C(CC(C)(C)CC1=O)N2,Ki,19.95,nM,7.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3coc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(=O)CC)c3c2)cc1,Ki,63.1,nM,7.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCC(=O)Nc1n[nH]c2ccc(-c3cccc(F)c3F)cc12,Ki,2.512,nM,8.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CC(CN2CCCC2)C1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,S=c1[nH]nc2c3c4c(sc3n3c(=S)[nH]nc3n12)CCC4,Ki,316.23,nM,6.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1ccc2nc(N)n(-c3nccs3)c2c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(CCl)c1ccc(Cl)cc1,IC50,2500.0,nM,5.6,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 (GSK-3beta).,2003.0
,Cc1cc(O)nc2[nH]nc(-c3cccc(-c4ccc(C#N)cc4)c3)c12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl,Ki,6.31,nM,8.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,C(=Cc1cncc(OCCc2c[nH]c3ccccc23)c1)c1ccncc1,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1nc2c(O)cccc2s1)Nc1ccccc1-c1ccccc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1n[nH]c2nc3ccccc3cc12)c1ccncc1,Ki,316.23,nM,6.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NC(CO)Cc1ccc(Cl)cc1)c1ccc(-c2ccncc2)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cnccn1)Nc1ccnc2c(F)cccc12,Ki,5.012,nM,8.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Clc1cc2nn[nH]c2cc1Cl,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CCO)c5)cnc(N)c34)cc2)cc1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncnc2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1[nH]c2cc(Cl)cc(Cl)c2c(-c2cc(Cl)ccc2O)c1O,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CC(CN2CCCC2)C1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2)c1,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1csc(NC(=O)c2sc3nc(-c4ccncc4)ccc3c2N)n1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOC(=O)c1c[nH]n2c(=O)cc(-c3ccncc3)nc12,Ki,316.23,nM,6.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOc1nc(C(=O)NCc2cccnc2)cc(N)c1C#N,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C(F)(F)F)c2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cccc(-c2cnc3[nH]cc(-c4ccccc4)c3c2)c1,Ki,158.49,nM,6.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COCC#Cc1cccc2c1Cc1c(-c3cccs3)n[nH]c1-2,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(-c2c(-c3ccncc3)nc(NCC(N)Cc3ccccc3)n(C)c2=O)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)NCCO)c2)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2ccc(-c3cncc(OCCNS(C)(=O)=O)c3)cc12,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2ccccc21,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1ccc(Cc2cc(-c3ccc4[nH]ncc4c3)on2)cc1,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NCCc2[nH]c(-c3ccncc3)cc21,Ki,39.81,nM,7.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc2c(c1)C(=Cc1c[nH]cn1)C(=O)N2,Ki,158.49,nM,6.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)CCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1nn(C)c2c1c(=O)c1cc(Cl)ccc1n2OCC(C)C,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(CCCN1CCCC1)Nc1n[nH]c2nnc(-c3ccccc3)cc12,IC50,11.0,nM,7.96,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)nc2)c1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C)c2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1nccn2c(-c3ccnc(NCC4(O)CC4)n3)c(-c3ccc(F)cc3F)nc12,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1cc(-c2cnn3c(N)c(-c4ccc(NC(=O)Nc5cccc(C(F)(F)F)c5)cc4)cnc23)cn1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COCCn1cc(-c2ccncn2)c(-c2ccc(Cl)cc2)n1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cccc2[nH]c(-c3ccncc3)nc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(OC2CCCC2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1Nc2ccccc2Nc2nnc(Cl)cc21,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOC(=O)c1ccc2[nH]c3c(c2c1)CCNC3=O,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CS(=O)(=O)c1cccc(C(=O)Nc2nc3ccccc3n2CCCO)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1cccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)n1,Ki,25.12,nM,7.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1Cc2c([nH]c3ccc(Cl)cc23)-c2sccc2N1,IC50,399.94,nM,6.4,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2NCCCN)c1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=O)c1c(-c2ccccc2)nn(C)c(=O)c1N,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NC(=O)C(Nc2ccccc2)=C1Cl,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)O)s3)c2cc1OC,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=[N+]([O-])c1cccc(-c2nnc3ccc(N4CCCCC4)nn23)c1,Ki,39.81,nM,7.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1,Ki,3162.28,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CS(=O)(=O)NC1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncc(C=CC(=O)NCCCn2ccnc2)c2scc(-c3ccc(Br)cc3)c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1ccc(-c2cccc3sncc23)cc1)Nc1ccc(F)c(C(F)(F)F)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NCc1ccccc1)c1cccc(-c2cnc3[nH]ccc3c2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cccc(F)c1)Nc1cccc(-c2ccc3cn[nH]c3c2)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(COc1cncc(-c2cc3ccncc3s2)c1)Cc1c[nH]c2ccccc12,Ki,12.59,nM,7.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)C(C)Nc1ncc(Cl)c(Nc2nccs2)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC1C2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)CC12,Ki,31.62,nM,7.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(OC)c1CNc1nc(NC2CCCCC2)nc2ccc(Cl)cc12,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(CCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCCOc1ncnc2[nH]cc(-c3ccccc3)c12,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(O)c1cc2c(-c3ccccc3)cncc2s1,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1[nH]c(C=C2C(=O)Nc3ccccc32)c(C)c1CCC(=O)O,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Clc1ccc(CNc2ccc3nnc(-c4ccccc4)n3n2)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1nnc(-c2cc3c(Oc4ccc(Cl)cc4)cncc3s2)o1,Ki,3.162,nM,8.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(-c2ccc(NC(=O)Nc3cc(F)cc(F)c3)cc2)c2c(N)noc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC1c2cccn2CCN1Cc1nc2scc(-c3ccco3)c2c(=O)[nH]1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOc1ccccc1-c1cccc(-c2n[nH]c3nc(O)cc(C)c23)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(-c2ccc3c(c2)Nc2ccc(CCOc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1OCC(O)CO,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COCCOCC#Cc1cc(-c2n[nH]c3c2C(=O)c2cc(CN4CCN(C)CC4)ccc2-3)cs1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(/C=C2\S/C(=N/c3ccc(C)c(C)c3)NC2=O)ccc1OCc1ccc2ccccc2c1,IC50,1079.0,nM,5.97,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2021.0
,C=Cn1cc(C2=C(c3nn(CCCN(C)C)c4ccccc34)C(=O)NC2=O)c2ccccc21,IC50,49.0,nM,7.31,Glycogen synthase kinase-3 beta,,,Inhibition of rabbit Glycogen synthase kinase-3 beta,2005.0
,CN(C)CCCn1nc(C2=C(c3cn(-c4cncc5ccccc45)c4ccccc34)C(=O)NC2=O)c2ccccc21,IC50,1300.0,nM,5.89,Glycogen synthase kinase-3 beta,,,Inhibition of rabbit Glycogen synthase kinase-3 beta,2005.0
,Cc1cc2c3c(c1)c(C1=C(c4cnc5ccccn45)C(=O)NC1=O)cn3CCN(C(=O)N1CCCCC1)C2,IC50,41.0,nM,7.39,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta dependent Tau protein serine-396 phosphorylation in human SY5Y cells,2004.0
,CSc1ccc(NC2=C(c3ccccc3)C(=O)NC2=O)cc1,IC50,404.0,nM,6.39,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1Nc2ccc(Br)cc2/C1=N/NC(=O)c1cc2cc(Br)ccc2o1,IC50,32.09,nM,7.49,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3 beta (unknown origin),2021.0
,COc1ccc2c(c1)/C(=N/NC(=O)c1cc3cc(Br)ccc3o1)C(=O)N2,IC50,40.13,nM,7.4,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3 beta (unknown origin),2021.0
,Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccc(F)cc3)nn2n1,Ki,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,N#Cc1ccccc1-c1ccc(CSc2nnc(-c3ccc4c(c3)OCO4)o2)cc1,IC50,39.0,nM,7.41,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using pIRS-1 as substrate preincubated for 15 mins,2012.0
,c1ccc2c(-c3cnc4cnc(-c5cn[nH]c5)cn34)c[nH]c2c1,IC50,5900.0,nM,5.23,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta at 10 uM by mobility shift assay,2010.0
,COc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2,IC50,21.98,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,Br.c1ccc(/N=c2/nc(-c3ccccc3)n(-c3ccccc3)s2)cc1,IC50,900.0,nM,6.05,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,Cl.c1ccc(-n2s/c(=N/Cc3cccnc3)nc2-c2cccc3ccccc23)cc1,IC50,900.0,nM,6.05,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,CN(C)CCCn1cc(C2=C(n3ccc4ncccc43)C(=O)NC2=O)c2ccc(Br)cc21,IC50,2260.0,nM,5.65,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-GSK3beta expressed in Escherichia coli BL21 (DE3),2009.0
,O=C1NC(=O)C(n2ccc3ncccc32)=C1c1cn(CCCN2CCOCC2)c2ccccc12,IC50,1790.0,nM,5.75,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-GSK3beta expressed in Escherichia coli BL21 (DE3),2009.0
,O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCOCCOCCn1cc2c2cccnc21,IC50,403.0,nM,6.39,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3beta (GSK3-beta),2003.0
,COc1cc(C2=C(c3cn(CCO)c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,410871,,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",2016.0
,O=C1NN=C(c2cccnc2)/C1=N/Nc1ccccc1Cl,Ki,200.0,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(N/N=C2\C(=O)NN=C2c2ccc(OC)cc2)cc1,Ki,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(N/N=C2\C(=O)NN=C2c2cnccc2OC)cc1,Ki,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(C2=NNC(=O)/C2=N\Nc2cccc(OC)c2)cc1,Ki,0.8,nM,9.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(C2=NNC(=O)/C2=N\Nc2ccc(C#N)cc2)cc1,Ki,2.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(C2=NNC(=O)/C2=N\Nc2ccncc2)cc1,Ki,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(C2=NNC(=O)/C2=N\Nc2ccc(N(C)C)cc2)cc1,Ki,110.0,nM,6.96,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(C2=NNC(=O)/C2=N\Nc2ccccc2)cc1OC,Ki,3.5,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccncc1C1=NNC(=O)/C1=N\Nc1ccc(C(=O)O)cc1,Ki,7.7,nM,8.11,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(C(C)(C)C)cc3)ccc12,IC50,3808.0,nM,5.42,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccc(OCc4ccccc4)cc3)cc12,IC50,23.0,nM,7.64,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(O)cc3)c(-c3ccccc3)cc12,IC50,55.0,nM,7.26,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccsc3)ccc12,IC50,935.0,nM,6.03,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CN1CCN(c2ccc(Nc3nccc(-c4cccc(Cl)c4)n3)cc2C(F)(F)F)CC1,Kd,9300.0,nM,5.03,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human full length GSK-3 beta (M1 to T433 residues) expressed in mammalian expression system by KdELECT kinase assay,2021.0
,O=C(CBr)c1ccc([N+](=O)[O-])cc1,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 (GSK-3beta).,2003.0
,NCC1(c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,IC50,590.0,nM,6.23,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta in human U87MG cells by ELISA,2008.0
,c1cc2[nH]ncc2cc1-c1cc(CN2CCCCC2)no1,Ki,3810.0,nM,5.42,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
PAULLONE 2,N#Cc1ccc2[nH]c3c(c2c1)CC(=O)Nc1ccccc1-3,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,Cl.NCCO/N=C1C(=C2/C(=O)Nc3ccc([N+](=O)[O-])cc32)/Nc2ccc(O)cc2/1,IC50,5.46,nM,8.26,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2021.0
LY-2090314,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2,IC50,1.1,nM,8.96,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
BISINDOLYLMALEIMIDE IX,Cn1cc(C2=C(c3cn(CCCSC(=N)N)c4ccccc34)C(=O)NC2=O)c2ccccc21,IC50,2.8,nM,8.55,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,Cc1cc(Nc2nc(Sc3ccc(NS(C)(=O)=O)cc3)nc3ccccc23)n[nH]1,Ki,67.0,nM,7.17,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,CC(=O)N(C)c1ccc(Sc2nc(Nc3cc(C)[nH]n3)c3ccccc3n2)cc1,Ki,17.0,nM,7.77,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,Cc1cc(Nc2nc(Sc3ccc(NC(=O)C4CC4)cc3)nc3ccccc23)n[nH]1,Ki,1314.0,nM,5.88,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,CC(C)C(=O)N1CCn2cc(C3=C(C4=CN=[N+]5C=CC=CC45)C(=O)NC3=O)c3cccc(c32)C1,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,"Inhibitory concentration to inhibit Ser396 phosphorylation of tau, a natural substrate of GSK-3 in SY5Y cells",2005.0
,Br.Cc1n/c(=N\Cc2cccnc2)sn1-c1ccccc1,IC50,600.0,nM,6.22,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,N#Cc1ccc(-c2nnc(Nc3ccccc3)o2)cc1,IC50,247.0,nM,6.61,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,COC(C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1,Ki,1995.26,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncc(-c2ccccc2C(F)(F)F)nc1C(=O)Nc1cnccc1N1CCCC(N)C1,IC50,97.0,nM,7.01,Glycogen synthase kinase-3 beta,438358,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,Nc1ncc(-c2ccccc2)nc1C(=O)Nc1cnccc1N1CCC(N)CC1,IC50,0.2,nM,9.7,Glycogen synthase kinase-3 beta,438361,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,Nc1ncc(-c2cc(N3CCOCC3)ccc2C(F)(F)F)nc1C(=O)Nc1ncccc1N1CCC(N)CC1,IC50,6500.0,nM,5.19,Glycogen synthase kinase-3 beta,438384,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,CC1CC2(CCC2)n2cc(C(=O)O)c(=O)c3c(N)c(F)c(NCCNc4ccccn4)c(c32)O1,IC50,250.0,nM,6.6,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta after 1 hr by KinaseGlo luciferase assay,2012.0
,COc1cc(-c2cc(-c3cc(C)cc(Cl)c3O)nc3ncnc(N)c23)ccc1O,IC50,113.0,nM,6.95,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,COc1cc(/C=C2\NC(=O)NC2=O)ccc1OCC(=O)C1CCOCC1,IC50,1975.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,O=C(Nc1n[nH]c2nc(-c3ccc(O)c(O)c3)ccc12)C1CC1,IC50,8.0,nM,8.1,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1,IC50,1412.0,nM,5.85,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1F,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta-mediated CRMP-2 phosphorylation by cell based assay,2012.0
,Cn1cc(C2=C(c3cccc(C[C@H](O)CO)c3)C(=O)NC2=O)c2ccccc21,IC50,8.2,nM,8.09,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,c1cnc2cc(-c3cnnn3C3C4CC5CC(C4)CC3C5)ccc2n1,IC50,2800.0,nM,5.55,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by colorimetric analysis,2012.0
,CN1CCN(c2ccc(Nc3nccc(-c4ccnc(Cl)c4)n3)cc2C(F)(F)F)CC1,Kd,2600.0,nM,5.58,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human full length GSK-3 beta (M1 to T433 residues) expressed in mammalian expression system by KdELECT kinase assay,2021.0
,O=C(Nc1ncnc2[nH]c(-c3ccc4ccccc4c3)nc12)C1CC1,IC50,169.0,nM,6.77,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2010.0
,Br.CCCCCc1n/c(=N\Cc2cccnc2)sn1-c1ccccc1,IC50,800.0,nM,6.1,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cc(C#N)ccc21,IC50,13.2,nM,7.88,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,CCN(CC)CCNC(=O)c1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2008.0
,NCC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]cnc23)CC1,IC50,1700.0,nM,5.77,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta in human PC3M cells by ELISA,2008.0
,Cc1ccc(CNc2ccc3nnc(-c4ccccc4)n3n2)cc1,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
SORAFENIB,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,Ki,3162.28,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOc1cc(/C=C2\Oc3ccc(OC)cc3C2=O)ccc1O,IC50,5010.0,nM,5.3,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta,2017.0
,O=C(Nc1ncnc2oc(-c3ccc(F)cc3)cc12)C1CCCC1,IC50,219.0,nM,6.66,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,O=C(CBr)c1ccc(Cl)cc1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 (GSK-3beta).,2003.0
,O=C1NC(=O)/C(=C/c2cc3ccccc3nc2Cl)S1,IC50,6130.0,nM,5.21,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using GS-2 peptide substrate incubated for 30 mins by kinase-Glo luminescent assay,2018.0
,CC(C)C(=O)N1CCn2cc(C3=C(c4cnc5ccccn45)C(=O)NC3=O)c3cccc(c32)C1,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,,"Inhibitory concentration to inhibit Ser396 phosphorylation of tau, a natural substrate of GSK-3 in SY5Y cells",2005.0
,COc1ccc(-c2cc3c(NC(=O)c4ccco4)ncnc3o2)cc1,IC50,2400.0,nM,5.62,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
BISARYLMALEIMIDE 1,O=C1NC(=O)C(c2cnc3cccnn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCCCC1)CC2,IC50,0.3,nM,9.52,Glycogen synthase kinase-3 beta,,,"Inhibitory concentration to inhibit Ser396 phosphorylation of tau, a natural substrate of GSK-3 in SY5Y cells",2005.0
,O=C(Nc1ncnc2oc(-c3ccccc3)cc12)C1CCCC1,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,COc1ccc(-c2nnc(Nc3ccc(Cl)cc3)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,COc1ccc(Nc2nnc(-c3ccc(Cl)cc3)o2)cc1,IC50,534.0,nM,6.27,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,COc1cccc(CN2CCC(CNC(=O)c3cncc(NC(=O)c4ccnc(NC(=O)C5CC5)c4)c3)CC2)c1,IC50,126.0,nM,6.9,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,O=C(Nc1cncc(OCC2CCN(Cc3ccccc3Cl)CC2)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,79.0,nM,7.1,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(CCN4C[C@@H](C)O[C@@H](C)C4)CC3)c2c1,IC50,1400.0,nM,5.85,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(CCC(=O)O)CC3)c2c1,IC50,690.0,nM,6.16,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COCCN1CCC(CNC(=O)c2n[nH]c3ccc(-c4ccc(OC)cc4)cc23)CC1,IC50,560.0,nM,6.25,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COCCN1CCC(CNC(=O)c2n[nH]c3ccc(-c4cccnc4OC)cc23)CC1,IC50,1400.0,nM,5.85,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COc1ccc(C(=O)CBr)cc1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of glycogen synthase kinase-3 beta (unknown origin) using GS-1 as substrate after 20 mins by scintillation counting analysis in presence of [gamma-32P]-ATP,2016.0
,Cn1cc(C2=C(c3nnc4ccccn34)C(=O)NC2=O)c2ccc(Cl)cc21,IC50,159.3,nM,6.8,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay,2015.0
,CC(=O)N1CC[C@@H](Nc2cncc(C(=O)c3cn(C(C)C)c4ncnc(N)c34)n2)[C@H]1c1ccccc1,IC50,860.0,nM,6.07,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C(=N)NO)cn1c23,IC50,71.0,nM,7.15,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(-c4nnn[nH]4)cn1c23,IC50,2.4,nM,8.62,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,C=Cn1cc(C2=C(c3nn(CCCN4CCOCC4)c4ncccc34)C(=O)NC2=O)c2ccccc21,IC50,8840.0,nM,5.05,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,Cn1c(NCC(=O)c2cccc(Cl)c2)nc(-c2ccncc2)cc1=O,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,Cn1c(NCCc2ccccc2)nc(-c2ccncc2)cc1=O,IC50,70.0,nM,7.16,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,O=c1cc(-c2ccncc2)nc(Cc2ccccc2)[nH]1,IC50,1300.0,nM,5.89,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,CC(C)Cc1nc(-c2ccncc2)cc(=O)[nH]1,IC50,2400.0,nM,5.62,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,Cc1nnc(-c2ccc3occ(-c4ccc([S+](C)[O-])cc4)c3c2)s1,IC50,72.0,nM,7.14,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,O=C(O)c1nc2ccccc2c2[nH]c3c(I)cccc3c12,Kd,474.59,nM,6.32,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human GSK-3beta assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,2023.0
,c1ccc(-c2ccc3[nH]ncc3c2)cc1,IC50,7509.0,nM,5.12,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,2023.0
AT-7519,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,IC50,89.0,nM,7.05,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2023.0
,Cn1cc(C2=C(c3cccc(NC[C@H](O)CO)c3)C(=O)NC2=O)c2cc(F)ccc21,Kd,0.05,nM,10.3,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to GSK-3beta (unknown origin) assessed as dissociation constant,2023.0
,Nc1ncc(-c2ccc(S(=O)(=O)N3C=COCC3)cc2)nc1C(=O)Nc1cccnc1,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of full length GST-tagged human recombinant GSK-3beta (1 to 420 residues) expressed in Escherichia coli,2023.0
,CC(C)Oc1cncc(-c2ccc3cnc(C(=O)NCC4CCOCC4)n3c2)c1,IC50,72.0,nM,7.14,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC(C)n1cc(-c2ccnc3[nH]c(C4CCN(CC(=O)N(C)C)CC4)cc23)ccc1=O,IC50,2100.0,nM,5.68,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of full length human GSK3beta in the presence of ATP at Km concentration,2021.0
,COc1ccc2c(c1)c(/C=C1\SC(=O)NC1=O)cn2C,IC50,890.0,nM,6.05,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human His6-taged GSK-3beta assessed as substrate phosphorylation incubated for 30 mins using RRRPASVPPSPSLSRHSSHQRR peptide as substrate in presence of [gamma-32P]ATP by scintillation counter method,2021.0
,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccc(Br)cc23)=C1c1ccccc1,IC50,69.0,nM,7.16,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2[nH]nc(C)c2c1,IC50,220.0,nM,6.66,Glycogen synthase kinase-3 beta,,,Inhibition of GSK2beta phosphorylation in human BT474 cells,2010.0
,Nc1ncc(-c2ccccc2)nc1C(=O)Nc1cnccc1N1CCC(C(=O)O)CC1,IC50,40.0,nM,7.4,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta (1 to 433 residues) expressed in mammalian expression system by Kinomescan method,2020.0
NOTOPTEROL,CC(C)=CC(O)C/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2022.0
,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2ccccc2)cc1-c1cnc2[nH]nc(C)c2n1,IC50,280.0,nM,6.55,Glycogen synthase kinase-3 beta,,,Inhibition of GSK2beta phosphorylation in human BT474 cells,2010.0
,O=C(Nc1ncnc2oc(-c3cccnc3)cc12)C1CCCC1,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta by scintillation proximity assay,2018.0
,COc1ccccc1-n1c(-c2nonc2N)nc2ccccc21,Ki,5000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,Cc1ccc2c(c1)nc(-c1nonc1N)n2C1CCC1,Ki,3200.0,nM,5.5,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,Nc1nonc1-c1nc2cc(CO)ccc2n1C1CCC1,Ki,3300.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,Cc1n[nH]c2cnc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12,IC50,64.0,nM,7.19,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2010.0
,O=C(NCCCn1cnc(Cl)c1Cl)c1ccc(O)c2[nH]c(-c3ccco3)nc12,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,C[C@H]1COc2c(NCCCc3ccccc3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,IC50,40.0,nM,7.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,C[C@H]1COc2c(NCCCc3ccccc3)c(F)c(N)c3c(=O)c(C#N)cn1c23,IC50,1.4,nM,8.85,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,COc1ccc(-c2ocnc2C(=O)NCCCn2cc(CNC(=O)/C=C/c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)nn2)cc1Cl,IC50,0.76,nM,9.12,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,COc1ccc(-c2ocnc2C(=O)NCCCc2ccc(NC(=O)/C=C/c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)cc2)cc1Cl,IC50,0.25,nM,9.6,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
KENPAULLONE,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1,Ki,19.95,nM,7.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOC(=O)c1ccc(CN2CCC(CNC(=O)c3n[nH]c4ccc(Br)cc34)CC2)o1,IC50,260.0,nM,6.58,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1,IC50,72.0,nM,7.14,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using prephosphorylated peptide as substrate measured after 30 mins by Kinase-glo luminescence assay,2019.0
,CCCCCCCC(=O)NNC(=O)c1c(O)c2cc(Cl)ccc2n(CC)c1=O,IC50,9420.0,nM,5.03,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2cc(Br)ccc2[nH]c1=O,IC50,3540.0,nM,5.45,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,CCCCCCCC(=O)NNC(=O)c1c(O)c2ccc(Cl)cc2n(C)c1=O,IC50,6660.0,nM,5.18,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,CCCCCCCC(=O)NNC(=O)c1c(O)c2ccccc2n(C)c1=O,IC50,8700.0,nM,5.06,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,COc1ccc2c(c1)/C(=C1\Nc3ccccc3\C1=N/OCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(=O)N2,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3beta (unknown origin) after 10 mins in presence of [gamma32P]ATP by beta counting method,2017.0
,CN1CCN(CCO/N=C2C(=C3/C(=O)Nc4cc(Br)ccc43)/Nc3ccccc3/2)CC1.Cl,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,,Inhibition of human N-terminal GST/His6-tagged GSK3beta (M1 to T420 residues) expressed in baculovirus infected sf9 cells using RBER-IRStide as substrate by filter binding assay,2017.0
,Nc1nccc(-c2c[nH]c3c([N+](=O)[O-])cccc23)n1,IC50,9950.0,nM,5.0,Glycogen synthase kinase-3 beta,,,Inhibition of full-length recombinant human His-tagged GSK3B recombinant in baculovirus expression system using Alexa-Fluor tracer-236 incubated for 60 mins by TR-FRET based Lantha-screen Eu kinase assay,2017.0
,c1cc(-c2cn(CCCN3CCOCC3)c3cnccc23)ccn1,IC50,7580.0,nM,5.12,Glycogen synthase kinase-3 beta,,,Inhibition of full-length recombinant human His-tagged GSK3B recombinant in baculovirus expression system using Alexa-Fluor tracer-236 incubated for 60 mins by TR-FRET based Lantha-screen Eu kinase assay,2017.0
,CC(C)n1cc(-c2ccncc2)c2ccncc21,IC50,660.0,nM,6.18,Glycogen synthase kinase-3 beta,,,Inhibition of full-length recombinant human His-tagged GSK3B recombinant in baculovirus expression system using Alexa-Fluor tracer-236 incubated for 60 mins by TR-FRET based Lantha-screen Eu kinase assay,2017.0
,Cn1cc(C2=C(c3nn(CCCN4CCOCC4)c4ncccc34)C(=O)NC2=O)c2ccccc21,IC50,340.0,nM,6.47,Glycogen synthase kinase-3 beta,,,Inhibition of GST-tagged GSK3beta (unknown origin) expressed in Escherichia coli BL21-CodonPlus (DE3) by Z'-LYTE assay,2017.0
,Fc1ccc(Cn2cc(-c3ccncc3)c3ccncc32)cc1,IC50,1010.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of full-length recombinant human His-tagged GSK3B recombinant in baculovirus expression system using Alexa-Fluor tracer-236 incubated for 60 mins by TR-FRET based Lantha-screen Eu kinase assay,2017.0
,Cc1cc2oc3ncc(OCc4ccccc4)c(-c4ccccc4)c3c2cc1O,Ki,5800.0,nM,5.24,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccncn2)cc1=O,IC50,12.0,nM,7.92,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,COc1cccc(-c2ocnc2C(=O)NCc2ccncc2)c1,IC50,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by fluorescence polarization assay,2012.0
,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1,IC50,79.43,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibition of catalytic activity of GSK3-beta by AlphaLISA assay,2012.0
,Cc1ccc(-c2ccc3scc(-c4ccc([S+](C)[O-])cc4)c3c2)o1,IC50,790.0,nM,6.1,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,Cc1ccc(-c2cnc3occ(-c4ccc([S+](C)[O-])cc4)c3c2)o1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,Cc1ccc(-c2cc3c(-c4ccc([S+](C)[O-])cc4)coc3cn2)o1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,O=C(Nc1ncnc2oc(-c3cccnc3)cc12)C1CC1,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,O=C(Nc1ncnc2oc(-c3ccc(Cl)cc3)cc12)C1CCCC1,IC50,550.0,nM,6.26,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,CN(C)CCCn1nc(C2=C(c3cn(-c4ccc5ccccc5c4)c4ccccc34)C(=O)NC2=O)c2ccccc21,IC50,1900.0,nM,5.72,Glycogen synthase kinase-3 beta,,,Inhibition of rabbit Glycogen synthase kinase-3 beta,2005.0
,COc1cc(/C=C/C(O)=C/C(=O)/C=C/c2ccc(OCc3ccccc3)cc2)ccc1O,IC50,900.0,nM,6.05,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide as substrate incubated for 30 mins by Glo-type luminescence assay,2016.0
,Cc1ccc(N2CCN(CCCNC(=O)c3nc(-c4cncnc4)no3)CC2)cc1C,IC50,3500.0,nM,5.46,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,Cc1cccc(N2CCN(CCCNC(=O)c3nc(-c4cccnc4)no3)CC2C)c1,IC50,710.0,nM,6.15,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,Cc1cccc(N2CCN(CCCNC(=O)c3nc(-c4cccnc4)no3)C(C)C2)c1,IC50,200.0,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by ATP-based competitive assay,2008.0
,O=C(O)c1ccc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3)n2)cc1,IC50,150.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=C(O)c1ccc(Nc2ncc(-c3ccncc3)c(Nc3ccccc3)n2)cc1,IC50,540.0,nM,6.27,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,OC12CC3CC(C1)CC(Nc1nc(N[C@H]4CC[C@H](O)CC4)ncc1Br)(C3)C2,IC50,125.0,nM,6.9,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=C(O)c1ccc(Nc2ncc3nnn(C45CC6CC(CC(O)(C6)C4)C5)c3n2)cc1,IC50,51.0,nM,7.29,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cccs1,IC50,31.0,nM,7.51,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,COc1ccccc1C1=C(c2cn(CCCN)c3ncccc23)C(=O)NC1=O,IC50,37.0,nM,7.43,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ccccn1,IC50,480.0,nM,6.32,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,O=C(NCc1ccccc1)c1ccc(O)c2[nH]c(-c3ccccc3)nc12,IC50,870.0,nM,6.06,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta at 5 uM,2007.0
,O=C(NCCc1ccccc1)c1ccc(O)c2[nH]c(-c3ccc(Cl)cc3Cl)nc12,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta at 5 uM,2007.0
LADUVIGLUSIB,Cc1cnc(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)[nH]1,IC50,4.9,nM,8.31,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using biotin-CREB peptide substrate after 1 hr by scintillation counting method,2017.0
MALEIMIDE,COc1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,IC50,1100.0,nM,5.96,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3 beta,2006.0
,CCOC(=O)Cn1sc(=O)n(-c2ccc(C(=O)OCC)cc2)c1=O,IC50,1012.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by Z'-LYTE kinase assay,2009.0
,Cl.Cn1c(N2CCNC(c3ccc(Br)cc3)C2)nc(-c2ccncn2)cc1=O,IC50,8.1,nM,8.09,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,COc1cc(F)ccc1C1CN(c2nc(-c3ccncc3)cc(=O)n2C)CCN1.Cl,IC50,0.9,nM,9.05,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,C[C@H]1CNCCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,76.0,nM,7.12,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,COc1ccccc1N1CCN(c2nc(-c3ccncn3)cc(=O)n2C)[C@H](C)C1,IC50,0.8,nM,9.1,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,COc1cc(F)ccc1C1CN(c2nc(-c3ccncn3)cc(=O)n2C)CCN1C(C)=O,IC50,1500.0,nM,5.82,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,COc1ccc(C2CN(c3nc(-c4ccncc4)cc(=O)n3C)CCN2)cc1.Cl,IC50,4.7,nM,8.33,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cn1c(N2CCNC(c3ccc(F)cc3)C2)nc(-c2ccncn2)cc1=O,IC50,8.6,nM,8.07,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cc1ccc(C(=O)CBr)cc1,IC50,2500.0,nM,5.6,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 (GSK-3beta).,2003.0
,Cc1ccc(-c2ccc3occ(-c4ccc(O)cc4)c3c2)o1,IC50,180.0,nM,6.75,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,COc1ccc(CSc2nnc(-c3ccc4c(c3)CCO4)o2)cc1F,IC50,44.0,nM,7.36,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,COc1ccc(CSc2nnc(-c3ccc4occc4c3)o2)cc1C(F)(F)F,IC50,4.9,nM,8.31,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,COc1cc2c(C)cc3c(c2cc1OC)C(=O)NC3=O,Ki,259.0,nM,6.59,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta at 1 uM by ATP competitive assay,2010.0
,CCc1cc2c(c3cc(OC)c(OC)cc13)C(=O)NC2=O,IC50,92.0,nM,7.04,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2010.0
,CC(=O)Nc1ccc(Sc2nc(Nc3cc(C)n[nH]3)c3ccccc3n2)cc1,Ki,1034.0,nM,5.99,Glycogen synthase kinase-3 beta,,,Inhibition of Gsk3beta,2009.0
,O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2008.0
,CCn1c(=O)sn(C)c1=O,IC50,5000.0,nM,5.3,Glycogen synthase kinase-3 beta,,,Inhibitory activity against recombinant rabbit Glycogen synthase kinase-3 beta,2002.0
,CS(=O)(=O)NCCc1ccc(NC(=O)c2ccc(O)c3[nH]c(-c4ccc(Cl)cc4Cl)nc23)cc1,IC50,80.0,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3cccc(C(F)(F)F)c3)nn2n1,Ki,150.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Fc1cc(F)cc(Nc2nccc(-c3c(-c4ccccc4)nn4ncccc34)n2)c1,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,FC(F)(F)c1cc(Nc2nccc(-c3c(-c4ccccc4)nn4ncccc34)n2)ccc1Cl,Ki,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Cc1ccc(-c2ccnc(Nc3ccc(S(N)(=O)=O)cc3)n2)s1,IC50,200.0,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,Brc1cnn2c(NCc3cccnc3)cc(-c3ccco3)nc12,IC50,310.0,nM,6.51,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
AZAKENPAULLONE,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ncccc2N1,IC50,150.0,nM,6.82,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human C-terminal his tagged GSK3beta (26 to 383 residues) expressed in Escherichia coli using GYSI(YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE) as peptide substrate incubated for 1 hr in presence of ATP by cook activity assay,2023.0
,O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1,IC50,12.0,nM,7.92,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(CCCN1CCOCC1)Nc1n[nH]c2nnc(-c3ccccc3)cc12,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCN1CCN(CCCC(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CSc1ccc(NC2=C(c3ccc([N+](=O)[O-])cc3)C(=O)NC2=O)cc1,IC50,392.0,nM,6.41,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,Cc1cc2c(NC(=O)C3CC3)n[nH]c2nc1-c1ccc(O)cc1,IC50,6.0,nM,8.22,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCCC(=O)Nc1n[nH]c2ncc(-c3ccc(-c4ccccc4)cc3)cc12,IC50,851.0,nM,6.07,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(Nc1n[nH]c2nc(-c3nccs3)c(Br)cc12)C1CC1,IC50,99.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1ccccc1,IC50,216.0,nM,6.67,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
INDIRUBIN-3-MONOXIME,O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12,IC50,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2007.0
,COc1c(NCCNc2cccc3ccccc23)c(F)c(N)c2c(=O)c(C(=O)O)cn(C3CC3)c12,IC50,31.0,nM,7.51,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,COCCN1CCC(CNC(=O)c2n[nH]c3ccc(-c4ccccc4C)cc23)CC1,IC50,580.0,nM,6.24,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,O=C(O)c1ccc(CN2CCC(CNC(=O)c3n[nH]c4ccc(-c5cccc(F)c5F)cc34)CC2)o1,IC50,12.0,nM,7.92,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COc1ccc(-c2ccc3[nH]nc(C(=O)NCC4CCN(Cc5ccc(C(=O)O)o5)CC4)c3c2)cn1,IC50,21.0,nM,7.68,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(I)ccc21,IC50,34.5,nM,7.46,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,Br.COc1ccc(-c2n/c(=N\Cc3cccnc3)sn2-c2ccccc2)cc1,IC50,1200.0,nM,5.92,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,O=C(CCl)c1c(Br)sc(Cl)c1Cl,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by liquid scintillation counting,2009.0
,CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)CCCN(C)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1c(C)n(Cc2ccccc2)c2ccc(C(=O)Nc3nc[nH]n3)cc12,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1nc2ccccc2n1Cc1nnc(NC2CCCCC2)s1,IC50,406.0,nM,6.39,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cccc(CO)c21,IC50,5.4,nM,8.27,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,CCOC(=O)CCc1cccc2c(C3=C(c4coc5ccccc45)C(=O)NC3=O)cn(C)c12,IC50,10.2,nM,7.99,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,CC(=O)N1CCN(c2nc(-c3ccncn3)cc(=O)n2C)[C@H](C)C1,IC50,49.0,nM,7.31,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,CN1CCN(c2nc(-c3ccncn3)cc(=O)n2C)CC1,IC50,630.0,nM,6.2,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,CCOc1ccccc1C1CN(c2nc(-c3ccncc3)cc(=O)n2C)CCN1.Cl,IC50,25.0,nM,7.6,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1,Ki,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,Cn1sc(=O)n(-c2ccc(Cl)cc2)c1=O,IC50,4000.0,nM,5.4,Glycogen synthase kinase-3 beta,,,Inhibitory activity against recombinant rabbit Glycogen synthase kinase-3 beta,2002.0
,COc1ccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)cc1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,Cn1sc(=O)n(-c2cccc(Br)c2)c1=O,IC50,4000.0,nM,5.4,Glycogen synthase kinase-3 beta,,,Inhibitory activity against recombinant rabbit Glycogen synthase kinase-3 beta,2002.0
,Oc1cc2c(oc3ncc(OCc4ccccc4)c(-c4ccccc4)c32)c2ccccc12,Ki,1600.0,nM,5.8,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,COc1ccc2c3ccnc(Cl)c3n(CC#N)c2c1,Kd,2582.84,nM,5.59,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human GSK-3beta assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,2023.0
,O=C1NC(=O)/C(=C/c2ccc(O)cc2)S1,IC50,8990.0,nM,5.05,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using GS-2 peptide substrate incubated for 30 mins by kinase-Glo luminescent assay,2018.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccc(OCCN(C)C)cc4)ncnc32)c1,IC50,6.31,nM,8.2,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,O=C1NC(=O)N(c2ccccc2)/C1=C/Nc1ccc([N+](=O)[O-])cc1,IC50,2350.0,nM,5.63,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,O=C1NC(=S)S/C1=C\c1cccc(OCCOc2ccc([N+](=O)[O-])cc2)c1,IC50,2570.0,nM,5.59,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,CCNCc1ccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)cc1,IC50,3.981,nM,8.4,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCS(C)(=O)=O)cc4)ncnc32)c1,IC50,7.943,nM,8.1,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,CCSc1ccc(/C=C2\NC(=O)NC2=O)cc1,IC50,7800.0,nM,5.11,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta by ELISA,2009.0
,Nc1nc(Nc2ccccc2)sc1C(=O)C1CC1,IC50,2400.0,nM,5.62,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,O=Nc1c(-c2c(O)[nH]c3cc(Br)ccc23)[nH]c2ccccc12,IC50,174.0,nM,6.76,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using (RREGGMSRPAS(p)VDG as substrate assessed as 32P[gamma-ATP] incorporation into substrate after 15 mins by autoradiography,2013.0
,Cn1cc(-c2ccc3occ(-c4cccc(-c5ccncc5)c4)c3n2)cn1,IC50,2863.0,nM,5.54,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,2023.0
,COc1ccc(-c2[nH]c3nccnc3c2C)cc1,IC50,460.0,nM,6.34,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCF,IC50,6.0,nM,8.22,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2023.0
,O=C(O)COc1cccc(CCCNC(=O)c2ccc(O)c3[nH]c(-c4ccc(Cl)cc4)nc23)c1,IC50,31.0,nM,7.51,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,Cc1ccc(S(=O)(=O)Nc2ccc(CCNC(=O)c3ccc(O)c4[nH]c(Cc5ccccc5)nc34)cc2)cc1,IC50,2800.0,nM,5.55,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,Cc1ccc(S(=O)(=O)Nc2ccc(CCNC(=O)c3ccc(O)c4[nH]c(-c5ccc(F)cc5)nc34)cc2)cc1,IC50,26.0,nM,7.58,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,O=C(NCCCn1ccnc1)c1ccc(O)c2[nH]c(-c3ccc(Cl)cc3Cl)nc12,IC50,15.0,nM,7.82,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
CC-401,c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1,IC50,2802.0,nM,5.55,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,2023.0
,C=C(C)n1c2c(c3cc(Br)ccc31)CC(=O)Nc1ccccc1-2,IC50,3999.45,nM,5.4,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1Cl,IC50,12.59,nM,7.9,Glycogen synthase kinase-3 beta,,,Inhibition of catalytic activity of GSK3-beta by AlphaLISA assay,2012.0
,COC(=O)/C=C/c1ccc2c(c1)-c1[nH]c3ccc(C(F)(F)F)cc3c1CC(=O)N2,IC50,349.95,nM,6.46,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCC#Cc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,IC50,294.7,nM,6.53,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(Br)ccc21,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,COc1ccccc1-n1ncc2c(N/N=C/c3ccncc3)ncnc21,IC50,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,Cc1ccc2c(-c3ccnc(Nc4ccc(C(F)(F)F)cc4)n3)cnn2n1,Ki,50.0,nM,7.3,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,SC1=Nc2ccccc2-c2[nH]c3ccc(Br)cc3c2C1,IC50,1999.86,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2cc(I)ccc2N1,IC50,4197.59,nM,5.38,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(F)c(Cl)cc21,IC50,184.0,nM,6.74,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,COc1cccc2c(C3=C(c4cn(C)c5cc(Cl)c(F)cc45)C(=O)NC3=O)coc12,IC50,260.0,nM,6.58,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cc(Br)ccc21,IC50,0.51,nM,9.29,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,Oc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,O=C1Cc2c([nH]c3ccc(C(F)(F)F)cc23)-c2cccnc2N1,IC50,5296.63,nM,5.28,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2cc(Br)ccc2N1,IC50,199.99,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,Cn1sc(=O)n(-c2ccc(F)cc2)c1=O,IC50,4000.0,nM,5.4,Glycogen synthase kinase-3 beta,,,Inhibitory activity against recombinant rabbit Glycogen synthase kinase-3 beta,2002.0
,C#Cc1nc(Nc2ccccc2)nc2[nH]cnc12,IC50,7400.0,nM,5.13,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK-3beta by kinase-profiling analysis,2020.0
,CC1=C(O)[C@@H](C/C(C)=C/CC[C@H](C)/C=C/C=C(\C)CCCc2ccoc2)OC1=O,IC50,4500.0,nM,5.35,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta,2017.0
,O=C(O)c1ccc(Nc2ncc3c(Cl)nn(-c4ccccc4)c3n2)cc1,IC50,180.0,nM,6.75,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=C(O)COc1ccc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3)n2)cc1,IC50,92.0,nM,7.04,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=C(O)CCc1ccc(Nc2ncc3nnn(-c4ccccc4)c3n2)cc1,IC50,24.0,nM,7.62,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=C(O)c1ccc(Nc2ncc([N+](=O)[O-])c(NC34CC5CC(CC(O)(C5)C3)C4)n2)cc1,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=C(CNC(=O)c1cnc2[nH]cc(-c3ccccc3)c2c1)NCCc1c[nH]cn1,IC50,2610.0,nM,5.58,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate in presence of gamma-33P-ATP,2016.0
,COC(=O)c1cccc(CSc2nnc(-c3ccncc3)o2)c1,IC50,1100.0,nM,5.96,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against human Glycogen synthase kinase-3,2002.0
,COc1ccc(CNC(=O)Nc2nc3ccc(C#N)cc3s2)cc1,IC50,110.0,nM,6.96,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using prephosphorylated peptide as substrate measured after 30 mins by Kinase-glo luminescence assay,2019.0
,COCCN1CCC(CNC(=O)c2n[nH]c3ccc(-c4cccc(F)c4F)cc23)CC1,Ki,15.0,nM,7.82,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant GSK-3beta after 60 mins by microfluidic assay in presence of ATP,2015.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12,IC50,5008.0,nM,5.3,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(Br)ccc12,IC50,198.0,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(SC)cc3)ccc12,IC50,7165.0,nM,5.14,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,COc1ccc(C2=NNC(=O)/C2=N\Nc2ccccc2Cl)cc1OC,Ki,44.0,nM,7.36,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(N/N=C2\C(=O)NN=C2c2cc(OC)c(OC)c(OC)c2)cc1,Ki,9.0,nM,8.05,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1cccc(C2=NNC(=O)/C2=N\Nc2ccc(N(C)C)cc2)c1,Ki,9.0,nM,8.05,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(C2=NNC(=O)/C2=N\Nc2ccc(N3CCOCC3)cc2)cc1,Ki,8.0,nM,8.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(C2=NNC(=O)/C2=N\Nc2ccc(N(C)C)cc2)cc1OC,Ki,87.0,nM,7.06,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(C2=C(c3cn(C)c4ccccc34)C(=O)NC2=O)cc1OC,IC50,6.6,nM,8.18,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(-c3nc(-c4ccnc(Nc5ccc(OC(F)(F)F)cc5)c4)no3)cc2)cc1,IC50,7660.0,nM,5.12,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,O=C(CBr)c1sc(Br)cc1Br,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by liquid scintillation counting,2009.0
,COc1cnc(NCc2ccccc2)nc1-c1cc2c([nH]1)CCNC2=O,IC50,98.0,nM,7.01,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,COc1cnc(/C=C/c2ccc(F)cc2)nc1-c1cc2c([nH]1)CCNC2=O,IC50,1220.0,nM,5.91,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,CC[S+]([O-])c1ccc(-c2coc3ccc(-c4ccc(C)o4)cc23)cc1,IC50,35.0,nM,7.46,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,COc1ccc(-c2coc3ccc(-c4ccc(C)o4)cc23)cc1,IC50,54.0,nM,7.27,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,Cc1ccc(-c2ccc3occ(-c4cccc([S+](C)[O-])c4)c3c2)o1,IC50,210.0,nM,6.68,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,Cc1c(CC(=O)Cl)csc1C(=O)CCl,IC50,5000.0,nM,5.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by liquid scintillation counting,2009.0
RG-1530,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2,Ki,19.95,nM,7.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4ccccc4F)cc3)c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Clc1ccc2c(c1)nnc1nnnn12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(CO)N1CCC(c2[nH]nc(-c3ccc(Cl)cc3F)c2-c2ccncn2)CC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1)c1c(F)cccc1F,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC1=NN(c2ccc(Cl)c(Cl)c2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(Cl)c4)c3)cc12,Ki,15.85,nM,7.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=S(=O)(Nc1ccc2c(c1)C(=NO)c1ccccc1-2)c1cccc(Br)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Cc1ccc(-c2cccnc2)cc1)Nc1ccc(SC(F)F)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCC1CCN(Cc2ccccc2Cl)CC1,IC50,27.0,nM,7.57,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCC1CCN(Cc2ccc(F)c(F)c2)CC1,IC50,62.0,nM,7.21,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccc(N)cc4)ncnc32)c1,IC50,2.512,nM,8.6,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,CCCc1cn(-c2ccc3[nH]ncc3c2)nn1,Ki,2026.0,nM,5.69,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,COc1ccccc1C1CCN(c2cc(-c3ccncn3)cc(=O)n2C)CC1,IC50,3210.0,nM,5.49,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in CHO AA8 cells co-expressing human tau protein after 2 hrs,2011.0
,Cn1c(N2CCCC(c3ccccc3)C2)cc(-c2ccncn2)cc1=O,IC50,4640.0,nM,5.33,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in CHO AA8 cells co-expressing human tau protein after 2 hrs,2011.0
,Cc1ccccc1-n1ncc2c(N/N=C/c3ccncc3)ncnc21,IC50,158.49,nM,6.8,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,COc1cc(F)ccc1[C@H]1CN(c2nc(-c3ccncn3)cc(=O)n2C)CCO1,IC50,0.47,nM,9.33,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,COc1cccc([C@H]2CN(c3nc(-c4ccncn4)cc(=O)n3C)CCO2)c1,IC50,4.6,nM,8.34,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,COc1ccccc1Nc1ncc(F)c(-c2ccc(C(N)=O)c(C(C)C)c2)n1,IC50,7943.28,nM,5.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2018.0
,C[C@@H]1CN(c2cccc(F)c2)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,0.5,nM,9.3,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,CC(C)Nc1c(F)c(N)c2c(=O)c(C(=O)O)cn(C3CC3)c2c1F,IC50,1200.0,nM,5.92,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,Nc1c(F)c(NCCCc2ccccc2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1,IC50,45.0,nM,7.35,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,Nc1c(F)c(NCCCn2ccnc2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1,IC50,45.0,nM,7.35,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,O=C1NC(=S)N/C1=C/c1ccc(-c2ccc(C(=O)O)cc2)o1,IC50,743.0,nM,6.13,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,C[C@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,IC50,44.0,nM,7.36,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,COCCN1CCC(CNC(=O)c2n[nH]c3ccc(-c4ccccc4F)cc23)CC1,IC50,72.0,nM,7.14,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,CCC(=O)NCCCN1CCC(CNC(=O)c2n[nH]c3ccc(OC)cc23)CC1,IC50,1130.0,nM,5.95,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,C[C@@H]1OCCN(c2nc(-c3ccncc3F)cc(=O)n2C)[C@H]1C,IC50,19.0,nM,7.72,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,CC(C)n1cc(C2=C(c3nnc4ccccn34)C(=O)NC2=O)c2ccccc21,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay,2015.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCCCCCCOc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,IC50,23.8,nM,7.62,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,C[C@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(N)=O)cn1c23,IC50,33.0,nM,7.48,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,IC50,16.0,nM,7.8,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,O[C@H]1CC[C@H](c2n[nH]cc2-c2ccnc(NC3CCCC3)n2)CC1,IC50,1900.0,nM,5.72,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)NCc1ccco1,IC50,77.1,nM,7.11,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21,IC50,1300.0,nM,5.89,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3Beta,2010.0
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2cc(F)ccc2[nH]c1=O,IC50,5800.0,nM,5.24,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,CCN(CC)Cc1ccc(OC)c(-c2cc3c(-c4ccc(C(=O)O)c(C(C)C)c4)ccnc3[nH]2)c1,IC50,1334.0,nM,5.88,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,2023.0
,CCCCCCCC(=O)NNC(=O)c1c(O)c2ccc(Cl)cc2[nH]c1=O,IC50,9000.0,nM,5.05,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2ccccc2n(CC2CC2)c1=O,IC50,5250.0,nM,5.28,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,Cc1ccc(C2=C(c3cn(CCCn4ccnc4)c4cc(C)ccc34)C(=O)NC2=O)cc1,IC50,48.0,nM,7.32,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,O=C1NC(NCc2ccncc2)=N/C1=C\c1ccc2ncsc2c1,IC50,3255.0,nM,5.49,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,C[C@H](c1ccccc1)N1c2cc(-n3c(=O)[nH]c4ncccc43)ccc2C(=O)NC1(C)C,IC50,10.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of N-terminal GST-tagged GSK-3beta (unknown origin) expressed in baculovirus preincubated for 5 mins using GSK3 substrate peptide measured after 60 mins in presence of [gamma-33P]ATP by scintillation counting method,2016.0
,Cn1cc(C2=C(c3cccc(CC(O)CO)c3)C(=O)NC2=O)c2cc(F)ccc21,IC50,1.8,nM,8.74,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,Cn1cc(C2=C(c3cccc(C[C@@H](O)CO)c3)C(=O)NC2=O)c2ccccc21,IC50,3.2,nM,8.49,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,Cn1cc(C2=C(c3c4n(c5ccccc35)CCN(C(N)=S)C4)C(=O)NC2=O)c2ccccc21,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,Cn1cc(C2=C(c3cccnc3)C(=O)NC2=O)c2ccccc21,IC50,42.0,nM,7.38,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,C[C@H]1COc2c(NCCCn3ccnc3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,IC50,150.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,Cc1cc(Nc2n[nH]c3ncc(F)cc23)nc(C2CCOCC2)n1,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,244259,,Inhibition Assay: Compounds are screened for their ability to inhibit the phosphorylation of tyrosine (TYR) residues through the use of western blotting of Jurkat cells dosed with the compounds. The phosphorylation of the specific TYR residues tested are GSK3α TYR 279 and GSK3β TYR 216.,2014.0
,O=C1NC(=O)C(c2cn3c4c(cc(F)cc24)CNCC3)=C1c1coc2ccccc12,IC50,3.7,nM,8.43,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,COCCn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(F)c(F)cc21,IC50,35.7,nM,7.45,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,COc1cc(C2=C(c3cn(CCCO)c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,IC50,3386.0,nM,5.47,Glycogen synthase kinase-3 beta,198673,,"Kinase Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",2015.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(=O)(=O)NCCN(C)C)cc4)ncnc32)c1,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,Cn1c(N2CCO[C@H](c3ccc(F)cc3)C2)nc(-c2ccncc2)cc1=O,IC50,77.0,nM,7.11,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F,IC50,140.0,nM,6.85,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2007.0
,O=S(=O)(Nc1ccc(-c2nc(-c3ccnc(Nc4ccc(OC(F)(F)F)cc4)c3)no2)cc1)c1ccc(OC(F)(F)F)cc1,IC50,8740.0,nM,5.06,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,CC(C)(C)c1ccc(Nc2cc(-c3noc(-c4ccc(NS(=O)(=O)c5ccc(C(C)(C)C)cc5)cc4)n3)ccn2)cc1,IC50,560.0,nM,6.25,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,CC(C)c1ccc(Nc2cc(-c3noc(-c4ccc(NS(=O)(=O)c5ccc(C(C)(C)C)cc5)cc4)n3)ccn2)cc1,IC50,2070.0,nM,5.68,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCc1cn(-c2c3c(nc4ccccc24)CCCC3)nn1,IC50,83.9,nM,7.08,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,O=C([O-])c1ccc(CN2CCC(CNC(=O)c3n[nH]c4ccc(Br)cc34)CC2)o1.[Na+],IC50,210.0,nM,6.68,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCC1CCN(Cc2cccc(F)c2)CC1,IC50,26.0,nM,7.58,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCC1CCN(Cc2ccccn2)CC1,IC50,193.0,nM,6.71,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,C=CC(=O)c1ccc2nc(NC(=O)NCc3ccc(OC)cc3)[nH]c2c1,IC50,1820.0,nM,5.74,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using prephosphorylated peptide as substrate measured after 30 mins by Kinase-glo luminescence assay,2019.0
,C[C@@H]1COCCN1c1nc(-c2ccncc2F)cc(=O)n1C,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,Cn1cc(C2=C(c3nnc4ccccn34)C(=O)NC2=O)c2cc(Cl)ccc21,IC50,74.1,nM,7.13,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay,2015.0
,Cn1cc(C2=C(c3nnc4ccccn34)C(=O)NC2=O)c2ccc(F)cc21,IC50,204.1,nM,6.69,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay,2015.0
,Cc1cccc2c(C3=C(c4nnc5ccccn45)C(=O)NC3=O)cn(C)c12,IC50,105.4,nM,6.98,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay,2015.0
,Cn1cc(C2=C(c3nnc4ccccn34)C(=O)NC2=O)c2ccccc21,IC50,154.1,nM,6.81,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay,2015.0
,COC(=N)c1nc2ccc3ncnc(Nc4ccc(Cl)cc4Cl)c3c2s1,IC50,221.0,nM,6.66,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin),2016.0
,O=C1NC(=O)C(c2cnc3ncccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCOCC1)CC2,IC50,297.0,nM,6.53,Glycogen synthase kinase-3 beta,,,"Inhibitory concentration to inhibit Ser396 phosphorylation of tau, a natural substrate of GSK-3 in SY5Y cells",2005.0
,Cc1ccc2c(-c3ccnc(Nc4ccc(F)c(F)c4)n3)c(-c3cccc(C(F)(F)F)c3)nn2n1,Ki,1580.0,nM,5.8,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,O=C(Nc1ccccc1)N[C@H]1CO[C@H]2[C@@H]1OC[C@@H]2Nc1nccc(-c2cccs2)n1,IC50,2700.0,nM,5.57,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using phosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,Cc1ccc(-c2ccc3occ(-c4ccc([S+](C)[O-])cc4)c3n2)o1,IC50,270.0,nM,6.57,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,Cc1ccccc1CC(=O)NNC(=O)Cn1c(C)nc2ccccc21,IC50,92.0,nM,7.04,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,Cc1nc2ccccc2n1CC(=O)NNC(=O)Cc1cccc2ccccc12,IC50,157.0,nM,6.8,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,Cn1c(N2CCNC(c3ccccc3Cl)C2)nc(-c2ccncn2)cc1=O,IC50,2.6,nM,8.59,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,IC50,19.95,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,2020.0
GW806290X,c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1,IC50,1.0,nM,9.0,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,2020.0
,CN1CCC(C2=C(C#N)[C@H](c3cccc4nonc34)c3c[nH]nc3N2)CC1,IC50,2.5,nM,8.6,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2008.0
,Cc1ccc2ncc(C3=C(c4cn5c6c(cccc46)CN(C=O)C(N4CCCCC4)C5)C(=O)NC3=O)n2c1,IC50,5.2,nM,8.28,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta (unknown origin) assessed as decrease in phosphorylation of CREB at serine-129 in presence of ATP[gamma-33P] by filter binding assay,2018.0
,O=CN1Cc2cccc3c(C4=C(c5cnc6ccccn56)C(=O)NC4=O)cn(c23)CC1N1CCCCC1,IC50,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta (unknown origin) assessed as decrease in phosphorylation of CREB at serine-129 in presence of ATP[gamma-33P] by filter binding assay,2018.0
,COc1cccc(C2=C(c3cn(C)c4cccc(OC)c34)C(=O)NC2=O)c1,IC50,1300.0,nM,5.89,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,C=CC(=O)N1C(=O)CC(c2ccc(C(=O)OC)cc2)Sc2ccccc21,IC50,6000.0,nM,5.22,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using GS-2 peptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,COc1ccc(CSc2nnc(-c3ccc4c(c3)CCO4)o2)cc1C(F)(F)F,IC50,5.7,nM,8.24,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,Fc1cccc(CCc2nnc(-c3ccc4c(c3)CCO4)o2)c1,IC50,340.0,nM,6.47,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,Fc1cccc(SCc2nnc(-c3ccc4c(c3)CCO4)o2)c1,IC50,680.0,nM,6.17,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,COc1ccc(CSc2nnc(-c3ccc4ncccc4c3)o2)cc1C(F)(F)F,IC50,18.0,nM,7.75,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,Cn1cnc2ccc(-c3nnc(SCc4cccc(C(F)(F)F)c4)o3)cc21,IC50,9.4,nM,8.03,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,CN1C(=O)C(Nc2ccccc2)=C(c2ccccc2)C1=O,IC50,5000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2005.0
,Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccccc3)nn2n1,Ki,50.0,nM,7.3,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Cc1ccc2c(c1)/C(=C1/Nc3ccccc3/C1=N\OCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(=O)N2,IC50,290.0,nM,6.54,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3beta (unknown origin) after 10 mins in presence of [gamma32P]ATP by beta counting method,2017.0
,Brc1cnn2c(NCc3cccnc3)cc(-c3ccccc3)nc12,IC50,570.0,nM,6.24,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,CNc1cc(NCc2cccnc2)n2ncc(Br)c2n1,IC50,4600.0,nM,5.34,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cccc13)CN(C(=O)C1CCOCC1)CC2,IC50,7.7,nM,8.11,Glycogen synthase kinase-3 beta,,,"Inhibitory concentration to inhibit Ser396 phosphorylation of tau, a natural substrate of GSK-3 in SY5Y cells",2005.0
,Nc1nonc1-c1nc2ccccc2n1C1CCCC1,Ki,210.0,nM,6.68,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(-c3ccc(C(=O)NCCO)cc3)ccnc21,IC50,5.9,nM,8.23,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2010.0
,COc1cccc2c(C3=C(c4cn(C)c5cc(C(F)(F)F)ccc45)C(=O)NC3=O)coc12,IC50,830.0,nM,6.08,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,Cc1ccc(-n2c(=O)sn(C)c2=O)cc1,IC50,5000.0,nM,5.3,Glycogen synthase kinase-3 beta,,,Inhibitory activity against recombinant rabbit Glycogen synthase kinase-3 beta,2002.0
,COc1ccc(-c2c[nH]c3c2-n2cccc2/C3=N/O)cc1O,IC50,5500.0,nM,5.26,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,Cc1cc(Nc2ncc(C)c(N3CC4CCCC(C3)N4CCC#N)n2)sn1,IC50,565.0,nM,6.25,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,CC(C)C[C@H](N)c1cc(C#N)c2cc(-c3ccncc3)ccc2n1,IC50,112.0,nM,6.95,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2022.0
,COc1ccc(Sc2nc(Nc3cc(C)[nH]n3)c3ccccc3n2)cc1OC,Ki,1168.0,nM,5.93,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,COCc1ccc2c(C3=C(c4cn(C)c5ccc(F)cc45)C(=O)NC3=O)coc2c1,IC50,23.8,nM,7.62,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCCCCCCn1cc(COc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)nn1,IC50,83.1,nM,7.08,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCC#Cc1ccc2c(c1)C(=O)N(C1CCC(=O)NC1=O)C2=O,IC50,19.7,nM,7.71,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,c1ccc(-c2cnc3cnc(-c4ccncc4)cn23)cc1,IC50,3100.0,nM,5.51,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta at 10 uM by mobility shift assay,2010.0
,CSc1nc(N[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(Cl)c(=O)[nH]1,IC50,2400.0,nM,5.62,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,COc1cc(/C=C2/NC(=O)NC2=O)cc(OC)c1OC,IC50,214.0,nM,6.67,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,COc1ccc(-c2cc(-c3ccc(F)cc3)[nH]c(=O)c2O)cc1,IC50,325.0,nM,6.49,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,Cc1ccc(Nc2nnc(-c3ccc([N+](=O)[O-])cc3)o2)cc1Cl,IC50,17.0,nM,7.77,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,O=[N+]([O-])c1ccc(-c2nnc(Nc3ccccc3)o2)cc1,IC50,209.0,nM,6.68,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,Clc1ccc(Nc2nnc(-c3ccccc3)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,COc1ccc(Nc2nnc(-c3ccccc3)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2ccccc2n(C)c1=O,IC50,7300.0,nM,5.14,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,Cn1cc(C2=C(c3nn(CCCO)c4ncccc34)C(=O)NC2=O)c2ccccc21,IC50,1090.0,nM,5.96,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,COc1ccc2c(c1)C(=O)/C(=C/c1ccc(O)c(O)c1)O2,IC50,5300.0,nM,5.28,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta,2017.0
,COc1ccc(C2=NNC(=O)/C2=N/Nc2ccc(Cl)cc2)cc1OC,Ki,2.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,O=C(c1ccccn1)C(Br)Br,IC50,2500.0,nM,5.6,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using GS1 as substrate and [gamma-32P]ATP after 20 mins by radiometric assay,2011.0
,COc1ccc(-c2[nH]c3nccnc3c2CC2CC2)cc1,IC50,1100.0,nM,5.96,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(Cc4ccc(C(F)(F)F)cc4)CC3)c2c1,IC50,640.0,nM,6.19,Glycogen synthase kinase-3 beta,335719,,"LanthaScreen TR-FRET Assay: Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screening assay, compounds were tested in duplicate at a concentration of 10 uM.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um). In a second assay, the same compounds were assayed at five concentrations ranging from 100 uM to 10 nM with ten-fold dilutions in duplicate.",2015.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(Cc4nc(C(=O)O)co4)CC3)c2c1,IC50,310.0,nM,6.51,Glycogen synthase kinase-3 beta,335725,,"LanthaScreen TR-FRET Assay: Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screening assay, compounds were tested in duplicate at a concentration of 10 uM.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um). In a second assay, the same compounds were assayed at five concentrations ranging from 100 uM to 10 nM with ten-fold dilutions in duplicate.",2015.0
,CC(C)(C)CN1CCC(NC(=O)c2csc(NC(=O)c3ccc4cc5n(c4c3)C3(CCC3)CNC5=O)n2)CC1,IC50,920.0,nM,6.04,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,COc1ccccc1C1=C(Nc2cccc(O)c2)C(=O)NC1=O,IC50,259.0,nM,6.59,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NCCC12CCN(c1c(Cl)cncc1-c1cc3ccccc3o1)CC2,Ki,18.0,nM,7.75,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSKbeta H350L mutant (2 to 3nd residues) using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method,2021.0
IRCININ 1,CC1=C(O)/C(=C/[C@H](C)CCC/C(C)=C/CCc2coc(Cc3ccoc3)c2)OC1=O,IC50,800.0,nM,6.1,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using GS2 peptide as substrate and [gamma33P]-ATP after 30 mins by scintillation counting,2013.0
,Nc1nc(Nc2cccnc2)sc1C(=O)c1ccccc1F,IC50,45.0,nM,7.35,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta in presence of 60 uM ATP,2011.0
,CN1CC=C(c2c(O)cc(O)c3c(=O)cc(-c4ccc(Sc5nc(-c6ccccc6)c[nH]5)cc4)oc23)CC1,IC50,356.0,nM,6.45,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK3beta in presence of ATP by ADP-glo luminescent assay,2020.0
,O=C(Nc1cccc(C(F)(F)F)c1)N[C@H]1CO[C@H]2[C@@H]1OC[C@@H]2Nc1nccc(-c2cccc(F)c2)n1,IC50,2060.0,nM,5.69,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using phosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,CN1CCOCCN(C)CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CC1,IC50,6.0,nM,8.22,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta,2003.0
,COc1ccccc1C1=C(c2cn(CCCNC(=O)OC(C)(C)C)c3ncccc23)C(=O)NC1=O,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccc(NC(C)=O)cc4)ncnc32)c1,IC50,12.59,nM,7.9,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,C=CC(=O)N1C(=O)CC(c2ccc(Cl)cc2)Sc2ccccc21,IC50,6700.0,nM,5.17,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using GS-2 peptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,CC(=O)/C=C/c1ccc2c(c1)-c1[nH]c3ccc(C(F)(F)F)cc3c1CC(=O)N2,IC50,1399.59,nM,5.85,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
TP-030n,CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,GSK3beta(GS3BLGM1) Takeda global kinase panel,2021.0
,Nc1nonc1-c1nc2cc(O)ccc2n1C1CCC1,Ki,1100.0,nM,5.96,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,CSC1=Nc2ccccc2-c2[nH]c3ccc(Br)cc3c2C1,IC50,1199.5,nM,5.92,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,CC(=O)OCn1c2c(c3cc(Br)ccc31)CC(=O)Nc1ccccc1-2,IC50,74.99,nM,7.12,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,O=C1Cc2c([nH]c3ccc(C(F)(F)F)cc23)-c2cc(I)ccc2N1,IC50,2197.86,nM,5.66,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,Cn1cc(C2=C(c3cn(CCCO)c4ccccc34)C(=O)NC2=O)c2ncccc21,IC50,1140.0,nM,5.94,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-GSK3beta expressed in Escherichia coli BL21 (DE3),2009.0
,O=C(CNC(=O)c1cnc2[nH]cc(-c3ccccc3)c2c1)NCCc1c[nH]c2ccccc12,IC50,1450.0,nM,5.84,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,CCC(=O)Nc1ccc(Sc2nc(Nc3cc(C)[nH]n3)c3ccccc3n2)cc1,Ki,1500.0,nM,5.82,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,O=C(/C=C(O)/C=C/c1ccc(OCc2ccc(F)cc2F)cc1)/C=C/c1ccc(OCc2ccc(F)cc2F)cc1,IC50,9630.0,nM,5.02,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide as substrate incubated for 30 mins by Glo-type luminescence assay,2016.0
,COc1ccc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(OCc3ccccc3)cc2)cc1,IC50,2780.0,nM,5.56,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide as substrate incubated for 30 mins by Glo-type luminescence assay,2016.0
,O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCc1ccc(c(N3CCCC3)n1)CCCn1cc2c2ccccc21,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2007.0
,O=C1NC(=O)/C(=C/c2ccc(-c3ccsc3)cc2)N1,IC50,6400.0,nM,5.19,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta by ELISA,2009.0
,O=C1N[C@H]2C[C@@H](C2)OCc2cccc(n2)Nc2cc([nH]n2)[C@H]2CC[C@H](C2)O1,IC50,5.5,nM,8.26,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) assessed as inhibition of substrate peptide phosphorylation using eIF4E-binding protein 1 as peptide substrate incubated for 1 hr in presence of ATP by Lance Ultra HTRF assay,2023.0
,Nc1nccc(-c2c[nH]c3cc(Br)c(Br)cc23)n1,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of glycogen synthase kinase-3 beta,2004.0
,Clc1ccc(-c2[nH]c3nccnc3c2CC2CCCCC2)cc1,IC50,8000.0,nM,5.1,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,CN(C)c1nc2ccc1CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CC2,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2007.0
,O=C(/C=C/c1ccc(OCc2ccc(F)cc2F)cc1)CC(=O)/C=C/c1ccc(OCc2ccc(F)cc2F)cc1,IC50,9060.0,nM,5.04,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide as substrate incubated for 30 mins by Glo-type luminescence assay,2016.0
,COc1ccc2c(c1)NC(=O)Cc1c-2[nH]c2ccc(C#N)cc12,IC50,130.02,nM,6.89,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,COc1ccccc1[C@H]1CN(c2nc(-c3ccncn3)cc(=O)n2C)CCO1,IC50,0.87,nM,9.06,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,O=C1NC(NC2CC3(CCC3)C2)=N/C1=C\c1ccc2ncsc2c1,IC50,4566.0,nM,5.34,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC2CC23CCCCC3)=N/C1=C\c1ccc2ncsc2c1,IC50,854.0,nM,6.07,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC2CCCCC(F)(F)C2)=N/C1=C\c1ccc2ncsc2c1,IC50,1359.0,nM,5.87,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CO[C@H]1CCCC[C@@H](NC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)C1,IC50,2786.0,nM,5.55,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC(CO)C2CCCCC2)=N/C1=C\c1ccc2ncsc2c1,IC50,4156.0,nM,5.38,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COCC(NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1)C1CCCCC1,IC50,6035.0,nM,5.22,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COC(CNC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1)C1CCCCC1,IC50,5601.0,nM,5.25,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC23CC4CC(CC(O)(C4)C2)C3)=N/C1=C\c1ccc2ncsc2c1,IC50,317.0,nM,6.5,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CN(C)C12CC3CC(CC(NC4=N/C(=C\c5ccc6ncsc6c5)C(=O)N4)(C3)C1)C2,IC50,1334.0,nM,5.88,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@@H](CO)c2ccccc2)=N/C1=C\c1ccc2ncsc2c1,IC50,647.0,nM,6.19,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NCCc2ccccn2)=N/C1=C\c1ccc2ncsc2c1,IC50,3709.0,nM,5.43,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CN1CCN(c2ccc(NC3=N/C(=C\c4ccc5ncsc5c4)C(=O)N3)cc2)CC1,IC50,999.0,nM,6.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CN1CCN(c2ncc(NC3=N/C(=C\c4ccc5ncsc5c4)C(=O)N3)cn2)CC1,IC50,1185.0,nM,5.93,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CC1(NC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)CCNC1=O,IC50,6284.0,nM,5.2,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
ALOISINE A,CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12,IC50,1500.0,nM,5.82,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta,2003.0
,O=C1NC(=O)C(c2nn(CCCN3CCOCC3)c3ncccc23)=C1c1cn(CCCn2ccnc2)c2ccccc12,IC50,680.0,nM,6.17,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,Cn1cc(C2=C(c3nn(CCCCn4ccnc4)c4ncccc34)C(=O)NC2=O)c2ccccc21,IC50,960.0,nM,6.02,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,Cn1sc(=O)n(-c2cccc3ccccc23)c1=O,IC50,3000.0,nM,5.52,Glycogen synthase kinase-3 beta,,,Inhibitory activity against recombinant rabbit Glycogen synthase kinase-3 beta,2002.0
,Cc1cc(Nc2ncc(C)c(N3CCC(CC#N)CC3)n2)sn1,IC50,757.0,nM,6.12,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,COC1=CC2C(=O)NC3=Cc4ccc(OC)cc4C(=C1OC)C32,IC50,2199.0,nM,5.66,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,2023.0
,CCCC(=O)Nc1n[nH]c2ncc(B3OC(C)(C)C(C)(C)O3)cc12,IC50,356.0,nM,6.45,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(n2ccc3ncccc32)=C1c1cn(CCn2ccnc2)c2ccccc12,IC50,260.0,nM,6.58,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-GSK3beta expressed in Escherichia coli BL21 (DE3),2009.0
,O=C1NC(=O)C(n2ccc3ncccc32)=C1c1cn(CCCCn2ccnc2)c2ccccc12,IC50,850.0,nM,6.07,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-GSK3beta expressed in Escherichia coli BL21 (DE3),2009.0
,Cc1ccc(C2=C(c3cn(CCCn4ccnc4)c4ccc(C)cc34)C(=O)NC2=O)cc1,IC50,7750.0,nM,5.11,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,Cc1ccc(C2=C(c3cn(CCCn4ccnc4)c4ccc(Br)cc34)C(=O)NC2=O)cc1,IC50,190.0,nM,6.72,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccc(Br)cc23)=C1c1ccc(F)cc1,IC50,140.0,nM,6.85,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,C[C@@H]1CO[C@@H](C)CN1c1nc(-c2ccncc2F)cc(=O)n1C,IC50,41.0,nM,7.39,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,Cn1c(N2CCO[C@H]3CCC[C@@H]32)nc(-c2ccncc2F)cc1=O,IC50,35.0,nM,7.46,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,NS(=O)(=O)c1ccc(Nc2nccc(-c3ccc4ccccc4c3)n2)cc1,IC50,310.0,nM,6.51,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,O=C1NCCC12CCN(c1c(Cl)cncc1-c1cc3ccccc3s1)CC2,Ki,4.0,nM,8.4,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSKbeta H350L mutant (2 to 3nd residues) using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method,2021.0
,CC[S@@+]([O-])c1ccc(-c2coc3ccc(-c4ccc(C)o4)cc23)cc1,IC50,190.0,nM,6.72,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,CN(C)CCn1cc(-c2ccn3c(-c4ccc(C(N)=O)c(OCc5cccc(F)c5)c4)cnc3c2)cn1,IC50,91.0,nM,7.04,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2017.0
,NC(=O)c1ccc(-c2ccnc(Nc3cc(-c4ccccc4)ccc3F)n2)cc1,IC50,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2018.0
,COc1ccccc1Nc1ncc(F)c(-c2ccc(C(=O)O)c(C(C)C)c2)n1,IC50,7943.28,nM,5.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2018.0
,COc1nc(-c2ccnc(NC(=O)C3CC3)c2)sc1C(=O)NCCCCNC(=O)COc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,IC50,639.2,nM,6.19,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,CCN(CCO)Cc1cc(Nc2nc(C)cn3c(-c4cn[nH]c4)cnc23)sn1,IC50,500.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3b (unknown origin),2018.0
,CCCCCCCC(=O)NNC(=O)c1c(O)c2cc(Br)ccc2n(C)c1=O,IC50,6280.0,nM,5.2,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,CCCCCCCC(=O)NNC(=O)c1c(O)c2ccc(Cl)cc2n(CC)c1=O,IC50,4830.0,nM,5.32,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2ccccc2n(CC=C(C)C)c1=O,IC50,7780.0,nM,5.11,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,O=C1NC(=O)C(c2nnc3ccccn23)=C1c1c[nH]c2ccccc12,IC50,477.2,nM,6.32,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay,2015.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCC1CCN(Cc2ccc(F)c(F)c2)CC1,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,O=C1NC(=O)C(c2nnc3ccccn23)=C1c1cn(CCCN2CCOCC2)c2ccccc12,IC50,199.7,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay,2015.0
,O=[N+]([O-])c1cccc(S(=O)(=O)Nc2ccc(-c3nc(-c4ccnc(Nc5ccc(OC(F)(F)F)cc5)c4)no3)cc2)c1,IC50,8320.0,nM,5.08,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,CC(=O)Nc1nc(C)c(S(=O)(=O)Oc2cccc3c2[nH]c2c(C4=C[C@@]5(O)CC/C=C\CCCCN6CCC4[C@]4(C[C@@H]7CCC(=O)CCCN7[C@H]45)C6)nccc23)s1,IC50,8500.0,nM,5.07,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSKbeta,2007.0
,COc1nc(-c2ccnc(NC(=O)C3CC3)c2)sc1C(N)=O,IC50,17.2,nM,7.76,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,COc1c(NCCNc2ccccn2)c(F)c(N)c2c(=O)c(C(=O)O)cn(C)c12,IC50,270.0,nM,6.57,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,C[C@@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,IC50,560.0,nM,6.25,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,CC(C)[C@@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,IC50,31.0,nM,7.51,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)O)cc4)ncnc32)c1,IC50,31.62,nM,7.5,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,C=CCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12,IC50,600.0,nM,6.22,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,O=C(O)CN1CCC(CNC(=O)c2n[nH]c3ccc(-c4cccc(F)c4F)cc23)CC1,IC50,27.0,nM,7.57,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,CSc1cnn2c(NCc3cccnc3)cc(-c3ccccc3)nc12,IC50,1800.0,nM,5.75,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,CCCC1=C(c2nnc(C)o2)C(c2cccc(C#N)c2Br)c2c[nH]nc2N1,IC50,0.7,nM,9.15,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2008.0
,COc1cc(N2CCc3nc(NC(=O)NCCc4cn(CC(F)F)cn4)sc3C2)cnc1Cl,Ki,4000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using ATP and GSM peptide substrate by radiometric peptide assay,2015.0
,COc1cncc(N2CCc3nc(NC(=O)NCCc4cn(CC(F)F)cn4)sc3C2)n1,Ki,4000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using ATP and GSM peptide substrate by radiometric peptide assay,2015.0
,Cc1c(-c2ccc(O)cc2)[nH]c2nccnc12,IC50,520.0,nM,6.28,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,COc1ccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)cc1,IC50,31.62,nM,7.5,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,NS(=O)(=O)c1ccc(Nc2cc(OC3CCCCC3)nc3ncnn23)cc1,IC50,190.0,nM,6.72,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using 10 uM ATP,2006.0
,O=C1NC(=O)C(c2cnc3cnccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCCCC1)CC2,IC50,8.7,nM,8.06,Glycogen synthase kinase-3 beta,,,"Inhibitory concentration to inhibit Ser396 phosphorylation of tau, a natural substrate of GSK-3 in SY5Y cells",2005.0
,O=C(Nc1n[nH]c2cc(-c3ccoc3)ccc12)C1CC1,IC50,35.0,nM,7.46,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCCC(=O)Nc1n[nH]c2ncc(-c3ccncc3)cc12,IC50,443.0,nM,6.35,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1,IC50,109.0,nM,6.96,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1cccc(C(=O)O)c1,IC50,186.0,nM,6.73,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(O)c(Cl)c1,IC50,173.0,nM,6.76,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cccc(O)c1,IC50,236.0,nM,6.63,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1cc(Cl)c(O)c(Cl)c1,IC50,58.0,nM,7.24,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCN1CCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCC1,IC50,18.0,nM,7.75,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta,2003.0
,O=C(Nc1nccc2c1[nH]c1cc(Cl)ccc12)C1CC1,IC50,5150.0,nM,5.29,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human full length GSK3beta expressed in baculovirus in Sf9 insect cells using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate by ADP-Glo kinase assay,2021.0
,COc1ccc2c(c1)[nH]c1c(NC(=O)C3CC3)nccc12,IC50,144.0,nM,6.84,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human full length GSK3beta expressed in baculovirus in Sf9 insect cells using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate by ADP-Glo kinase assay,2021.0
,O=C1NC(NC23CC4CC(CC(C4)C2)C3)=N/C1=C\c1ccc2[nH]ncc2c1,IC50,7771.0,nM,5.11,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1Nc2cc(Br)ccc2/C1=c1/[nH]c2ccccc2/c1=C\O,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2014.0
,CNC(=O)C1Cc2nc(-c3ccc4ccccc4c3)n(-c3ccnc(N[C@@H]4CCCN(C(=O)C5CC5)C4)n3)c2C1,IC50,1659.7,nM,5.78,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) incubated for 20 mins in presence of 33P-ATP,2023.0
,NC(=O)c1cnc(-c2ccnc(NC(=O)C3CC3)c2)cn1,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1cccc(C(=O)O)c1,IC50,134.0,nM,6.87,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1ccc(-c2cc3[nH]ccnc-3n2)cc1,IC50,1100.0,nM,5.96,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
TIDEGLUSIB,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2021.0
,COc1cc(F)cc(F)c1C1CN(c2nc(-c3ccncc3)cc(=O)n2C)CCN1.Cl,IC50,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,C[C@@H]1CN(c2ccccc2F)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,0.2,nM,9.7,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,C[C@@H]1CN(c2ccc(F)cc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,0.4,nM,9.4,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,Cn1c(N2CCNC(c3ccccc3Cl)C2)nc(-c2ccncc2)cc1=O,IC50,9.6,nM,8.02,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cc1ccc2c(-c3ccnc(Nc4ccc(Cl)c(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,O=C1C(Nc2ccc(Cl)cc2)=C(c2ccccc2)C(=O)N1Cc1ccccc1,IC50,5000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2005.0
,O=C1Cc2c(n(CCO)c3ccc(Br)cc23)-c2ccccc2N1,IC50,299.92,nM,6.52,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,O=C1NN=C(c2ccccn2)/C1=N/Nc1ccccc1Cl,Ki,650.0,nM,6.19,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1cccc(C2=C(c3cn(C)c4ccccc34)C(=O)NC2=O)c1,IC50,90.0,nM,7.05,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,O=C1Cc2c([nH]c3ccc(C(F)(F)F)cc23)-c2cc(CC#CO)ccc2N1,IC50,199.99,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,COc1cc(C2=C(c3cn(CCN4CCN(C)CC4)c4ccccc34)C(=O)NC2=O)c2occc2c1,IC50,0.14,nM,9.85,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl,Kd,720.0,nM,6.14,Glycogen synthase kinase-3 beta,,,Binding constant for GSK3B kinase domain,2011.0
,Cc1[nH]nc2c1[C@H](c1ccccc1)C1=C(CC(C)(C)CC1=O)N2,IC50,232.0,nM,6.63,Glycogen synthase kinase-3 beta,318296,,"HTS Assay: The GSK3beta primary screen was conducted in assay ready 1536 plates (Aurora 29847) that contain 2.5 mL/well of 10 mM compound. Human GSK3beta as a GST fusion expressed in baculoviral system was purchased from BPS Bioscience (San Diego, Calif.). The GSK3beta peptide substrate was from American Peptide (Sunnyvale, Calif.; Cat 311153). 1 L/well of CABPE (22.5 nM GSK3beta , 8 uM peptide in AB buffer (12.5 mM DTT, 0.25 mg/mL BSA, 0.5 unit/mL Heparin)), 0.5 L/well of 125 uM of ATP, and 1 L/well of positive control 50 uM of GW8510 (positive control) or AB (DMSO only neutral control) in respective wells according to plate design using BioRAPTR (Beckman, Brea, Calif.). Reactions were incubated at room temperature for 60 minutes. 2.5 uL/well of ADP-Glo (Promega, V9103) was added with BioRAPTR, and incubated at room temperature for 40 minutes followed by addition of 5 uL/well of ADP-Glo detection reagent (Promega, V9103) with Combi nL (Thermo, Waltham, Mass.).",2015.0
,Cc1nc2ccccc2n1CC(=O)NNC(=O)CCC(=O)c1ccc(Oc2ccccc2)cc1,IC50,80.0,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,COc1ccc(Nc2nnc(Cn3c(C)nc4ccccc43)s2)cc1,IC50,151.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,Cc1nc2ccccc2n1Cc1nnc(Nc2ccc(Br)cc2)s1,IC50,173.0,nM,6.76,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,Nc1ncnc2oc(-c3cccnc3)c(-c3ccc(NS(=O)(=O)c4cccs4)cc3)c12,IC50,23.0,nM,7.64,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by fluorescence anisotropy binding assay,2008.0
,Cc1nc2ccccc2n1CC(=O)NNC(=O)Cc1cc2ccccc2[nH]1,IC50,135.0,nM,6.87,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,Cc1nc2ccccc2n1Cc1nnc(Nc2ccc(F)cc2)s1,IC50,134.0,nM,6.87,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,COc1ccc(Sc2nc(Nc3cc(C)[nH]n3)c3ccccc3n2)cc1,Ki,124.0,nM,6.91,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,CC(=O)Nc1ccc(Sc2nc(Nc3cc[nH]n3)c3ccccc3n2)cc1,Ki,605.0,nM,6.22,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,Cc1cc(Nc2nc(Oc3ccccc3)nc3ccccc23)n[nH]1,Ki,51.0,nM,7.29,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,COc1ccccc1Sc1nc(Nc2cc(C)[nH]n2)c2ccccc2n1,Ki,216.0,nM,6.67,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,COc1cc(/C=N/Nc2ncnc3c2cnn3-c2ccccc2)ccc1O,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,c1cc(-c2nnn[nH]2)ccc1CSc1nnc(-c2ccc3c(c2)OCO3)o1,IC50,172.0,nM,6.76,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using pIRS-1 as substrate preincubated for 15 mins,2012.0
,c1ccc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCO5)o3)cc2)cc1,IC50,176.0,nM,6.75,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using pIRS-1 as substrate preincubated for 15 mins,2012.0
,N#Cc1cc(F)ccc1-c1ccc(CSc2nnc(-c3ccc4c(c3)OCO4)o2)cc1,IC50,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using pIRS-1 as substrate preincubated for 15 mins,2012.0
,CN1CCN(C2CCC(n3cc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)CC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccc(Cl)c(Cl)c4)c3)cc12,Ki,31.62,nM,7.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN1CCN(c2cccc(Nc3nccc(-c4c(C(N)=O)nc5ccccn45)n3)c2)CC1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2008.0
,NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)Nc1ncnc2[nH]cc(-c3ccccc3)c12,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOc1nc(C(=O)NCc2ccncc2)cc(N)c1C#N,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1c(C=O)c(O)n2c(nc3ccccc32)c1C#N,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)C(CO)NC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Brc1cnn2c(NCc3cccnc3)cc(C3CC3)nc12,IC50,1130.0,nM,5.95,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,COc1ccncc1NC(=O)c1ccnc2[nH]c(-c3ccc(F)cc3)nc12,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,O=C(Nc1ncnc2oc(-c3ccc(F)cc3)cc12)C1CC1,IC50,575.0,nM,6.24,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,COc1ccc(C2=C(Nc3ccc(SC)cc3)C(=O)NC2=O)cc1,IC50,243.0,nM,6.61,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1cccc(C2=C(Nc3cc(Cl)c(O)c(Cl)c3)C(=O)NC2=O)c1,IC50,142.0,nM,6.85,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1ccc2c(-c3ccnc(Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)cnn2n1,Ki,630.0,nM,6.2,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCn1cc2c2cccnc21,IC50,620.0,nM,6.21,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3beta (GSK3-beta),2003.0
,C[C@@H]1CN(C)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,C[C@@H]1CN(c2cccc(C#N)c2)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,2.2,nM,8.66,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,Cl.Cn1c(N2CCNC(c3ccccc3)C2)nc(-c2ccncc2)cc1=O,IC50,18.0,nM,7.75,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cl.Cn1c(N2CCNC(c3cccc(F)c3)C2)nc(-c2ccncc2)cc1=O,IC50,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,O=C(Nc1cc(-c2ccc(O)cc2)cc2[nH]ncc12)C1CC1,IC50,630.96,nM,6.2,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) after 1 hr by fluorescence polarization assay,2017.0
,O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ncc(C(F)(F)F)cc1Cl,IC50,26.0,nM,7.58,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,CN(C)c1cc2cc(n1)CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CCC2,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2007.0
,Cl.Cn1c(N2CCN[C@H](c3ccc(Cl)cc3)C2)nc(-c2ccncc2)cc1=O,IC50,110.0,nM,6.96,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cl.Cn1c(N2CCNC(c3ccc(Br)cc3)C2)nc(-c2ccncc2)cc1=O,IC50,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,COc1cc(F)cc(F)c1C1CN(c2nc(-c3ccncn3)cc(=O)n2C)CCN1.Cl,IC50,1.7,nM,8.77,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,IC50,810.0,nM,6.09,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3beta (unknown origin) after 10 mins in presence of [gamma32P]ATP by beta counting method,2017.0
,O=C(/C=C/c1ccc(OCc2cc(F)cc(F)c2)cc1)CC(=O)/C=C/c1ccc(OCc2cc(F)cc(F)c2)cc1,IC50,9660.0,nM,5.01,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide as substrate incubated for 30 mins by Glo-type luminescence assay,2016.0
,N#Cc1ccc(-c2nc(Nc3cc(C4CC4)[nH]n3)c3ccccc3n2)cc1,Ki,70.0,nM,7.16,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3beta (unknown origin) using HSSPHQ(Sp)EDEEE as substrate by pyruvate kinase-lactate dehydrogenase coupled assay,2017.0
,CS(=O)(=O)Nc1n[nH]c2ncc(-c3ccccc3)cc12,IC50,3572.0,nM,5.45,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)ccc23)CC1,IC50,12.0,nM,7.92,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1cccc(C2=C(Nc3cccc(C(=O)O)c3)C(=O)NC2=O)c1,IC50,195.0,nM,6.71,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1cc(/C=C/C(O)=C/C(=O)/C=C/c2ccc(C)cc2)ccc1O,IC50,2090.0,nM,5.68,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide as substrate incubated for 30 mins by Glo-type luminescence assay,2016.0
,Cc1ccccc1CN1CCC(CNC(=O)c2cncc(NC(=O)c3ccnc(NC(=O)C4CC4)c3)c2)CC1,IC50,157.0,nM,6.8,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,Cc1cccc(CN2CCC(CNC(=O)c3cncc(NC(=O)c4ccnc(NC(=O)C5CC5)c4)c3)CC2)c1,IC50,198.0,nM,6.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,NC1=NONC1N1N=NC(c2n[nH]c(-c3ccncc3)n2)C1CN1CCCCC1,IC50,280.0,nM,6.55,Glycogen synthase kinase-3 beta,,,Inhibitory activity against GSK3-beta,2005.0
,COC[C@@H](CC(C)C)NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,1461.0,nM,5.83,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CC(=O)OC12CC3CC(CC(NC4=N/C(=C\c5ccc6ncsc6c5)C(=O)N4)(C3)C1)C2,IC50,2437.0,nM,5.61,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(=O)/C(=C/c2ccc(OCc3ccccc3)c(OCc3ccccc3)c2)N1,IC50,1378.0,nM,5.86,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,Oc1ccc(Nc2ncnc3[nH]cnc23)cc1CN(CCCl)CCCl,IC50,10.8,nM,7.97,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,COc1ccc(/C=C2\SC(=O)NC2=O)cc1S(=O)(=O)O,IC50,537.0,nM,6.27,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,c1ccc(Nc2nnc(-c3ccccc3)o2)cc1,IC50,980.0,nM,6.01,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,Oc1ccc(-c2nnc(Nc3ccccc3)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,COc1ccc(Nc2nnc(-c3ccc(SC)cc3)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,CC(=O)Cc1ccc2c(c1)-c1[nH]c3ccc(C(F)(F)F)cc3c1CC(=O)N2,IC50,89.95,nM,7.05,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,COc1ccc(CC(=O)Nc2cc([C@H]3CC[C@@H](OC(=O)N4C[C@@H](C#N)[C@@H]4C)C3)[nH]n2)cn1,Ki,0.78,nM,9.11,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged human recombinant GSK3beta H350L mutant expressed in baculovirus-infected Sf21 cells assessed as reduction in production of ADP using 5-FAMKRREILSRRPpSYR-COOH peptide as substrate preincubated with enzyme for 15 mins followed by further incubation with ATP for 30 mins by fluorescence-based microfluidic mobility shift assay,2020.0
,COc1ccc(CC(=O)Nc2cc([C@@H]3CC[C@H](OC(=O)N[C@H]4CC[C@H](O)CC4)C3)[nH]n2)cn1,Ki,1.85,nM,8.73,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged human recombinant GSK3beta H350L mutant expressed in baculovirus-infected Sf21 cells assessed as reduction in production of ADP using 5-FAMKRREILSRRPpSYR-COOH peptide as substrate preincubated with enzyme for 15 mins followed by further incubation with ATP for 30 mins by fluorescence-based microfluidic mobility shift assay,2020.0
,Cc1cncc(C#Cc2sc(NC(=O)NC[C@H](C)OCC3CC3)nc2C)c1,Ki,4000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3B (unknown origin),2021.0
,Nc1ccc2c(c1)nc(-c1nonc1N)n2C1CCC1,Ki,2100.0,nM,5.68,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,COCCN1CCC(CNC(=O)c2n[nH]c3ccc(-c4cncc(OC)c4)cc23)CC1,IC50,26.0,nM,7.58,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,Cn1cc(C2=C(c3cn(CCN4CCOCC4)c4ccccc34)C(=O)NC2=O)c2ncccc21,IC50,900.0,nM,6.05,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-GSK3beta expressed in Escherichia coli BL21 (DE3),2009.0
,COc1ccc2c(c1)c(C1=C(n3ccc4ncccc43)C(=O)NC1=O)cn2CCCn1ccnc1,IC50,480.0,nM,6.32,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-GSK3beta expressed in Escherichia coli BL21 (DE3),2009.0
,O=C1NC(=O)C(n2ccc3ncccc32)=C1c1cn(CCCn2ccnc2)c2ccc(Br)cc12,IC50,140.0,nM,6.85,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-GSK3beta expressed in Escherichia coli BL21 (DE3),2009.0
,O=C(O)Cc1ccc(CSc2nnc(-c3ccncc3)o2)cc1,IC50,8000.0,nM,5.1,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against human Glycogen synthase kinase-3,2002.0
,COc1ccc(-c2cc3c(NC(=O)C4CCCCC4)ncnc3o2)cc1,IC50,1820.0,nM,5.74,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,O=C(Nc1n[nH]c2nc(-c3ccccc3)c(Br)cc12)C1CC1,IC50,75.0,nM,7.12,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CC(C)c1n[nH]c(Cl)c1-c1ccnc(Nc2ccc(N3CCC(N(C)C)CC3)cn2)n1,IC50,9600.0,nM,5.02,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2010.0
,CC(C)(C)CNC(=O)CC1CNC(=O)c2cc(-c3ccncc3)cn21,IC50,4608.0,nM,5.34,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2013.0
,O=C1NC(=O)C(c2ccccc2[N+](=O)[O-])=C1Nc1ccc(O)c(Cl)c1,IC50,90.0,nM,7.05,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by luminescent assay,2011.0
,O=C1NC(=O)C(c2cnc3ncccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCCCC1)CC2,IC50,53.0,nM,7.28,Glycogen synthase kinase-3 beta,,,"Inhibitory concentration to inhibit Ser396 phosphorylation of tau, a natural substrate of GSK-3 in SY5Y cells",2005.0
,CC(=O)N1CCn2cc(C3=C(c4cnc5ccccn45)C(=O)NC3=O)c3cccc(c32)C1,IC50,111.0,nM,6.96,Glycogen synthase kinase-3 beta,,,"Inhibitory concentration to inhibit Ser396 phosphorylation of tau, a natural substrate of GSK-3 in SY5Y cells",2005.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)NCc1ccc2c(c1)CCO2,IC50,103.0,nM,6.99,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,Cn1c(NCC(=O)c2cccc(C#N)c2)nc(-c2ccncc2)cc1=O,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,423.0,nM,6.37,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 500 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,O=c1[nH]cc(-c2cccc(Cl)n2)c2sc(-c3ccncc3)cc12,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in baculovirus by fluorescence polarization assay,2011.0
,O=C(Cc1ccc(CSc2nnc(-c3ccncc3)o2)cc1)NCCc1ccccc1F,IC50,1200.0,nM,5.92,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against human Glycogen synthase kinase-3,2002.0
,Oc1ccc(-c2[nH]c3nccnc3c2CC2CC2)cc1,IC50,3000.0,nM,5.52,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,Br.FC(F)(F)c1ccc(-c2n/c(=N\Cc3cccnc3)sn2-c2ccccc2)cc1,IC50,1600.0,nM,5.8,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,CN1CCN(C)CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CC1,IC50,110.0,nM,6.96,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta,2003.0
,O=C1C(c2cccc3ccccc23)Oc2cc3c(cc2N1Cc1ccc(F)cc1)OCO3,IC50,8100.0,nM,5.09,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human His-tagged GSK3beta using GS-2 peptide as substrate in presence of [33P]gamma-ATP after 15 mins by microbeta counting method,2017.0
,Clc1ccc(Nc2nnc(-c3ccc(Cl)cc3)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,CSc1ccc(-c2nnc(Nc3ccc(Cl)cc3)o2)cc1,IC50,855.0,nM,6.07,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,COc1ccc(Nc2nnc(-c3ccc(C#N)cc3)o2)cc1,IC50,18.0,nM,7.75,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,CCN(CC)S(=O)(=O)c1cc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)ccc1Cl,IC50,330.0,nM,6.48,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,COc1ccccc1C1=C(c2cn(CCCO)c3ncccc23)C(=O)NC1=O,IC50,4.0,nM,8.4,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,CN(C)CCCn1cc(C2=C(c3cccc4ccccc34)C(=O)NC2=O)c2cccnc21,IC50,140.0,nM,6.85,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,Cn1sc(=O)n(-c2ccc(C(F)(F)F)cc2)c1=O,IC50,6000.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Inhibitory activity against recombinant rabbit Glycogen synthase kinase-3 beta,2002.0
,C(=N/Nc1ncnc2c1cnn2-c1ccccn1)\c1ccncc1,IC50,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,Fc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1,IC50,316.23,nM,6.5,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,O=C(Nc1cncc(N2CCOCC2)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,73.0,nM,7.14,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC1=NN(c2ccccc2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1sc(=O)n(-c2ccccc2Br)c1=O,IC50,6000.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Inhibitory activity against recombinant rabbit Glycogen synthase kinase-3 beta,2002.0
,CCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12,IC50,400.0,nM,6.4,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,C[S+]([O-])c1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,236.0,nM,6.63,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,O=C1Cc2c([nH]c3cc(Br)ccc23)-c2ccccc2N1,IC50,139.96,nM,6.85,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,O=C1Cc2c([nH]c3ccccc23)-c2cc(Br)ccc2N1,IC50,199.99,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2sccc2N1,IC50,119.95,nM,6.92,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,NCCn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(F)ccc21,IC50,41.1,nM,7.39,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,O=C(/C=C(O)/C=C/c1ccc(OCc2cc(F)cc(F)c2)cc1)/C=C/c1ccc(OCc2cc(F)cc(F)c2)cc1,IC50,8300.0,nM,5.08,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide as substrate incubated for 30 mins by Glo-type luminescence assay,2016.0
,CNC(=O)c1cnc2oc3ccc(O)cc3c2c1-c1ccccc1,Ki,9000.0,nM,5.05,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GST-fused GSK-3beta expressed in insect Sf9 cells using RBER-CHKtide as substrate assessed as incorporation of 33Pi after 60 mins by microplate scintillation counting analysis,2012.0
,Cn1c(N2CCO[C@@H]3COC[C@H]32)nc(-c2ccncc2F)cc1=O,IC50,3.1,nM,8.51,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,Cc1cc(Nc2nc(Nc3ccccc3)nc3ccccc23)n[nH]1,Ki,24.0,nM,7.62,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
"12,13-DEHYDRO-8-O-ACETYLMANZAMINE A",CC(=O)Oc1cccc2c1[nH]c1c(C3=C/C4=C/C/C=C\CCCCN5CCC3[C@]3(C[C@@H]6/C=C\CCCCN6[C@@H]43)C5)nccc12,IC50,4800.0,nM,5.32,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSKbeta,2007.0
,Oc1cccc2c1[nH]c1c(C3=C[C@@]4(O)CC/C=C\CCCCN5CC[C@@H]3[C@]3(CC6/C=C\CCCCN6[C@H]34)C5)nccc12,IC50,4800.0,nM,5.32,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSKbeta,2007.0
,CCCCCCCCCCCC(=O)NNC(=O)C1Sc2ccccc2N(CC)C1=O,IC50,8000.0,nM,5.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using peptide substrate GS2 assessed as ATP remaining by Kinase-Glo luminescent kinase assay,2014.0
,COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1,Ki,7100.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2006.0
,CCOc1nc(NC(C)=O)cc(N)c1C#N,Ki,7100.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2006.0
BMS-777607,CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1,IC50,2000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,CCN1C(=O)C(Nc2ccccc2)=C(c2ccccc2)C1=O,IC50,5000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2005.0
,COc1ccc(-n2cnc3cc(C(=O)CBr)ccc32)cc1,IC50,580.0,nM,6.24,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide substrate after 30 mins by Glow-type luminescence assay in presence of 1 uM ATP,2011.0
,CC(=O)Nc1ccc(-c2c(-c3cccnc3)oc3ncnc(N)c23)cc1,IC50,1628.0,nM,5.79,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by fluorescence anisotropy binding assay,2008.0
,O=Cc1ccc2c(c1)[nH]c1c(NC(=O)C3CC3)nccc12,IC50,400.0,nM,6.4,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human full length GSK3beta expressed in baculovirus in Sf9 insect cells using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate by ADP-Glo kinase assay,2021.0
,CN(C)CCNS(=O)(=O)c1ccc(-c2ccc(/C=C3\SC(=N)NC3=O)o2)cc1,IC50,510.0,nM,6.29,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2007.0
,CCS(=O)(=O)Nc1ccc(CCNC(=O)c2ccnc3[nH]c(-c4ccsc4)nc23)cc1,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,O=C(NCCCc1ccc(Cl)nc1)c1ccnc2[nH]c(-c3ccc(F)cc3)nc12,IC50,17.0,nM,7.77,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,O=C(Nc1cccnc1)c1ccnc2[nH]c(-c3ccsc3)nc12,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,CCOc1ccncc1NC(=O)c1ccnc2[nH]c(-c3ccc(F)cc3)nc12,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,COc1ccc(-c2nc3c(C(=O)Nc4cnccc4C)ccnc3[nH]2)cc1,IC50,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,Nc1n[nH]c2cnc(-c3ccccc3)cc12,IC50,1260.0,nM,5.9,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CS(=O)(=O)CCCOc1cccc2c1ccn2-c1ccnc(N[C@H]2CC[C@H](C(=O)N3CCC(O)CC3)CC2)n1,Kd,5400.0,nM,5.27,Glycogen synthase kinase-3 beta,,,Binding affinity to GSK3B (unknown origin),2013.0
,Cn1cc(-c2[nH][nH]c(=O)c2-c2cn(C)c3ccccc23)c2ccccc21,IC50,34.0,nM,7.47,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK-3beta,2020.0
,Cc1ccc(C(=O)CC2(O)C(=O)Nc3ccc(Nc4ccco4)cc32)cc1,IC50,1717.0,nM,5.76,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate measured after 60 mins by ADP-Glo luminescence assay,2019.0
,Clc1cccc(-n2cc(-c3ccncc3)nn2)c1,IC50,1800.0,nM,5.75,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by colorimetric analysis,2012.0
,O=C(O)CCC(=O)Nc1n[nH]c2cc(Cl)ccc12,IC50,1180.0,nM,5.93,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(Cl)ccc12,IC50,354.0,nM,6.45,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,C/C=C/c1ccc2c(NC(=O)CCC)n[nH]c2c1,IC50,2459.0,nM,5.61,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(Cc3ccccc3)ccc12,IC50,4140.0,nM,5.38,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,OC1(c2ccccc2)CSC(=S)N1Cc1ccncc1,IC50,102.0,nM,6.99,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK-3beta preincubated for 3 hrs followed by ATP and substrate addition measured by serial dilution assay,2021.0
,Cc1ccc(-c2cnc(N)c(/N=C/c3ccnc(NC(=O)C4CC4)c3)c2)cc1,IC50,372.0,nM,6.43,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,O=C(CBr)c1cc(Br)c(Br)s1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by liquid scintillation counting,2009.0
,COc1ccc(/C=C2\SC(=O)NC2=O)c(O)c1,IC50,7080.0,nM,5.15,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using GS-2 peptide substrate incubated for 30 mins by kinase-Glo luminescent assay,2018.0
,Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12,IC50,3860.0,nM,5.41,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2010.0
,COc1ccc(CSc2nnc(-c3ccc4c(c3)CCO4)o2)cc1Cl,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,COc1cc2c(C3=C(c4coc5ccccc45)C(=O)NC3=O)cn(C)c2cc1I,IC50,223.0,nM,6.65,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
AT-9283,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1,Kd,7.0,nM,8.15,Glycogen synthase kinase-3 beta,Active,,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",2017.0
,CN(C)c1cc2sncc2cc1NC(=O)C(=O)O,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1sc2c(Br)ccc(Cl)c2c1N,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1,Ki,50.12,nM,7.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1c(NCc2ccc(Cl)c(Cl)c2)c(Nc2ccncc2)c1=O,Ki,63.1,nM,7.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccc[nH]2)C(=O)N3)c1)Cc1ccccc1,Ki,2.512,nM,8.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCc1nn(-c2cccc(OC)c2)c2ncnc(N/N=C/c3ccncc3)c12,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ccc(F)cc1Cl,IC50,6.0,nM,8.22,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,Nc1c(F)c(NCCNc2ccccn2)c2c3c1c(=O)c(C(=O)O)cn3C1(CCO2)CC1,IC50,37.0,nM,7.43,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta after 1 hr by KinaseGlo luciferase assay,2012.0
,CC1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn(c23)C12CCC2,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta after 1 hr by KinaseGlo luciferase assay,2012.0
,Br.CCCCC/N=c1\nc(-c2ccccc2)n(-c2ccccc2)s1,IC50,1400.0,nM,5.85,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,N#CCCc1ccc2c(c1)-c1[nH]c3ccc(C(F)(F)F)cc3c1CC(=O)N2,IC50,33.04,nM,7.48,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,CC(C)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3cc(-c4ccccc4)no3)n2)cc1,Ki,650.0,nM,6.19,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta,2019.0
,CC(C)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3cc(-c4ccccc4)on3)n2)cc1,Ki,530.0,nM,6.28,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta,2019.0
,COc1ccc2c(c1)NC(=O)Cc1c-2[nH]c2ccc([N+](=O)[O-])cc12,IC50,69.98,nM,7.16,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,Cn1cc(C2=C(c3cn(CCCN4CCOCC4)c4ccccc34)C(=O)NC2=O)c2ncccc21,IC50,760.0,nM,6.12,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-GSK3beta expressed in Escherichia coli BL21 (DE3),2009.0
,COc1ccc2c(c1)-c1[nH]c3ccc(Br)cc3c1CC(=O)N2,IC50,15.0,nM,7.82,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2010.0
,COC(=O)c1ccc2[nH]c3c(c2c1)CC(=O)Nc1ccccc1-3,IC50,7200.0,nM,5.14,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2010.0
,Cc1ccc(-c2ccc3occ(-c4ccc(C(N)=O)cc4)c3c2)o1,IC50,69.0,nM,7.16,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,Cc1ccc(-c2ccc3occ(-c4ccc(F)cc4)c3c2)o1,IC50,110.0,nM,6.96,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,COc1nc(-c2ccnc(NC(=O)C3CC3)c2)sc1C(=O)NCCCCCCNc1c2c(nc3ccccc13)CCCC2,IC50,18.0,nM,7.75,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human full length N-terminal GST-tagged GSK-3beta expressed in Sf9 insect cells using prephosphorylated polypeptide as substrate after 30 mins by kinase-Glo reagent based luminescence assay,2018.0
,c1ccc(CNc2cc(-c3c[nH]c4ncccc34)ncn2)cc1,Ki,7.943,nM,8.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC1CCCCC1Nc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)c1cccc2c(S(=O)(=O)N(CCN)c3cncc(-c4ccc5cnccc5c4)c3)cccc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
ENTRECTINIB,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1,Ki,31.62,nM,7.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CS(=O)(=O)NCCOc1cncc(-c2ccc3cnccc3c2)c1,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN(C)C)cnc(N)c34)cc2)c1,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1nccn2c(-c3ccnc(NCCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1nc2ccccc2n1CCCO)c1cccc([N+](=O)[O-])c1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cc2c(-c3ccc(Nc4nc5ccccc5o4)cc3)cnc(N)c2s1,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(C2=C(c3c[nH]c4cnccc34)C(=O)NC2=O)cc(OC)c1OC,IC50,9.0,nM,8.05,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,COc1cc(C2=C(c3c[nH]c4cccnc34)C(=O)NC2=O)cc(OC)c1OC,IC50,215.0,nM,6.67,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,CC(C)OC1Cn2cc(C3=C(c4cnc5ccccn45)C(=O)NC3=O)c3cccc(c32)CN1C=O,IC50,1.3,nM,8.89,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta (unknown origin) assessed as decrease in phosphorylation of CREB at serine-129 in presence of ATP[gamma-33P] by filter binding assay,2018.0
,CCCCC1CN(c2nc(-c3ccncc3F)cc(=O)n2C)CCO1,IC50,12.0,nM,7.92,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,C[C@@H]1[C@@H](C)OCCN1c1nc(-c2ccncc2F)cc(=O)n1C,IC50,4.9,nM,8.31,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,C[C@@H]1CN(C)CCN1c1nc(-c2ccncc2)cc(=O)n1C,IC50,80.0,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,O=C(Nc1n[nH]c2cc(-c3ccc4[nH]ccc4c3)ccc12)C1CC1,IC50,42.0,nM,7.38,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccccc1Cl,IC50,337.0,nM,6.47,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1cccc(O)c1,IC50,407.0,nM,6.39,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCCCn1c(NC(=O)c2cccc(C#N)c2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1sn(-c2ccccc2)c(=O)n1CCCl,IC50,548.0,nM,6.26,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by Z'-LYTE kinase assay,2009.0
,Clc1cccc(CSc2nnc(-c3ccc4c(c3)CCO4)o2)c1,IC50,94.0,nM,7.03,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,COc1ccc(-c2coc3ccc(-c4nnc(SCc5cccc(C(F)(F)F)c5)o4)cc23)cc1,IC50,8.4,nM,8.08,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1ccc(O)c(Cl)c1,IC50,152.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccccc2)=C1Nc1cccc(C(=O)O)c1,IC50,291.0,nM,6.54,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccccc2)=C1Nc1cc(Cl)c(O)c(Cl)c1,IC50,149.0,nM,6.83,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,Cl.OCC/N=c1\nc(-c2ccccc2)n(-c2ccccc2)s1,IC50,600.0,nM,6.22,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,Br.COc1ccc(-n2s/c(=N/CCO)nc2-c2ccccc2)cc1,IC50,4600.0,nM,5.34,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccc(C#N)cc4)ncnc32)c1,IC50,15.85,nM,7.8,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,CCN(CC)c1cc(-c2ccncn2)cc(=O)n1C,IC50,2210.0,nM,5.66,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in CHO AA8 cells co-expressing human tau protein after 2 hrs,2011.0
,COCCCNC(=O)c1nc(-c2ccc(S(=O)(=O)N3CCN(C)CC3)cc2)cnc1N,Ki,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,CN1CCN(S(=O)(=O)c2ccc(-c3cnc(N)c(C(=O)Nc4ncns4)n3)cc2)CC1,Ki,0.99,nM,9.0,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,CN1CCN(S(=O)(=O)c2ccc(-c3cnc(N)c(C(=O)Nc4cnccc4CN4CCCC4)n3)cc2)CC1,Ki,0.22,nM,9.66,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,Nc1ncc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)nc1C(=O)Nc1cccnc1,Ki,4.4,nM,8.36,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,COCCNS(=O)(=O)c1ccc(-c2cnc(N)c(C(=O)Nc3cccnc3)n2)cc1,Ki,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,Cc1ccncc1NC(=O)c1ccnc2[nH]c(N3CCC(c4ccccc4)C3)nc12,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,CS(=O)(=O)Nc1ccc(CCNC(=O)c2ccnc3[nH]c(-c4ccc(Cl)cc4)nc23)cc1,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,CCOc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccccc4F)ncnc32)c1,IC50,125.89,nM,6.9,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(CCC4CCCC(C)C4)CC3)c2c1,IC50,310.0,nM,6.51,Glycogen synthase kinase-3 beta,335742,,"LanthaScreen TR-FRET Assay: Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screening assay, compounds were tested in duplicate at a concentration of 10 uM.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um). In a second assay, the same compounds were assayed at five concentrations ranging from 100 uM to 10 nM with ten-fold dilutions in duplicate.",2015.0
,COc1ccc(-c2[nH]c3nccnc3c2CC2CCCCC2)cc1,IC50,6800.0,nM,5.17,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,O=C(CCc1cnc2[nH]cc(-c3ccccc3)c2c1)NCCc1c[nH]c2ccccc12,IC50,1030.0,nM,5.99,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)NCc1ccc2[nH]ccc2c1,IC50,462.0,nM,6.33,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccc(F)cc3)c2c1)NCc1ccncc1,IC50,22.8,nM,7.64,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,N#Cc1ccc(-c2c[nH]c3ncc(/C=C/C(=O)NCc4ccncc4)cc23)cc1,IC50,63.1,nM,7.2,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,Cc1cc(-c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2NC2CCC(N(C)C)CC2)on1,IC50,7740.0,nM,5.11,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta (unknown origin) in presence of ATP,2013.0
,CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1C,IC50,2600.0,nM,5.58,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2013.0
,O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1ccccc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
SNS-314,O=C(Nc1cccc(Cl)c1)Nc1ncc(CCNc2ncnc3ccsc23)s1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1nccn2c(-c3ccnc(NCC(C)(C)C(=O)O)n3)c(-c3ccc(F)cc3F)nc12,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1,Ki,6.31,nM,8.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(=O)O)cc2)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cc(F)c(Cl)cc21,IC50,0.95,nM,9.02,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,C=CCOc1ccc2c(C3=C(c4cn(C)c5ccc(Br)cc45)C(=O)NC3=O)coc2c1,IC50,48.3,nM,7.32,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,Cn1cc(C2=C(c3coc4ccc(F)cc34)C(=O)NC2=O)c2cc(C#CC3CC3)ccc21,IC50,16.1,nM,7.79,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,OCCCc1cn(-c2ccc3[nH]ncc3c2)nn1,Ki,5216.0,nM,5.28,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,Nc1nc(-c2ccc3[nH]ncc3c2)cs1,Ki,4472.0,nM,5.35,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,Clc1ccccc1Cn1cc(-c2ccc3[nH]ncc3c2)nn1,Ki,45.0,nM,7.35,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,c1cc2[nH]ncc2cc1-n1cc(CC2CCCCC2)nn1,Ki,891.0,nM,6.05,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3c(C#N)cnn23)cc1,IC50,460.0,nM,6.34,Glycogen synthase kinase-3 beta,,,Inhibitory concentration for Glycogen synthase kinase-3 beta was determined in the presence of 10 um ATP (Km 50 uM),2005.0
,COc1cc(C2=C(c3c[nH]c4ccncc34)C(=O)NC2=O)cc(OC)c1OC,IC50,40.0,nM,7.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
EUTYPOID B,O=C1OCC(Cc2ccc(O)cc2)=C1c1ccc(O)cc1,IC50,780.0,nM,6.11,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by luminescent assay,2011.0
,Cn1cc(C2=C(c3nn(CCn4ccnc4)c4ncccc34)C(=O)NC2=O)c2ccccc21,IC50,810.0,nM,6.09,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)nc1Cl,IC50,398.11,nM,6.4,Glycogen synthase kinase-3 beta,,,Inhibition of catalytic activity of GSK3-beta by AlphaLISA assay,2012.0
,COCc1ccccc1-c1c[nH]c(=O)c2cc(-c3ccncc3)sc12,IC50,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,,,Inhibition of human flag-tagged GSK3-beta expressed in HEK-MSRII cells assessed as CRMP-2 phosphorylation by alphaLISA assay,2011.0
,Cc1nc(C)n2nc(-c3ccccc3)nc(NCCNc3ccc(C#N)cn3)c12,IC50,310.0,nM,6.51,Glycogen synthase kinase-3 beta,213537,,"Biochemical Assay: The ingredients required for this purpose are mixed in a black 384-well microtiter plate with transparent base (from Greiner, catalog number 781092). The requirements in this connection for each well of the 384-well microtiter plate are 5 nM GSK3β (from Upstate, catalog number xy), 40 μM GSK3β substrate GSM (sequence H-RRRPASVPPSPSLSRHS-(pS)-HQRR, from Upstate, catalog number 2-533), 30 μM nicotinamide adenine dinucleotide NADH (Roche Diagnostics, catalog number 10107735), 50 μM adenosine triphosphate ATP (from Sigma, catalog number A7966) and 2 mM phosphoenolpyruvate (from Roche, catalog number 128112). The required reaction buffer in which the biochemical reaction takes place consists of 50 mM Trizma hydrochloride Tris-HCl pH: 7.5 (from Sigma, catalog number T3253), 5 mM magnesium chloride MgCl2 (from Sigma, catalog number M8266), 0.2 mM DL-dithiothreitol DTT (from Sigma, catalog number D9779), 2 mM ethylenediaminetetraacetic acid EDTA (from Sigma, catalog number E6758), 0.01% Triton X-100 (from Sigma, catalog number T8787) and 0.05% bovine serum albumin BSA (from Sigma, catalog number B4287). Active substances are dissolved in dimethyl sulfoxide DMSO (from Sigma, catalog number D8418) in a concentration of 10 mM. Active substances are added in serial concentrations of 10 μM, 1 μM, 0.1 μM, 0.01 μM, 0.001 μM, 0.0001 μM, 0.00001 μM, 0.000001 μM to the mixtures of the biochemical reaction. As control, dimethyl sulfoxide is added instead of substance in a final concentration of 0.1%. The reaction is incubated at 30° C. for 2 hours and then the resulting fluorescence is measured in a Tecan Safire-XFLUOR4 instrument, version V4.50 (serial number 12901300283) with the specifications: measurement mode−fluorescence measured from below, extinction wavelength 340 nm, emission wavelength 465 nm, slit width extinction 5 nm, slit width emission 5 nm, gain mode 120, delay 0 μs, number of light flashes per measurement 3, and an integration time of 40 μs.",2013.0
,COc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ccc(-c2csc3c(C=Cc4nc5ccccc5[nH]4)cnc(N)c23)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccccc1-c1c(C(=O)O)n(CCCOc2cccc3ccccc23)c2ccccc12,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(C2=C(c3cn(CCOC(=O)C(N)CC(C)C)c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,IC50,12.0,nM,7.92,Glycogen synthase kinase-3 beta,284793,,"Kinase Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",2015.0
,O=C(NCC1CCN(CCc2ccccc2)CC1)c1n[nH]c2ccc(-c3cccnc3)cc12,IC50,39.0,nM,7.41,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(CCCN4C[C@@H](C)O[C@@H](C)C4)CC3)c2c1,IC50,2100.0,nM,5.68,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(Cc4noc(C(N)=O)n4)CC3)c2c1,IC50,490.0,nM,6.31,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COc1ccc(CCN2CCC(CNC(=O)c3n[nH]c4ccc(OC)cc34)CC2)cc1,IC50,560.0,nM,6.25,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(Cc4ccc(Cl)cc4Cl)CC3)c2c1,IC50,310.0,nM,6.51,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(CCCN(C)C)CC3)c2c1,IC50,1700.0,nM,5.77,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCCCC4)cc3OC)nc2N1C1CCCC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCn1c2cc(Cl)c(F)cc2c(=O)c2c(=O)o[nH]c21,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(-c2ccc(NC(=O)Nc3ccc(F)c(C)c3)cc2)c2c(N)noc12,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncc(-c2ccncc2)c2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cnccn1)Nc1cccc2c(O)cccc12,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(NC(=O)Nc2ccc(-c3cccc4onc(N)c34)cc2)cc1Cl,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN1CCC(NC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)CC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1cnc2[nH]cc(-c3ccnc(NC4CCCCC4)n3)c2c1,Ki,31.62,nM,7.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cc(F)ccc1-c1ccc(CSc2nnc(-c3ccc4c(c3)OCCO4)o2)cc1,IC50,140.0,nM,6.85,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3 beta using Ulight-CFFKNIVTPRTPPPSQGK-amide substrate incubated for 90 mins by LANCE method relative to control,2015.0
,O=C(Nc1cnccc1OCC1CC1)c1ccnc(NC(=O)C2CC2)c1,IC50,65.0,nM,7.19,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) assessed as decrease in tau phosphorylation by high content cell based assay,2016.0
,O=C(Nc1cnccc1-c1cccc(F)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,16.0,nM,7.8,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,Cc1ccc(C(=O)CC2(O)C(=O)Nc3ccc(NC(=O)c4ccccc4)cc32)cc1,IC50,1717.0,nM,5.76,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK3beta (636 to 661 residues) assessed as reduction in human muscle glycogen synthase type 1 fragment phosphorylation using YRRAAVPPSPSLSRHSSPHQ(pS)EDE as substrate in presence of ATP incubated for 60 mins by ADP-Glo kinase assay,2023.0
,NC(COc1cncc(-c2ccc3[nH]c(=O)oc3c2)c1)Cc1c[nH]c2ccccc12,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)csc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Cc1cccs1)Nc1nc2ccccc2s1,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(C(C)NC(=O)c2ccc(-c3ccncn3)cc2)c1,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(NC2=C(c3ccccc3)C(=O)N(C)C2=O)cc1,IC50,2000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2005.0
,COc1ccccc1CCCNc1cc(-c2ccncn2)cc(=O)n1C,IC50,260.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta expressed in baculovirus infected SF9 cells after 60 mins,2011.0
,Cn1c(N2CCC(O)(c3ccccc3)CC2)cc(-c2ccncn2)cc1=O,IC50,8.5,nM,8.07,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta expressed in baculovirus infected SF9 cells after 60 mins,2011.0
,COc1ccccc1[C@@H]1CN(c2cc(-c3ccncn3)cc(=O)n2C)CCO1,IC50,1530.0,nM,5.82,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in CHO AA8 cells co-expressing human tau protein after 2 hrs,2011.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)n1,IC50,39.81,nM,7.4,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,O=C(CBr)c1ccc(Br)cc1,IC50,500.0,nM,6.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using GS1 as substrate and [gamma-32P]ATP after 20 mins by radiometric assay,2011.0
,O=C(CBr)c1ccc(N2CCOCC2)cc1,IC50,6000.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using GS1 as substrate and [gamma-32P]ATP after 20 mins by radiometric assay,2011.0
,Cn1cc(C2=C(C(=O)CBr)C(=O)NC2=O)c2ccccc21,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide substrate after 30 mins by Glow-type luminescence assay in presence of 1 uM ATP,2011.0
,Cc1ccnc(Nc2cc(C)nc(-c3ccccc3)n2)c1,Ki,316.23,nM,6.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccnc2[nH]c3cc(C(C)C)ccc3c(=O)c12,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccccc1CCN(C)c1cc(-c2ccncn2)cc(=O)n1C,IC50,1690.0,nM,5.77,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in CHO AA8 cells co-expressing human tau protein after 2 hrs,2011.0
,COc1ccccc1C1CCCN(c2cc(-c3ccncn3)cc(=O)n2C)C1,IC50,2320.0,nM,5.63,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in CHO AA8 cells co-expressing human tau protein after 2 hrs,2011.0
,O=C(O)c1ccc(Nc2ncc(C3C=NN=N3)c(Nc3ccccc3)n2)cc1,IC50,1170.0,nM,5.93,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,Cc1cccc(N2CCN(CCCNC(=O)c3nc(-c4ccncc4)no3)CC2C)c1,IC50,1130.0,nM,5.95,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,O=C(NCCCN1CCN(c2ccccc2F)CC1)c1nc(-c2cncnc2)no1,IC50,2990.0,nM,5.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,Cc1cccc(N2CCN(CCCNC(=O)c3nc(-c4cccnc4)no3)CC2)c1,IC50,1060.0,nM,5.97,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,Cc1ccccc1N1CCN(CCCNC(=O)c2nc(-c3cccnc3)no2)CC1,IC50,710.0,nM,6.15,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,O=[N+]([O-])c1cnc(N[C@H]2CC[C@H](O)CC2)nc1Nc1ccccc1,IC50,281.0,nM,6.55,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,NCC1(c2ccc(Cl)cc2)CCN(c2ncnc3[nH]cnc23)CC1,IC50,1300.0,nM,5.89,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta in human PC3M cells by ELISA,2008.0
,O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCOCCOCCOCCn1cc2c2ccccc21,IC50,26.0,nM,7.58,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3beta (GSK3-beta),2003.0
,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2ccc(O)cc21,IC50,15.0,nM,7.82,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,COc1cc(C=C2SC(=Nc3ccccc3)NC2=O)ccc1O,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1ccc(Nc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1,Ki,289.0,nM,6.54,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,COc1cc(-c2ccc3[nH]nc(C(=O)Nc4ccccc4)c3c2)ccc1O,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NN=Cc1ccc(O)cc1O)Nc1cccc2nsnc12,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc2ncc3c(N)nc4c(C)c(N)ccc4c3c2cc1OC,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4sncc34)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)CC(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCOCCOCCOCCOCCn1cc2c2ccccc21,IC50,51.0,nM,7.29,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3beta (GSK3-beta),2003.0
GW644007X,COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O,IC50,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
GW817396X,COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1,IC50,7.943,nM,8.1,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,CCCC(=O)Nc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1,IC50,630.96,nM,6.2,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,Cc1cccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)c1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)Cc1c(-c2n[nH]c(-c3ccncc3)n2)nnn1-c1nonc1N,IC50,6920.0,nM,5.16,Glycogen synthase kinase-3 beta,,,Inhibitory activity against human glycogen synthase kinase-3beta (GSK3-beta) at 100 uM ATP,2003.0
,CC(=O)OCN1C(=O)Cc2c([nH]c3ccc(Br)cc23)-c2ccccc21,IC50,500.03,nM,6.3,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,NNC(=O)c1nnn(-c2nonc2N)c1CN1CCCCC1,IC50,9600.0,nM,5.02,Glycogen synthase kinase-3 beta,,,Inhibitory activity against human glycogen synthase kinase-3beta (GSK3-beta) at 100 uM ATP,2003.0
GW827102X,FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1,Ki,50.0,nM,7.3,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Fc1ccc(Nc2nccc(-c3c(-c4ccc(Cl)cc4)nn4ncccc34)n2)cc1F,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,N#Cc1ccc2[nH]c3c(c2c1)CC(=O)Nc1ccsc1-3,IC50,330.37,nM,6.48,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,Nc1nonc1-n1nnc(-c2n[nH]c(-c3ccncc3)n2)c1CN1CCCC1,IC50,240.0,nM,6.62,Glycogen synthase kinase-3 beta,,,Inhibitory activity against human glycogen synthase kinase-3beta (GSK3-beta) at 100 uM ATP,2003.0
,Fc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1F,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,2020.0
,O=C(/C=C(O)/C=C/c1ccc(OCc2ccccc2)cc1)/C=C/c1ccc(O)cc1,IC50,2010.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide as substrate incubated for 30 mins by Glo-type luminescence assay,2016.0
,COc1ccc(NC2=C(c3ccccc3)C(=O)N(Cc3ccccc3)C2=O)cc1,IC50,5000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2005.0
,Cn1c(NCCNc2c3c(nc4ccccc24)CCCC3)nc(-c2ccncn2)cc1=O,IC50,5630.0,nM,5.25,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK-3beta using prephosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescence assay,2021.0
,Cn1c(NCCCCCNc2c3c(nc4ccccc24)CCCC3)nc(-c2ccncc2)cc1=O,IC50,1280.0,nM,5.89,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK-3beta using prephosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescence assay,2021.0
,Cn1c(NCCCCCCNc2c3c(nc4ccccc24)CCCC3)nc(-c2ccncc2)cc1=O,IC50,520.0,nM,6.28,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK-3beta using prephosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescence assay,2021.0
,O=C(CBr)c1scc(Br)c1Br,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by liquid scintillation counting,2009.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccccc3)ccc12,IC50,390.0,nM,6.41,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta by kinetic assay,2010.0
,N#Cc1cccc(-n2c(-c3nonc3N)nc3ccccc32)c1,Ki,2500.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,COc1cccc(-n2c(-c3nonc3N)nc3ccccc32)c1,Ki,5000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,COC(=O)c1ccc2c(c1)nc(-c1nonc1N)n2C1CCC1,Ki,3300.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,CC(C)Cn1cc(-c2ccccc2)nc1-c1nonc1N,Ki,3300.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,CN(C)S(=O)(=O)Nc1ccc(CCNC(=O)c2ccnc3[nH]c(-c4ccc(F)cc4)nc23)cc1,IC50,27.0,nM,7.57,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,CCCC(=O)Nc1n[nH]c2cc(C(F)(F)F)ccc12,IC50,195.0,nM,6.71,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)Cc3ccccc3)cc21,IC50,80.0,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
,FC(F)(F)Oc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1,IC50,316.23,nM,6.5,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,O=C1Nc2ccc(NC(=O)c3ccccc3)cc2C1=Cc1ccc(O)cc1,IC50,4340.0,nM,5.36,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK-3 beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate incubated for 60 mins in presence of ATP by luminescence based analysis,2022.0
,COc1cccc(C2=NNC(=O)/C2=N\Nc2ccc(N3CCOCC3)cc2)c1,Ki,59.0,nM,7.23,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(C2=NNC(=O)/C2=N\Nc2cccnc2)cc1,Ki,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1cccc(N/N=C2\C(=O)NN=C2c2ccc(OC)c(OC)c2)c1,Ki,0.4,nM,9.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccncc1C1=NNC(=O)/C1=N\Nc1ccc(Cl)cc1,Ki,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,N[C@H]1CC[C@H](Nc2cc(Nc3ccc(S(=O)(=O)c4ccccc4)cc3)n3ncc(Br)c3n2)CC1,IC50,5300.0,nM,5.28,Glycogen synthase kinase-3 beta,,,Inhibitory concentration for Glycogen synthase kinase-3 beta was determined in the presence of 10 um ATP (Km 50 uM),2005.0
GW632580X,COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21,IC50,40.0,nM,7.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(O)cc3Cl)ccc12,IC50,55.0,nM,7.26,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CC(C)(O)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1ccc(CSc2nc(-c3ccncc3)n[nH]2)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Clc1ccc(-c2n[nH]cc2-c2ccncn2)cc1Cl,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC#Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1,Ki,39.81,nM,7.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCCC#Cc1ccc(CN2CC(C(=O)O)C2)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(Nc2nc(Cl)cc(NCc3ccccc3)n2)n[nH]1,Ki,50.12,nM,7.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1F,Ki,25.12,nM,7.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,C(=N/Nc1ncnc2c1cnn2-c1nccs1)\c1ccncc1,IC50,39.81,nM,7.4,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,COc1cccc(-n2nc(C(C)C)c3c(N/N=C/c4ccncc4)ncnc32)c1,IC50,31.62,nM,7.5,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,Nc1nccc(-c2ccc(F)cc2)c1/N=C/c1ccnc(NC(=O)C2CC2)c1,IC50,1204.0,nM,5.92,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,Nc1ncccc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,629.0,nM,6.2,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,COc1ccccc1C1=C(c2cn(CCCNS(N)(=O)=O)c3ncccc23)C(=O)NC1=O,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,Brc1cnn2c(NCc3cccnc3)cc(C3CCCCC3)nc12,IC50,27.0,nM,7.57,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,Nc1ncnc2oc(-c3cccnc3)c(-c3ccc(NC(=O)c4cccc(F)c4)cc3)c12,IC50,1585.0,nM,5.8,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by fluorescence anisotropy binding assay,2008.0
GW810372X,COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1,Ki,50.0,nM,7.3,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,CC(C)(C)n1c(=O)n(-c2ccccc2)c2nc(Nc3ccccc3)ncc21,IC50,2400.0,nM,5.62,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=C1NC(=O)/C(=C/c2c[nH]c3ccccc23)S1,IC50,4930.0,nM,5.31,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human His6-taged GSK-3beta assessed as substrate phosphorylation incubated for 30 mins using RRRPASVPPSPSLSRHSSHQRR peptide as substrate in presence of [gamma-32P]ATP by scintillation counter method,2021.0
,CC(C)Oc1ccc2c(-c3ccnc(Nc4ccc(N5CCN(C)CC5)cc4)n3)cnn2n1,IC50,850.0,nM,6.07,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2008.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(Nc2ccncc2)n1,IC50,1.1,nM,8.96,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCCO5)n3)c2c1,Ki,10.0,nM,,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,CCS(=O)(=O)Nc1ccc(CCNC(=O)c2ccnc3[nH]c(-c4ccoc4)nc23)cc1,IC50,1.0,nM,9.0,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
PYRAZOLOPYRIDAZINE 2,COc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1OC,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,N=C1NC(=O)/C(=C\c2ccc(-c3ccccc3Cl)o2)S1,IC50,565.0,nM,6.25,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,Cc1ccc(-c2ccc(/C=C3/SC(=N)NC3=O)o2)c([N+](=O)[O-])c1,IC50,320.0,nM,6.5,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,CCCCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl,IC50,1193.0,nM,5.92,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,NC1=NC(=O)/C(=C\c2ccc(-c3ccccc3[N+](=O)[O-])o2)S1,IC50,2495.0,nM,5.6,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
KRM-7777,CCn1sc(=O)n(Cc2ccccc2)c1=O,IC50,7149.0,nM,5.15,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by Z'-LYTE kinase assay,2009.0
INDIRUBIN 1,CC(=O)O/N=C1C(=C2/C(=O)Nc3cc(Cl)c(Cl)cc32)/Nc2ccccc2/1,IC50,3.981,nM,8.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) expressed in Sf9 cells using GS1 as substrate and [gamma32]ATP after 30 min by scinitllation counting,2007.0
,COCCN1CCC(CNC(=O)c2n[nH]c3ccc(-c4ccc(OC)nc4)cc23)CC1,IC50,790.0,nM,6.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) expressed in CHO cells assessed as Tau phosphorylation after 2 hrs,2015.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(Cc4ccc(OCc5ccccc5)cc4)CC3)c2c1,IC50,350.0,nM,6.46,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(CCCC(=O)O)CC3)c2c1,IC50,230.0,nM,6.64,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COc1ccc(-c2ccc3[nH]nc(C(=O)NCC4CCN(Cc5ccc(C(=O)O)o5)CC4)c3c2)cc1,IC50,300.0,nM,6.52,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COc1cc(C=C(C#N)c2n[nH]c(N)c2C#N)ccc1O,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1ccc2nc(N)n(-c3nc(-c4ccccc4)cs3)c2c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)c1ccc(Nc2cc(-c3csc(Br)c3)[nH]n2)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(Cc1cc(Cl)c(O)c2ncccc12)C1CCCCC1,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2ccc(-c3cncc(OCC(CN)Cc4ccccc4)c3)cc12,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)n[nH]c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)Oc1ccc(F)c(-c2cnc(N)c(C(=O)Nc3cnccc3N3CCCC(C(=O)O)C3)n2)c1,IC50,40.0,nM,7.4,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK3beta,2021.0
,O=C(Nc1cccnc1)c1ccnc(NC(=O)C2CC2)c1,IC50,24.0,nM,7.62,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,O=C(Nc1cccnc1O)c1ccnc(NC(=O)C2CC2)c1,IC50,490.0,nM,6.31,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,Cc1nc2ccc(-c3cc(N)nc(N)c3)nc2n1C(C)C,Kd,9586.0,nM,5.02,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human GSK-3beta assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,2023.0
,O=C1Nc2ccc3ncsc3c2C1=CNc1ccc(S(=O)(=O)Nc2ccccn2)cc1,Ki,3.162,nM,8.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Cc1ccccc1)Nc1cc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)ccc1Cl,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccccc1Nc1nccc(-c2c(-c3cccc(NC(=O)Cc4ccccc4)c3)nc3sccn23)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CS(=O)(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1,Ki,79.43,nM,7.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1ccc(-c2ccncc2)cc1NCc1ccccc1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CSc1ccc2nc3c(c(Cl)c2c1)CCNC3=O,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1ncc2nc1OCC(O)C(O)COc1ccc(Cl)cc1NC(=O)N2,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc2c1Nc1cc(Nc3ccncc3)ccc1C(=O)N2,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN1CC=C(c2c(O)cc(O)c3c(=O)cc(-c4ccc(Sc5nc6ccccc6n5C)cc4Cl)oc23)CC1,IC50,59.0,nM,7.23,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK3beta in presence of ATP by ADP-glo luminescent assay,2020.0
,Cc1csc(-c2cnc(N)c(NC(=O)c3ccnc(NC(=O)C4CC4)c3)c2)c1,IC50,219.0,nM,6.66,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,CC(=O)Nc1ccc2[nH]cc(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1,IC50,250.0,nM,6.6,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,Cc1cc2cc(-c3csc4c(-c5cccc(S(C)(=O)=O)c5)cnc(N)c34)ccc2[nH]1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2ccc(-c3cncc(OCCN(C)S(C)(=O)=O)c3)cc12,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCN(CC)CC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12,Ki,3162.28,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOCC5CC5)c4)n[nH]c2-3)CC1,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(C=O)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1Nc2cc(CCOc3ccc(N4CCOCC4)cc3)ccc2Nc2cc(-c3cn(Cc4cc(F)c(F)c(F)c4)c4cnccc34)ccc21,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3noc4ncnc(N)c34)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,C#Cc1cc2c(cc1OC)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(C)cc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccc2nccnc12,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Oc1ccc(Nc2[nH]nc(-c3ccc(O)cc3)c2-c2ccc(O)cc2)cc1,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(CCl)c1cc(Cl)sc1Cl,IC50,5000.0,nM,5.3,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 (GSK-3beta).,2003.0
,COc1cc2c(CNC3CCN(S(=O)(=O)c4ccc([N+](=O)[O-])cc4)CC3)cc3c(c2cc1OC)C(=O)NC3=O,IC50,310.0,nM,6.51,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl,Ki,7100.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2006.0
,Cc1cc(Nc2n[nH]c3ncc(F)cc23)nc(-c2ccccc2Cl)c1,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,251328,,"Inhibition Assay: Compounds of the present invention were screened for their ability to inhibit GSK-3β (AA 1-420) activity using a standard coupled enzyme system (Fox et al., Protein Sci. 1998, 7, 2249). Reactions were carried out in a solution containing 100 mM HEPES (pH 7.5), 10 mM MgCl2, 25 mM NaCl, 300 μM NADH, 1 mM DTT and 1.5% DMSO. Final substrate concentrations in the assay were 20 μM ATP (Sigma Chemicals, St Louis, Mo.) and 300 μM peptide (American Peptide, Sunnyvale, Calif.). Reactions were carried out at 30 C. and 20 nM GSK-3β. Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate, 300 μM NADH, 30 μg/ml pyruvate kinase and 10 μg/ml lactate dehydrogenase.",2014.0
,Fc1ccccc1-c1cc(NCOc2cccnc2)n2ncc(Br)c2n1,IC50,130.0,nM,6.89,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,COCCn1cc(-c2ccnc(Nc3cccc(OC)c3)n2)c2cccnc21,IC50,2200.0,nM,5.66,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,CCN(CC)c1ccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)cc1,IC50,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,COc1cccc(-n2nc(C)c3c(N/N=C/c4ccncc4)ncnc32)c1,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,C(=N/Nc1ncnc2c1cnn2-c1ccncc1)\c1ccncc1,IC50,3.162,nM,8.5,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,O=C1OC(Nc2ncc3nnn(-c4ccccc4)c3n2)c2ccccc21,IC50,23.0,nM,7.64,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=[N+]([O-])c1cnc(Nc2ccccc2)nc1Nc1ccccc1,IC50,2800.0,nM,5.55,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,C=Cc1ccc2c(-c3ccnc(NC4CC4)n3)cnn2n1,IC50,3200.0,nM,5.5,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2008.0
,Nc1nonc1-n1nnc(C(=O)N/N=C/c2ccncc2)c1CN1CCCC1,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Inhibitory activity against human glycogen synthase kinase-3beta (GSK3-beta) at 100 uM ATP,2003.0
,O=C(O)CN1CCC(CNC(=O)c2n[nH]c3ccc(-c4ccccc4F)cc23)CC1,IC50,45.0,nM,7.35,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,Nc1nonc1-n1nnc(C(=O)NCCc2ccncc2)c1CN1CCCCC1,IC50,1160.0,nM,5.94,Glycogen synthase kinase-3 beta,,,Inhibitory activity against human glycogen synthase kinase-3beta (GSK3-beta) at 100 uM ATP,2003.0
,COc1cc2c(cc1OC)-c1[nH]c3ccc(Br)cc3c1CC(=O)N2,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta expressed in insect Sf9 cells,2010.0
,Clc1cnccc1-c1c[nH]c2cnccc12,IC50,9610.0,nM,5.02,Glycogen synthase kinase-3 beta,,,Inhibition of full-length recombinant human His-tagged GSK3B recombinant in baculovirus expression system using Alexa-Fluor tracer-236 incubated for 60 mins by TR-FRET based Lantha-screen Eu kinase assay,2017.0
,COc1ccc2c(-c3ccnc(Nc4ccc(C#N)cc4)n3)cnn2n1,Ki,50.0,nM,7.3,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
ALSTERPAULLONE 2,N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2007.0
GW434756X,Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1,IC50,2200.0,nM,5.66,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,CN(C)CCCn1cc(C2=C(c3ccccc3Cl)C(=O)NC2=O)c2cccnc21,IC50,15.0,nM,7.82,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(C(=O)O)c1,IC50,136.0,nM,6.87,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(Nc1n[nH]c2nc(-c3ccccc3)c(Cl)cc12)C1CC1,IC50,234.0,nM,6.63,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCCC(=O)Nc1n[nH]c2ncc(-c3ccccc3)cc12,IC50,56.0,nM,7.25,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1,IC50,18.0,nM,7.75,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(N2CCc3ccccc32)=C1c1cccc([N+](=O)[O-])c1,IC50,161.0,nM,6.79,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1ccc(C2=C(Nc3cccc(C(=O)O)c3)C(=O)NC2=O)cc1,IC50,214.0,nM,6.67,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CSc1ccc(NC2=C(c3ccc(Cl)cc3)C(=O)NC2=O)cc1,IC50,529.0,nM,6.28,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1cc(Cl)c(O)c(Cl)c1,IC50,91.0,nM,7.04,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(O)cc1,IC50,317.0,nM,6.5,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1cccc(Cl)c1,IC50,447.0,nM,6.35,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccccc1,IC50,514.0,nM,6.29,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cccc(C(=O)O)c1,IC50,79.0,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1ccccc1C1=C(c2cn(CCCNS(C)(=O)=O)c3ncccc23)C(=O)NC1=O,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,COc1cccc(Nc2nccc(-c3cnn4nc(OC)ccc34)n2)c1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,COc1cc(F)ccc1-c1ccnc(NC(=O)C2CCC(NC(C)=O)C2)c1,IC50,857.0,nM,6.07,Glycogen synthase kinase-3 beta,308361,,"In Vitro Kinase Inhibition Assay: In vitro kinase assay analysis may be performed using standard techniques described in the art. These techniques are also used by commercial services providers in order to offer in vitro kinase activity assay services, e.g. the assays offered by Millipore Inc. (worldwide website www(dot)millipore.com), ProQinase GmbH (worldwide website www(dot)proqinase.de) and others. All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50ul reaction volume. The reaction mixture was pipetted in four steps in the following order: 20ul of assay buffer (standard buffer),5ul of ATP solution (in H2O, 5 ul of test compound (in 10% DMSO), 10ul of substrate/10ul of enzyme solution (premixed)The assay for all enzymes contained 60 mM HEPES-NaOH (pH 7.5), 3 mM MgCl2, 3 mM MnCl2, 3uM Na-Orthovanadate, 1.2 mM DTT, 50 ug/ml PEG2000, 1 uM [33P]-ATP (approx. 5x1005 cpm per well).",2015.0
,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,IC50,40.0,nM,7.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using 10 uM ATP,2006.0
,O=c1sn(-c2ccccc2)c(=S)n1-c1ccccc1,IC50,8000.0,nM,5.1,Glycogen synthase kinase-3 beta,,,Inhibitory activity against recombinant rabbit Glycogen synthase kinase-3 beta,2002.0
,COc1ccc(-c2ocnc2C(=O)NCc2ccn3ccnc3c2)cc1Cl,IC50,630.96,nM,6.2,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta-mediated CRMP-2 phosphorylation by cell based assay,2012.0
,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCCCC1)CC2,IC50,1.6,nM,8.8,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta dependent Tau protein serine-396 phosphorylation in human SY5Y cells,2004.0
,Cc1cn(CCCNC(=O)c2ccc(O)c3[nH]c(-c4cccs4)nc23)cn1,IC50,50.0,nM,7.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,Cc1cc(Nc2c[nH]c3ncc(F)cc23)nc(C23CC4CC(CC(C4)C2)C3)n1,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,244261,,Inhibition Assay: Compounds are screened for their ability to inhibit the phosphorylation of tyrosine (TYR) residues through the use of western blotting of Jurkat cells dosed with the compounds. The phosphorylation of the specific TYR residues tested are GSK3α TYR 279 and GSK3β TYR 216.,2014.0
,O=C1C(Nc2ccccc2)=C(c2ccccc2)C(=O)N1Cc1ccccc1,IC50,5000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2005.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCC1CCN(Cc2ccccc2F)CC1,IC50,15.0,nM,7.82,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,Cc1cc(-c2cc(-c3nc4ccc(CN5CCN(C)CC5)cc4[nH]3)c(=O)[nH]n2)cc(C)c1O,IC50,1.5,nM,8.82,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2008.0
,COc1ccccc1C1=C(c2cn(CCCn3ccnc3)c3ccc(C)cc23)C(=O)NC1=O,IC50,65.0,nM,7.19,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,COc1ccc2c(c1)c(C1=C(c3ccccc3[N+](=O)[O-])C(=O)NC1=O)cn2CCCn1ccnc1,IC50,34.0,nM,7.47,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,COc1ccc2c(c1)c(C1=C(c3ccccc3C)C(=O)NC1=O)cn2CCCn1ccnc1,IC50,8008.0,nM,5.1,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccc(Br)cc23)=C1c1ccc2ccccc2c1,IC50,69.0,nM,7.16,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,CN1Cc2nn(C)c(C#N)c2-c2cnc3[nH]cc(c3c2)-c2cn(nc2C(F)(F)F)CCCC1=O,Kd,7294.3,nM,5.14,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human GSK-3beta assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,2023.0
,Cn1cc(-c2ccc3cnc(NC(=O)C4CCN(S(C)(=O)=O)CC4)cc3c2)cn1,Kd,3.745,nM,8.43,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human GSK-3beta assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,2023.0
,COc1ccccc1C1C2=C(CC(C)(C)CC2=O)Nc2n[nH]c(C(F)(F)F)c21,IC50,12.0,nM,7.92,Glycogen synthase kinase-3 beta,318305,,"HTS Assay: The GSK3beta primary screen was conducted in assay ready 1536 plates (Aurora 29847) that contain 2.5 mL/well of 10 mM compound. Human GSK3beta as a GST fusion expressed in baculoviral system was purchased from BPS Bioscience (San Diego, Calif.). The GSK3beta peptide substrate was from American Peptide (Sunnyvale, Calif.; Cat 311153). 1 L/well of CABPE (22.5 nM GSK3beta , 8 uM peptide in AB buffer (12.5 mM DTT, 0.25 mg/mL BSA, 0.5 unit/mL Heparin)), 0.5 L/well of 125 uM of ATP, and 1 L/well of positive control 50 uM of GW8510 (positive control) or AB (DMSO only neutral control) in respective wells according to plate design using BioRAPTR (Beckman, Brea, Calif.). Reactions were incubated at room temperature for 60 minutes. 2.5 uL/well of ADP-Glo (Promega, V9103) was added with BioRAPTR, and incubated at room temperature for 40 minutes followed by addition of 5 uL/well of ADP-Glo detection reagent (Promega, V9103) with Combi nL (Thermo, Waltham, Mass.).",2015.0
,Cc1cc(Nc2n[nH]c3ncc(F)cc23)nc([C@H]2CCCC[C@@H]2C)n1,IC50,300.0,nM,6.52,Glycogen synthase kinase-3 beta,244260,,Inhibition Assay: Compounds are screened for their ability to inhibit the phosphorylation of tyrosine (TYR) residues through the use of western blotting of Jurkat cells dosed with the compounds. The phosphorylation of the specific TYR residues tested are GSK3α TYR 279 and GSK3β TYR 216.,2014.0
,COCCN1CCC(CNC(=O)c2n[nH]c3ccc(OC)cc23)CC1,IC50,870.0,nM,6.06,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(CC(=O)O)CC3)c2c1,IC50,670.0,nM,6.17,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COC(=O)c1coc(CN2CCC(CNC(=O)c3n[nH]c4ccc(Br)cc34)CC2)n1,IC50,360.0,nM,6.44,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,Cc1ccccc1-n1nncc1-c1ccncc1,IC50,6300.0,nM,5.2,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by colorimetric analysis,2012.0
,Cc1nc2ccccc2n1CC(=O)NNC(=O)Cc1ccc(Cl)cc1,IC50,131.0,nM,6.88,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,O=C1NC(=O)/C(=C/c2ccc(O)c([N+](=O)[O-])c2)S1,IC50,9220.0,nM,5.04,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using GS-2 peptide substrate incubated for 30 mins by kinase-Glo luminescent assay,2018.0
,O=C1NCCc2cc(-c3ccnc(NC(=O)C4CC4)c3)ccc21,IC50,2.4,nM,8.62,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,NCC1(c2ccc(Cl)cc2)CCN(c2ccnc3[nH]ccc23)CC1,IC50,1400.0,nM,5.85,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta in human PC3M cells by ELISA,2008.0
,Oc1ccc2oc3ncc(OCc4ccccc4)c(-c4ccccc4)c3c2c1,Ki,5800.0,nM,5.24,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,Nc1ncnc2onc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cnccn1)Nc1ccnc2ccc(N3CC4COCC4C3)cc12,Ki,7.943,nM,8.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCN4CCOCC4)cc2-3)cn1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(C=Cc1ccc(Br)cc1)Nc1cccc2cnccc12,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)CC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12,Ki,6.31,nM,8.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccccc1NC(=O)Nc1ccc(NC(=O)c2csc3ncnc(N)c23)cc1,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NCc1cc(Nc2ncnc(-c3ccccc3)n2)ccc1O,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
ILORASERTIB,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(-c2ccc3c(c2)NC(=O)c2ccc(-c4ccccc4NS(C)(=O)=O)cc2N3)cc(OC)c1OC,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cccc(Cl)c1,IC50,70.0,nM,7.16,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1cccc(C2=C(Nc3cccc(Cl)c3)C(=O)NC2=O)c1,IC50,257.0,nM,6.59,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CC(C)OC1=NNC(=O)C1=Cc1c[nH]c2ccccc12,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1cc(C(F)(F)F)c2c(-c3cccc(C(F)(F)F)c3)n[nH]c2[nH]1,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(OCC(F)(F)F)nccn23)n1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(CSc2nnc(-c3ccc4[nH]ncc4c3)o2)cc1C(F)(F)F,IC50,16.0,nM,7.8,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,Cn1cc(C2=C(c3coc4cc(F)c(F)cc34)C(=O)NC2=O)c2ccc3ccccc3c21,IC50,314.0,nM,6.5,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cn1,IC50,79.43,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibition of catalytic activity of GSK3-beta by AlphaLISA assay,2012.0
,COc1cc(CNC(=O)c2ncoc2-c2ccc(OC)c(Cl)c2)ccn1,IC50,31.62,nM,7.5,Glycogen synthase kinase-3 beta,,,Inhibition of catalytic activity of GSK3-beta by AlphaLISA assay,2012.0
,COc1ccc(-c2ocnc2C(=O)NCc2ccnc(C)n2)cc1Cl,IC50,39.81,nM,7.4,Glycogen synthase kinase-3 beta,,,Inhibition of catalytic activity of GSK3-beta by AlphaLISA assay,2012.0
,Cc1cc(-c2cc3c(=O)[nH]cc(-c4cccc(NS(C)(=O)=O)c4)c3s2)ccn1,IC50,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in baculovirus by fluorescence polarization assay,2011.0
,N#CCc1cccc(-c2c[nH]c(=O)c3cc(-c4ccncc4)sc23)c1,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in baculovirus by fluorescence polarization assay,2011.0
,CCOc1ccc(-c2c[nH]c(=O)c3cc(-c4ccncc4)sc23)cn1,IC50,125.89,nM,6.9,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in baculovirus by fluorescence polarization assay,2011.0
,O=c1[nH]cc(-c2cccc3cccnc23)c2sc(-c3ccncc3)cc12,IC50,7943.28,nM,5.1,Glycogen synthase kinase-3 beta,,,Inhibition of human flag-tagged GSK3-beta expressed in HEK-MSRII cells assessed as CRMP-2 phosphorylation by alphaLISA assay,2011.0
,COc1ccncc1-c1ccc2[nH]nc(C(=O)NCC3CCN(Cc4ccc(C(=O)O)o4)CC3)c2c1,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,335736,,"LanthaScreen TR-FRET Assay: Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screening assay, compounds were tested in duplicate at a concentration of 10 uM.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um). In a second assay, the same compounds were assayed at five concentrations ranging from 100 uM to 10 nM with ten-fold dilutions in duplicate.",2015.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(Cc4ccc(C(=O)O)o4)CC3)c2c1,IC50,400.0,nM,6.4,Glycogen synthase kinase-3 beta,335739,,"LanthaScreen TR-FRET Assay: Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screening assay, compounds were tested in duplicate at a concentration of 10 uM.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um). In a second assay, the same compounds were assayed at five concentrations ranging from 100 uM to 10 nM with ten-fold dilutions in duplicate.",2015.0
,O=C1NC(=S)SC1=C1C(=O)Nc2ccc(Br)cc21,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)s2)c1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(Cl)ccc12,Ki,7.943,nM,8.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)CC(=O)NC1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1ccc2c(c1)C(c1ccc3c(n1)CCCC3O)C(=O)N2,Ki,31.62,nM,7.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CS(=O)(=O)NC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1,Ki,15.85,nM,7.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NC(CO)c1ccccc1)N1CC=C(c2c[nH]c3ncccc23)CC1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2c1C(c1ccccc1Br)C(C#N)=C(N)O2,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2ncc(C#N)c(-c3ccccc3)c12,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc2n1CC1CC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)CC(=O)NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1nnc(-c2cc3c(Oc4ccc(C(F)(F)F)cc4)cncc3s2)o1,Ki,3.981,nM,8.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
AZD-1080,N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Oc1ccc2nc(-c3ccc(Sc4ccc(-c5nc6ccc(O)cc6[nH]5)cc4)cc3)[nH]c2c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1Nc2ccccc2Nc2cc(-c3ccncc3Cl)ccc21,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(COc1cncc(C=Cc2ccncc2)c1)Cc1ccccc1,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1ncc2nc1OCCCCCOc1cc(OCC(O)CO)c(Cl)cc1NC(=O)N2,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1c(Cl)c(N2CCC(CN)C2)nc2[nH]cc(C(=O)O)c(=O)c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,OC1CCN(c2ncnc3[nH]cc(-c4ccccc4)c23)CC1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#CC(=Cc1ccc(O)c(O)c1)C(=O)NCc1ccccc1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(O)c1ccc(CN2CCC(CNC(=O)c3n[nH]c4ccc(-c5ccccc5F)cc34)CC2)o1,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,335735,,"LanthaScreen TR-FRET Assay: Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screening assay, compounds were tested in duplicate at a concentration of 10 uM.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um). In a second assay, the same compounds were assayed at five concentrations ranging from 100 uM to 10 nM with ten-fold dilutions in duplicate.",2015.0
,O=C(O)c1ccc(CN2CCC(CNC(=O)c3n[nH]c4ccc(Br)cc34)CC2)o1,IC50,210.0,nM,6.68,Glycogen synthase kinase-3 beta,335737,,"LanthaScreen TR-FRET Assay: Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screening assay, compounds were tested in duplicate at a concentration of 10 uM.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um). In a second assay, the same compounds were assayed at five concentrations ranging from 100 uM to 10 nM with ten-fold dilutions in duplicate.",2015.0
,Cn1cc(C2=C(c3coc4cc(OCC5CC5)ccc34)C(=O)NC2=O)c2cc(F)c(Cl)cc21,IC50,1290.0,nM,5.89,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,c1ccn2c(NC3CCCCC3)c(-c3ccc4[nH]ncc4c3)nc2c1,Ki,2611.0,nM,5.58,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,CCCCNc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12,Ki,19.0,nM,7.72,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,Cc1cc(Nc2n[nH]c3ncc(F)cc23)nc(-c2ccccc2)c1C,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,251330,,"Inhibition Assay: Compounds of the present invention were screened for their ability to inhibit GSK-3β (AA 1-420) activity using a standard coupled enzyme system (Fox et al., Protein Sci. 1998, 7, 2249). Reactions were carried out in a solution containing 100 mM HEPES (pH 7.5), 10 mM MgCl2, 25 mM NaCl, 300 μM NADH, 1 mM DTT and 1.5% DMSO. Final substrate concentrations in the assay were 20 μM ATP (Sigma Chemicals, St Louis, Mo.) and 300 μM peptide (American Peptide, Sunnyvale, Calif.). Reactions were carried out at 30 C. and 20 nM GSK-3β. Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate, 300 μM NADH, 30 μg/ml pyruvate kinase and 10 μg/ml lactate dehydrogenase.",2014.0
,COC(=O)c1ccc2c(c1)[nH]c1c(NC(=O)C3CC3)nccc12,IC50,71.0,nM,7.15,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human full length GSK3beta expressed in baculovirus in Sf9 insect cells using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate by ADP-Glo kinase assay,2021.0
,Cc1ccc(C)c(N2CCN(CCCNC(=O)c3nc(-c4cncnc4)no3)CC2)c1,IC50,3380.0,nM,5.47,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,COc1ccccc1N1CCN(CCCNC(=O)c2nc(-c3cccnc3)no2)CC1,IC50,410.0,nM,6.39,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,O=C(O)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,IC50,50.0,nM,7.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2008.0
,Cn1c(NCC(=O)c2cccc(F)c2)nc(-c2ccncc2)cc1=O,IC50,25.0,nM,7.6,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,Cn1c(CCCc2ccccc2)nc(-c2ccncc2)cc1=O,IC50,90.0,nM,7.05,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,CC(C)c1nc(-c2ccncc2)cc(=O)[nH]1,IC50,2100.0,nM,5.68,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,CC(CCC(=O)O)(c1ccc(O)c(N)c1)c1ccc(O)c(N)c1,Ki,1995.26,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NCc1ccc(Cl)cc1)c1cc2c(-c3ccccc3)n[nH]c2s1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)Oc1ccc(-c2noc(-c3ccc(NC4CCC(C(=O)O)C4)cc3)n2)cc1Cl,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCCNc1cc(-c2ccncc2)cc2[nH]nc(N)c12,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(C2(c3cccc(C)c3)CC2C(=O)Nc2ccncc2)c1,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#CC1=C(N)n2c(sc(=Cc3ccco3)c2=O)=C(C(N)=O)C1c1ccco1,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1ccc(F)c(-c2c[nH]c(=O)c3cc(-c4ccncc4)sc23)c1,IC50,79.43,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibition of human flag-tagged GSK3-beta expressed in HEK-MSRII cells assessed as CRMP-2 phosphorylation by alphaLISA assay,2011.0
,O=C1Nc2cc(Br)ccc2/C1=C1\Nc2ccccc2\C1=N/O,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2023.0
,COc1ccccc1-c1c2c(nc3[nH]nc(C)c13)CC(C)(C)CC2=O,IC50,54.0,nM,7.27,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human wildtype full length GSK-3beta,2023.0
,O=C(NCCCn1cnc(Cl)c1Cl)c1ccc(O)c2[nH]c(-c3cccs3)nc12,IC50,8.0,nM,8.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,COc1cc(C2=C(c3cn(CCCOC(=O)C(N)CC(C)C)c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,IC50,134.0,nM,6.87,Glycogen synthase kinase-3 beta,284792,,"Kinase Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",2015.0
,CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3c(Br)cnn23)cc1,IC50,3400.0,nM,5.47,Glycogen synthase kinase-3 beta,,,Inhibitory concentration for Glycogen synthase kinase-3 beta was determined in the presence of 10 um ATP (Km 50 uM),2005.0
,COC(=O)c1csc(CN2CCC(CNC(=O)c3n[nH]c4ccc(OC)cc34)CC2)n1,IC50,130.0,nM,6.89,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(CCc4ccc(O)cc4)CC3)c2c1,IC50,350.0,nM,6.46,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,Cc1nc(C2CCCCC2)nc(Nc2n[nH]c3ncc(F)cc23)c1C,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,244251,,Inhibition Assay: Compounds are screened for their ability to inhibit the phosphorylation of tyrosine (TYR) residues through the use of western blotting of Jurkat cells dosed with the compounds. The phosphorylation of the specific TYR residues tested are GSK3α TYR 279 and GSK3β TYR 216.,2014.0
,Fc1cnc2[nH]nc(Nc3cc(C(F)(F)F)cc(-c4ccccc4Cl)n3)c2c1,IC50,50.0,nM,7.3,Glycogen synthase kinase-3 beta,251326,,"Inhibition Assay: Compounds of the present invention were screened for their ability to inhibit GSK-3β (AA 1-420) activity using a standard coupled enzyme system (Fox et al., Protein Sci. 1998, 7, 2249). Reactions were carried out in a solution containing 100 mM HEPES (pH 7.5), 10 mM MgCl2, 25 mM NaCl, 300 μM NADH, 1 mM DTT and 1.5% DMSO. Final substrate concentrations in the assay were 20 μM ATP (Sigma Chemicals, St Louis, Mo.) and 300 μM peptide (American Peptide, Sunnyvale, Calif.). Reactions were carried out at 30 C. and 20 nM GSK-3β. Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate, 300 μM NADH, 30 μg/ml pyruvate kinase and 10 μg/ml lactate dehydrogenase.",2014.0
,Cn1c(NCCC2CCCCC2)nc(-c2ccncc2)cc1=O,IC50,39.0,nM,7.41,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,O=C(Nc1ccc2cn[nH]c2c1)c1ccc(Cl)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOC(=O)c1c(NC(=O)C2C(C)(C)C2(C)C)sc2cnccc12,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOc1ccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)cc1NC(=O)Cc1ccccc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)s2)c1,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1ccc(Cn2cc(-c3ccc4[nH]nc(-c5ccccc5)c4c3)nn2)cc1,Ki,19.95,nM,7.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccccc1Nc1nccc(-c2c(-c3cccc(NC(=O)c4ccccc4)c3)nc3sccn23)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1cncc1C(OCc1c(-c2ccc(OC(F)(F)F)cc2)cc(C#N)c(=O)n1C)c1ccc(C#N)cc1,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccccc1-n1cc(-c2ccccn2)nn1,IC50,490.0,nM,6.31,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by colorimetric analysis,2012.0
,Nc1n[nH]c2c(OCCCn3cccc3)ccc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1ccc2nc(-c3ccc([N+](=O)[O-])o3)cn2c1,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cnccn1)Nc1ccnc2ccc(C(F)(F)F)cc12,Ki,3.981,nM,8.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1ccc(CNc2nc3ccc(-c4ccncc4)cc3s2)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN1CCN(CCCNc2cccc(-c3nc4c(C(N)=O)cccc4[nH]3)n2)CC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc2c(cc1OC)CN(CC(=O)Nc1ccc3c(c1)/C(=C/c1cnc[nH]1)C(=O)N3)CC2,IC50,272.0,nM,6.57,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) in presence of 10 uM ATP incubated for 1 hr by Z'Lyte assay,2015.0
,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CCCC3)c2)[nH]1,IC50,136.0,nM,6.87,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(Cc4ccccc4)CC3)c2c1,IC50,250.0,nM,6.6,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COC(=O)c1coc(CN2CCC(CNC(=O)c3n[nH]c4ccc(OC)cc34)CC2)n1,IC50,210.0,nM,6.68,Glycogen synthase kinase-3 beta,335724,,"LanthaScreen TR-FRET Assay: Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screening assay, compounds were tested in duplicate at a concentration of 10 uM.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um). In a second assay, the same compounds were assayed at five concentrations ranging from 100 uM to 10 nM with ten-fold dilutions in duplicate.",2015.0
,Cc1cc(Nc2n[nH]c3ccc(F)cc23)nc(C2CCCCC2)n1,IC50,25.0,nM,7.6,Glycogen synthase kinase-3 beta,244263,,Inhibition Assay: Compounds are screened for their ability to inhibit the phosphorylation of tyrosine (TYR) residues through the use of western blotting of Jurkat cells dosed with the compounds. The phosphorylation of the specific TYR residues tested are GSK3α TYR 279 and GSK3β TYR 216.,2014.0
,COc1cccc(-n2ncc3c(N/N=C/c4cccc(N)c4)ncnc32)c1,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,COc1ccc(CNC(=O)Nc2nc3ccc(C#N)cc3[nH]2)cc1,IC50,86.0,nM,7.07,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using prephosphorylated peptide as substrate measured after 30 mins by Kinase-glo luminescence assay,2019.0
,O=C(Nc1cc(-c2ccc3ccncc3c2)ccn1)C1CC1,IC50,74.0,nM,7.13,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccc(CN(C)C)cc4)ncnc32)c1,IC50,5.012,nM,8.3,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,COc1ccc(CNC(=O)Nc2nc3ccc(C(C)=O)cc3[nH]2)cc1,IC50,260.0,nM,6.58,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using prephosphorylated peptide as substrate measured after 30 mins by Kinase-glo luminescence assay,2019.0
,Fc1cc(F)cc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCO5)o3)cc2)c1,IC50,195.0,nM,6.71,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,O=[N+]([O-])c1cccc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCCO5)o3)cc2)c1,IC50,164.0,nM,6.79,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,O=[N+]([O-])c1cccc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCO5)o3)cc2)c1,IC50,86.0,nM,7.07,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,N#Cc1cc(F)ccc1-c1ccc(CSc2nnc(-c3ccncc3)o2)cc1,IC50,56.0,nM,7.25,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,CC(=O)Nc1cc(-c2nnc(SCc3cccc(C#N)c3)o2)ccn1,IC50,19.0,nM,7.72,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccccc1,IC50,1390.0,nM,5.86,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2010.0
,COc1ccccc1[C@H]1CN(c2cc(-c3ccncn3)cc(=O)n2C)CCO1,IC50,6.1,nM,8.21,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta expressed in baculovirus infected SF9 cells after 60 mins,2011.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccoc3)ccc12,IC50,260.0,nM,6.58,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(Cl)c(Br)cc12,IC50,55.0,nM,7.26,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CC(=O)N1CC[C@@H](Nc2cncc(C(=O)c3cn(C(C)C)c4ncnc(N)c34)n2)[C@H]1c1ccc(F)cc1,IC50,340.0,nM,6.47,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(NC(=O)C2CC2)c1,IC50,9.8,nM,8.01,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,O=C(Nc1cnccc1-c1ccc(F)cc1C(F)(F)F)c1ccnc(NC(=O)C2CC2)c1,IC50,0.87,nM,9.06,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,COc1ccc(C=C2SC(=Nc3ccccc3)NC2=O)cc1O,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCCCO)c2)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(O)CO)c5)cnc(N)c34)cc2)cc1,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C,Ki,2511.89,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1ccc([N+](=O)[O-])cc1)N1CCc2[nH]c3c(Cl)cc(Cl)cc3c2C1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)C(=O)Oc1ccc2c(c1)nc(NC(=O)c1cccc([N+](=O)[O-])c1)n2CCCO,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1nc(-c2ccnc(NC(=O)C3CC3)c2)ncc1C(N)=O,IC50,5.9,nM,8.23,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(Oc3ccnc(Nc4ccccc4)n3)c3ccccc23)cc1,Kd,1200.0,nM,5.92,Glycogen synthase kinase-3 beta,304681,,"Enzyme Inhibition Assay: The kinase enzyme binding activities of compounds disclosed herein were determined using a proprietary assay which measures active site-directed competition binding to an immobilized ligand (Fabian, M. A. et al., Nature Biotechnol., 2005, 23:329-336). These assays were conducted by DiscoverX (formerly Ambit; San Diego, Calif.). The Kd value (Dissociation constant value) was calculated as the index of affinity of the compounds to each kinase. The enzyme inhibitory activities of compounds disclosed herein were determined by FRET using synthetic peptides labelled with both donor and acceptor fluorophores (Z-LYTE, Invitrogen Ltd., Paisley, UK). In all cases, the site-specific protease cleaves non-phosphorylated peptide only and eliminates the FRET signal. Phosphorylation levels of each reaction were calculated using the ratio of coumarin emission (donor) over fluorescein emission (acceptor), for which low ratios indicate high phosphorylation and high ratios indicate low phosphorylation levels.",2015.0
,Cc1cc(Nc2n[nH]c3ncc(F)cc23)nc(C2CCCCCC2)n1,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,244254,,Inhibition Assay: Compounds are screened for their ability to inhibit the phosphorylation of tyrosine (TYR) residues through the use of western blotting of Jurkat cells dosed with the compounds. The phosphorylation of the specific TYR residues tested are GSK3α TYR 279 and GSK3β TYR 216.,2014.0
,CS(=O)(=O)Nc1ccc(CCNC(=O)c2ccc(O)c3[nH]c(C4CCCC4)nc23)cc1,IC50,44.0,nM,7.36,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,Cn1c(N2CCCCC2)cc(-c2ccncn2)cc1=O,IC50,62.0,nM,7.21,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta expressed in baculovirus infected SF9 cells after 60 mins,2011.0
,O=C1NCCOc2cc(-c3ccnc(NC(=O)C4CC4)c3)ccc21,IC50,4.7,nM,8.33,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,O=C1NCCCc2cc(-c3ccnc(NC(=O)C4CC4)c3)ccc21,IC50,2.4,nM,8.62,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,O=C1NCc2cc(-c3ccnc(NC(=O)C4CC4)c3)ccc21,IC50,11.0,nM,7.96,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,CC(C)Oc1nc(-c2ccnc(NC(=O)C3CC3)c2)sc1C(N)=O,IC50,0.45,nM,9.35,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,CCCCNc1nccc(-c2cc(C(=O)NCCCc3cccnc3)c(=O)[nH]n2)n1,IC50,36.0,nM,7.44,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,O=c1sn(CCc2ccccc2)c(=O)n1Cc1ccccc1,IC50,3000.0,nM,5.52,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,Fc1cccc(CSc2nnc(-c3ccc4c(c3)CCO4)o2)c1,IC50,54.0,nM,7.27,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,Clc1ccc(CSc2nnc(-c3ccc4c(c3)CCO4)o2)cc1,IC50,280.0,nM,6.55,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,COc1ccc(-c2coc3ccc(-c4nnc(SCc5cccc(C#N)c5)o4)cc23)cc1,IC50,3.5,nM,8.46,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(CCNS(C)(=O)=O)CC3)c2c1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,Cc1nc2ccccc2n1Cc1nnc(Nc2ccc([N+](=O)[O-])cc2)s1,IC50,107.0,nM,6.97,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,COc1ncccc1-c1ccc2[nH]nc(C(=O)NCC3CCN(Cc4ccc(C(=O)O)o4)CC3)c2c1,IC50,360.0,nM,6.44,Glycogen synthase kinase-3 beta,335731,,"LanthaScreen TR-FRET Assay: Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screening assay, compounds were tested in duplicate at a concentration of 10 uM.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um). In a second assay, the same compounds were assayed at five concentrations ranging from 100 uM to 10 nM with ten-fold dilutions in duplicate.",2015.0
,Cn1cc(C2=C(c3ccc(-c4ccccc4)cc3)C(=O)NC2=O)c2ccccc21,IC50,730.0,nM,6.14,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,O=C(O)c1ccc(Nc2ncc(Br)c(Nc3ccccc3)n2)cc1,IC50,3200.0,nM,5.5,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,OC12CC3CC(C1)CC(Nc1nc(N[C@H]4CC[C@H](O)CC4)ncc1C(F)(F)F)(C3)C2,IC50,41.0,nM,7.39,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2ccc(Cl)cc2n(C)c1=O,IC50,4030.0,nM,5.39,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2)CC1,IC50,200.0,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2008.0
,N#Cc1cccc(C(=O)C(Br)Br)c1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using GS1 as substrate and [gamma-32P]ATP after 20 mins by radiometric assay,2011.0
,CNC(=O)c1cc(-c2ccc3[nH]ncc3c2)on1,Ki,4272.0,nM,5.37,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,FC(F)(F)c1ccc(-c2cc3[nH]ccnc-3n2)cc1,IC50,7200.0,nM,5.14,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,O=C1N=C(NCc2ccccc2)S/C1=C\c1ccc(O)cc1,IC50,27.1,nM,7.57,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK-3beta expressed in Baculovirus using Ser/Thr9 peptide as substrate by Z' LYTE assay,2016.0
,CC(=O)c1ccc(-c2coc3ccc(-c4ccc(C)o4)cc23)cc1,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,C[S+]([O-])c1ccc(-c2coc3ccc(-c4nnc(S)o4)cc23)cc1,IC50,94.0,nM,7.03,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,c1ccc(Cc2c(-c3ccccc3)[nH]c3nccnc23)cc1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
RUBOXISTAURIN,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,Kd,2600.0,nM,5.58,Glycogen synthase kinase-3 beta,,,Binding constant for full-length GSK3B,2008.0
,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCOCC1)CC2,IC50,1.3,nM,8.89,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2010.0
,CCOC(=O)Cn1sc(=O)n(-c2cccc(C(=O)OCC)c2)c1=O,IC50,467.0,nM,6.33,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by Z'-LYTE kinase assay,2009.0
,Cc1cccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c1,Ki,70.0,nM,7.16,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,Nc1n[nH]c2ccc(-c3cc(Cc4ccccc4)no3)cc12,Ki,450.0,nM,6.35,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,Cc1ccc(-c2cc3c(NC(=O)C4CCCC4)ncnc3o2)cc1,IC50,240.0,nM,6.62,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,Nc1c(F)c(NCCN2CCOCC2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1,IC50,2100.0,nM,5.68,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,Nc1c(F)c(NCCNc2ccccn2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CCCC1,IC50,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CCC(=O)C3)c2)[nH]1,IC50,73.0,nM,7.14,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,NCC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,IC50,1400.0,nM,5.85,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta in human PC3M cells by ELISA,2008.0
,O=C1NC(=S)S/C1=C\c1ccc(O)c([N+](=O)[O-])c1,IC50,3970.0,nM,5.4,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2008.0
,CNC(=O)N1CCN(CCCOc2ccc3c(c2)-c2[nH]nc(-c4ccc(C#N)nc4)c2C3)CC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CCO)c5)cnc(N)c34)cc2F)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3sccc3n2)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(c1cc(Cc2n[nH]c(=O)c3c2CCCC3)ccc1F)N1CCN(c2ncccn2)CC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(Cc1cccc2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1c[nH]c2cc(-c3ccsc3)nc-2n1,IC50,800.0,nM,6.1,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,c1cc2[nH]ncc2cc1-n1cc(C2CCCC2)nn1,Ki,1298.0,nM,5.89,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,c1ccc(Cc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1,Ki,542.0,nM,6.27,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,c1ccc(CCCc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1,Ki,528.0,nM,6.28,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,Clc1cc(Cl)cc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c1,Ki,28.0,nM,7.55,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,CCCc1cc(-c2ccc3[nH]ncc3c2)on1,Ki,2530.0,nM,5.6,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,CN(C)CCCn1nc(C2=C(c3cn(-c4ccccc4)c4ccccc34)C(=O)NC2=O)c2ccccc21,IC50,270.0,nM,6.57,Glycogen synthase kinase-3 beta,,,Inhibition of rabbit Glycogen synthase kinase-3 beta,2005.0
,c1ccc(CCNc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1,Ki,5450.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)c(-c3ccccc3)s2)cc1,Ki,3402.0,nM,5.47,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,c1cn2c(NC3CCCCC3)c(-c3ccc4[nH]ncc4c3)nc2s1,Ki,642.0,nM,6.19,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,O=C(NCc1ccccc1)Nc1cccc2ccccc12,IC50,17.1,nM,7.77,Glycogen synthase kinase-3 beta,246654,,"Inhibition Assay: The GSK-3β activity was determined by incubation of a mixture of recombinant human GSK-3 enzyme, a phosphate source and GSK-3 substrate in the presence and in the absence of the corresponding test compound, and by measuring the GSK-3 activity of this mixture.Recombinant human glycogen synthase kinase 313 was assayed in MOPS 8 mM pH 7.3, EDTA 0.2 mM, MgCl2 10 mM and sodium orthovanadate 0.25 mM in the presence of 62.5 μM of Phospho-Glycogen Synthase Peptide-2 (GS-2), 0.5 μCi γ-33P-ATP and unlabelled ATP at a final concentration of 12.5 μM. The final assay volume was 20 μl. After incubation for 30 minutes at 30° C., 15 μl aliquots were spotted onto P81 phosphocellulose papers. Filters were washed four times for at least 10 minutes each and counted with 1.5 ml of scintillation cocktail in a scintillation counter.",2014.0
,CN(c1ncnc2[nH]c3cc(Cl)ccc3c12)C1CCCN(C(=O)CC#N)C1,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2022.0
,O=C(CCl)c1cc(Cl)c(Cl)s1,IC50,3000.0,nM,5.52,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2022.0
WUWEIZISU B,COc1cc2c(c(OC)c1OC)-c1c(cc3c(c1OC)OCO3)C[C@H](C)[C@H](C)C2,IC50,73.0,nM,7.14,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK3-beta,2022.0
,COc1ccc(-c2cc(=O)c3c(OC)c([C@@H]4O[C@H](C(=O)NC5CCCCC5)[C@@H](O)[C@H](O)[C@H]4O)c(OC)cc3o2)cc1OC,IC50,9000.0,nM,5.05,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) using peptide YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate incubated for 5 to 60 mins by ADP-Glo kinase assay,2022.0
,N#Cc1ccc(NCCNc2nc(-c3ccc(Cl)cc3Cl)cn3nc(C(=O)O)cc23)nc1,IC50,21.0,nM,7.68,Glycogen synthase kinase-3 beta,213535,,"Biochemical Assay: The ingredients required for this purpose are mixed in a black 384-well microtiter plate with transparent base (from Greiner, catalog number 781092). The requirements in this connection for each well of the 384-well microtiter plate are 5 nM GSK3β (from Upstate, catalog number xy), 40 μM GSK3β substrate GSM (sequence H-RRRPASVPPSPSLSRHS-(pS)-HQRR, from Upstate, catalog number 2-533), 30 μM nicotinamide adenine dinucleotide NADH (Roche Diagnostics, catalog number 10107735), 50 μM adenosine triphosphate ATP (from Sigma, catalog number A7966) and 2 mM phosphoenolpyruvate (from Roche, catalog number 128112). The required reaction buffer in which the biochemical reaction takes place consists of 50 mM Trizma hydrochloride Tris-HCl pH: 7.5 (from Sigma, catalog number T3253), 5 mM magnesium chloride MgCl2 (from Sigma, catalog number M8266), 0.2 mM DL-dithiothreitol DTT (from Sigma, catalog number D9779), 2 mM ethylenediaminetetraacetic acid EDTA (from Sigma, catalog number E6758), 0.01% Triton X-100 (from Sigma, catalog number T8787) and 0.05% bovine serum albumin BSA (from Sigma, catalog number B4287). Active substances are dissolved in dimethyl sulfoxide DMSO (from Sigma, catalog number D8418) in a concentration of 10 mM. Active substances are added in serial concentrations of 10 μM, 1 μM, 0.1 μM, 0.01 μM, 0.001 μM, 0.0001 μM, 0.00001 μM, 0.000001 μM to the mixtures of the biochemical reaction. As control, dimethyl sulfoxide is added instead of substance in a final concentration of 0.1%. The reaction is incubated at 30° C. for 2 hours and then the resulting fluorescence is measured in a Tecan Safire-XFLUOR4 instrument, version V4.50 (serial number 12901300283) with the specifications: measurement mode−fluorescence measured from below, extinction wavelength 340 nm, emission wavelength 465 nm, slit width extinction 5 nm, slit width emission 5 nm, gain mode 120, delay 0 μs, number of light flashes per measurement 3, and an integration time of 40 μs.",2013.0
,O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ccccc1Cl,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,CCN(CC)Cc1c(C(=O)N/N=C/c2ccncc2)nnn1-c1nonc1N,IC50,410.0,nM,6.39,Glycogen synthase kinase-3 beta,,,Inhibitory activity against human glycogen synthase kinase-3beta (GSK3-beta) at 100 uM ATP,2003.0
,N#CCc1ccc(Nc2nccc(Nc3cc(C4CC4)[nH]n3)n2)cc1,IC50,1.2,nM,8.92,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal NanoLuc-fused full length lysed GSK3B (unknown origin) transfected in HEK293T cells incubated for 2 hrs in presence of tracer K8 by NanoBRET assay,2023.0
,Cn1cc(C2C(=O)NC(=O)C2c2coc3ccccc23)c2cc(Br)ccc21,IC50,21.0,nM,7.68,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2016.0
,COc1cc(NCc2cccnc2)n2ncc(Br)c2n1,IC50,1410.0,nM,5.85,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ccccc1C(F)(F)F,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,Nc1nonc1-n1nnc(C(=O)NCCc2ccncc2)c1CN1CCCC1,IC50,2100.0,nM,5.68,Glycogen synthase kinase-3 beta,,,Inhibitory activity against human glycogen synthase kinase-3beta (GSK3-beta) at 100 uM ATP,2003.0
,O=c1[nH]cnc2[nH]c(-c3ccnc(/C=C/c4ccc(CN5CCOCC5)cc4)c3)cc12,IC50,300.0,nM,6.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3b,2008.0
,CCCn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,C#Cc1cnn2c(NCc3cccnc3)cc(-c3ccccc3)nc12,IC50,9820.0,nM,5.01,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,COc1ccc(-n2c(-c3nonc3N)nc3ccccc32)cc1,Ki,5000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,N#Cc1cccc(-c2nc3c(NC(=O)C4CC4)ncnc3[nH]2)c1,IC50,781.0,nM,6.11,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2010.0
,OCCNc1cc2cc(-c3cccnc3)ccc2cn1,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)c1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NC(CO)c1ccccc1)c1ccc(-c2ccncc2)cc1,Ki,158.49,nM,6.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1n[nH]c2cccc(-c3ccc(Br)cc3)c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1c(F)cccc1F,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc(OCCCn4cccc4)c4[nH]nc(N)c34)cc2)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(CCC(=O)Nc1cc(C(F)(F)F)ccc1Cl)NN=Cc1c[nH]c2ccccc12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cnc(Nc2nc(NC(C)C)ncc2Br)s1,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COC(=O)c1ccccc1-c1ccc2c(c1)Nc1ccccc1NC2=O,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COCc1nnn(-c2nonc2N)c1C(=O)NN=C(C)c1ccc(O)cc1O,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
TOZASERTIB,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NCC1CCN(Cc2ccc(F)cc2)CC1)c1cncc(NC(=O)c2ccnc(NC(=O)C3CC3)c2)c1,IC50,244.0,nM,6.61,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,O=C(Nc1cncc(OCC2CCN(Cc3ccccc3F)CC2)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,77.0,nM,7.11,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,Cn1cc(C2=C(N(C(=O)OC(C)(C)C)c3ccccc3)C(=O)NC2=O)c2ccccc21,IC50,3100.0,nM,5.51,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,Cn1cc(C2=C(Oc3ccccc3)C(=O)NC2=O)c2ccccc21,IC50,2800.0,nM,5.55,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,Cn1cc(C2=C(c3cccs3)C(=O)NC2=O)c2ccccc21,IC50,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,Cn1cc(C2=C(c3cccc(N)c3)C(=O)NC2=O)c2ccccc21,IC50,1.8,nM,8.74,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN)cc21,IC50,1020.0,nM,5.99,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CNC)cc21,IC50,303.0,nM,6.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](C)N)cc21,IC50,1210.0,nM,5.92,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
,COc1ccc2c(C3=C(c4cn(C)c5cc(Cl)c(F)cc45)C(=O)NC3=O)coc2c1,IC50,870.0,nM,6.06,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(C3CC3)ccc21,IC50,235.0,nM,6.63,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cccc(O)c21,IC50,55.0,nM,7.26,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(OC(F)F)cc5)cc4)csc23)cn1,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc2[nH]cc(C=C3C(=O)Nc4ccccc43)c2c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)C1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(OC)cc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)c1,Ki,39.81,nM,7.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COCC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(C)nccn23)n1,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)CNC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1Cl)c1ccccc1F,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1Cl,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)ccc(F)c12,Ki,7.943,nM,8.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
MERIDIANIN A,Nc1nccc(-c2c[nH]c3cccc(O)c23)n1,IC50,1300.0,nM,5.89,Glycogen synthase kinase-3 beta,,,Inhibition of glycogen synthase kinase-3 beta,2004.0
,Cc1n[nH]c2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12,IC50,260.0,nM,6.58,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2010.0
,Cc1n[nH]c2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12,IC50,160.0,nM,6.8,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2010.0
,CCC(N)(C#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12)CC,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COCc1cccc2c(C3=C(c4coc5cc(CO)ccc45)C(=O)NC3=O)cn(C)c12,IC50,0.73,nM,9.14,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,COc1ccccc1-c1ccnc(Nc2cccc(S(C)(=O)=O)c2)n1,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(C=NNc2ncnc3c2[nH]c2ccccc23)cc1OC,Ki,125.89,nM,6.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(Nc2nc(Sc3ccccc3Cl)nc3ccccc23)n[nH]1,Ki,126.0,nM,6.9,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,Cc1cc(Nc2nc(Sc3ccc4ccccc4c3)nc3ccccc23)n[nH]1,Ki,150.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,CC(=O)Nc1ccc(Sc2nc(Nc3cc(C4CC4)[nH]n3)c3ccccc3n2)cc1,Ki,338.0,nM,6.47,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(Nc2ccc(OC(F)(F)F)cc2)n1,IC50,1.8,nM,8.74,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,CN(C)C(=O)c1ccccc1-c1c[nH]c(=O)c2cc(-c3ccncc3)sc12,IC50,316.23,nM,6.5,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in baculovirus by fluorescence polarization assay,2011.0
,CS(=O)(=O)Nc1cccc(-c2c[nH]c(=O)c3cc(-c4ccnc5[nH]ccc45)sc23)c1,IC50,19.95,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of human full length His-tagged GSK3-beta expressed in baculovirus by alphaLISA assay,2011.0
,CCOC(=O)c1nc(CN2CCC(CNC(=O)c3n[nH]c4ccc(OC)cc34)CC2)cs1,IC50,950.0,nM,6.02,Glycogen synthase kinase-3 beta,335728,,"LanthaScreen TR-FRET Assay: Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screening assay, compounds were tested in duplicate at a concentration of 10 uM.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um). In a second assay, the same compounds were assayed at five concentrations ranging from 100 uM to 10 nM with ten-fold dilutions in duplicate.",2015.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(Cc4ccnc(C(=O)O)c4)CC3)c2c1,IC50,450.0,nM,6.35,Glycogen synthase kinase-3 beta,335743,,"LanthaScreen TR-FRET Assay: Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screening assay, compounds were tested in duplicate at a concentration of 10 uM.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um). In a second assay, the same compounds were assayed at five concentrations ranging from 100 uM to 10 nM with ten-fold dilutions in duplicate.",2015.0
,COc1cccc(C2=C(Nc3cccc(O)c3)C(=O)NC2=O)c1,IC50,472.0,nM,6.33,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CN(C1=C(c2ccccc2)C(=O)NC1=O)c1ccccc1,IC50,2613.0,nM,5.58,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1ccc(C2=C(Nc3cc(Cl)c(O)c(Cl)c3)C(=O)NC2=O)cc1,IC50,83.0,nM,7.08,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(O)c1coc(CN2CCC(CNC(=O)c3n[nH]c4ccc(-c5cccc(F)c5F)cc34)CC2)n1,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,335727,,"LanthaScreen TR-FRET Assay: Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screening assay, compounds were tested in duplicate at a concentration of 10 uM.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um). In a second assay, the same compounds were assayed at five concentrations ranging from 100 uM to 10 nM with ten-fold dilutions in duplicate.",2015.0
,CN1C(=O)Cc2c([nH]c3ccc(Br)cc23)-c2ccccc21,IC50,2100.0,nM,5.68,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta expressed in insect Sf9 cells,2010.0
,Cn1cc(C2=C(c3cn(CCCn4ccnc4)c4ccccc34)C(=O)NC2=O)c2ncccc21,IC50,660.0,nM,6.18,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-GSK3beta expressed in Escherichia coli BL21 (DE3),2009.0
,O=C(Nc1cnccc1C(F)(F)F)c1ccnc(NC(=O)C2CC2)c1,IC50,19.0,nM,7.72,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,O=C(Nc1cnccc1-c1ccc(Cl)cc1)c1ccnc(NC(=O)C2CC2)c1,IC50,5.9,nM,8.23,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,O=C(Nc1cnccc1-c1ccc(F)cc1Cl)c1ccnc(NC(=O)C2CC2)c1,IC50,1.2,nM,8.92,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,O=C(Nc1cnccc1-c1cc(F)ccc1F)c1ccnc(NC(=O)C2CC2)c1,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,O=C(Nc1cnccc1-c1cccc(F)c1F)c1ccnc(NC(=O)C2CC2)c1,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,NC(=O)Cn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(NC(=O)N2CCC(c3nc4c(C(N)=O)cccc4[nH]3)CC2)c1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(N2CCN(C)CC2)ccc1C(=O)Nc1n[nH]c2ccc(Cc3cc(F)cc(F)c3)cc12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1cc(-c2cccc(F)c2)[nH]c2c(-c3ccc(F)cc3)cnn12,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(C(C)NC(=O)N2CC=C(c3c[nH]c4ncccc34)CC2)c1,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4sc(C)nc4c3)csc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(-c2ccc3c(c2)Nc2c(O)cccc2NC3=O)ccc1O,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cc2c(-c3ccccc3)cncc2s1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NCCC(C(=O)Nc1ccc2[nH]ncc2c1)c1ccc(Cl)c(Cl)c1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)C1Cc2nc(-c3ccc(Cl)c(Cl)c3)n(-c3ccnc(N[C@H]4CCCN(C(=O)C5CC5)C4)n3)c2C1,IC50,3889.7,nM,5.41,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) incubated for 20 mins in presence of 33P-ATP,2023.0
,Cc1cc(Nc2nc(Sc3ccc(Cl)cc3Cl)nc3ccccc23)n[nH]1,Ki,8.0,nM,8.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,Cc1cc(Nc2nc(Sc3ccc(Cl)c(Cl)c3)nc3ccccc23)n[nH]1,Ki,15.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,COc1ccc(CCNc2cc(-c3ccncn3)cc(=O)n2C)cc1,IC50,731.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta expressed in baculovirus infected SF9 cells after 60 mins,2011.0
,COc1ccc(-c2ocnc2C(=O)NCCCc2ccc(NC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)cc2)cc1Cl,IC50,0.92,nM,9.04,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,COc1ccc(-c2ocnc2C(=O)NCCCn2cc(CNC(=O)CCc3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)nn2)cc1I,IC50,0.81,nM,9.09,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,O=C1C(c2ccc(O)c(O)c2)=C2C(=C(c3ccc(O)c(O)c3)C(=O)N2CCc2ccc(O)c(O)c2)c2cc(O)c(O)cc21,IC50,200.0,nM,,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged human recombinant GSK3beta expressed in baculovirus-infected Sf21 cells incubated for 60 mins in presence of ATP by ADP-glo analysis,2023.0
,O=c1oc2cc(O)c(O)cc2c2c3c4cc(O)c(O)cc4oc(=O)c3n(CCc3ccc(O)c(O)c3)c12,IC50,3100.0,nM,5.51,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged human recombinant GSK3beta expressed in baculovirus-infected Sf21 cells incubated for 60 mins in presence of ATP by ADP-glo analysis,2023.0
,O=C1NC(=O)C(c2cnc3cnccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCOCC1)CC2,IC50,11.0,nM,7.96,Glycogen synthase kinase-3 beta,,,"Inhibitory concentration to inhibit Ser396 phosphorylation of tau, a natural substrate of GSK-3 in SY5Y cells",2005.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccncc3)ccc12,IC50,661.0,nM,6.18,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCC(CO)Nc1nc(Nc2cccc(-c3ccccn3)c2)c2ncn(C(C)C)c2n1,IC50,4100.0,nM,5.39,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2010.0
,O=C(O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccccc3)n2)cc1,IC50,490.0,nM,6.31,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=C(O)COc1ccc(Nc2ncc3nnn(-c4ccccc4)c3n2)cc1,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=C(Nc1n[nH]c2nc(-c3ccccc3)ccc12)C1CC1,IC50,425.0,nM,6.37,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCCC(=O)Nc1n[nH]c2ncc(-c3cccc(F)c3F)cc12,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccc([N+](=O)[O-])cc2)=C1Nc1cc(Cl)c(O)c(Cl)c1,IC50,71.0,nM,7.15,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CC(=NNC(=N)N)c1cc(NC(=O)NCCCN(C)CCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(-c2cc3nccn3c(Nc3ccccc3C(N)=O)n2)cc1OC,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncnc2c1sc1ncnc(N)c12,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21,Ki,316.23,nM,6.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(F)c(-c2ccc3nnc(N)n3c2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccccc3)nn2n1,Ki,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Oc1cnc2oc3c4ccccc4c(O)cc3c2c1-c1ccccc1,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,O=C1NC(NC2CCCCCCC2)=N/C1=C\c1ccc2ncsc2c1,IC50,4259.0,nM,5.37,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@@H]2CCCCC[C@@H]2O)=N/C1=C\c1ccc2ncsc2c1,IC50,847.0,nM,6.07,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cc1cc(Nc2ncc(C)c(N3CC(O)(C4CC4)C3)n2)sn1,IC50,1139.0,nM,5.94,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,CN(C)CCOc1ccc(/C=C/c2cc(-c3cc4c(=O)[nH]cnc4[nH]3)ccn2)cc1,IC50,530.0,nM,6.28,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3b,2008.0
,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cc(F)ccc21,IC50,0.35,nM,9.46,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,COc1ccc(COc2ccc3c(C4=C(c5cn(C)c6ccc(Br)cc56)C(=O)NC4=O)coc3c2)cc1,IC50,335.0,nM,6.47,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,O=c1sn(CCc2ccccc2)c(=O)n1Cc1ccc(F)cc1,IC50,1863.0,nM,5.73,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by Z'-LYTE kinase assay,2009.0
,O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCOCCn1cc2c2cccnc21,IC50,48.0,nM,7.32,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3beta (GSK3-beta),2003.0
,Nc1c(F)c(NCCNc2ccccn2)c2c3c1c(=O)c(C(=O)O)cn3C1(CCC1)CCO2,IC50,36.0,nM,7.44,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta after 1 hr by KinaseGlo luciferase assay,2012.0
,NS(=O)(=O)c1ccc(Nc2cc(NC3CCCCC3)nc3ncnn23)cc1,IC50,970.0,nM,6.01,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using 10 uM ATP,2006.0
,OC12CC3CC(C1)CC(n1nnc4cnc(N[C@H]5CC[C@H](O)CC5)nc41)(C3)C2,IC50,744.0,nM,6.13,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=[N+]([O-])c1cnc(N[C@H]2CC[C@H](O)CC2)nc1NC12CC3CC(CC(O)(C3)C1)C2,IC50,198.0,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,Cn1c(=O)c2cnc(Nc3ccc(C(=O)O)cc3)nc2n1-c1ccccc1,IC50,960.0,nM,6.02,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,Cc1ccc2c(-c3ccnc(Nc4ccc(Cl)c(C(F)(F)F)c4)n3)c(-c3ccc(F)cc3)nn2n1,Ki,50.0,nM,7.3,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Cc1ccc(N2CCN(CCCNC(=O)c3nc(-c4cccnc4)no3)CC2)cc1,IC50,1330.0,nM,5.88,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,O=C(NCCCN1CCN(c2ccccc2)CC1)c1nc(-c2cccnc2)no1,IC50,860.0,nM,6.07,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,Cc1cc(C)cc(Nc2nccc(-c3cnn4ncccc34)n2)c1,Ki,10.0,nM,,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,COC[C@@H]1COc2ccc(-c3nnc(SCc4ccc(-c5ccccc5C#N)cc4)o3)cc2O1,IC50,758.0,nM,6.12,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using pIRS-1 as substrate preincubated for 15 mins,2012.0
,COc1ccc2c(c1)[nH]c1c(CO)nccc12,IC50,8300.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2021.0
,Nc1nonc1-c1nc2ccccc2n1C1CCC1,Ki,380.0,nM,6.42,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,Nc1nonc1-c1nc2ccccc2n1CC1CC1,Ki,290.0,nM,6.54,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,Cc1ccc(C(=O)Nc2c[nH]nc2C(=O)CCCOC(C)C)cn1,IC50,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,O=C(Nc1cnccc1-c1ccc(F)cc1)c1ccnc(Nc2ccc(OC(F)F)cc2)n1,IC50,0.45,nM,9.35,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,Nc1nccc(C(=O)Nc2cnccc2N2CCC(F)(F)CC2)n1,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
MERIDIANIN E,Nc1nccc(-c2c[nH]c3c(Br)ccc(O)c23)n1,IC50,2500.0,nM,5.6,Glycogen synthase kinase-3 beta,,,Inhibition of glycogen synthase kinase-3 beta,2004.0
,O=C(Nc1cc(-c2nc(OCC3CC3)c(C(=O)N3CC(F)C3)s2)ccn1)C1CC1,IC50,42.1,nM,7.38,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2023.0
,CCCC(=O)Nc1n[nH]c2cc(-c3cc(F)cc(F)c3)ccc12,IC50,2700.0,nM,5.57,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta by kinetic assay,2010.0
,COc1ccc(N/N=C2\C(=O)NN=C2c2cccc(OC)c2)cc1,Ki,18.0,nM,7.75,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1cccc(C2=NNC(=O)/C2=N\Nc2cccnc2)c1,Ki,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(C2=NNC(=O)/C2=N\Nc2cccc(Cl)c2)cc1,Ki,1.9,nM,8.72,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(C2=NNC(=O)/C2=N\Nc2ccc(N3CCOCC3)cc2)cc1OC,Ki,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,O=C(Nc1cccnc1F)c1ccnc(NC(=O)C2CC2)c1,IC50,1600.0,nM,5.8,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) assessed as decrease in tau phosphorylation by high content cell based assay,2016.0
,O=C(Nc1cnccc1Oc1ccccc1)c1ccnc(NC(=O)C2CC2)c1,IC50,200.0,nM,6.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) assessed as decrease in tau phosphorylation by high content cell based assay,2016.0
,Nc1ncnc2c1c(I)nn2C1CCC(O)CC1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(C)c(NC(=O)c2cc(-c3ccco3)nc3ccccc23)c1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@H](CCN)c3ccccc3)cc21,IC50,1570.0,nM,5.8,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
,CCOC(=O)C1Cc2nc(-c3ccc4ccccc4c3)n(-c3ccnc(N[C@H]4CCCN(C(=O)C5CC5)C4)n3)c2C1,IC50,2248.0,nM,5.65,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) incubated for 20 mins in presence of 33P-ATP,2023.0
,CCOC(=O)C1Cc2nc(-c3ccc4ccccc4c3)n(-c3ccnc(N[C@@H]4CCCN(C(=O)C5CC5)C4)n3)c2C1,IC50,1249.5,nM,5.9,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) incubated for 20 mins in presence of 33P-ATP,2023.0
ENCORAFENIB,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,Kd,425.0,nM,6.37,Glycogen synthase kinase-3 beta,Active,,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",2017.0
,COc1ccccc1CCNc1cc(-c2ccncn2)cc(=O)n1C,IC50,800.0,nM,6.1,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in CHO AA8 cells co-expressing human tau protein after 2 hrs,2011.0
,N#Cc1cscc1-c1c[nH]c(=O)c2cc(-c3ccncc3)sc12,IC50,12.59,nM,7.9,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in baculovirus by fluorescence polarization assay,2011.0
,Fc1ccc(-c2ncn(CCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1,Ki,5450.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,O=C1Cc2c([nH]c3ccc(C(F)(F)F)cc23)-c2ccccc2N1,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta expressed in insect Sf9 cells,2010.0
,CCOC(=O)CN1CCC(CNC(=O)c2n[nH]c3ccc(Br)cc23)CC1,IC50,530.0,nM,6.28,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,Cc1ccc(-c2ccc3ncc(-c4ccc([S+](C)[O-])cc4)n3c2)o1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,C[S+]([O-])c1ccc(-c2coc3ccc(-c4nnc(N)o4)cc23)cc1,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,COc1ccc(-c2ocnc2C(=O)NCc2cccnc2)cc1,IC50,251.19,nM,6.6,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by fluorescence polarization assay,2012.0
,O=C(NCc1ccncc1)c1ncoc1-c1ccc(C(F)(F)F)cc1,IC50,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by fluorescence polarization assay,2012.0
,COc1ccc(-c2ocnc2C(=O)NCCc2ccncc2)cc1Cl,IC50,19.95,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of catalytic activity of GSK3-beta by AlphaLISA assay,2012.0
,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)c(F)c1,IC50,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta-mediated CRMP-2 phosphorylation by cell based assay,2012.0
,CS(=O)(=O)Nc1ccc(CCNC(=O)c2ccc(O)c3[nH]c(-c4ccc(F)cc4Cl)nc23)cc1,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,CS(=O)(=O)Nc1ccc(CCNC(=O)c2ccc(O)c3[nH]c(-c4ccncc4)nc23)cc1,IC50,110.0,nM,6.96,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,O=C1CCCN2[C@@H](CC1)C[C@]13CN4CCCC/C=C\CC[C@](O)(C=C(c5nccc6c5[nH]c5c(OS(=O)(=O)c7ccc(Cl)cc7)cccc56)C1CC4)[C@H]23,IC50,7200.0,nM,5.14,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSKbeta,2007.0
,O=C1NC(NC23CC4CC(CC2C4)C3)=N/C1=C\c1ccc2ncsc2c1,IC50,855.0,nM,6.07,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@H](CO)c2ccccc2)=N/C1=C\c1ccc2ncsc2c1,IC50,1570.0,nM,5.8,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cl.Cl.NC[C@H](NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1)c1ccccc1,IC50,1115.0,nM,5.95,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Clc1ccc(Cl)c(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c1,Ki,16.0,nM,7.8,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,O=C1NC(NC2CCCC2)=N/C1=C\c1ccc2ncsc2c1,IC50,8301.0,nM,5.08,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cn1c(N2CCOCC2)cc(-c2ccncn2)cc1=O,IC50,5040.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in CHO AA8 cells co-expressing human tau protein after 2 hrs,2011.0
,NC1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Brc1ccc2c(c1)-c1[nH]ncc1C2,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Fc1ccc(-c2nc3occn3c2-c2ccnc(NC3CCNCC3)n2)cc1,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(OC(F)F)ccc12,Ki,12.59,nM,7.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3Cl)n2)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1c(N2CCO[C@@H](c3ccccc3F)C2)nc(-c2ccncn2)cc1=O,IC50,3.2,nM,8.49,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,Cn1c(N2CCO[C@@H](c3ccc(C#N)cc3)C2)nc(-c2ccncn2)cc1=O,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccnc(Cl)c2)cc1=O,IC50,903.0,nM,6.04,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,COc1cc(-c2csc3c(C=CC(=O)NCCN(C)C)cnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(-c2ocnc2C(=O)NCc2ccccc2)cc1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by fluorescence polarization assay,2012.0
,NC(=O)c1cccc(-c2ocnc2C(=O)NCc2ccncc2)c1,IC50,7943.28,nM,5.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by fluorescence polarization assay,2012.0
,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)c(C)c1,IC50,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,,,Inhibition of catalytic activity of GSK3-beta by AlphaLISA assay,2012.0
,Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccncc2)cc1=O,IC50,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccncc2Cl)cc1=O,IC50,430.0,nM,6.37,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,C[C@H]1COc2c(NCCCn3ccnc3)c(F)c(N)c3c(=O)c(-c4nnn[nH]4)cn1c23,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,O=C(Nc1cnccc1N1CCC(F)(F)CC1)c1ccnc(NC(=O)[C@H]2C[C@@H](Cl)C2)c1,IC50,0.16,nM,9.8,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cncc(-c2ccccc2)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,9.0,nM,8.05,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CCOC(O)(Nc1ccc(C(=O)O)cc1)Nc1nc2c(s1)CC(N1C(=O)c3ccccc3C1=O)CC2,IC50,4600.0,nM,5.34,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human His-tagged GSK3beta expressed in baculovirus expression system using ser/thr-9 peptide as substrate measured after 1 hr by Z'-Lyte assay,2018.0
,CCCN(C(=O)Nc1cccc(C(=O)O)c1)C1CCc2nc(NC(=O)Nc3cccc(C(=O)O)c3)sc2C1,IC50,1500.0,nM,5.82,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human His-tagged GSK3beta expressed in baculovirus expression system using ser/thr-9 peptide as substrate measured after 1 hr by Z'-Lyte assay,2018.0
,O=C1NC(=S)N/C1=C/c1ccc(-c2ccc(Cl)c(Cl)c2)o1,IC50,678.0,nM,6.17,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,N=C1NC(=O)/C(=C\c2ccc(-c3cccc(C(=O)O)c3)o2)S1,IC50,308.0,nM,6.51,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,O=C1NC(=S)N/C1=C/c1ccc(-c2cccc(C(=O)O)c2)o1,IC50,338.0,nM,6.47,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,c1ccc(-c2noc(CSc3nnc(-c4ccncc4)o3)n2)cc1,IC50,521.0,nM,6.28,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate measured in presence of [gamma-33P]ATP by radiometric assay,2019.0
,COc1ccc(-c2ocnc2C(=O)NCc2ccnnc2)cc1Cl,IC50,19.95,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of catalytic activity of GSK3-beta by AlphaLISA assay,2012.0
,COc1ncc(-c2ocnc2C(=O)NCc2ccncc2)cc1Cl,IC50,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta-mediated CRMP-2 phosphorylation by cell based assay,2012.0
,O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1ccc(Cn2nnc(-c3ccc4[nH]ncc4c3)c2-c2ccccc2)cc1,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(O)ccc1-n1cc(C(N)=O)c(=O)c2ccc(-c3ccncc3)cc21,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Oc1cc(O)cc(C=Cc2ccc(O)c(O)c2)c1,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCNC(=O)c1ccc(Nc2nc(CCC(F)(F)F)c3cc[nH]c3n2)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(O)c1cc(Nc2n[nH]c3ncc(F)cc23)nc(C2CCCCC2)n1,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,244262,,Inhibition Assay: Compounds are screened for their ability to inhibit the phosphorylation of tyrosine (TYR) residues through the use of western blotting of Jurkat cells dosed with the compounds. The phosphorylation of the specific TYR residues tested are GSK3α TYR 279 and GSK3β TYR 216.,2014.0
,O=C(NCc1ccncc1)c1ncoc1-c1ccc(Oc2ccccc2)c(Cl)c1,IC50,794.33,nM,6.1,Glycogen synthase kinase-3 beta,,,Inhibition of catalytic activity of GSK3-beta by AlphaLISA assay,2012.0
,COc1ccc(-c2ocnc2C(=O)NCc2ccnc(Cl)c2)cc1Cl,IC50,19.95,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of catalytic activity of GSK3-beta by AlphaLISA assay,2012.0
,CCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O,IC50,6100.0,nM,5.21,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using GS2 peptide as substrate and [gamma33P]-ATP after 30 mins by scintillation counting,2013.0
,Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1,Ki,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Cc1nc(NC(=O)NCCOCC2CC2)sc1C#Cc1ccc2cncn2c1,Ki,4000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3B (unknown origin),2021.0
,CC(C)(C)Nc1c(Nc2ccnc(Nc3ccc(-c4ccncc4)cc3)n2)c(=O)c1=O,Ki,102.0,nM,6.99,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3B after 1 hr by scintillation counter analysis in presence of gamma-[33P]ATP,2012.0
,CN1CCN(S(=O)(=O)c2ccc(-c3cnc(N)c(C(=O)Nc4cccnc4)c3)cc2)CC1,Ki,64.0,nM,7.19,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,CN(C)CCNS(=O)(=O)c1ccc(-c2cnc(N)c(C(=O)Nc3cccnc3)n2)cc1,Ki,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,Cn1cc(Nc2ncc(Br)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)cn1,IC50,34.0,nM,7.47,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta by TR-FRET analysis,2012.0
,O=C(CCl)c1c(Br)sc(Br)c1Br,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 (GSK-3beta).,2003.0
,O=C(NCC1CCN(Cc2cccc([N+](=O)[O-])c2)CC1)c1n[nH]c2ccccc12,IC50,7200.0,nM,5.14,Glycogen synthase kinase-3 beta,335746,,"LanthaScreen TR-FRET Assay: Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screening assay, compounds were tested in duplicate at a concentration of 10 uM.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um). In a second assay, the same compounds were assayed at five concentrations ranging from 100 uM to 10 nM with ten-fold dilutions in duplicate.",2015.0
,N#Cc1ccc(NCCNc2nc(-c3ccc(Cl)cc3Cl)cn3nc(CNC4CC4)cc23)nc1,IC50,80.0,nM,7.1,Glycogen synthase kinase-3 beta,213541,,"Biochemical Assay: The ingredients required for this purpose are mixed in a black 384-well microtiter plate with transparent base (from Greiner, catalog number 781092). The requirements in this connection for each well of the 384-well microtiter plate are 5 nM GSK3β (from Upstate, catalog number xy), 40 μM GSK3β substrate GSM (sequence H-RRRPASVPPSPSLSRHS-(pS)-HQRR, from Upstate, catalog number 2-533), 30 μM nicotinamide adenine dinucleotide NADH (Roche Diagnostics, catalog number 10107735), 50 μM adenosine triphosphate ATP (from Sigma, catalog number A7966) and 2 mM phosphoenolpyruvate (from Roche, catalog number 128112). The required reaction buffer in which the biochemical reaction takes place consists of 50 mM Trizma hydrochloride Tris-HCl pH: 7.5 (from Sigma, catalog number T3253), 5 mM magnesium chloride MgCl2 (from Sigma, catalog number M8266), 0.2 mM DL-dithiothreitol DTT (from Sigma, catalog number D9779), 2 mM ethylenediaminetetraacetic acid EDTA (from Sigma, catalog number E6758), 0.01% Triton X-100 (from Sigma, catalog number T8787) and 0.05% bovine serum albumin BSA (from Sigma, catalog number B4287). Active substances are dissolved in dimethyl sulfoxide DMSO (from Sigma, catalog number D8418) in a concentration of 10 mM. Active substances are added in serial concentrations of 10 μM, 1 μM, 0.1 μM, 0.01 μM, 0.001 μM, 0.0001 μM, 0.00001 μM, 0.000001 μM to the mixtures of the biochemical reaction. As control, dimethyl sulfoxide is added instead of substance in a final concentration of 0.1%. The reaction is incubated at 30° C. for 2 hours and then the resulting fluorescence is measured in a Tecan Safire-XFLUOR4 instrument, version V4.50 (serial number 12901300283) with the specifications: measurement mode−fluorescence measured from below, extinction wavelength 340 nm, emission wavelength 465 nm, slit width extinction 5 nm, slit width emission 5 nm, gain mode 120, delay 0 μs, number of light flashes per measurement 3, and an integration time of 40 μs.",2013.0
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2ccc(Cl)cc2n(Cc2ccccc2)c1=O,IC50,5990.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,N#Cc1cccc(-c2nc(Nc3cc(C4CC4)[nH]n3)c3ccccc3n2)c1,Ki,9.0,nM,8.05,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3beta (unknown origin) using HSSPHQ(Sp)EDEEE as substrate by pyruvate kinase-lactate dehydrogenase coupled assay,2017.0
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2cc(Cl)ccc2n(C)c1=O,IC50,5950.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2cc(Cl)ccc2n(CC)c1=O,IC50,3180.0,nM,5.5,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,COc1cc(F)ccc1C1CN(c2nc(-c3ccncc3)cc(=O)n2C)CCN1Cc1ccccc1.Cl,IC50,1200.0,nM,5.92,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,COc1cc(F)ccc1C1CN(c2nc(-c3ccncn3)cc(=O)n2C)CCN1.Cl,IC50,44.0,nM,7.36,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,COc1ccc(C2CN(c3nc(-c4ccncn4)cc(=O)n3C)CCN2)cc1.Cl,IC50,3.5,nM,8.46,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cn1c2c(c3cc(Br)ccc31)CC(=O)Nc1ccccc1-2,IC50,399.94,nM,6.4,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCCC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(O)C1CN(Cc2ccc(OCc3ccccc3)cc2Cl)C1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(O)c1ccccc1Nc1ccnc(Nc2ccc([N+](=O)[O-])cc2)n1,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCN(C(C)=O)c1ccc(Nc2nc(NC3CC3)c3nc[nH]c3n2)cc1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(-c2cnc3c(Br)cnn3c2)cc1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cnccn1)Nc1ccnc2c(C(F)(F)F)cccc12,Ki,15.85,nM,7.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1ccc(-c2cc3[nH]ccnc-3n2)cc1,IC50,4800.0,nM,5.32,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2sccc2N1,IC50,34.99,nM,7.46,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,CCCC(=O)Nc1n[nH]c2nnc(-c3ccccc3)c(-c3ccccc3)c12,IC50,691.0,nM,6.16,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCCC(=O)Nc1n[nH]c2cnc(-c3ccccc3)nc12,IC50,2697.0,nM,5.57,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCCC(=O)Nc1n[nH]c2cnc(-c3ccccc3)cc12,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(N2CCc3ccccc32)=C1c1cccc(Cl)c1,IC50,460.0,nM,6.34,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccccc1[N+](=O)[O-],IC50,131.0,nM,6.88,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CN(C1=C(c2ccc(Cl)cc2)C(=O)NC1=O)c1ccccc1,IC50,2285.0,nM,5.64,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(Nc1n[nH]c2ncc(-c3ccccc3)cc12)C1CCCC1,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccccc2)=C1Nc1ccc(Cl)c(C(=O)O)c1,IC50,143.0,nM,6.84,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(Nc1n[nH]c2cc(-c3cccs3)ccc12)C1CC1,IC50,215.0,nM,6.67,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,Brc1cnn2c(NCc3cccnc3)cc(-c3cccs3)nc12,IC50,480.0,nM,6.32,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccc(O)cc2N1,IC50,18.0,nM,7.75,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2010.0
,COc1ccc2c(c1)NC(=O)Cc1c-2[nH]c2ccc(C(F)(F)F)cc12,IC50,240.0,nM,6.62,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2010.0
,Cn1cc(C2=C(c3coc4cc(O)ccc34)C(=O)NC2=O)c2cc(F)ccc21,IC50,3.5,nM,8.46,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,COc1cccc2c(C3=C(c4cn(C)c5c(Br)cc(Br)cc45)C(=O)NC3=O)coc12,IC50,88.7,nM,7.05,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,Cn1cc(C2=C(c3coc4ccc(F)cc34)C(=O)NC2=O)c2cc(I)ccc21,IC50,180.0,nM,6.75,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cccc(CO)c21,IC50,5.1,nM,8.29,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,Clc1ccc(-c2nnc(Nc3ccccc3)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,FC(F)(F)c1ccc(-c2nnc(Nc3ccccc3)o2)cc1,IC50,632.0,nM,6.2,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1,IC50,3300.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2018.0
,CCc1nc2c(c3cc(OC)c(OC)cc13)C(=O)NC2=O,Ki,79.43,nM,7.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(C#N)ccc21,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(C=C2SC(=O)NC2=O)ccc1O,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2c1C(c1ccccc1I)C(C#N)=C(N)O2,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC[S@+]([O-])c1ccc(-c2coc3ccc(-c4ccc(C)o4)cc23)cc1,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,CC(C)Cn1cc(C#N)nc1-c1nonc1N,Ki,3300.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,N#Cc1ccccc1-n1c(-c2nonc2N)nc2ccccc21,Ki,3300.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,Cc1cn(CC(C)C)c(-c2nonc2N)n1,Ki,690.0,nM,6.16,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,O=C(Nc1cccc(C2Nc3ccc4ccccc4c3C3C=CCC32)c1)c1ccc(F)cc1,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ncc(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,1684.0,nM,5.77,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,c1cc(-c2cn(CCC3CC3)c3cnccc23)ccn1,IC50,1140.0,nM,5.94,Glycogen synthase kinase-3 beta,,,Inhibition of full-length recombinant human His-tagged GSK3B recombinant in baculovirus expression system using Alexa-Fluor tracer-236 incubated for 60 mins by TR-FRET based Lantha-screen Eu kinase assay,2017.0
,O=[N+]([O-])c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2008.0
,N#Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2008.0
,c1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(-c2cocn2)c1,IC50,8.0,nM,8.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2008.0
,O=C(NCCCCCCNC(=O)NCc1cccnc1)NCc1cccnc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3C)cc2)c1,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
ALVOCIDIB,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,Kd,730.0,nM,6.14,Glycogen synthase kinase-3 beta,,,Binding constant for GSK3B kinase domain,2011.0
IRCININ 2,CC1=C(O)/C(=C/[C@H](C)CC/C=C(/C)CCCc2coc(Cc3ccoc3)c2)OC1=O,IC50,2344.23,nM,5.63,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using GS2 peptide as substrate and [gamma33P]-ATP after 30 mins by scintillation counting,2013.0
,COc1cnc(Nc2ccccc2)nc1-c1cc2c([nH]1)CCNC2=O,IC50,16.0,nM,7.8,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,COc1cccc(C2=C(Nc3ccc(SC)cc3)C(=O)NC2=O)c1,IC50,203.0,nM,6.69,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COC(=O)COc1ccc(Nc2ncc3nnn(-c4ccccc4)c3n2)cc1,IC50,477.0,nM,6.32,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O[C@H]1CC[C@H](Nc2ncc3nnn(-c4ccccc4)c3n2)CC1,IC50,279.0,nM,6.55,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CCN(Cc2ccccc2)C1,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(Nc1n[nH]c2nc(-c3cccs3)c(Br)cc12)C1CC1,IC50,39.0,nM,7.41,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)c(F)c4)ncnc32)c1,IC50,15.85,nM,7.8,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccc(NS(C)(=O)=O)cc4)ncnc32)c1,IC50,15.85,nM,7.8,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,Cc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1,IC50,158.49,nM,6.8,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
GW794607X,CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1,IC50,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,CN(C)C(=O)N1CCn2cc(C3=C(c4cnc5ccccn45)C(=O)NC3=O)c3cccc(c32)C1,IC50,12.0,nM,7.92,Glycogen synthase kinase-3 beta,,,"Inhibitory concentration to inhibit Ser396 phosphorylation of tau, a natural substrate of GSK-3 in SY5Y cells",2005.0
,CN(C)C(=O)N1CCn2cc(C3=C(c4ccn5ncccc45)C(=O)NC3=O)c3cccc(c32)C1,IC50,38.0,nM,7.42,Glycogen synthase kinase-3 beta,,,"Inhibitory concentration to inhibit Ser396 phosphorylation of tau, a natural substrate of GSK-3 in SY5Y cells",2005.0
,Nc1nonc1-n1nnc(-c2n[nH]c(-c3ccncc3)n2)c1CN1CCCCC1,IC50,280.0,nM,6.55,Glycogen synthase kinase-3 beta,,,Inhibitory activity against human glycogen synthase kinase-3beta (GSK3-beta) at 100 uM ATP,2003.0
,NC[C@@H](NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1,IC50,63.1,nM,7.2,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin),2018.0
,COCCCn1cc(C2=C(c3ccccc3O)C(=O)NC2=O)c2cccnc21,IC50,45.0,nM,7.35,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,CC(=O)N(c1ccncc1)c1c(NC(C)C(C)(C)C)c(=O)c1=O,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN1CCN(c2ccc(Nc3nc(N)c(C(=O)c4c(Cl)cccc4Cl)s3)cc2)CC1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(C)=O)c3c2)cc1,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOC(=O)c1cccc2[nH]c(-c3ccc(N4CCC(N)C4)cc3)nc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1nc(-c2cc3c(Oc4ccc(I)cc4)cncc3s2)[nH]o1,Ki,31.62,nM,7.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCC1CC(NS(=O)(=O)C2CC2)CC1c1ncc2cnc3[nH]ccc3n12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)Nc1n[nH]c2ccc(N)cc12,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12,Ki,3162.28,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCOCCO)c2)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CS(=O)(=O)N(Cc1ccc2[nH]c(=O)c3cccn3c2c1)C1CC1,Ki,1995.26,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NCCCOc1cncc(C=Cc2ccncc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncnc2scc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)N(C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1)C(C)C,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)O)c2)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cccc2[nH]c(-c3ccc(NC(=O)c4cccc(S(=O)(=O)N5CCOCC5)c4)cc3)nc12,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2C)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(S(N)(=O)=O)cc4)c(=O)c3=O)ccc21,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1[nH]cnc2c1oc1ccc(Cl)cc12,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(=O)n2ccc(CN(C)C)c(O)c2n1,Ki,79.43,nM,7.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc1)CCN2,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cncc(-c2ccccc2F)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC(C)C(=O)Nc1cc(C(=O)Nc2cnccc2OCC(F)F)ccn1,IC50,1.8,nM,8.74,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC(C)(C)C(=O)Nc1cc(C(=O)Nc2cnccc2N2CCC(F)(F)CC2)ccn1,IC50,4.2,nM,8.38,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cncc(-c2ccccc2)c1)c1ccnc(NC(=O)C2CC(F)(F)C2)c1,IC50,4.1,nM,8.39,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cnccc1-c1ccc(Cl)cc1)c1ccnc(NC(=O)[C@H]2C[C@@H](F)C2)c1,IC50,6.9,nM,8.16,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cncc(-c2ccccc2Cl)c1)c1ccnc(NC(=O)C2CCC(F)(F)C2)c1,IC50,4.1,nM,8.39,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,Cc1cccc(NC(=O)Nc2ccc(-c3cccc(C(N)=O)c3)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOC(=O)Cc1nc2c3cc(Br)ccc3[nH]c(=O)n2n1,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(CN(C)C)cc1Nc1nccc(-c2c(-c3cccc(NC(=O)Cc4ccccc4)c3)nc3sccn23)n1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NCCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(Cc1ccccc1)Cc1c(O)ccc2c1O/C(=C\c1ccc3c(c1)OCO3)C2=O,IC50,310.0,nM,6.51,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant GSK-3beta (unknown origin) using GS peptide as substrate in presence of ATP incubated for 1 hrs by ADP-Glo kinase assay,2022.0
,CN(C)CC1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C(N)=O)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1sc(=O)n(Cc2ccccc2)c1=O,IC50,1400.0,nM,5.85,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant N-terminal His6-tagged human GSK3beta H350L mutant expressed in baculovirus infected Sf21 insect cells using polypeptide GS-2 as substrate after 30 mins in presence of ATP by kinase-glo luminescence assay,2017.0
,C[C@@H]1C[C@H]2CN1CCn1nc3c(cccc3c1O)-c1nc3c(cccc3nc1O)O2,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2006.0
,CCOC(=O)c1[nH]ncc1/C=C1\C(=O)Nc2ccc([N+](=O)[O-])cc21,IC50,1770.0,nM,5.75,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK3beta (636 to 661 residues) assessed as reduction in human muscle glycogen synthase type 1 fragment phosphorylation using YRRAAVPPSPSLSRHSSPHQ(pS)EDE as substrate in presence of ATP incubated for 60 mins by ADP-Glo kinase assay,2023.0
,COc1cccc(N/N=C2\C(=O)NN=C2c2ccccc2)c1,Ki,35.0,nM,7.46,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,CC(=O)N1CCC(Nc2ncc3c(n2)-c2c(c(C(N)=O)nn2C)CC3)CC1,IC50,28.0,nM,7.55,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2010.0
,Cc1ccc2[nH]c3c(c2c1)CC(=O)Nc1ccsc1-3,IC50,1300.17,nM,5.89,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,COc1ccc(CN2C(=O)C(c3cccc4ccccc34)Oc3ccccc32)cc1,IC50,8100.0,nM,5.09,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human His-tagged GSK3beta using GS-2 peptide as substrate in presence of [33P]gamma-ATP after 15 mins by microbeta counting method,2017.0
,CNC(=O)C1CCC(CNC(=O)c2ncoc2-c2ccc(OC)cc2)CC1,IC50,316.23,nM,6.5,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by fluorescence polarization assay,2012.0
,O=C(NCc1ccncc1)c1ncoc1-c1cccc(O)c1,IC50,630.96,nM,6.2,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by fluorescence polarization assay,2012.0
,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2cccnc2N1,IC50,6000.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Inhibition of human glycogen synthase kinase-3 beta,2004.0
,Nc1nc(NCCNc2ncc(-n3ccnc3)c(-c3ccc(Cl)cc3Cl)n2)ccc1[N+](=O)[O-],IC50,0.6,nM,9.22,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using biotin-CREB peptide substrate after 1 hr by scintillation counting method,2017.0
,O=C1NC(=S)S/C1=C\c1cccc(OCCOc2ccc(Br)cc2)c1,IC50,3570.0,nM,5.45,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,COC(=O)c1cccc(CSc2nnc(-c3ccc4c(c3)CCO4)o2)c1,IC50,630.0,nM,6.2,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,C=CCn1c2c(c3cc(Br)ccc31)CC(=O)Nc1ccccc1-2,IC50,4000.0,nM,5.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta expressed in insect Sf9 cells,2010.0
,O=C(Nc1cnccc1-c1ccc(OC(F)(F)F)cc1)c1ccnc(NC(=O)C2CC2)c1,IC50,270.0,nM,6.57,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) assessed as decrease in tau phosphorylation by high content cell based assay,2016.0
,O=C1CCCc2oc3cc(C(F)(F)F)ccc3c(=O)c21,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1nonc1-n1nnc(C(=O)NCc2ccncc2)c1CN1CCCCC1,IC50,9300.0,nM,5.03,Glycogen synthase kinase-3 beta,,,Inhibitory activity against human glycogen synthase kinase-3beta (GSK3-beta) at 100 uM ATP,2003.0
,Fc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NC(NC2CCCCC2(F)F)=N/C1=C\c1ccc2ncsc2c1,IC50,5557.0,nM,5.25,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cc1cc(Nc2nc(Sc3c(Cl)cccc3Cl)nc3ccccc23)n[nH]1,Ki,113.0,nM,6.95,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,Cc1cc(Nc2nc(Sc3ccc(Cl)cc3)nc3ccccc23)n[nH]1,Ki,44.0,nM,7.36,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,COCCc1cccc2c(C3=C(c4coc5ccccc45)C(=O)NC3=O)cn(CCOC)c12,IC50,114.0,nM,6.94,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1,Ki,10.0,nM,,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1,Ki,40.0,nM,7.4,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
GW805758X,CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,Ki,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Nc1nc(NCCNc2ncc(-c3ncc[nH]3)c(-c3ccc(Cl)cc3Cl)n2)ccc1[N+](=O)[O-],IC50,0.6,nM,9.22,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using biotin-CREB peptide substrate after 1 hr by scintillation counting method,2017.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCCCCCCCCCCOc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,IC50,98.0,nM,7.01,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCCOCCOc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,IC50,104.9,nM,6.98,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)NCCc1ccccn1,IC50,19.0,nM,7.72,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate in presence of gamma-33P-ATP,2016.0
,O=C(CN1CCOCC1)Nc1ccc(CCNC(=O)c2ccc(O)c3[nH]c(-c4ccc(F)cc4)nc23)cc1,IC50,40.0,nM,7.4,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,Cc1ccc(C)c(N2CCN(CCCNC(=O)c3nc(-c4cccnc4)no3)CC2)c1,IC50,860.0,nM,6.07,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccc(O)cc4)ncnc32)c1,IC50,12.59,nM,7.9,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,O=C(O)c1ccc(Nc2ncc3nnn(-c4ccccc4)c3n2)cc1,IC50,49.0,nM,7.31,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,COc1ccc(Nc2cc(-c3noc(-c4ccc(NS(=O)(=O)c5ccc(C(C)(C)C)cc5)cc4)n3)ccn2)cc1,IC50,9890.0,nM,5.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cc2c(C)n[nH]c2cn1,IC50,680.0,nM,6.17,Glycogen synthase kinase-3 beta,,,Inhibition of GSK2beta phosphorylation in human BT474 cells,2010.0
MANZAMINE,O[C@]12C=C(c3[nH]ccc4c5ccccc5nc3-4)[C@@H]3CCN(CCCC/C=C\CC1)C[C@@]31C[C@@H]3/C=C\CCCCN3[C@H]12,IC50,8400.0,nM,5.08,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,Cn1c(OCCc2ccccc2)nc(-c2ccncc2)cc1=O,IC50,200.0,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,Cc1nc(-c2ccc3occ(-c4ccc([S+](C)[O-])cc4)c3c2)no1,IC50,680.0,nM,6.17,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,Cc1ccc(-c2ccc3occ(-c4ccc([S+](C)[O-])cc4)c3c2)o1,IC50,35.0,nM,7.46,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,COC(=O)c1ccc(-c2coc3ccc(-c4ccc(C)o4)cc23)cc1,IC50,200.0,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
PHA-793887,CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C,IC50,79.0,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2010.0
,Cn1cc(C2=C(c3cccc(NCCCO)c3)C(=O)NC2=O)c2ccccc21,IC50,1.0,nM,9.0,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,COc1cccc(C2=C(c3cn(C)c4cc(C)ccc34)C(=O)NC2=O)c1,IC50,35.0,nM,7.46,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCN)cc21,IC50,1140.0,nM,5.94,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
,NCCn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(Br)ccc21,IC50,116.0,nM,6.94,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,O=C1NC(=O)C(c2cn(CCO)c3ccc(Br)cc23)=C1c1coc2ccccc12,IC50,21.4,nM,7.67,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,CCC(=O)Nc1n[nH]c2ncc(-c3ccccc3)cc12,IC50,43.0,nM,7.37,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1cccc(Nc2nccc(C3=C(c4ccccc4)NN4C=CC=CC34)n2)c1,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(O)cc3)c(-c3ccc(O)cc3)cc12,IC50,56.0,nM,7.25,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(-c3cc(Cl)cc(Cl)c3)ccc12,IC50,5413.0,nM,5.27,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2c(Cl)c(Cl)c(-c3ccccc3)cc12,IC50,12.0,nM,7.92,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CNC(=O)c1nn(C)c2c1CCc1cnc(NC3CCN(C(=O)C4CCN(S(C)(=O)=O)CC4)CC3)nc1-2,IC50,358.0,nM,6.45,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2010.0
,Cn1nccc1CNC(=O)c1ccc2cc(-c3n[nH]cc3-c3ccccc3)[nH]c2c1,IC50,1260.0,nM,5.9,Glycogen synthase kinase-3 beta,,,Inhibition of GST-tagged full length GSK3-beta assessed as inhibition of ATP consumption after 60 mins by luminescence assay,2010.0
,Cc1oncc1CNC(=O)c1ccc2cc(-c3n[nH]cc3-c3ccccc3)[nH]c2c1,IC50,2290.0,nM,5.64,Glycogen synthase kinase-3 beta,,,Inhibition of GST-tagged full length GSK3-beta assessed as inhibition of ATP consumption after 60 mins by luminescence assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(O)c(O)c3)ccc12,IC50,27.0,nM,7.57,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(N)nc3)ccc12,IC50,1088.0,nM,5.96,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccc(CC)cc3)cc12,IC50,12.0,nM,7.92,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,COc1ccc(N/N=C2\C(=O)NN=C2c2ccncc2)cc1,Ki,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1cccc(C2=NNC(=O)/C2=N\Nc2ccccn2)c1,Ki,8.0,nM,8.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,CCN(CC)c1ccc(N/N=C2\C(=O)NN=C2c2ccc(OC)cc2)cc1,Ki,16.0,nM,7.8,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,CCN(CC)c1ccc(N/N=C2\C(=O)NN=C2c2ccc(OC)c(OC)c2)cc1,Ki,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccncc1C1=NNC(=O)/C1=N\Nc1cccnc1,Ki,23.0,nM,7.64,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2c1,IC50,470.0,nM,6.33,Glycogen synthase kinase-3 beta,,,Inhibition of GSK2beta phosphorylation in human BT474 cells,2010.0
,CC#CC(=O)NCCCN1CCC(CNC(=O)c2n[nH]c3ccc(OC)cc23)CC1,IC50,530.0,nM,6.28,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,C/C=C/C(=O)NCCCN1CCC(CNC(=O)c2n[nH]c3ccc(OC)cc23)CC1,IC50,1510.0,nM,5.82,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COCCN1CCC(CNC(=O)c2n[nH]c3ccc(-c4cnccc4OC)cc23)CC1,IC50,45.0,nM,7.35,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(CCCNC(=O)c4ccccc4)CC3)c2c1,IC50,580.0,nM,6.24,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,Cc1cc(Nc2n[nH]c3ncc(F)cc23)nc(C2CCCC2)n1,IC50,48.0,nM,7.32,Glycogen synthase kinase-3 beta,244255,,Inhibition Assay: Compounds are screened for their ability to inhibit the phosphorylation of tyrosine (TYR) residues through the use of western blotting of Jurkat cells dosed with the compounds. The phosphorylation of the specific TYR residues tested are GSK3α TYR 279 and GSK3β TYR 216.,2014.0
,COc1cc2c(cc1OC)-c1[nH]c3ccc(C(F)(F)F)cc3c1CC(=O)N2,IC50,75.0,nM,7.12,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2010.0
,COc1ccc(CSc2nnc(-c3ccc4c(c3)CCO4)o2)cc1,IC50,220.0,nM,6.66,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,COc1ccc(-n2cnc3ccc(-c4nnc(SCc5ccc(OC)c(C(F)(F)F)c5)o4)cc32)cc1,IC50,8.6,nM,8.07,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(F)c2)n1,Ki,31.62,nM,7.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NCc1ccccc1)Nc1ncc([N+](=O)[O-])s1,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1[nH]cc(I)c2nc(-c3ccccc3)cn12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(NC(=O)c2cnn3c(-c4ccccc4)ccnc23)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=NNC(=O)c1nnn(-c2nonc2N)c1-c1ccccc1)c1ccco1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(COc1cncc(-c2ccc3c(c2)CC(=O)N3)c1)Cc1c[nH]c2ccccc12,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2cnc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12,IC50,670.0,nM,6.17,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2010.0
,COc1ccc(-c2ocnc2C(=O)NCC2CCC(C(=O)N(C)C)CC2)cc1,IC50,316.23,nM,6.5,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by fluorescence polarization assay,2012.0
,CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(Cc5ccccc5)CC4)cc3)n2)s1,IC50,6000.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,Clc1ccccc1CSc1nnc(-c2ccc3c(c2)CCO3)o1,IC50,200.0,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,N#Cc1cccc(CSc2nnc(-c3ccc4c(c3)CCO4)o2)c1,IC50,91.0,nM,7.04,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,O=C(Nc1cnccc1OCC(F)(F)F)c1ccnc(Nc2ccccc2)n1,IC50,0.2,nM,9.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,Cc1cc(C#N)ccc1Nc1nccc(C(=O)Nc2cnccc2-c2ccccc2)n1,IC50,0.43,nM,9.37,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCCF,IC50,36.5,nM,7.44,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2023.0
,Cc1nc(-c2ccc(F)c(C)c2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,117.0,nM,6.93,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,c1ccc(-c2cc3[nH]ccnc-3n2)cc1,IC50,2300.0,nM,5.64,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,C[C@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23,IC50,0.57,nM,9.24,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C(C)(C)C,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1ccc(-c2ccc3c(-c4ccnc(Nc5ccc6c(c5)OCCO6)n4)cnn3n2)cc1,Ki,120.0,nM,6.92,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,O=C(Nc1ncnc2oc(-c3ccc(Cl)cc3)cc12)C1CC1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,CCCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1,Ki,790.0,nM,6.1,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,O=C(NCCCNc1c2c(nc3ccccc13)CCCC2)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCC1CC1,IC50,103.6,nM,6.99,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,COc1ccc(-c2cc(=O)c3c(OC)c([C@H]4O[C@H](C(=O)N[C@H](C)C(F)(F)F)[C@@H](O)[C@H](O)[C@H]4O)c(OC)cc3o2)cc1OC,IC50,2300.0,nM,5.64,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta in human SH-SY5Y cells after 2 hrs by ELISA,2019.0
,NCCCn1cc(C2=C(c3cccc4ccccc34)C(=O)NC2=O)c2cccnc21,IC50,31.0,nM,7.51,Glycogen synthase kinase-3 beta,,,Inhibition of full length recombinant His-tagged human Glycogen synthase kinase-3 beta expressed in Baculovirus expression system,2019.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCC1CCN(Cc2ccccc2)CC1,IC50,19.0,nM,7.72,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
PF-00562271,CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O,Kd,707.0,nM,6.15,Glycogen synthase kinase-3 beta,Active,,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",2017.0
,COc1cnc(COc2ccc(F)cc2)cc1-c1cc2c([nH]1)CCNC2=O,IC50,7830.0,nM,5.11,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,COc1cnc(COc2ccc(F)cc2)nc1-c1cc2c([nH]1)CCNC2=O,IC50,1120.0,nM,5.95,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,O=C(NCC1CCOC1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,IC50,26.0,nM,7.58,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human N-terminal GST-tagged GSK3beta (1 to 420 end residues) expressed in baculovirus expression system using unphosphorylated peptide as substrate incubated enzyme-substrate mixture for 90 mins in presence of ATP by LANCE assay,2020.0
,O=C(NCC1CCOCC1)c1n[nH]c2ccc(-c3cccnc3)cc12,IC50,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human N-terminal GST-tagged GSK3beta (1 to 420 end residues) expressed in baculovirus expression system using unphosphorylated peptide as substrate incubated enzyme-substrate mixture for 90 mins in presence of ATP by LANCE assay,2020.0
,COCc1ccncc1-c1ccc2[nH]nc(C(=O)NCC3CCOCC3)c2c1,IC50,28.0,nM,7.55,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human N-terminal GST-tagged GSK3beta (1 to 420 end residues) expressed in baculovirus expression system using unphosphorylated peptide as substrate incubated enzyme-substrate mixture for 90 mins in presence of ATP by LANCE assay,2020.0
,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1n1ccc2cnc3[nH]ccc3c21,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2017.0
,Cc1ccc(-c2c[nH]c(C3COCCN3Cc3c[nH]c4ccccc34)n2)cc1,IC50,120.0,nM,6.92,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2013.0
,COc1nc(-c2ccnc(NC(=O)C3CC3)c2)sc1C(=O)NCCCCCCNC(=O)COc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,IC50,242.7,nM,6.62,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCCOCCn1cc(COc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)nn1,IC50,46.9,nM,7.33,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCCCCCCCCOc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,IC50,70.4,nM,7.15,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCCOCCOCCOCCOc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,IC50,69.3,nM,7.16,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,Cc1nc(NC(=O)NCCc2cn(CC(F)F)cn2)sc1C#Cc1cccnc1,Ki,4000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3B (unknown origin),2021.0
,O=C1NC(N[C@H]2CC[C@H](O)CC2)=N/C1=C\c1ccc2ncsc2c1,IC50,9624.0,nM,5.02,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CO[C@H]1CCC[C@H]1NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,9933.0,nM,5.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cc1ccccc1C1=C(c2cn(CCCn3ccnc3)c3cc(Br)ccc23)C(=O)NC1=O,IC50,140.0,nM,6.85,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,N#Cc1cccc(NC(=O)N[C@H]2CO[C@H]3[C@@H]2OC[C@@H]3Nc2nccc(-c3cccc(F)c3)n2)c1,IC50,2080.0,nM,5.68,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using phosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,O=C(Nc1cccc(C(F)(F)F)c1)N[C@H]1CO[C@H]2[C@@H]1OC[C@@H]2Nc1nccc(-c2ccco2)n1,IC50,2950.0,nM,5.53,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using phosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(F)(F)F)c(Cl)cc3OCCCC(=O)O)cc2)ccn1,IC50,860.0,nM,6.07,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK-3beta using Ser/Thr 6 peptide as substrate preincubated for 60 mins followed by ATP and substrate addition and measured after 45 mins by Z'lyte assay,2021.0
,Cc1cc(Nc2ncc(C)c(N3CC4CCC(C3)N4CC#N)n2)sn1,IC50,1677.0,nM,5.78,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,Cc1ccc2c(c1)c(C1=C(c3ccccc3[N+](=O)[O-])C(=O)NC1=O)cn2CCCn1ccnc1,IC50,8150.0,nM,5.09,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3cc(Br)ccc23)=C1c1ccccc1F,IC50,60.0,nM,7.22,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,CC(C)(C)NC(=O)OC12CC3CC(CC(NC4=N/C(=C\c5ccc6ncsc6c5)C(=O)N4)(C3)C1)C2,IC50,1798.0,nM,5.75,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@H]2c3ccccc3C[C@@H]2O)=N/C1=C\c1ccc2ncsc2c1,IC50,429.0,nM,6.37,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COCC(Cc1ccccc1)NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,4249.0,nM,5.37,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CC(=O)N1CCc2ccc(NC3=N/C(=C\c4ccc5ncsc5c4)C(=O)N3)cc21,IC50,1831.0,nM,5.74,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CN1CCN(c2ccc(NC3=N/C(=C\c4ccc5c(c4)OCO5)C(=O)N3)cc2)CC1,IC50,1200.0,nM,5.92,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC2CCCCC2)=N/C1=C\c1ccc2c(c1)OCO2,IC50,8398.0,nM,5.08,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CO[C@@H]1CCC[C@@H](NC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)C1,IC50,5750.0,nM,5.24,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)c3ccoc3)c2)[nH]1,IC50,3654.0,nM,5.44,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,CCc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,492.1,nM,6.31,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 500 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,O=C1NC(NC23CC4CC(CC(C4)C2)C3)=N/C1=C\c1ccc2ncoc2c1,IC50,202.0,nM,6.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CN1CCN(S(=O)(=O)c2ccc(-c3cncc(C(=O)Nc4cccnc4)n3)cc2)CC1,Ki,370.0,nM,6.43,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,O=C1NC(=O)c2c1c1cnn(-c3ccccc3Cl)c1n1cccc21,IC50,810.0,nM,6.09,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using (RREGGMSRPAS(p)VDG as substrate assessed as 32P[gamma-ATP] incorporation into substrate after 15 mins by autoradiography,2013.0
,Nc1nccc(CNC(=O)c2ccc3c(c2)/C(=C/Cc2cccc(C(=O)O)c2)C(=O)N3)n1,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2022.0
,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2ccccc21,IC50,35.0,nM,7.46,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2022.0
,CC(C)Oc1cccc(-c2ccc3cnc(C(=O)NCC4CCOCC4)n3c2)c1,IC50,72.0,nM,7.14,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2022.0
,Cc1ccc(-c2ccc3ncn(-c4ccc([S+](C)[O-])cc4)c3c2)o1,IC50,200.0,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
GW801372X,COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,COC(=O)Nc1ccc2c(c1)C(=Cc1ccc([N+](=O)[O-])cc1)C(=O)N2,IC50,348.0,nM,6.46,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK-3 beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate incubated for 60 mins in presence of ATP by luminescence based analysis,2022.0
,CC(C)c1c(-c2ccc(Cl)cc2)[nH]c2nccnc12,IC50,750.0,nM,6.12,Glycogen synthase kinase-3 beta,,,Inhibition of human glycogen synthase kinase-3 beta,2004.0
,Brc1ccc(-c2cc3[nH]ccnc-3n2)cc1,IC50,6000.0,nM,5.22,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,Fc1cccc(CSc2nnc(-c3ccncc3)o2)c1,IC50,1400.0,nM,5.85,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against human Glycogen synthase kinase-3,2002.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccc(OCc5ccc(F)cc5)cc4)ncnc32)c1,IC50,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,C(=N/Nc1ncnc2c1cnn2-c1ccccc1)\c1ccncc1,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,C=CCOc1ccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)cc1,IC50,158.49,nM,6.8,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
ENZASTAURIN,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,Kd,8.3,nM,8.08,Glycogen synthase kinase-3 beta,,,Binding constant for GSK3B kinase domain,2011.0
,Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Br)c4)cc3)c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cncc2cccc(S(=O)(=O)N3CCCNCC3C)c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(Nc2nccc(Nc3cc(C4CCCCC4)no3)n2)cc(OC)c1OC,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1c(NCc2cccc(C(F)(F)F)c2)c(Nc2ccncc2)c1=O,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NCCc2[nH]c(-c3ccnc(-c4ccccc4F)c3)cc21,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN1C(=O)CC(c2ccccc2)N=C1SCc1cn(-c2ccccc2F)nn1,IC50,122.0,nM,6.91,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin) after 30 mins by Kinase-Glo assay,2019.0
,c1ccc(Nc2ncnc3[nH]c(-c4ccccc4)nc23)cc1,IC50,16.0,nM,7.8,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2010.0
,COc1cccc(Nc2nccc(C3=CNN4C=CC=CC34)n2)c1,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,COc1ccc(-c2coc3ccc(-c4nnc(SCc5ccc(OC)c(C(F)(F)F)c5)o4)cc23)cc1,IC50,25.0,nM,7.6,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,OC1CCCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)C1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
GEFITINIB,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(c1ncnc2[nH]c3cc(Br)ccc3c12)[C@H]1CCCN(CCC#N)C1,IC50,319.0,nM,6.5,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,C#Cc1ccc2c(c1)[nH]c1ncnc(N(C)C3CCCN(CCC#N)C3)c12,IC50,25.12,nM,7.6,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,N#Cc1ccc(-c2ccc(CSc3nnc(-c4ccncc4)o3)cc2)cc1,IC50,153.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,O=C1Nc2ccccc2Nc2cc(-c3ccncc3)ccc21,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1,Ki,12.59,nM,7.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#CCOc1ccc(Nc2nc(Nc3cccc(S(N)(=O)=O)c3)ncc2Br)cc1,Ki,125.89,nM,6.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCC(=O)Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12,Ki,3.162,nM,8.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1cccc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCO5)o3)cc2)c1,IC50,29.0,nM,7.54,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,C=CC(=O)N1C(=O)CC(c2ccc(C#N)cc2)Sc2ccccc21,IC50,6200.0,nM,5.21,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using GS-2 peptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,C=CC(=O)Nc1cccc(C2=C(c3cn(C(C)C)c4ncccc34)C(=O)NC2=O)c1,IC50,34.0,nM,7.47,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1ccc(Cl)c(C(=O)O)c1,IC50,74.0,nM,7.13,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CSc1cc(NCc2cccnc2)n2ncc(Br)c2n1,IC50,1180.0,nM,5.93,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,CS(=O)(=O)c1ccc(-c2nnc(Nc3ccc(Cl)cc3)o2)cc1,IC50,671.0,nM,6.17,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,N#Cc1ccc(-c2nnc(Nc3ccc(Cl)cc3)o2)cc1,IC50,719.0,nM,6.14,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
ELRAGLUSIB,Cn1cc(C2=C(c3coc4ccc(F)cc34)C(=O)NC2=O)c2cc3c(cc21)OCO3,IC50,710.0,nM,6.15,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,COCc1cccc2c(C3=C(c4coc5ccccc45)C(=O)NC3=O)cn(C)c12,IC50,0.23,nM,9.64,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,COc1cccc2c(C3=C(c4cn(C)c5ccc(Br)cc45)C(=O)NC3=O)coc12,IC50,7.5,nM,8.12,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,Nc1nonc1-c1nc2ccccc2n1CC1CCC1,Ki,690.0,nM,6.16,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,Cn1cc(C2=C(Sc3ccccc3)C(=O)NC2=O)c2ccccc21,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,CC(=O)C1=C(c2c[nH]c3ccccc23)C(=O)NC1=O,IC50,4470.0,nM,5.35,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide substrate after 30 mins by Glow-type luminescence assay in presence of 1 uM ATP,2011.0
,O=C1NC(=O)C(c2ccccc2[N+](=O)[O-])=C1Nc1cccc(O)c1,IC50,251.0,nM,6.6,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2sc(C(=O)NCCc3ccc(Cl)cc3)cc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CCN)c3ccccc3)cc21,IC50,41.0,nM,7.39,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
,O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1ccc(O)c(Cl)c1,IC50,59.0,nM,7.23,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1ccc(C2=C(c3cn(C)c4ccccc34)C(=O)NC2=O)c(OC)c1,IC50,2.4,nM,8.62,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccc(O)cc3)cc12,IC50,80.0,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta by kinetic assay,2010.0
,COCCNC(=O)c1nc(-c2ccc(S(=O)(=O)N3CCN(C)CC3)cc2)cnc1N,Ki,90.0,nM,7.05,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,O=C(NCC1CCCCC1)c1cc2c(-c3ccccc3)n[nH]c2s1,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1cnc2nc(-c3ccc4[nH]ncc4c3)c(NC3CCCCC3)n2c1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
BISARYLMALEIMIDE 2,O=C1NC(=O)C(c2cncc3ccoc23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCOCC1)CC2,IC50,0.7943,nM,9.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) expressed in Sf9 cells using GS1 as substrate and [gamma32]ATP after 30 min by scinitllation counting,2007.0
PYRAZOLOPYRIMIDINE 2,COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1,IC50,2.512,nM,8.6,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) expressed in Sf9 cells using GS1 as substrate and [gamma32]ATP after 30 min by scinitllation counting,2007.0
,O=C1NCCc2[nH]c(-c3ccnc(Cl)c3)cc21,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC1CCCCC1Nc1nccc(Nc2ccccc2C(=O)O)n1,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1sc2ccc(Cl)c(Cl)c2c1NC(=O)c1ccc(Cl)cc1,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc2nnc(SCc3cn4ccccc4n3)n2c2ccccc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1n[nH]c2nnc(-c3ccccc3)c(-c3ccccc3)c12,Ki,158.49,nM,6.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=S(=O)(O)c1ccc(NCc2ccc3c(c2)OCO3)c2c(O)cccc12,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,FC(F)(F)c1cccc(CNc2cc(-c3c[nH]c4ncccc34)ncn2)c1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CSc1cnc2c(ccc3cnccc32)c1O,Ki,125.89,nM,6.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,C=CCc1cccc2c(=NO)cc(-c3ccccc3)oc12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=NNC(=N)N)c1cc(NC(=O)c2cccc(C(=O)Nc3cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c3)c2)cc(C(C)=NNC(=N)N)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(CO)ccc4F)cc3)c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1ccccc1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC1(O)CC(c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn23)C1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2,Ki,158.49,nM,6.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1cc(-c2ccncc2)nc(NC2CCCCC2)[nH]1,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(NCc2ccc(-c3ccc(F)cc3)nc2)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(c1cc(Br)c(O)c(I)c1)c1cc(Br)c(O)c(I)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)c1ccc(-c2c(-c3ccc4[nH]nc(N)c4c3)nnn2Cc2ccccc2)cc1,Ki,25.12,nM,7.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1Nc2ccccc2C1=Cc1ccc[nH]1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1cc(-c2ccncc2)nc(NCc2cc(F)cc(F)c2)[nH]1,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,C(=NNc1nc2ccccc2[nH]1)c1c[nH]c2ccccc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cc2c(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cncc2s1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(Nc2nccc(Nc3ccccc3C(=O)O)n2)cc1F,Ki,3.162,nM,8.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,[2H]C([2H])([2H])Oc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#CC1=C(c2ccccc2)CC(c2ccc(Cl)cc2)C(C(=O)c2ccccc2)C1=O,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NCc1ccc(Cl)c(Cl)c1)Nc1ccc2[nH]ncc2c1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(O)ccc1-n1c2cc(Cl)ccc2c(=O)c2c(N)nc(N)nc21,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNC(=O)COc1ccc(Nc2nc(Nc3ccc(C)c(S(N)(=O)=O)c3)ncc2F)cc1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COC(=O)c1c(-c2ccc(NC(=O)Nc3ccccc3)cc2)c2c(N)ncnn2c1C,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(Nc1nccc(-c2c[nH]c3ncccc23)n1)c1ccccc1,Ki,125.89,nM,6.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(N2CCN(CCCNC(=O)c3nc(-c4cncnc4)no3)C(C)C2)c1,IC50,2610.0,nM,5.58,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
TAK-715,CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=O)NC1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2CCC(N)=O,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NCc1ccc(Br)cc1)Nc1ccc2[nH]ncc2c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(C(=O)Nc2nc3ccc(Cl)cc3s2)c(OC)c1,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3csc4ccnc(N)c34)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,C(=Cc1cncc(OC2CCNC2)c1)c1ccncc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)cncc21,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCOc1nc(NC(C)=O)cc(N)c1C#N,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCNC(=O)c1ccc(Nc2nc(CC)c3cc[nH]c3n2)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(CCl)c1cc(Br)cs1,IC50,3000.0,nM,5.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by liquid scintillation counting,2009.0
,COc1cccc(C2=NNC(=O)/C2=N\Nc2ccc(C#N)cc2)c1,Ki,4.0,nM,8.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,CN(c1ncnc2[nH]c3cc(Cl)ccc3c12)C1CCCN(CCC#N)C1,IC50,764.0,nM,6.12,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,C#Cc1ccc2c(c1)[nH]c1ncnc(N(C)[C@H]3CCCN(CCC#N)C3)c12,IC50,6.0,nM,8.22,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,CN(c1ncnc2[nH]c3ccc(Cl)cc3c12)C1CCCN(CCC#N)C1,IC50,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,COc1ccc2c(c1)[nH]c1ncnc(N(C)C3CCCN(CCC#N)C3)c12,IC50,7943.28,nM,5.1,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,O=C(NCCCN1CCN(c2ccccc2F)CC1)c1nc(-c2cccnc2)no1,IC50,1480.0,nM,5.83,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(-c3nc(-c4ccnc(Nc5ccc(Cl)cc5F)c4)no3)cc2)cc1,IC50,2850.0,nM,5.54,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,CCS(=O)(=O)c1ccc(-c2coc3ccc(-c4ccc(C)o4)cc23)cc1,IC50,38.0,nM,7.42,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,Cc1ccc(-c2ccc3occ(-c4ccc(C(=O)O)cc4)c3c2)o1,IC50,50.0,nM,7.3,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,COc1cccc(-c2coc3ccc(-c4ccc(C)o4)cc23)c1,IC50,74.0,nM,7.13,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,Cc1ccc(-c2ccc3occ(-c4ccncc4)c3c2)o1,IC50,77.0,nM,7.11,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,COP(=O)(OC)c1ccc(-c2coc3ccc(-c4ccc(C)o4)cc23)cc1,IC50,280.0,nM,6.55,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCc1cn(CCNc2c3c(nc4ccc(OC)cc24)CCCC3)nn1,IC50,14.6,nM,7.84,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,Cc1nc2ccccn2c1-c1csc(Nc2ccc(O)cc2)n1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4snc(N)c34)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNCC(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1,Ki,125.89,nM,6.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1[nH]cc(I)c2nc(-c3cccc(Cl)c3)cn12,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3C3CC3)cc12,Ki,7.943,nM,8.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(N/N=C2\C(=O)NN=C2c2cccnc2)cc1,Ki,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,CS(=O)(=O)Nc1ccc(CCNC(=O)c2ccnc3[nH]c(-c4ccc(F)cc4)nc23)cc1,IC50,44.0,nM,7.36,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,O=C(NCCc1cccc(O)c1)c1ccnc2[nH]c(-c3ccc(F)cc3)nc12,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,O=C(CBr)c1ccccc1,IC50,5000.0,nM,5.3,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 (GSK-3beta).,2003.0
,O=[N+]([O-])c1ccc2[nH]c3c(c2c1)CC(S)=Nc1ccccc1-3,IC50,599.79,nM,6.22,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,Cn1nc(C(N)=O)cc1-c1ccnc(NC(=O)C2CC2)c1,IC50,24.0,nM,7.62,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,Cc1nn(-c2ccccc2)c2c1c1c(c3cccn32)C(=O)NC1=O,IC50,690.0,nM,6.16,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using (RREGGMSRPAS(p)VDG as substrate assessed as 32P[gamma-ATP] incorporation into substrate after 15 mins by autoradiography,2013.0
,COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCc4cccc(F)c4)cc2NC3=O)ccc1O,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3o2)cc1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Oc1ccc(-c2n[nH]c(Nc3cccc(Cl)c3)c2-c2ccc(O)cc2)cc1,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(O)c1ccccc1Nc1ncnc(Nc2cccc(F)c2)n1,Ki,50.12,nM,7.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncnc2scc(C(=O)Nc3ccc(NC(=O)Nc4ccccc4)cc3)c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(CC(=O)Nc2cc([C@H]3CC[C@@H](OC(=O)N4CCC4(C)C)C3)[nH]n2)cn1,Ki,1.26,nM,8.9,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged human recombinant GSK3beta H350L mutant expressed in baculovirus-infected Sf21 cells assessed as reduction in production of ADP using 5-FAMKRREILSRRPpSYR-COOH peptide as substrate preincubated with enzyme for 15 mins followed by further incubation with ATP for 30 mins by fluorescence-based microfluidic mobility shift assay,2020.0
,Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3cccc(C(F)(F)F)c3)nn2n1,Ki,790.0,nM,6.1,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1O,IC50,11.0,nM,7.96,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,O=C1NC(=O)c2c1c1c3ccccc3ccc1c1[nH]c3ccccc3c21,IC50,4380.0,nM,5.36,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta,2003.0
,CCN(CC)C/C=C/c1nc(O)c2c(ccc3nc(Nc4c(Cl)cccc4Cl)n(C)c32)c1C,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta,2003.0
,O=C(O)c1ccc(Nc2ncc3[nH]c(=O)n(-c4ccccc4)c3n2)cc1,IC50,4000.0,nM,5.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,Cn1c(=O)n(-c2ccccc2)c2nc(Nc3ccccc3)ncc21,IC50,1700.0,nM,5.77,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,OC12CC3CC(C1)CC(Nc1nc(N[C@H]4CC[C@H](O)CC4)ncc1Cl)(C3)C2,IC50,230.0,nM,6.64,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=C(O)c1ccc(Nc2ncc3nnn(C45CC6CC(CC(C6)C4)C5)c3n2)cc1,IC50,75.0,nM,7.12,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,c1ccc(Nc2ncc3nnn(-c4ccccc4)c3n2)cc1,IC50,628.0,nM,6.2,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,CCN(CC)Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,IC50,79.0,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2008.0
,CN1CCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCC1,IC50,71.0,nM,7.15,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta,2003.0
,Nc1c(F)c(NCCn2ccnc2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1,IC50,3400.0,nM,5.47,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,CNCCCn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(F)ccc21,IC50,202.0,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,O=C1NC(=O)C(c2cn(CCO)c3ccc(F)cc23)=C1c1coc2ccccc12,IC50,4.8,nM,8.32,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,CC[C@@H]1CN(Cc2ccccc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,43.0,nM,7.37,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,C[C@@H]1CN(c2ccc(Cl)cc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,1.2,nM,8.92,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,C[C@@H]1CN(c2ccncc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,3.8,nM,8.42,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,COc1ccccc1C1CN(c2nc(-c3ccncn3)cc(=O)n2C)CCN1.Cl,IC50,1.8,nM,8.74,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,COc1cc(F)ccc1C1CN(c2nc(-c3ccncn3)cc(=O)n2C)CCN1Cc1ccccc1.Cl,IC50,220.0,nM,6.66,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cn1c(N2CCNC(c3ccc(Cl)c(Cl)c3)C2)nc(-c2ccncn2)cc1=O,IC50,2.3,nM,8.64,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cn1c(N2CCNC(c3cccc(Cl)c3)C2)nc(-c2ccncc2)cc1=O,IC50,5.4,nM,8.27,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cl.Cn1c(N2CCNC(c3ccc(C#N)cc3)C2)nc(-c2ccncn2)cc1=O,IC50,7.4,nM,8.13,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,C[C@H]1CN(C)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,C[C@@H]1CNCCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,C[C@H]1CN(c2nc(-c3ccncn3)cc(=O)n2C)CCN1Cc1ccccc1,IC50,780.0,nM,6.11,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,C[C@@H]1CN(c2nc(-c3ccncn3)cc(=O)n2C)CCN1Cc1ccccc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,Cc1nc(C2CCOCC2)nc(Nc2n[nH]c3ncc(F)cc23)c1C,IC50,800.0,nM,6.1,Glycogen synthase kinase-3 beta,244253,,Inhibition Assay: Compounds are screened for their ability to inhibit the phosphorylation of tyrosine (TYR) residues through the use of western blotting of Jurkat cells dosed with the compounds. The phosphorylation of the specific TYR residues tested are GSK3α TYR 279 and GSK3β TYR 216.,2014.0
,CC[C@@H]1COCCN1c1nc(-c2ccncc2F)cc(=O)n1C,IC50,19.0,nM,7.72,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,CCOc1ccncc1NC(=O)c1ccnc2[nH]c(-c3cccnc3)nc12,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,CCCNC(=O)c1cnc2oc3ccc(O)cc3c2c1-c1ccccc1,Ki,4400.0,nM,5.36,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GST-fused GSK-3beta expressed in insect Sf9 cells using RBER-CHKtide as substrate assessed as incorporation of 33Pi after 60 mins by microplate scintillation counting analysis,2012.0
,C[C@@H]1CN(c2nc(-c3ccncc3F)cc(=O)n2C)[C@H](C)CO1,IC50,453.0,nM,6.34,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,O=C(NCC1CCN(Cc2cccc(Cl)c2)CC1)c1cncc(NC(=O)c2ccnc(NC(=O)C3CC3)c2)c1,IC50,231.0,nM,6.64,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,O=C(Nc1cncc(C(=O)NC2CCN(Cc3cccc(Cl)c3)CC2)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,63.0,nM,7.2,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,O=C(Nc1cncc(OCC2CCN(Cc3ccccc3)CC2)c1)c1ccnc2[nH]ccc12,IC50,837.0,nM,6.08,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,Clc1cc(-c2c[nH]c3ncccc23)cc(NC2CCCCC2)n1,Ki,58.0,nM,7.24,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta,2013.0
,COc1ccc(Nc2nnc(-c3ccc(OC)cc3)o2)cc1,IC50,662.0,nM,6.18,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,COC(=O)C1=C(Nc2ccccc2Cl)O/C(=C\c2c[nH]c3ncccc23)C1=O,IC50,51.0,nM,7.29,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) pretreated for 30 mins followed by substrate addition measured after 5 hrs in presence of 1 mM ATP,2017.0
,Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1,Ki,3162.28,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(N)=O)n2)cc(OC)c1OC,Ki,6.31,nM,8.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)c1ccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)cc1NC(=O)Cc1ccccc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)cc1OC,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1,Ki,63.1,nM,7.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(Cc1ccccc1)c1cc(-c2c[nH]c3ncccc23)cc(Cl)n1,Ki,39.81,nM,7.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]ncc34)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1c(-c2nc3ccccc3[nH]2)c(O)cc2oc(C)cc(=O)c12,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Clc1cc(-c2c[nH]c3ncccc23)ncn1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12,Ki,158.49,nM,6.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1nn(-c2ccccc2)c2c1c(=O)c1cc(Cl)ccc1n2O,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(C)c2oc(Nc3ccc(-c4cccc(C(N)=O)c4N)cc3F)nc2c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN1CCC1COc1cncc(CCc2ccncc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Cc1ccc(OC(F)(F)F)cc1)N1CCC2(CC1)NCCc1c2[nH]c2ccccc12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ncc3c2)n1,Ki,7.943,nM,8.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC1CCN(C(=O)CC#N)CC1c1ncc2cnc3[nH]ccc3n12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=S(=O)(Nc1ccc(-c2nc(-c3ccnc(Nc4ccc(OC(F)(F)F)cc4)c3)no2)cc1)c1ccc(F)cc1,IC50,2690.0,nM,5.57,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(-c3nc(-c4ccnc(Nc5ccc(C(F)(F)F)cc5)c4)no3)cc2)cc1,IC50,1490.0,nM,5.83,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,O=C(Nc1cc(-c2ccc3cccnc3c2)ccn1)C1CC1,IC50,240.0,nM,6.62,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OC1CCC1,IC50,0.37,nM,9.43,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCC1CC1,IC50,0.29,nM,9.54,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,O=C1Nc2ccccc2Nc2nnc(I)cc21,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1ccc(NC2CCCCC2N)nc1Nc1cccc(Cl)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cccc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N=C1NC(=O)/C(=C/c2ccc(O)c(C(=O)O)c2)S1,IC50,84.8,nM,7.07,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK-3beta expressed in Baculovirus using Ser/Thr9 peptide as substrate by Z' LYTE assay,2016.0
,Nc1c(F)c(NCCNc2ccccn2)c2c3c1c(=O)c(C(=O)O)cn3C1(CCCC1)CCO2,IC50,250.0,nM,6.6,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta after 1 hr by KinaseGlo luciferase assay,2012.0
,CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1,Ki,2100.0,nM,5.68,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2018.0
,CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NCCOc1cccc(Nc2ccnc(N)n2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=O)Nc1cc(N)c(C#N)c(-c2ccc3ccccc3c2)n1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)CN3CCCC3=O)c2)[nH]1,IC50,126.0,nM,6.9,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,CCN1C(=O)C(C)(C)c2cc3[nH]c4c(c3cc21)CCCc1c(C)n[nH]c1-4,IC50,7700.0,nM,5.11,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCC#Cc1ccc2c(c1)C(=O)N(C1CCC(=O)NC1=O)C2=O,IC50,27.7,nM,7.56,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,N#Cc1cccc2c(-c3ccnc(N)n3)c[nH]c12,IC50,5160.0,nM,5.29,Glycogen synthase kinase-3 beta,,,Inhibition of full-length recombinant human His-tagged GSK3B recombinant in baculovirus expression system using Alexa-Fluor tracer-236 incubated for 60 mins by TR-FRET based Lantha-screen Eu kinase assay,2017.0
,CS(=O)(=O)Nc1ccc(CCNC(=O)c2ccc(O)c3[nH]c(Cc4ccccc4)nc23)cc1,IC50,1600.0,nM,5.8,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,O=C(NCCCn1cnc(Cl)c1Cl)c1ccc(O)c2[nH]c(-c3ccc(Cl)cc3Cl)nc12,IC50,6.0,nM,8.22,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,Nc1ncnc2oc(-c3cccnc3)c(-c3ccc(NS(=O)(=O)c4ccccc4)cc3)c12,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by fluorescence anisotropy binding assay,2008.0
,CC(=O)Nc1cccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)c1,Ki,79.43,nM,7.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
BELUMOSUDIL,CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,OCCCn1cnc(-c2ccc(F)cc2)c1-c1ccncc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)c1nc2ccc1CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CCC2,IC50,37.0,nM,7.43,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2007.0
,COc1cc(C=C(C#N)c2nc3ccccc3[nH]2)c(Br)cc1O,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Fc1ccc(-c2nc3sccn3c2-c2ccncc2)cc1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1c(F)c(NC2CCCCC2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1,IC50,600.0,nM,6.22,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,COc1cccc(C2=C(c3cn(C)c4ccc(Cl)cc34)C(=O)NC2=O)c1,IC50,6.4,nM,8.19,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CCN)cc21,IC50,4000.0,nM,5.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21,IC50,2600.0,nM,5.58,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
,Cn1cncc1CNC(=O)c1ccc2cc(-c3n[nH]cc3-c3ccccc3)[nH]c2c1,IC50,540.0,nM,6.27,Glycogen synthase kinase-3 beta,,,Inhibition of GST-tagged full length GSK3-beta assessed as inhibition of ATP consumption after 60 mins by luminescence assay,2010.0
,c1ccc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCCO5)o3)cc2)cc1,IC50,234.0,nM,6.63,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](C)N)cc21,IC50,400.0,nM,6.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
,CC(=O)Nc1ccc2c(c1)c(-c1cc(NC3CC3)n3ncc(C#N)c3n1)cn2CCC(=O)O,IC50,6000.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,CCS(=O)(=O)Nc1ccc(CCNC(=O)c2ccnc3[nH]c(-c4ccc(F)cc4F)nc23)cc1,IC50,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,CS(=O)(=O)NCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)ccc1F,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NC(=O)C(c2nn(CCCN3CCOCC3)c3ccccc23)=C1c1cn(-c2ccc3ccccc3c2)c2ccccc12,IC50,2400.0,nM,5.62,Glycogen synthase kinase-3 beta,,,Inhibition of rabbit Glycogen synthase kinase-3 beta,2005.0
,O=C1NC(=O)C(c2nn(CCCN3CCCC3)c3ccccc23)=C1c1cn(-c2ccc3ccccc3c2)c2ccccc12,IC50,2500.0,nM,5.6,Glycogen synthase kinase-3 beta,,,Inhibition of rabbit Glycogen synthase kinase-3 beta,2005.0
,CN1CCN(CCCn2nc(C3=C(c4cn(-c5ccc6ccccc6c5)c5ccccc45)C(=O)NC3=O)c3ccccc32)CC1,IC50,1200.0,nM,5.92,Glycogen synthase kinase-3 beta,,,Inhibition of rabbit Glycogen synthase kinase-3 beta,2005.0
,CSc1ccc(-c2coc3ccc(-c4ccc(C)o4)cc23)cc1,IC50,66.0,nM,7.18,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,Cc1ccc(-c2ccc3occ(-c4ccc([S@@+](C)[O-])cc4)c3c2)o1,IC50,140.0,nM,6.85,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,CCn1c(CCCc2ccccc2)nc(-c2ccncc2)cc1=O,IC50,1900.0,nM,5.72,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,CC1(C)COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,IC50,49.0,nM,7.31,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,COc1cnccc1-c1cc(=O)n(C)c(N2CCO[C@@H](c3ccc(F)cc3)C2)n1,IC50,791.0,nM,6.1,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,Cn1c(N2CCOC(c3ccccc3)C2)nc(-c2ccncc2)cc1=O,IC50,51.0,nM,7.29,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,Nc1c(F)c(NCCNc2ccccn2)cc2c1c(=O)c(C(=O)O)cn2C1CC1,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,CCN1CCOCCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CC1,IC50,4.0,nM,8.4,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta,2003.0
,Cc1nn(-c2ccc(Cl)cc2Cl)c2c1c1c(c3cccn32)C(=O)NC1=O,IC50,240.0,nM,6.62,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using (RREGGMSRPAS(p)VDG as substrate assessed as 32P[gamma-ATP] incorporation into substrate after 15 mins by autoradiography,2013.0
,O=C1NC(=O)C(c2cn(-c3cccnc3)c3ccccc23)=C1c1[nH]nc2ccccc12,IC50,200.0,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of rabbit Glycogen synthase kinase-3 beta,2005.0
,CN(C)CCCn1nc(C2=C(c3cn(-c4cccc5ccccc45)c4ccccc34)C(=O)NC2=O)c2ccccc21,IC50,890.0,nM,6.05,Glycogen synthase kinase-3 beta,,,Inhibition of rabbit Glycogen synthase kinase-3 beta,2005.0
,CC(C)n1cc(C(=O)c2cncc(N[C@@H]3CCN(C=O)[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc21,IC50,180.0,nM,6.75,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,c1ccc(-c2c(-c3ccc4[nH]ncc4c3)nc3ncccn23)cc1,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,Nc1ncnc2sc(Br)c(-c3ccc(NC(=O)Cc4cccc(Cl)c4)cc3)c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1ncc2nc1OCCCCCOc1cc(OCCO)c(Cl)cc1NC(=O)N2,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1ccc(-c2ccncc2)cc1NCc1cccc(F)c1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncnc2c1c(I)nn2C1OC(CO)C(O)C1O,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,OCCCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(CCNc2cc(-c3ccncn3)cc(=O)n2C)c1,IC50,401.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta expressed in baculovirus infected SF9 cells after 60 mins,2011.0
,COc1ccccc1CNc1cc(-c2ccncn2)cc(=O)n1C,IC50,9000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in CHO AA8 cells co-expressing human tau protein after 2 hrs,2011.0
,c1cc2[nH]ncc2cc1-n1cc(C2CC2)nn1,Ki,3466.0,nM,5.46,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,Clc1cccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c1,Ki,23.0,nM,7.64,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,Fc1cccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c1,Ki,26.0,nM,7.58,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,Fc1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1,Ki,70.0,nM,7.16,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,COc1ccc(NC(=O)c2nc(-c3ccc(S(=O)(=O)N4CCN(C)CC4)cc3)cnc2N)cc1,Ki,690.0,nM,6.16,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,CN(C)CCN(C)C(=O)c1ccc(-c2cnc(N)c(C(=O)Nc3cccnc3)n2)cc1,Ki,16.0,nM,7.8,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,Nc1ncc(-c2ccc(S(N)(=O)=O)cc2)nc1C(=O)Nc1cccnc1,Ki,12.0,nM,7.92,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,Nc1ncc(-c2ccc(S(=O)(=O)N3CCCCC3)cc2)nc1C(=O)Nc1cccnc1,Ki,0.4,nM,9.4,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,O=C1Nc2ccccc2/C1=C/c1c[nH]nc1-c1ccccc1[N+](=O)[O-],IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) after 10 mins by mobility shift assay,2013.0
,CS(=O)(=O)c1ccc(-c2nnc(Nc3ccccc3)o2)cc1,IC50,439.0,nM,6.36,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,Fc1ccc(-c2ncn(C3CCN(Cc4ccccc4)C3)c2-c2ccc3[nH]ncc3c2)cc1,Ki,5450.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,CC(C)Cn1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCC(=O)Nc1nn(C(=O)CC)c2nc3ccccc3cc12,Ki,125.89,nM,6.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,C#Cc1cn(C2CCCC2)c2ncnc(N)c12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCCCC2)n1,Ki,1000.0,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
R-406,COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC,Ki,1995.26,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1ccc(Cl)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(-c2cc(-c3cc(Br)ccc3O)[nH]c(=O)c2C#N)s1,Ki,316.23,nM,6.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(CCC#N)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1[nH]sc2c1c(=O)c1cc(F)c(NCc3ccccc3)c(F)c1n2C1CC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(C)c2c(n1)sc1c(N)ncnc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(O)nc2[nH]nc(-c3cccc(-c4ccc(Cl)cc4)c3)c12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cc2c(Oc3ccc(Br)cc3)cncc2s1,Ki,158.49,nM,6.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cnccn1)Nc1ccnc2ccccc12,Ki,7.943,nM,8.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(O)c1ccccc1Nc1ncnc(Nc2ccc3cn[nH]c3c2)n1,Ki,15.85,nM,7.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(C(=O)Nc2c(C#N)sc3ccc(Cl)c(Cl)c23)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNC(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C1CCCCC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cncc(C=Cc2ccncc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1C(c2ccc3ccccc3c2)Oc2ccccc2N1Cc1ccc(F)cc1,IC50,8700.0,nM,5.06,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human His-tagged GSK3beta using GS-2 peptide as substrate in presence of [33P]gamma-ATP after 15 mins by microbeta counting method,2017.0
,O=C1C(c2cccc3ccccc23)Oc2cc3c(cc2N1Cc1ccccc1)OCO3,Ki,6300.0,nM,5.2,Glycogen synthase kinase-3 beta,,,Non-competitive inhibition of recombinant human His-tagged GSK3beta using GS-2 peptide as substrate in presence of [33P]gamma-ATP after 15 mins by microbeta counting method,2017.0
,CN1CCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCCOCC1,IC50,4.0,nM,8.4,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta,2003.0
,COc1nc(-c2ccnc(NC(=O)C3CC3)c2)sc1C(=O)NCCCNc1c2c(nc3cc(Cl)ccc13)CCCC2,IC50,98.0,nM,7.01,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human full length N-terminal GST-tagged GSK-3beta expressed in Sf9 insect cells using prephosphorylated polypeptide as substrate after 30 mins by kinase-Glo reagent based luminescence assay,2018.0
,COc1nc(-c2ccnc(NC(=O)C3CC3)c2)sc1C(=O)NCCNc1c2c(nc3ccccc13)CCCC2,IC50,68.0,nM,7.17,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human full length N-terminal GST-tagged GSK-3beta expressed in Sf9 insect cells using prephosphorylated polypeptide as substrate after 30 mins by kinase-Glo reagent based luminescence assay,2018.0
,COC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCNc1c2c(nc3ccccc13)CCCC2,IC50,99.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human full length N-terminal GST-tagged GSK-3beta expressed in Sf9 insect cells using prephosphorylated polypeptide as substrate after 30 mins by kinase-Glo reagent based luminescence assay,2018.0
,CCOC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCNc1c2c(nc3ccccc13)CCCC2,IC50,180.0,nM,6.75,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human full length N-terminal GST-tagged GSK-3beta expressed in Sf9 insect cells using prephosphorylated polypeptide as substrate after 30 mins by kinase-Glo reagent based luminescence assay,2018.0
,Nc1nccc(-c2ccccc2)c1/N=C/c1ccnc(NC(=O)C2CC2)c1,IC50,633.0,nM,6.2,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,Nc1ncc(-c2ccncc2)cc1/N=C/c1ccnc(NC(=O)C2CC2)c1,IC50,38.0,nM,7.42,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,C=CCn1cc(C2=C(c3nn(CCCN4CCOCC4)c4ncccc34)C(=O)NC2=O)c2ccccc21,IC50,960.0,nM,6.02,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,CN(C)CCCn1nc(C2=C(c3cn(C)c4ccccc34)C(=O)NC2=O)c2cccnc21,IC50,5690.0,nM,5.25,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,Cn1c(NCC(=O)c2ccccc2F)nc(-c2ccncc2)cc1=O,IC50,27.0,nM,7.57,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,O=c1cc(-c2ccc(F)cc2)[nH]c2c(-c3ccc(F)cc3)cnn12,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCCNc1cc(-c2c[nH]c3ncccc23)ncn1,Ki,50.12,nM,7.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NS(=O)(=O)c1cccc(Nc2ncc3ccn(-c4ccccc4)c3n2)c1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(C(=O)CNc2nc(-c3ccncc3)cc(=O)n2C)c1,IC50,38.0,nM,7.42,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,O=c1cc(-c2ccncc2)nc(-c2ccccc2)[nH]1,IC50,1800.0,nM,5.75,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,CCCn1c(CCCc2ccccc2)nc(-c2ccncc2)cc1=O,IC50,9800.0,nM,5.01,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,Cn1cc(C2=C(c3nnc4ccccn34)C(=O)NC2=O)c2cc(Br)ccc21,IC50,63.5,nM,7.2,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay,2015.0
,Cc1ccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)cc1,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NS(=O)(=O)c1ccc(NCCSc2ccc(O)cc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C(C)C(=O)N(C)C)c5)cnc(N)c34)cc2)cc1,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1Nc2ccccc2C1=Cc1c[nH]c2ccccc12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cncc(OCC2CCN(Cc3ccc(F)cc3)CC2)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,31.0,nM,7.51,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,c1ccc(-c2ccc(CSc3nnc(-c4ccncc4)o3)cc2)cc1,IC50,83.0,nM,7.08,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,N#Cc1ccccc1-c1ccc(CSc2nnc(-c3ccncc3)o2)cc1,IC50,41.0,nM,7.39,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using pIRS-1 as substrate preincubated for 15 mins,2012.0
,COCCn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(OC)ncc21,IC50,127.0,nM,6.9,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,COCCc1cccc2c(C3=C(c4coc5ccccc45)C(=O)NC3=O)cn(C)c12,IC50,11.2,nM,7.95,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,CN1CCOCCOCCN(C)CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CC1,IC50,8.0,nM,8.1,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta,2003.0
,CN(C)CCCn1nc(C2=C(c3cn(-c4cccs4)c4ccccc34)C(=O)NC2=O)c2ccccc21,IC50,370.0,nM,6.43,Glycogen synthase kinase-3 beta,,,Inhibition of rabbit Glycogen synthase kinase-3 beta,2005.0
,Cc1nc(-c2ccc(O)cc2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,893.0,nM,6.05,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,NC(=O)c1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,39.0,nM,7.41,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,NC(=O)c1nc(-c2ccccc2O)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,23.0,nM,7.64,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,CC1N(c2nc(-c3ccncc3F)cc(=O)n2C)CCOC1(C)C,IC50,9.7,nM,8.01,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,CCCCCCCC(=O)NNC(=O)c1c(O)c2cc(Cl)ccc2n(C)c1=O,IC50,8480.0,nM,5.07,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,O=C(O)c1ccc(Nc2ncc(F)c(Nc3ccccc3)n2)cc1,IC50,4170.0,nM,5.38,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=C(NCCCN1CCN(c2cccc(Cl)c2)CC1)c1nc(-c2cccnc2)no1,IC50,890.0,nM,6.05,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CCC3)c2)[nH]1,IC50,132.0,nM,6.88,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,O=[N+]([O-])c1ccccc1-c1ccc(CSc2nnc(-c3ccc4c(c3)OCCO4)o2)cc1,IC50,90.0,nM,7.05,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,CC(=O)Nc1cc(-c2nnc(SCc3ccc(-c4ccccc4C#N)cc3)o2)ccn1,IC50,17.0,nM,7.77,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,O=C(Nc1cc(-c2ccc(O)cc2)cc2[nH]ncc12)c1ccccn1,IC50,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate in presence of [gamma-33P]-ATP,2017.0
,O=C(NCC1CCN(Cc2ccccc2)CC1)c1cncc(NC(=O)c2ccnc(NC(=O)C3CC3)c2)c1,IC50,305.0,nM,6.52,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,O=C(NC1CCN(Cc2ccc(F)cc2)CC1)c1cncc(NC(=O)c2ccnc3[nH]ccc23)c1,IC50,4935.0,nM,5.31,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,COc1cccc(CNC(=O)c2cnc(-c3ccncc3)nc2)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1c(NCc2ccccc2F)c(Nc2ccncc2)c1=O,Ki,158.49,nM,6.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cc2c(-c3cccc(F)c3)cncc2s1,Ki,19.95,nM,7.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCS(=O)(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1,Ki,39.81,nM,7.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)Cc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1,Ki,1995.26,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2ccc(Cl)cc2n(CC)c1=O,IC50,2480.0,nM,5.61,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,COc1cc(/C=C2\SC(=O)NC2=O)ccc1O,IC50,6010.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using GS-2 peptide substrate incubated for 30 mins by kinase-Glo luminescent assay,2018.0
,CN(C)CCCOc1cc(-c2ccncc2)cc2[nH]nc(N)c12,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(O)CNc1nccc(-c2c(-c3ccc(F)cc3F)nc3c(CC4CC4)nccn23)n1,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(CNc2cc(-c3c[nH]c4ncccc34)ncn2)c1,Ki,7.943,nM,8.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCC(N)C3)c21,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=O)c1cccc(-c2cnc3[nH]ccc3c2)c1,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COCCN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(COc1cncc(-c2cc3cnccc3s2)c1)Cc1c[nH]c2ccccc12,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COCOc1cccc(OCOC)c1-c1ccc(NS(C)(=O)=O)cc1C(=O)OC,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1ccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cc2ccncc2s1,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(O)c1ccc(N2C(=O)c3ccccc3C2=O)cc1O,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc2[nH]nc(C(=O)NCC3CCN(Cc4ccc(C(=O)[O-])nc4)CC3)c2c1.[Na+],IC50,320.0,nM,6.5,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,Cc1cc(Nc2n[nH]c3ccc(F)cc23)nc(C2CCOCC2)n1,IC50,200.0,nM,6.7,Glycogen synthase kinase-3 beta,244257,,Inhibition Assay: Compounds are screened for their ability to inhibit the phosphorylation of tyrosine (TYR) residues through the use of western blotting of Jurkat cells dosed with the compounds. The phosphorylation of the specific TYR residues tested are GSK3α TYR 279 and GSK3β TYR 216.,2014.0
,CNC(=O)c1cc(-c2ccccc2)[nH]n1,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)N(CCCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)s1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(OC)c(NC(=O)c2cnn3c(-c4ccccc4)ccnc23)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Fc1ccc(-c2nc3cnccn3c2-c2ccnc(NCC3CC3)n2)cc1,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
PALBOCICLIB,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,Ki,1995.26,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCO5)n3)c2c1,Ki,10.0,nM,,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Clc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1Cl,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Kd,230.0,nM,6.64,Glycogen synthase kinase-3 beta,,,Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged GSK3B (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay,2019.0
,CC(C)(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,IC50,50.12,nM,7.3,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,2020.0
,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cc2c(-c3ccc(F)cc3)cncc2s1,Ki,79.43,nM,7.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)Nc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12,Ki,39.81,nM,7.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)cc1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1,Ki,1900.0,nM,5.72,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2018.0
,CCOC(O)(Nc1cccc(C(=O)O)c1)Nc1nc2c(s1)CC(N1C(=O)c3ccccc3C1=O)CC2,IC50,670.0,nM,6.17,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human His-tagged GSK3beta expressed in baculovirus expression system using ser/thr-9 peptide as substrate measured after 1 hr by Z'-Lyte assay,2018.0
,CCCCNc1n[s+]([O-])nc1Nc1ccc(F)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(C)cc(N2CCN(CCCNC(=O)c3nc(-c4cccnc4)no3)CC2)c1,IC50,900.0,nM,6.05,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,Cn1cc(-c2cnc3c(-c4csc(C(=O)NCC(F)(F)F)c4)cnn3c2)cn1,IC50,84.0,nM,7.08,Glycogen synthase kinase-3 beta,,,Inhibition of full-length recombinant human His-tagged GSK3B expressed in baculovirus expression system by Z'-LYTE assay,2016.0
,O=C(CCCCNC(=S)Nc1ccc2c(c1)C(=O)NC2=O)NO,IC50,4110.0,nM,5.39,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using GSM as substrate incubated for 30 mins by luminescence based assay,2019.0
,CC(=O)Nc1cc(-c2nnc(SCc3ccccc3)o2)ccn1,IC50,35.0,nM,7.46,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,Nc1nccc(-c2ccc(Cl)cc2)c1/N=C/c1ccnc(NC(=O)C2CC2)c1,IC50,2000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,Cc1csc(-c2cnc(N)c(/N=C/c3ccnc(NC(=O)C4CC4)c3)c2)c1,IC50,315.0,nM,6.5,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,Nc1ncc(-c2ccccc2)cc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,148.0,nM,6.83,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,COc1ccc(Nc2nnc(-c3ccc([N+](=O)[O-])cc3)o2)cc1,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,O=C(CSc1nnc(Cn2c(C(F)(F)F)nc3ccccc32)o1)Nc1ccccc1,IC50,130.0,nM,6.89,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,N#Cc1ncc2nc1OCCCCCOc1cc(OCCCO)c(Cl)cc1NC(=O)N2,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,OCCNc1cc2cc(-c3ccncc3)ccc2cn1,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,FC(F)(F)Oc1ccc(-c2ccc3[nH]cc(C4=CCNCC4)c3c2)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCN1CCN(c2ccc(Nc3nccc(-c4c(-c5cccc(C(=O)Nc6ccccc6F)c5)nc5ccccn45)n3)cc2)CC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1,Ki,1995.26,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
CENISERTIB,Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1,Ki,3162.28,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc2cnc3c(c2cc1OC)C(=O)NC3=O,Ki,125.89,nM,6.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)c1cc(-c2ccncc2)cc2[nH]nc(N)c12,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)CN(C)C(=O)c1ccc2cc(-c3n[nH]cc3-c3ccccc3)[nH]c2c1,IC50,6760.0,nM,5.17,Glycogen synthase kinase-3 beta,,,Inhibition of GST-tagged full length GSK3-beta assessed as inhibition of ATP consumption after 60 mins by luminescence assay,2010.0
,COc1ccc2nc3c(c(NCCCNC(=O)c4sc(-c5ccnc(NC(=O)C6CC6)c5)nc4OC)c2c1)CCCC3,IC50,65.0,nM,7.19,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human full length N-terminal GST-tagged GSK-3beta expressed in Sf9 insect cells using prephosphorylated polypeptide as substrate after 30 mins by kinase-Glo reagent based luminescence assay,2018.0
,COc1cc(CC(=O)Nc2cc(-c3[nH]c(SC)nc3-c3ccc(F)cc3)ccn2)cc(OC)c1OC,IC50,510.0,nM,6.29,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(Cc3ccccn3)ns2)n1,IC50,500.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3b (unknown origin),2018.0
,Cc1nc(-c2ccccc2O)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,11.0,nM,7.96,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,COc1cccc(CCC(=O)Nc2cc(-c3[nH]c(SC)nc3-c3ccc(F)cc3)ccn2)c1,IC50,471.0,nM,6.33,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)CC3CC3)c2)[nH]1,IC50,215.0,nM,6.67,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,O=C(Nc1cncc(C(=O)NC2CCN(Cc3ccccc3)CC2)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,81.0,nM,7.09,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,FC(F)(F)c1cc(Nc2nccc(-c3cnn4ncccc34)n2)ccc1Cl,Ki,10.0,nM,,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,COc1ccc2nc3c(c(NCCNC(=O)c4sc(-c5ccnc(NC(=O)C6CC6)c5)nc4OC)c2c1)CCCC3,IC50,83.0,nM,7.08,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human full length N-terminal GST-tagged GSK-3beta expressed in Sf9 insect cells using prephosphorylated polypeptide as substrate after 30 mins by kinase-Glo reagent based luminescence assay,2018.0
,COc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)cnn2n1,Ki,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,COc1ccccc1C1=C(Nc2ccc(O)c(Cl)c2)C(=O)NC1=O,IC50,139.0,nM,6.86,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccccc2)=C1Nc1cccc(Cl)c1,IC50,301.0,nM,6.52,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
GSK-690693,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21,Kd,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Binding constant for GSK3B kinase domain,2011.0
,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@H](CN)c3ccccc3)cc21,IC50,190.0,nM,6.72,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
,COc1ccc(-c2ccnc(N[C@H]3CO[C@H]4[C@@H]3OC[C@@H]4NC(=O)Nc3cccc(C#N)c3)n2)cc1,IC50,87.0,nM,7.06,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using phosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,COc1ccc(-c2ccnc(N[C@H]3CO[C@H]4[C@@H]3OC[C@@H]4NC(=O)Nc3cc(OC)cc(OC)c3)n2)cc1,IC50,421.0,nM,6.38,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using phosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,O=C(NC1CCOCC1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,IC50,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human N-terminal GST-tagged GSK3beta (1 to 420 end residues) expressed in baculovirus expression system using unphosphorylated peptide as substrate incubated enzyme-substrate mixture for 90 mins in presence of ATP by LANCE assay,2020.0
,O=C(NC1CCCOC1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,IC50,31.0,nM,7.51,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human N-terminal GST-tagged GSK3beta (1 to 420 end residues) expressed in baculovirus expression system using unphosphorylated peptide as substrate incubated enzyme-substrate mixture for 90 mins in presence of ATP by LANCE assay,2020.0
,CC(C)Oc1cncc(-c2ccc3[nH]nc(C(=O)NCC4CCOCC4)c3c2)c1,IC50,4.0,nM,8.4,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human N-terminal GST-tagged GSK3beta (1 to 420 end residues) expressed in baculovirus expression system using unphosphorylated peptide as substrate incubated enzyme-substrate mixture for 90 mins in presence of ATP by LANCE assay,2020.0
,COc1ccc(NC(=O)c2ccc(NC3=C(c4ccccc4)C(=O)NC3=O)cc2)cc1,IC50,120.0,nM,6.92,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1,Ki,5450.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,C[C@@H]1CN(Cc2ccccc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,8.3,nM,8.08,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,O=C1NC(=O)C(c2nnc3ccccn23)=C1c1cn(CCCn2ccnc2)c2ccccc12,IC50,36.0,nM,7.44,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay,2015.0
,COc1ccc2c(c1)c(C1=C(c3nnc4ccccn34)C(=O)NC1=O)cn2C,IC50,941.8,nM,6.03,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay,2015.0
,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)[C@H]3C[C@@H](Cl)C3)c2)[nH]1,IC50,170.0,nM,6.77,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,CC(=O)Nc1cc(-c2[nH]c(SCc3ccccc3)nc2-c2ccc(F)cc2)ccn1,IC50,560.0,nM,6.25,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,O=C(Nc1cc(-c2[nH]cnc2-c2ccc(F)cc2)ccn1)C1CC1,IC50,64.0,nM,7.19,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,CC(=O)/N=C1/NC(=O)/C(=C\c2ccc(-c3ccc(C(=O)O)cc3)o2)S1,IC50,3724.0,nM,5.43,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,N=C1NC(=O)/C(=C\c2ccc(-c3ccc(Cl)cc3Cl)o2)S1,IC50,1196.0,nM,5.92,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,Nc1nccc(-c2cccc(F)c2)c1/N=C/c1ccnc(NC(=O)C2CC2)c1,IC50,891.0,nM,6.05,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,Cc1ccc(-n2cc(CSC3=NC(c4ccccc4)CC(=O)N3C)nn2)cc1C,IC50,82.0,nM,7.09,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin) after 30 mins by Kinase-Glo assay,2019.0
,Clc1ccccc1-c1cc(NCOc2cccnc2)n2ncc(Br)c2n1,IC50,35.0,nM,7.46,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,Cc1ccccc1-n1nc(C)c2c3c(c4cccn4c21)C(=O)NC3=O,IC50,440.0,nM,6.36,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using (RREGGMSRPAS(p)VDG as substrate assessed as 32P[gamma-ATP] incorporation into substrate after 15 mins by autoradiography,2013.0
,Nc1nccc(-c2cc3c([nH]2)[C@@H](CCF)CNC3=O)n1,IC50,146.0,nM,6.84,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,COc1cccc(NC(=O)c2nc(-c3ccc(S(=O)(=O)N4CCN(C)CC4)cc3)cnc2N)c1,Ki,74.0,nM,7.13,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,Cc1cc(-c2cnc(N)c(C(=O)Nc3cccnc3)n2)ccc1S(=O)(=O)N1CCN(C)CC1,Ki,6.3,nM,8.2,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,Cc1ccc(-c2ccc3occ(-c4ccc([S@+](C)[O-])cc4)c3c2)o1,IC50,34.0,nM,7.47,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,CC(C)Cn1c(-c2nonc2N)nc2ccccc21,Ki,390.0,nM,6.41,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(O)cc3)c(Br)cc12,IC50,70.0,nM,7.16,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta by kinetic assay,2010.0
,O=C1NN=C/C1=N/Nc1ccccc1Cl,Ki,1490.0,nM,5.83,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(CCc4ccncc4)CC3)c2c1,IC50,510.0,nM,6.29,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,Cc1ccc(-c2ccc3[nH]nc(C(=O)NCC4CCN(CCc5ccccc5)CC4)c3c2)cn1,IC50,40.0,nM,7.4,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,c1cnn2ncc(-c3ccnc(NC4CC4)n3)c2c1,IC50,1600.0,nM,5.8,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2008.0
,CN(C)CC(O)COc1ccc(Nc2nccc(-c3cnn4nc(N5CCOCC5)ccc34)n2)cc1,IC50,690.0,nM,6.16,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2008.0
,CS(=O)(=O)Nc1ccc(CCNC(=O)c2ccc(O)c3[nH]c(-c4ccccc4)nc23)cc1,IC50,25.0,nM,7.6,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta at 5 uM,2007.0
,O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1ccc(O)cc1,IC50,123.0,nM,6.91,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCCn1cnc(C2C=C(C3=C(c4noc5ccccc45)C(=O)NC3=O)c3ccccc32)c1,IC50,0.73,nM,9.14,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2017.0
,Cc1cc(Nc2nc(Sc3ccccc3)nc3ccccc23)n[nH]1,Ki,171.0,nM,6.77,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,NC(=O)c1ccc(-c2ccnc(NC(=O)C3CC3)c2)cn1,IC50,90.0,nM,7.05,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,CCC(CO)CNC(=O)O[C@@H]1CC[C@H](c2cc(NC(=O)Cc3ccc(OC)nc3)n[nH]2)C1,Ki,1.41,nM,8.85,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged human recombinant GSK3beta H350L mutant expressed in baculovirus-infected Sf21 cells assessed as reduction in production of ADP using 5-FAMKRREILSRRPpSYR-COOH peptide as substrate preincubated with enzyme for 15 mins followed by further incubation with ATP for 30 mins by fluorescence-based microfluidic mobility shift assay,2020.0
,Cc1ccc(N2CCN(CCCNC(=O)c3nc(-c4cccnc4)no3)CC2)c(C)c1,IC50,1430.0,nM,5.84,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,COc1cccc(C2=NNC(=O)/C2=N\Nc2ccccc2Cl)c1,Ki,850.0,nM,6.07,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,c1ccc(-n2cc(-c3ccncc3)c3ccncc32)cc1,IC50,8300.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human His/GST-tagged GSK3beta (2 to 433 residues) expressed in baculovirus infected Sf9 cells using Ulight-glycogen synthase peptide as substrate incubated for 30 mins by TR-FRET LANCE method,2020.0
,Cc1nc(-c2ccoc2)c(-c2cnc3[nH]nc(C)c3n2)cc1OC[C@@H](N)Cc1c[nH]c2ccccc12,IC50,280.0,nM,6.55,Glycogen synthase kinase-3 beta,,,Inhibition of GSK2beta phosphorylation in human BT474 cells,2010.0
,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)Cc3ccc(C(F)(F)F)cc3)c2)[nH]1,IC50,3242.0,nM,5.49,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,Cc1nc2ccccc2n1CC(=O)NNC(=O)Cc1ccc([N+](=O)[O-])cc1,IC50,205.0,nM,6.69,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,Cc1nc2ccccc2n1Cc1nnc(Nc2ccccc2Cl)s1,IC50,122.0,nM,6.91,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,O=C(Nc1cc(-c2[nH]c(Cc3ccccc3)nc2-c2ccc(F)cc2)ccn1)C1CC1,IC50,59.0,nM,7.23,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,CN(C)C1Cn2cc(C3=C(c4cnc5ccccn45)C(=O)NC3=O)c3cccc(c32)CN1C=O,IC50,1.6,nM,8.8,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta (unknown origin) assessed as decrease in phosphorylation of CREB at serine-129 in presence of ATP[gamma-33P] by filter binding assay,2018.0
,COc1ccc(CCNc2ncc(C(=O)NCCCN3CCCC3=O)c(NC3CCCC3)n2)cc1OC,IC50,1680.0,nM,5.78,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2013.0
,Cc1ccc(-c2cnc(N)c(NC(=O)c3ccnc(NC(=O)C4CC4)c3)c2)cc1,IC50,127.0,nM,6.9,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,c1ccc(CSc2nnc(-c3ccc4c(c3)CCO4)o2)cc1,IC50,210.0,nM,6.68,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,CCc1ccc(-n2cc(CSc3nnc(Cn4c(C(F)(F)F)nc5ccccc54)o3)nn2)cc1,IC50,390.0,nM,6.41,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCc1cc(nc(N3CCCC3)c1)CCCn1cc2c2ccccc21,IC50,11.0,nM,7.96,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2007.0
,Fc1ccc(Nc2nccc(-c3c(-c4cccc(C(F)(F)F)c4)nn4ncccc34)n2)cc1F,Ki,310.0,nM,6.51,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,FC(F)(F)c1ccc(-c2nnc(Nc3ccc(Cl)cc3)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,COc1cc(/C=C2\C(=O)Nc3ccc(NC(C)=O)cc32)cc(OC)c1OC,IC50,232.9,nM,6.63,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate measured after 60 mins by ADP-Glo luminescence assay,2019.0
,O=C1Nc2ccccc2/C1=C/c1ccccn1,IC50,4.19,nM,8.38,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate measured after 60 mins by ADP-Glo luminescence assay,2019.0
,O=C1NC(=O)N(c2ccccc2)/C1=C/Nc1ccc(C(=O)O)cc1,IC50,3510.0,nM,5.46,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,CS(=O)(=O)Nc1ccc(-c2c(-c3cccnc3)oc3ncnc(N)c23)cc1,IC50,475.0,nM,6.32,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by fluorescence anisotropy binding assay,2008.0
,CN(C)Cc1ccncc1NC(=O)c1nc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)cnc1N,Ki,0.48,nM,9.32,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,CSc1ccc(-c2nnc(Nc3ccccc3)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,COc1cccc(C2=C(Nc3ccc(Cl)c(C(=O)O)c3)C(=O)NC2=O)c1,IC50,85.0,nM,7.07,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(Nc1n[nH]c2cc(-c3cccc(F)c3)ccc12)C1CC1,IC50,828.0,nM,6.08,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1,IC50,694.0,nM,6.16,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,NC(c1ccc(Cl)cc1)C1CCN(c2ncnc3[nH]ccc23)CC1,IC50,7500.0,nM,5.12,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta in human PC3M cells by ELISA,2008.0
GW778894X,N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2008.0
,NCCNC(=O)c1cnc2oc3ccc(O)cc3c2c1-c1ccccc1,Ki,4800.0,nM,5.32,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GST-fused GSK-3beta expressed in insect Sf9 cells using RBER-CHKtide as substrate assessed as incorporation of 33Pi after 60 mins by microplate scintillation counting analysis,2012.0
,O=c1[nH]ccc2oc(-c3ccncc3)cc12,IC50,125.89,nM,6.9,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in baculovirus by fluorescence polarization assay,2011.0
,COc1cccc2c(C3=C(c4cn(C)c5cc(I)c(F)cc45)C(=O)NC3=O)coc12,IC50,247.0,nM,6.61,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,C#CCOc1ccc2c(C3=C(c4cn(C)c5ccc(Br)cc45)C(=O)NC3=O)coc2c1,IC50,25.3,nM,7.6,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,COc1cc2c(C3=C(c4coc5ccccc45)C(=O)NC3=O)cn(C)c2cc1Cl,IC50,440.0,nM,6.36,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,O=C(O)/C=C\c1ccc(Nc2ncc3nnn(-c4ccccc4)c3n2)cc1,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=C1CN(c2ccccc2)c2nc(Nc3ccc(C(=O)O)cc3)ncc2N1,IC50,3500.0,nM,5.46,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,COc1nn(-c2ccccc2)c2nc(Nc3ccc(C(=O)O)cc3)ncc12,IC50,760.0,nM,6.12,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,N=C1N[C@H]2c3c([nH]c(Br)c3Br)C(=O)C3CCC[C@@]32N1,IC50,3000.0,nM,5.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2017.0
,Clc1cc(Cl)cc(Nc2nccc(-c3cnn4ncccc34)n2)c1,Ki,10.0,nM,,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,COc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1,Ki,50.0,nM,7.3,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,COc1cc(Nc2nccc(-c3cnn4nc(C)ccc34)n2)cc(C(F)(F)F)c1,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Cc1[nH]c2ccccc2c1C1=C(NCCc2ccc(F)cc2)C(=O)N(C)C1=O,IC50,53.0,nM,7.28,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 30 mins by luminescence assay,2010.0
,Cn1c(N2CCO[C@@H](c3ccc(C#N)cc3F)C2)nc(-c2ccncn2)cc1=O,IC50,6.5,nM,8.19,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
ABEMACICLIB,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,Kd,13.0,nM,7.89,Glycogen synthase kinase-3 beta,Active,,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",2017.0
,Cc1ccccc1Nc1nccc(-c2cnn3ncccc23)n1,Ki,6000.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(C(F)(F)F)c1,Ki,10.0,nM,,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,COc1ccc(C2=NNC(=O)/C2=N\Nc2cccc(Cl)c2)cc1OC,Ki,0.4,nM,9.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,Cn1c(N2CCO[C@@H](c3c(F)cccc3Cl)C2)nc(-c2ccncn2)cc1=O,IC50,0.64,nM,9.19,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CNC(=O)C(N)CCCCn1cc(CCCCNC(=O)CCCCCn2nc(N)c3cc(-c4c(-c5ccccc5)nn5ccccc45)nnc32)nn1)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C,Kd,2500.0,nM,,Glycogen synthase kinase-3 beta,,,Binding affinity to full length wild type human GSK3beta (M1 to T433 residues) expressed in mammalian expression system by KINOMEscan assay,2017.0
,N#Cc1cccc(CSc2nnc(-c3ccc4c(c3)OCCO4)o2)c1,IC50,86.0,nM,7.07,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using pIRS-1 as substrate preincubated for 15 mins,2012.0
,N#Cc1ccc(CSc2nnc(-c3ccc4c(c3)OCCO4)o2)cc1,IC50,166.0,nM,6.78,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using pIRS-1 as substrate preincubated for 15 mins,2012.0
SB-203580,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,Kd,1700.0,nM,5.77,Glycogen synthase kinase-3 beta,,,Binding constant for full-length GSK3B,2008.0
,O=C1Cc2c([nH]c3ccc(Cl)cc23)-c2ccccc2N1,IC50,24.0,nM,7.62,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta expressed in insect Sf9 cells,2010.0
,C=CCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCNC(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1C(c2ccc3ccccc3c2)Oc2cc3c(cc2N1Cc1ccccc1)OCO3,IC50,6900.0,nM,5.16,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human His-tagged GSK3beta using GS-2 peptide as substrate in presence of [33P]gamma-ATP after 15 mins by microbeta counting method,2017.0
,Cc1ccccc1-c1c(-c2ccc3[nH]nc(C)c3c2)nnn1Cc1ccccc1,Ki,12.59,nM,7.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc2c(c1)c(-c1cc3nc(Br)cnc3[nH]1)cn2C,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1c(F)c(NCCNc2cccc3ccccc23)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1,IC50,47.0,nM,7.33,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,Nc1c(F)c(NCCc2ccncc2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,N#Cc1ccc(C(=O)CBr)cc1,IC50,1500.0,nM,5.82,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using GS1 as substrate and [gamma-32P]ATP after 20 mins by radiometric assay,2011.0
,N#Cc1cccc(-c2nc3c(Nc4ccccc4)ncnc3[nH]2)c1,IC50,26.0,nM,7.58,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2010.0
,Cc1nc2ccccc2n1Cc1nnc(Nc2ccccc2Br)s1,IC50,190.0,nM,6.72,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,Cc1nc2ccccc2n1CC(=O)NNC(=O)c1ccc[nH]1,IC50,124.0,nM,6.91,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,CCCCNc1nnc(Cn2c(C)nc3ccccc32)s1,IC50,582.0,nM,6.24,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,Cc1nc2ccccc2n1Cc1nnc(Nc2ccccc2F)s1,IC50,76.0,nM,7.12,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,Cc1nc2ccccc2n1Cc1nnc(Nc2ccc(Cl)cc2)s1,IC50,145.0,nM,6.84,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,O=C1Cc2c([nH]c3cc(Cl)cc(Cl)c23)-c2ccccc2N1,IC50,5000.35,nM,5.3,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,Nc1nonc1-c1nc2ccccc2n1C1CCCCC1,Ki,240.0,nM,6.62,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,Cc1ccc(-c2ccc3occ(-c4ccc([S+](C)[O-])cc4)c3c2)nn1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,CC(C)C1=NNC(=O)/C1=N\Nc1ccccc1Cl,Ki,3700.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,O=C1C(c2cccc3ccccc23)Oc2ccccc2N1Cc1ccc(F)cc1,Ki,5600.0,nM,5.25,Glycogen synthase kinase-3 beta,,,Non-competitive inhibition of recombinant human His-tagged GSK3beta using GS-2 peptide as substrate in presence of [33P]gamma-ATP after 15 mins by microbeta counting method,2017.0
,O=C(O)c1ccc(-c2ccnc(Nc3cccc(-c4ccccc4)c3)n2)cc1,IC50,398.11,nM,6.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2018.0
,NC(=O)c1ccc(-c2ccnc(Nc3cccc(-c4ccccc4)c3)n2)cc1,IC50,31.62,nM,7.5,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2018.0
,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(S(N)(=O)=O)c(Cl)c3)o2)S1,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2007.0
,Nc1n[nH]c2nnc(-c3ccccc3)cc12,IC50,530.0,nM,6.28,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1ccc(C2=C(Nc3cccc(O)c3)C(=O)NC2=O)cc1,IC50,481.0,nM,6.32,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccccc2[N+](=O)[O-])=C1Nc1cc(Cl)c(O)c(Cl)c1,IC50,52.0,nM,7.28,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,Cc1nc(-c2ccc(F)c(F)c2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,59.0,nM,7.23,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,CCCCCCCCCCCCCCCC(=O)N1CCN(C(=O)C2Sc3ccccc3N(CC)C2=O)CC1,IC50,8700.0,nM,5.06,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant N-terminal His6-tagged human GSK3beta H350L mutant expressed in baculovirus infected Sf21 insect cells using polypeptide GS-2 as substrate after 30 mins in presence of ATP by kinase-glo luminescence assay,2017.0
,Cn1c(N2CCOCC2)nc(-c2ccncc2F)cc1=O,IC50,67.0,nM,7.17,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1,Kd,80.0,nM,7.1,Glycogen synthase kinase-3 beta,Active,,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",2017.0
,Cn1c(N2CCOC(c3ccc(F)cc3)C2)nc(-c2ccncc2)cc1=O,IC50,27.0,nM,7.57,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,Cn1cc(C2=C(c3nn(CCN4CCOCC4)c4ncccc34)C(=O)NC2=O)c2ccccc21,IC50,360.0,nM,6.44,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,COc1ccc(-c2ccc(CSc3nnc(-c4ccncc4)o3)cc2)cc1,IC50,176.0,nM,6.75,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,COc1ccc2nc(Cl)c(/C=C3\SC(=O)NC3=O)cc2c1,IC50,3550.0,nM,5.45,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using GS-2 peptide substrate incubated for 30 mins by kinase-Glo luminescent assay,2018.0
,COc1cc(C#Cc2sc(NC(=O)NCCOCC3CC3)nc2C)cnc1OC,Ki,4000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3B (unknown origin),2021.0
,CNc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NC(CCO)c1ccccc1)c1ccc(-c2ccncc2)cc1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCc1nn(-c2cccc(OC)c2)c2ncnc(N/N=C/c3ccncc3)c12,IC50,12.59,nM,7.9,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,O=C(NCc1ccc(F)cc1F)c1cc(-c2ccncc2)n[nH]c1=O,IC50,65.0,nM,7.19,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,Cn1cc(-c2cc(-c3nc4ccccc4[nH]3)c(=O)[nH]n2)ccc1=O,IC50,160.0,nM,6.8,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,O=C1Nc2ccccc2Nc2cc(-c3ccncc3F)ccc21,Ki,158.49,nM,6.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)Oc1cc(-c2ccnc(NC(=O)C3CC3)c2)ncc1C(N)=O,IC50,4.4,nM,8.36,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3c(Cl)cnn23)cc1,IC50,5100.0,nM,5.29,Glycogen synthase kinase-3 beta,,,Inhibitory concentration for Glycogen synthase kinase-3 beta was determined in the presence of 10 um ATP (Km 50 uM),2005.0
ADAVOSERTIB,C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1nc(-c2cccc(O)c2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,43.0,nM,7.37,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,Cc1nc(-c2ccccc2)c(-c2ccnc(NC(=O)CCn3cncn3)c2)[nH]1,IC50,5180.0,nM,5.29,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,Cc1nc(C(N)=O)[nH]c1-c1ccnc(NC(=O)C2CC2)c1,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,NC(=O)c1nc(-c2cccc(OC(F)(F)F)c2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,352.0,nM,6.45,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,Cc1cc(S(=O)(=O)N2CCN(C)CC2)ccc1-c1cnc(N)c(C(=O)Nc2cccnc2)n1,Ki,0.46,nM,9.34,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,O=C1NC(=O)/C(=C/c2cccs2)S1,IC50,7990.0,nM,5.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using GS-2 peptide substrate incubated for 30 mins by kinase-Glo luminescent assay,2018.0
,C/C(=C1/SC(=N)NC1=O)c1ccc(-c2ccc(S(N)(=O)=O)cc2)o1,IC50,430.0,nM,6.37,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2007.0
,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(S(N)(=O)=O)c(C(F)(F)F)c3)o2)S1,IC50,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2007.0
,CNS(=O)(=O)c1ccc(-c2ccc(/C=C3\SC(=N)NC3=O)o2)cc1,IC50,80.0,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2007.0
,NC(=O)c1ccc(Nc2ncnc3[nH]cc(-c4ccccc4)c23)cc1,Ki,158.49,nM,6.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1[nH]c2sc3c(c2c2nc(-c4ccccc4)nn12)CCCC3,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncnc(Nc2cc(CNC(=O)C(F)(F)F)c(O)c(-c3ccc(Cl)cc3)c2)n1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1cccc(Cl)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)c1ccc(N)c2ccccc12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccco2)C(=O)N3)c1)Cc1c[nH]c2ccccc12,Ki,63.1,nM,7.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccccc1NC(=O)Nc1ccc(-c2coc3ncnc(N)c23)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(O)Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)[C@H]3C[C@H](Cl)C3)c2)[nH]1,IC50,395.0,nM,6.4,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,CCCCNC(=O)N1Cc2n[nH]c(NC(=O)Cc3ccc(N4CCCC4)cc3)c2C1,IC50,300.0,nM,6.52,Glycogen synthase kinase-3 beta,,,Inhibitory activity against GSK3-beta,2006.0
,CCN(CC)CCCNc1cccc(-c2nc3c(C(N)=O)cccc3[nH]2)n1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccc(F)cc3)cc12,Ki,19.95,nM,7.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3nsc4ncnc(N)c34)cc2)c1,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Clc1csc2ncnc(Nc3ccccc3)c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Kd,148.0,nM,6.83,Glycogen synthase kinase-3 beta,,,Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged GSK3B (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay,2019.0
,Cc1ccc2c(-c3ccnc(Nc4ccc(F)c(F)c4)n3)c(-c3ccc(F)cc3)nn2n1,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,O=c1nc(-c2ccc3[nH]ncc3c2)cc(-c2ccccc2)[nH]1,Ki,39.81,nM,7.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(OC)c(Nc2ccc3nnc(-c4ccccc4)n3n2)cc1Cl,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccc(F)cc3)cc12,Ki,12.59,nM,7.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
ALISERTIB,COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O,Ki,3162.28,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(CN)CNc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,OCCC(Nc1nc2ccc(-c3ccncc3)cc2s1)c1ccccc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOC(=O)C1=c2sc(=Cc3ccco3)c(=O)n2C(N)=C(C#N)C1c1ccco1,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,FC(F)(F)c1ccccc1CNc1nccc(-c2c[nH]c3ncccc23)n1,Ki,12.59,nM,7.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)cc1,Ki,63.1,nM,7.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCN(CC)CCNC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1c(O)cccc1NC(=O)c1cnn2c(-c3ccccc3)ccnc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)c1ccc(-c2cc(-c3ccc([N+](=O)[O-])cc3)nc(NS(=O)(=O)c3ccc(N)cc3)n2)cc1,Ki,316.23,nM,6.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)NCCN1CCOCC1,IC50,46.0,nM,7.34,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate in presence of gamma-33P-ATP,2016.0
,CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4)n3)c2c1,IC50,260.0,nM,6.58,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2018.0
,COCc1cncc(-c2ccc3[nH]nc(C(=O)NCC4CCOCC4)c3c2)c1,IC50,6.0,nM,8.22,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human N-terminal GST-tagged GSK3beta (1 to 420 end residues) expressed in baculovirus expression system using unphosphorylated peptide as substrate incubated enzyme-substrate mixture for 90 mins in presence of ATP by LANCE assay,2020.0
,CN1CCN(CCNC(=O)c2cc3c(NCCNc4ccc(C#N)cn4)nc(-c4ccc(Cl)cc4Cl)cn3n2)CC1,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,213536,,"Biochemical Assay: The ingredients required for this purpose are mixed in a black 384-well microtiter plate with transparent base (from Greiner, catalog number 781092). The requirements in this connection for each well of the 384-well microtiter plate are 5 nM GSK3β (from Upstate, catalog number xy), 40 μM GSK3β substrate GSM (sequence H-RRRPASVPPSPSLSRHS-(pS)-HQRR, from Upstate, catalog number 2-533), 30 μM nicotinamide adenine dinucleotide NADH (Roche Diagnostics, catalog number 10107735), 50 μM adenosine triphosphate ATP (from Sigma, catalog number A7966) and 2 mM phosphoenolpyruvate (from Roche, catalog number 128112). The required reaction buffer in which the biochemical reaction takes place consists of 50 mM Trizma hydrochloride Tris-HCl pH: 7.5 (from Sigma, catalog number T3253), 5 mM magnesium chloride MgCl2 (from Sigma, catalog number M8266), 0.2 mM DL-dithiothreitol DTT (from Sigma, catalog number D9779), 2 mM ethylenediaminetetraacetic acid EDTA (from Sigma, catalog number E6758), 0.01% Triton X-100 (from Sigma, catalog number T8787) and 0.05% bovine serum albumin BSA (from Sigma, catalog number B4287). Active substances are dissolved in dimethyl sulfoxide DMSO (from Sigma, catalog number D8418) in a concentration of 10 mM. Active substances are added in serial concentrations of 10 μM, 1 μM, 0.1 μM, 0.01 μM, 0.001 μM, 0.0001 μM, 0.00001 μM, 0.000001 μM to the mixtures of the biochemical reaction. As control, dimethyl sulfoxide is added instead of substance in a final concentration of 0.1%. The reaction is incubated at 30° C. for 2 hours and then the resulting fluorescence is measured in a Tecan Safire-XFLUOR4 instrument, version V4.50 (serial number 12901300283) with the specifications: measurement mode−fluorescence measured from below, extinction wavelength 340 nm, emission wavelength 465 nm, slit width extinction 5 nm, slit width emission 5 nm, gain mode 120, delay 0 μs, number of light flashes per measurement 3, and an integration time of 40 μs.",2013.0
,CCOC(=O)c1cc2c(N3CCCC(Nc4nc(N)c(C(C)=O)s4)C3)nc(-c3ccc(Cl)cc3Cl)cn2n1,IC50,8.0,nM,8.1,Glycogen synthase kinase-3 beta,213538,,"Biochemical Assay: The ingredients required for this purpose are mixed in a black 384-well microtiter plate with transparent base (from Greiner, catalog number 781092). The requirements in this connection for each well of the 384-well microtiter plate are 5 nM GSK3β (from Upstate, catalog number xy), 40 μM GSK3β substrate GSM (sequence H-RRRPASVPPSPSLSRHS-(pS)-HQRR, from Upstate, catalog number 2-533), 30 μM nicotinamide adenine dinucleotide NADH (Roche Diagnostics, catalog number 10107735), 50 μM adenosine triphosphate ATP (from Sigma, catalog number A7966) and 2 mM phosphoenolpyruvate (from Roche, catalog number 128112). The required reaction buffer in which the biochemical reaction takes place consists of 50 mM Trizma hydrochloride Tris-HCl pH: 7.5 (from Sigma, catalog number T3253), 5 mM magnesium chloride MgCl2 (from Sigma, catalog number M8266), 0.2 mM DL-dithiothreitol DTT (from Sigma, catalog number D9779), 2 mM ethylenediaminetetraacetic acid EDTA (from Sigma, catalog number E6758), 0.01% Triton X-100 (from Sigma, catalog number T8787) and 0.05% bovine serum albumin BSA (from Sigma, catalog number B4287). Active substances are dissolved in dimethyl sulfoxide DMSO (from Sigma, catalog number D8418) in a concentration of 10 mM. Active substances are added in serial concentrations of 10 μM, 1 μM, 0.1 μM, 0.01 μM, 0.001 μM, 0.0001 μM, 0.00001 μM, 0.000001 μM to the mixtures of the biochemical reaction. As control, dimethyl sulfoxide is added instead of substance in a final concentration of 0.1%. The reaction is incubated at 30° C. for 2 hours and then the resulting fluorescence is measured in a Tecan Safire-XFLUOR4 instrument, version V4.50 (serial number 12901300283) with the specifications: measurement mode−fluorescence measured from below, extinction wavelength 340 nm, emission wavelength 465 nm, slit width extinction 5 nm, slit width emission 5 nm, gain mode 120, delay 0 μs, number of light flashes per measurement 3, and an integration time of 40 μs.",2013.0
,N#Cc1sc(NCCNc2nc(-c3ccc(Cl)cc3Cl)cn3nc(C(=O)NCC(=O)O)cc23)nc1N,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,213540,,"Biochemical Assay: The ingredients required for this purpose are mixed in a black 384-well microtiter plate with transparent base (from Greiner, catalog number 781092). The requirements in this connection for each well of the 384-well microtiter plate are 5 nM GSK3β (from Upstate, catalog number xy), 40 μM GSK3β substrate GSM (sequence H-RRRPASVPPSPSLSRHS-(pS)-HQRR, from Upstate, catalog number 2-533), 30 μM nicotinamide adenine dinucleotide NADH (Roche Diagnostics, catalog number 10107735), 50 μM adenosine triphosphate ATP (from Sigma, catalog number A7966) and 2 mM phosphoenolpyruvate (from Roche, catalog number 128112). The required reaction buffer in which the biochemical reaction takes place consists of 50 mM Trizma hydrochloride Tris-HCl pH: 7.5 (from Sigma, catalog number T3253), 5 mM magnesium chloride MgCl2 (from Sigma, catalog number M8266), 0.2 mM DL-dithiothreitol DTT (from Sigma, catalog number D9779), 2 mM ethylenediaminetetraacetic acid EDTA (from Sigma, catalog number E6758), 0.01% Triton X-100 (from Sigma, catalog number T8787) and 0.05% bovine serum albumin BSA (from Sigma, catalog number B4287). Active substances are dissolved in dimethyl sulfoxide DMSO (from Sigma, catalog number D8418) in a concentration of 10 mM. Active substances are added in serial concentrations of 10 μM, 1 μM, 0.1 μM, 0.01 μM, 0.001 μM, 0.0001 μM, 0.00001 μM, 0.000001 μM to the mixtures of the biochemical reaction. As control, dimethyl sulfoxide is added instead of substance in a final concentration of 0.1%. The reaction is incubated at 30° C. for 2 hours and then the resulting fluorescence is measured in a Tecan Safire-XFLUOR4 instrument, version V4.50 (serial number 12901300283) with the specifications: measurement mode−fluorescence measured from below, extinction wavelength 340 nm, emission wavelength 465 nm, slit width extinction 5 nm, slit width emission 5 nm, gain mode 120, delay 0 μs, number of light flashes per measurement 3, and an integration time of 40 μs.",2013.0
,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CC(=O)C3)c2)[nH]1,IC50,183.0,nM,6.74,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,Cc1cccc(NC(=O)Nc2ccc(-c3csc4nc(N)nc(N)c34)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2C,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCNS(C)(=O)=O)cnc(N)c34)cc2)c1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)=O)c2)[nH]1,IC50,152.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,O=C(Nc1cc(-c2[nH]c(-c3ccco3)nc2-c2ccc(F)cc2)ccn1)C1CC1,IC50,156.0,nM,6.81,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccccc4)c3)cc12,Ki,63.1,nM,7.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=O)Nc1ccc2c(c1)nc(-c1nonc1N)n2C1CCC1,Ki,3300.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,Cn1cc(C2=C(c3coc4ccc(F)cc34)C(=O)NC2=O)c2cc(Cl)ccc21,IC50,42.0,nM,7.38,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cccc(CCC(=O)O)c21,IC50,1.2,nM,8.92,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,FC(F)(F)c1cccc(-c2nnc3ccc(NC4CCNCC4)nn23)c1,Ki,2900.0,nM,5.54,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,Cc1ccc(-c2ccc3occ(-c4ccc(C(C)O)cc4)c3c2)o1,IC50,160.0,nM,6.8,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,c1cc(-c2cn(CC3CC3)c3cnccc23)ccn1,IC50,8300.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human His/GST-tagged GSK3beta (2 to 433 residues) expressed in baculovirus infected Sf9 cells using Ulight-glycogen synthase peptide as substrate incubated for 30 mins by TR-FRET LANCE method,2020.0
,CN1CC=C(c2c(O)cc(O)c3c(=O)cc(-c4ccc(Sc5nc6ccccc6[nH]5)cc4Cl)oc23)CC1,IC50,216.0,nM,6.67,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK3beta in presence of ATP by ADP-glo luminescent assay,2020.0
,CC[C@@]1(c2ccccc2)C2=C(CC(C)(C)CC2=O)Nc2n[nH]cc21,IC50,515.0,nM,6.29,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta by mobility shift micro-fluidic assay,2019.0
,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4ccc(OC(F)F)cc4)cc3)c12,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=O)OCCn1nc(-c2cccc(Br)c2)c2c(C(F)(F)F)cc(=O)[nH]c21,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
OSI-632,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCn1c(C)c(-c2ccnc(Nc3cccc(OC)c3)n2)sc1=O,Ki,12.59,nM,7.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(O)C1CN(Cc2ccc(OCc3cccc(C(F)(F)F)c3)cc2Cl)C1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=S(=O)(NCCNCC=Cc1ccc(Br)cc1)c1cccc2cnccc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cc(Cl)cc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCC(O)C1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=O)Nc1cc(N)c(C#N)c(-c2ccsc2)n1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,FC(F)(F)c1cccc(CSc2nnc(-c3ccc4c(c3)CCO4)o2)c1,IC50,68.0,nM,7.17,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1C,Ki,158.49,nM,6.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(CN)CNc1cc(-c2c[nH]c3ncccc23)cc(F)n1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc2c(-c3ccnc(Nc4ccc([N+](=O)[O-])cc4)n3)cnn2n1,Ki,70.0,nM,7.16,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Cn1cc(Nc2ncc(Cl)c(Nc3ccccc3C(N)=O)n2)cn1,Ki,7.943,nM,8.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(-c2cc3c(=O)[nH]c4ccccc4n3c2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(Cl)c1,Ki,3.981,nM,8.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCNC(C)=O)cc2NC3=O)ccc1O,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1cc(Nc2ncc(Br)c(Nc3ccccc3C(N)=O)n2)cn1,Ki,5.012,nM,8.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
CYC-116,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)cnc2c(-c3ccc4c(c3)OCO4)cnn12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NN=Cc2c[nH]c3cc(NC(=O)C4CC4c4ccccc4)cc1c23,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(F)c(F)cc12,Ki,25.12,nM,7.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCC(=O)Nc1n[nH]c2nc3ccccc3cc12,Ki,158.49,nM,6.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(CN(C)C)cc1Nc1nccc(-c2c(-c3cccc(NC(=O)c4c(F)cccc4F)c3)nc3sccn23)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2OC)c1,Ki,39.81,nM,7.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(OCC2CCC(C(=O)O)C2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(c1cccc(-c2cnc3[nH]ccc3c2)c1)N1CCOCC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cccc(CCOC(C)(C)C)c21,IC50,148.0,nM,6.83,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,COCCn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(Br)cnc21,IC50,25.2,nM,7.6,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,COc1ccc(-c2cc3c(NC(=O)CCSC)ncnc3o2)cc1,IC50,537.0,nM,6.27,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,COc1cc(CCC(=O)Nc2cc(-c3[nH]c(SCc4ccccc4)nc3-c3ccc(F)cc3)ccn2)cc(OC)c1OC,IC50,1149.0,nM,5.94,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,C[C@H]1C[C@@H](c2ccncc2NC(=O)c2nc(-c3ncccc3F)ccc2N)C[C@@H](O)[C@]1(C)O,IC50,540.0,nM,6.27,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2020.0
,O=C(NCc1ccc(Cl)cc1)c1cc(-c2ccc(O)c(F)c2)n[nH]c1=O,IC50,39.0,nM,7.41,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)NCCc1ccncc1,IC50,43.5,nM,7.36,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,NC(=O)c1ccc(-c2c[nH]c3ncc(/C=C/C(=O)NCc4ccncc4)cc23)cc1,IC50,4.43,nM,8.35,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCCCC(=O)O)c2)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)C1CCCN(C(=O)c2cc(-c3ccc4[nH]ncc4c3)on2)C1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1CCCN1Cc1ccc2c(c1)[nH]c(=O)c1cccn12,Ki,50.12,nM,7.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1CC(c2ccc(Cl)cc2Cl)Cc2nc3cc(Cl)ccc3c(O)c21,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1,Ki,125.89,nM,6.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1cc2cc(-c3ccc4cn[nH]c4c3)cnc2[nH]1,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(C)c2)c1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(C=C2SC(=S)NC2=O)ccc1O,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cn(-c2ccc(O)cc2Cl)c2cc(-c3ccncc3)ccc2c1=O,Ki,125.89,nM,6.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(C)cc(NC(=O)Nc2ccc(-c3c(C)sc4ncnc(N)c34)cc2)c1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNCC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)Cc1cc(-c2ccc3[nH]nc(N)c3c2)on1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1ccc2[nH]ncc2c1)c1ccc(Cl)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NN=Cc1ccc(Sc2nc3ccccc3[nH]2)o1)c1cccc([N+](=O)[O-])c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(Cl)ccc1NC(=S)NNC(=O)C(O)(c1ccccc1)c1ccccc1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COCCN(CCOC)c1cc(-c2c[nH]c3ncccc23)cc(Cl)n1,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,OCCCn1cnc(-c2ccccc2)c1-c1ccncc1,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(Nc2nc(Sc3cccc(Cl)c3)nc3ccccc23)n[nH]1,Ki,33.0,nM,7.48,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,Cc1nc2c(sc3c(Br)ccc(Cl)c32)c(=O)o1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOc1ccc(C=C2SC(=N)NC2=O)c(O)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(-c2ccc3c(c2)Nc2ccc([N+](=O)[O-])cc2NC3=O)ccc1O,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12,Ki,2.512,nM,8.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2ccc(-c3cccnc3)cc12,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)NC(=O)c1ccc2nc3[nH]c4ccccc4c3nc2c1,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCNc1c2c(nc3ccccc13)CCCC2,IC50,34.0,nM,7.47,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human full length N-terminal GST-tagged GSK-3beta expressed in Sf9 insect cells using prephosphorylated polypeptide as substrate after 30 mins by kinase-Glo reagent based luminescence assay,2018.0
,COc1cc(Nc2nccc(-c3cnn4nc(OC)ccc34)n2)cc(OC)c1,Ki,120.0,nM,6.92,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)c1,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1,Ki,790.0,nM,6.1,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1,Ki,10.0,nM,,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1,Ki,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCC1CCN(Cc2cccc(Br)c2)CC1,IC50,49.0,nM,7.31,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,COc1ccccc1C1=C(Nc2cccc(Cl)c2)C(=O)NC1=O,IC50,114.0,nM,6.94,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccccc2)=C1Nc1cccc(O)c1,IC50,704.0,nM,6.15,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,C1=CC2C(c3ccnc(Nc4ccccc4)n3)=CNN2C=C1,IC50,150.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,Brc1cnn2c(NCOc3cccnc3)cc(-c3ccccc3)nc12,IC50,600.0,nM,6.22,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,Cn1cc(C2=C(c3coc4cc(OCC5CCC5)ccc34)C(=O)NC2=O)c2cc(F)c(Cl)cc21,IC50,4090.0,nM,5.39,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(Nc2ccc(OC(F)F)cc2)n1,IC50,0.45,nM,9.35,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,O=C(Nc1cc(-c2ccc3ccccc3c2)ccn1)C1CC1,IC50,610.0,nM,6.21,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,O=C(Nc1cc(-c2cccc(O)c2)cc2[nH]ncc12)c1ccccn1,IC50,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) after 1 hr by fluorescence polarization assay,2017.0
,O=C(Nc1cc(-c2cccc3[nH]ccc23)cc2[nH]ncc12)C1CC1,IC50,7943.28,nM,5.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) after 1 hr by fluorescence polarization assay,2017.0
,O=C(Nc1cc(-c2cccc3[nH]ccc23)cc2[nH]ncc12)c1ccccn1,IC50,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) after 1 hr by fluorescence polarization assay,2017.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(Nc2ccc(Cl)cc2)n1,IC50,0.49,nM,9.31,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,O=C(Nc1cncc(-c2ccncc2)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,4.8,nM,8.32,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cnccc1-c1ccc(F)cc1)c1ccnc(NC(=O)C2CC2)c1,IC50,180.0,nM,6.75,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) assessed as decrease in tau phosphorylation by high content cell based assay,2016.0
,CC(C)c1c2cc(-c3ccnc(Nc4ccc5c(N6CCN(C)CC6)ccnc5c4)n3)ccc2nn1C,IC50,0.8,nM,9.1,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK3B using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate incubated for 2 hrs by [gamma-33P]-ATP assay,2021.0
,N[C@H]1CC[C@H](Nc2cc(Nc3ccc(S(=O)(=O)c4cccs4)cc3)n3ncc(Cl)c3n2)CC1,IC50,4000.0,nM,5.4,Glycogen synthase kinase-3 beta,,,Inhibitory concentration for Glycogen synthase kinase-3 beta was determined in the presence of 10 um ATP (Km 50 uM),2005.0
,CC(C)(C)C(=O)N1Cc2c(NC(=O)c3cc(F)cc(F)c3)n[nH]c2C1(C)C,IC50,3630.0,nM,5.44,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2010.0
,CC(C)Cn1cc(-c2ccncc2)c2ccncc21,IC50,8300.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human His/GST-tagged GSK3beta (2 to 433 residues) expressed in baculovirus infected Sf9 cells using Ulight-glycogen synthase peptide as substrate incubated for 30 mins by TR-FRET LANCE method,2020.0
,O=C(Nc1cc(-c2cn(-c3ccccc3)c3cnccc23)ccn1)C1CC1,IC50,630.0,nM,6.2,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human His/GST-tagged GSK3beta (2 to 433 residues) expressed in baculovirus infected Sf9 cells using Ulight-glycogen synthase peptide as substrate incubated for 30 mins by TR-FRET LANCE method,2020.0
,COc1ccc(-c2cc3c(NC(=O)C(C)C)ncnc3o2)cc1,IC50,130.0,nM,6.89,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,Cc1nc(C2CCCCC2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,4640.0,nM,5.33,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccoc3)cc12,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta by kinetic assay,2010.0
,CCN(CCN(C)C)S(=O)(=O)c1ccc(-c2cnc(N)c(C(=O)Nc3cccnc3)n2)cc1,Ki,8.4,nM,8.08,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,CNC(=O)C1Cc2nc(-c3ccc4ccccc4c3)n(-c3ccnc(N[C@H]4CCCN(C(=O)C5CC5)C4)n3)c2C1,IC50,1800.1,nM,5.75,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) incubated for 20 mins in presence of 33P-ATP,2023.0
,COc1ccc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCCO5)o3)cc2)cc1,IC50,127.0,nM,6.9,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,COc1ccc(Nc2nnc(-c3ccc(C)cc3)o2)cc1,IC50,805.0,nM,6.09,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCC1CCN(Cc2ccc(F)cc2)CC1,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCC1CCN(Cc2cccc(F)c2)CC1,IC50,9.0,nM,8.05,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCC1CCN(Cc2ccccc2)CC1,IC50,8.0,nM,8.1,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCC1CCN(Cc2ccc(Br)cc2)CC1,IC50,26.0,nM,7.58,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCC1CCN(Cc2ccccc2F)CC1,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,Cc1ccc(S(=O)(=O)N2CCN(c3nc(-c4ccncn4)cc(=O)n3C)[C@H](C)C2)cc1,IC50,19.0,nM,7.72,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,Cn1c(N2CCNC(c3ccc(Cl)c(Cl)c3)C2)nc(-c2ccncc2)cc1=O,IC50,4.3,nM,8.37,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cl.Cn1c(N2CCNC(c3cccc(Br)c3)C2)nc(-c2ccncn2)cc1=O,IC50,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,FC(F)(F)c1cc(Br)cc(Nc2nccc(-c3cnn4ncccc34)n2)c1,Ki,10.0,nM,,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,CCC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,Ki,120.0,nM,6.92,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Cc1cc(-c2ccccc2Cl)nc(Nc2n[nH]c3ncc(F)cc23)c1C,IC50,300.0,nM,6.52,Glycogen synthase kinase-3 beta,251329,,"Inhibition Assay: Compounds of the present invention were screened for their ability to inhibit GSK-3β (AA 1-420) activity using a standard coupled enzyme system (Fox et al., Protein Sci. 1998, 7, 2249). Reactions were carried out in a solution containing 100 mM HEPES (pH 7.5), 10 mM MgCl2, 25 mM NaCl, 300 μM NADH, 1 mM DTT and 1.5% DMSO. Final substrate concentrations in the assay were 20 μM ATP (Sigma Chemicals, St Louis, Mo.) and 300 μM peptide (American Peptide, Sunnyvale, Calif.). Reactions were carried out at 30 C. and 20 nM GSK-3β. Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate, 300 μM NADH, 30 μg/ml pyruvate kinase and 10 μg/ml lactate dehydrogenase.",2014.0
,O=C(Nc1cncc(-c2ccc(F)cc2)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,6.4,nM,8.19,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,Cn1c(NCC(O)c2ccccc2)nc(-c2ccncc2)cc1=O,IC50,23.0,nM,7.64,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,COc1ccc(CSc2nnc(-c3ccc4ncsc4c3)o2)cc1C(F)(F)F,IC50,3.1,nM,8.51,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,COc1ccc(-n2cnc3ccc(-c4nnc(SCc5cccc(C(F)(F)F)c5)o4)cc32)cc1,IC50,2.5,nM,8.6,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,Cn1cc(C2=C(c3cc(Cl)ccc3Cl)C(=O)NC2=O)c2ccccc21,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,NC1(c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta in human U87MG cells by ELISA,2008.0
,COc1ccccc1C1=C(Nc2cc(Cl)c(O)c(Cl)c2)C(=O)NC1=O,IC50,82.0,nM,7.09,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CC(C)c1ccncc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,23.0,nM,7.64,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,N#CCCN1CCC2CCN(c3ncnc4[nH]c5cc(I)ccc5c34)C2C1,IC50,132.0,nM,6.88,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,Cn1cc(-c2ccc(N3CCOCC3)cc2)c2sc(-c3ccncc3)cc2c1=O,IC50,251.19,nM,6.6,Glycogen synthase kinase-3 beta,,,Inhibition of human full length His-tagged GSK3-beta expressed in baculovirus by alphaLISA assay,2011.0
,Nc1nccc2scc(-c3ccc(NC(=O)Nc4ccccc4C(F)(F)F)cc3)c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12,IC50,1800.0,nM,5.75,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,O=c1[nH]c2ccc(Cl)cc2c(-c2ccccc2)c1C1=NNC(c2ccccc2)C1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1,Ki,31.62,nM,7.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Clc1cc(NC2CCCCC2)nc(-c2c[nH]c3ncccc23)n1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1[nH]c2sc3c(c2c2nc(-c4cccnc4)nn12)CCCC3,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCN(CCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COC(=O)Nc1ccc2c(c1)/C(=C\c1ccc([N+](=O)[O-])cc1)C(=O)N2,IC50,348.0,nM,6.46,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK3beta (636 to 661 residues) assessed as reduction in human muscle glycogen synthase type 1 fragment phosphorylation using YRRAAVPPSPSLSRHSSPHQ(pS)EDE as substrate in presence of ATP incubated for 60 mins by ADP-Glo kinase assay,2023.0
,O=C1Nc2ccccc2C1Cc1cccnc1,IC50,4.2,nM,8.38,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK3beta (636 to 661 residues) assessed as reduction in human muscle glycogen synthase type 1 fragment phosphorylation using YRRAAVPPSPSLSRHSSPHQ(pS)EDE as substrate in presence of ATP incubated for 60 mins by ADP-Glo kinase assay,2023.0
,O=C1Nc2ccccc2C12CC2c1ccccn1,IC50,1231.0,nM,5.91,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK3beta (636 to 661 residues) assessed as reduction in human muscle glycogen synthase type 1 fragment phosphorylation using YRRAAVPPSPSLSRHSSPHQ(pS)EDE as substrate in presence of ATP incubated for 60 mins by ADP-Glo kinase assay,2023.0
,COc1cnc(COc2ccc(F)cc2F)cc1-c1cc2c([nH]1)CCNC2=O,IC50,4000.0,nM,5.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,Fc1cc(F)cc(Nc2nccc(-c3cnn4ncccc34)n2)c1,Ki,10.0,nM,,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Cn1sc(=O)n(-c2ccc(Br)cc2)c1=O,IC50,3000.0,nM,5.52,Glycogen synthase kinase-3 beta,,,Inhibitory activity against recombinant rabbit Glycogen synthase kinase-3 beta,2002.0
,FC(F)(F)c1cccc(Nc2nccc(-c3c(-c4ccc(Cl)cc4)nn4ncccc34)n2)c1,Ki,2510.0,nM,5.6,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,FC(F)(F)c1cc(Nc2nccc(-c3c(-c4ccc(Cl)cc4)nn4ncccc34)n2)ccc1Cl,Ki,3980.0,nM,5.4,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,COc1ccc(C(=O)CCC(=O)NNC(=O)Cn2c(C)nc3ccccc32)cc1,IC50,561.0,nM,6.25,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,CCOc1ccc(Nc2nnc(Cn3c(C)nc4ccccc43)s2)cc1,IC50,293.0,nM,6.53,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,COc1ccc(CNc2cc(-c3c[nH]c4ncccc34)cc(F)n2)cc1,Ki,31.62,nM,7.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COCCNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1nc(-c2ccc3[nH]ncc3c2)cs1,Ki,2861.0,nM,5.54,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,O=C(Nc1cc(Br)ccn1)Nc1cccc2c1C1CCCCN1C2=O,IC50,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2023.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(N)cc3)ccc12,IC50,76.0,nM,7.12,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,COc1ccncc1C1=NNC(=O)/C1=N\Nc1ccc(C#N)cc1,Ki,8.3,nM,8.08,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,C[C@H]1CN(C)CCN1c1nc(-c2ccncc2)cc(=O)n1C,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,COCc1cn(-c2ccc3[nH]ncc3c2)nn1,Ki,5450.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,c1cc2[nH]ncc2cc1-c1c[nH]nn1,Ki,448.0,nM,6.35,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,Clc1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1,Ki,197.0,nM,6.71,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,Fc1ccccc1Cn1cc(-c2ccc3[nH]ncc3c2)nn1,Ki,91.0,nM,7.04,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCOCCn1cc2c2ccccc21,IC50,136.0,nM,6.87,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3beta (GSK3-beta),2003.0
,CCOc1nc(C(=O)NCc2ccc(S(N)(=O)=O)cc2)cc(N)c1C#N,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncnc2c1c(-c1ccc(Oc3ccc(CO)cc3)cc1)cn2C1CCOC1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1[nH]c2sccc2c2nc(-c3ccncc3)nn12,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2c1C(c1ccccc1Cl)C(C#N)=C(N)O2,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1Nc2cc(-c3ccc(O)cc3)ccc2C1=Cc1ccc[nH]1,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(C=C2SC(=Nc3ccccc3)NC2=O)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(COc1cc(C=Cc2ccncc2)cnc1Cl)Cc1c[nH]c2ccccc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,OCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)c1,Ki,150.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,CN(C)C[C@@H](OC(=O)N1Cc2c(NC(=O)C(C)(C)C)n[nH]c2C1(C)C)c1ccccc1,IC50,227.0,nM,6.64,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,CN(c1ncnc2[nH]c3cc(Cl)ccc3c12)[C@H]1CCCN(CCC#N)C1,IC50,489.0,nM,6.31,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,CC(=O)c1ccc(S(=O)(=O)Nc2ccc(-c3nc(-c4ccnc(Nc5ccc(OC(F)(F)F)cc5)c4)no3)cc2)cc1,IC50,1020.0,nM,5.99,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,COC(=O)c1ccc(S(=O)(=O)Nc2ccc(-c3nc(-c4ccnc(Nc5ccc(OC(F)(F)F)cc5)c4)no3)cc2)s1,IC50,1190.0,nM,5.92,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)NCCc1c[nH]c2ccccc12,IC50,356.0,nM,6.45,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)NCCc1ccccc1,IC50,248.0,nM,6.61,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)NCc1ccccn1,IC50,167.0,nM,6.78,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,COC(=O)C(=O)c1c(C(=O)OC)nc2n[nH]c(=N)n2c1-c1ccc(O)c(OC)c1,IC50,2456.0,nM,5.61,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccncc3)c2c1)NCc1ccncc1,IC50,2.75,nM,8.56,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,O=C(/C=C/c1cnc2[nH]cc(-c3cccnc3)c2c1)NCc1ccncc1,IC50,16.5,nM,7.78,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,Cc1ncc(CC(=O)Nc2cc([C@H]3CC[C@@H](OC(=O)N4C[C@@H](C#N)[C@@H]4C)C3)[nH]n2)s1,Ki,1.72,nM,8.76,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged human recombinant GSK3beta H350L mutant expressed in baculovirus-infected Sf21 cells assessed as reduction in production of ADP using 5-FAMKRREILSRRPpSYR-COOH peptide as substrate preincubated with enzyme for 15 mins followed by further incubation with ATP for 30 mins by fluorescence-based microfluidic mobility shift assay,2020.0
,O=C(NCCc1ccccc1)c1ccc(O)c2[nH]c(-c3ccccc3)nc12,IC50,580.0,nM,6.24,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta at 5 uM,2007.0
,COc1ccc(CNC(=O)Nc2nc3ccc(C(=O)CBr)cc3[nH]2)cc1,IC50,130.0,nM,6.89,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using prephosphorylated peptide as substrate measured after 30 mins by Kinase-glo luminescence assay,2019.0
DONEPEZIL,COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCC1CCN(Cc2ccccc2)CC1,IC50,16.0,nM,7.8,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,CCn1c2c(c3cc(Br)ccc31)CC(=O)Nc1ccccc1-2,IC50,1499.68,nM,5.82,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,CC(C)(C)OC(=O)n1c2c(c3cc(Br)ccc31)CC(=O)Nc1ccccc1-2,IC50,2301.44,nM,5.64,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,CCN1C(=O)C(Nc2ccc(OC)cc2)=C(c2ccccc2)C1=O,IC50,5000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2005.0
,Cc1nc2ccccc2n1CC(=O)NNC(=O)C(=O)c1c[nH]c2ccccc12,IC50,72.0,nM,7.14,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,COc1ccc(-c2cc(=O)c3c(OC)c([C@@H]4O[C@H](C(=O)N[C@H](C)C(F)(F)F)[C@@H](O)[C@H](O)[C@H]4O)c(OC)cc3o2)cc1OC,IC50,600.0,nM,6.22,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) using peptide YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate incubated for 5 to 60 mins by ADP-Glo kinase assay,2022.0
,Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)cnn2n1,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Fc1ccc(Nc2nccc(-c3c(-c4ccccc4)nn4ncccc34)n2)cc1F,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,C[C@@H]1CNCCN1c1nc(-c2ccncc2)cc(=O)n1C,IC50,29.0,nM,7.54,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,Nc1c(F)c(NCCNc2ccccn2)c2c3c1c(=O)c(C(=O)O)cn3C1(CCCC1)CO2,IC50,12.0,nM,7.92,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
PALINURIN,CC1=C(O)[C@@H](C/C(C)=C/CCC(C)/C=C/C=C(\C)CCCc2ccoc2)OC1=O,IC50,1905.46,nM,5.72,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using GS2 peptide as substrate and [gamma33P]-ATP after 30 mins by scintillation counting,2013.0
,C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23,IC50,0.86,nM,9.07,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,c1ccc(Nc2nccc(-c3c(-c4ccccc4)nn4ncccc34)n2)cc1,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc(N(C)C)cc3)on2)CC1,IC50,10.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2013.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(NC(=O)C2CCC2)c1,IC50,5.7,nM,8.24,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,Oc1ccc(-c2cc3[nH]ccnc-3n2)cc1,IC50,1200.0,nM,5.92,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
ATUVECICLIB,COc1cc(F)ccc1-c1ncnc(Nc2cccc(C[S@](C)(=N)=O)c2)n1,IC50,87.0,nM,7.06,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK3beta,2020.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCC1CCN(Cc2ccccc2F)CC1,IC50,261.0,nM,6.58,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCC1CCN(Cc2ccc(Cl)cc2)CC1,IC50,45.0,nM,7.35,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,N#CCCN1CCC2CCN(c3ncnc4[nH]c5cc(Br)ccc5c34)C2C1,IC50,66.0,nM,7.18,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,CN(c1ncnc2[nH]c3cc(Cl)ccc3c12)[C@@H]1CCCN(CCC#N)C1,IC50,794.33,nM,6.1,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,CN(c1ncnc2[nH]c3cc(Br)ccc3c12)[C@@H]1CCCN(CCC#N)C1,IC50,398.11,nM,6.4,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,Cc1nnc(-c2ccc3occ(-c4ccc([S+](C)[O-])cc4)c3c2)[nH]1,IC50,81.0,nM,7.09,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(Cl)[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1,IC50,300.0,nM,6.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK2beta phosphorylation in human BT474 cells,2010.0
INDOLYLYLMALEIMIDE 1,O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCOCCOCCn1cc2c2cccnc21,IC50,17.0,nM,7.77,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3beta (GSK3-beta),2003.0
,CC(=O)Nc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1,IC50,158.49,nM,6.8,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1,IC50,15.85,nM,7.8,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,FC(F)(F)c1cccc(Nc2nccc(-c3c(-c4ccccc4)nn4ncccc34)n2)c1,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,NC(=O)C1Cc2nc(-c3ccc(Cl)c(Cl)c3)n(-c3ccnc(N[C@@H]4CCCN(C(=O)C5CC5)C4)n3)c2C1,IC50,470.0,nM,6.33,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) incubated for 20 mins in presence of 33P-ATP,2023.0
,CCn1sc(=O)n(Cc2ccccc2)c1=S,IC50,6000.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Inhibitory activity against recombinant rabbit Glycogen synthase kinase-3 beta,2002.0
,O=C1Cc2c([nH]c3ccccc23)-c2cc(I)ccc2N1,IC50,250.03,nM,6.6,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,O=C1Cc2c([nH]c3ncccc23)-c2ccccc2N1,IC50,5495.41,nM,5.26,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,O=C1Cc2c([nH]c3c(Cl)cccc23)-c2ccccc2N1,IC50,199.99,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(F)cc3)nn2n1,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,CCS(=O)(=O)Nc1ccc(CCNC(=O)c2ccc(O)c3[nH]c(-c4ccc(Cl)cc4Cl)nc23)cc1,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,C[C@H]1COc2c(NCCCn3ccnc3)c(F)c(N)c3c(=O)c(C(N)=O)cn1c23,IC50,180.0,nM,6.75,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,C[C@H]1COc2c(NCCCn3ccnc3)c(F)c(N)c3c(=O)c(C(=N)NO)cn1c23,IC50,140.0,nM,6.85,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,C[C@H]1COc2c(NCCCn3ccnc3)c(F)c(N)c3c(=O)c(C#N)cn1c23,IC50,1.0,nM,9.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,Fc1cccc(CNc2nnc(-c3ccc4c(c3)CCO4)o2)c1,IC50,330.0,nM,6.48,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,COc1ccc(CSc2nnc(C3=CC=C4NC=CN4C3)o2)cc1C(F)(F)F,IC50,6.5,nM,8.19,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,COc1ccccc1C1=C(c2cn(CCCNC=O)c3ncccc23)C(=O)NC1=O,IC50,8.0,nM,8.1,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,Cc1ccc(-c2cc3[nH]ccnc-3n2)cc1,IC50,2600.0,nM,5.58,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,O=C(Nc1cnccc1C(=O)C(F)(F)F)c1ccnc(NC(=O)C2CC2)c1,IC50,0.95,nM,9.02,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,Oc1ccccc1-c1cc2[nH]ccnc-2n1,IC50,6500.0,nM,5.19,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,O=C(Nc1cnccc1-c1ccccc1C(F)(F)F)c1ccnc(NC(=O)C2CC2)c1,IC50,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,CN(C)CCn1cnc(-c2ccc(F)cc2)c1-c1ccc2[nH]ncc2c1,Ki,5450.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,Cn1c(N(CCCCCN)CCc2ccccc2)nc(-c2ccncc2)cc1=O,IC50,150.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,O=c1cc(-c2ccncc2)nc(CCCc2ccccc2)[nH]1,IC50,500.0,nM,6.3,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,N#Cc1ccc2c(c1)-c1[nH]c3ccccc3c1CC(=O)N2,IC50,1300.17,nM,5.89,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,CCN1C(=O)C(Nc2ccc(Cl)cc2)=C(c2ccccc2)C1=O,IC50,5000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2005.0
,CC(C)(O)C(=O)N1CCN(c2ccc(C(F)(F)F)c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c2)CC1,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,Cn1c(N(CCCCN)CCc2ccccc2)nc(-c2ccncc2)cc1=O,IC50,130.0,nM,6.89,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,O=c1cc(-c2ccncc2)nc(CCc2ccccc2)[nH]1,IC50,8900.0,nM,5.05,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,CCNc1nc(-c2ccc3[nH]ncc3c2)cs1,Ki,3925.0,nM,5.41,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,O=C1/C(=C\c2ccc(O)c(O)c2)Oc2ccccc21,IC50,2630.0,nM,5.58,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK-3 beta (unknown origin) after 60 mins by z'-lyte kinase assay,2015.0
,COc1ccccc1C1=C(c2cn(CCCn3ccnc3)c3ccc(Br)cc23)C(=O)NC1=O,IC50,5200.0,nM,5.28,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccc(Br)cc23)=C1c1ccccc1F,IC50,32.0,nM,7.5,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,CC(C)(C)c1ccc(C2=C(c3cn(CCCn4ccnc4)c4ccc(Br)cc34)C(=O)NC2=O)cc1,IC50,420.0,nM,6.38,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccc(Br)cc23)=C1c1cc(C(F)(F)F)cc(C(F)(F)F)c1,IC50,590.0,nM,6.23,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,Cc1ccc(C2=C(c3cn(CCCn4ccnc4)c4cc(Br)ccc34)C(=O)NC2=O)cc1,IC50,380.0,nM,6.42,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,Nc1c(F)c(NCCc2c[nH]c3ccccc23)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1,IC50,660.0,nM,6.18,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,Nc1c(F)c(NCCCCc2ccccc2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1,IC50,290.0,nM,6.54,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,COc1c(NCCNc2ccccn2)c(F)c(N)c2c(=O)c(C(=O)O)cn(C3CC3)c12,IC50,160.0,nM,6.8,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,Nc1ccc(CCNc2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)cc1,IC50,900.0,nM,6.05,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(-c3nc(-c4ccnc(Nc5ccc(F)c(F)c5)c4)no3)cc2)cc1,IC50,1320.0,nM,5.88,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,Cc1cc(C#Cc2sc(NC(=O)NC[C@H](C)OCC3CC3)nc2C)cnc1C,Ki,4000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3B (unknown origin),2021.0
,COCCN1CCC(CNC(=O)c2ncc3ccc(-c4cncc(OC(C)C)c4)cn23)CC1,IC50,9.0,nM,8.05,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCc1cn(-c2c3c(nc4ccccc24)CCCC3)nn1,IC50,51.7,nM,7.29,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCc1cn(CCNc2c3c(nc4ccc(OC)cc24)CCCC3)nn1,IC50,37.1,nM,7.43,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,CS(=O)(=O)Nc1ccc(CCNC(=O)c2ccc(O)c3[nH]c(-c4ccc(F)cc4)nc23)cc1,IC50,1.0,nM,9.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,CC(=O)Nc1cnc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,N#Cc1ccc(CSc2nnc(-c3ccc4c(c3)OCO4)o2)cc1,IC50,130.0,nM,6.89,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using pIRS-1 as substrate preincubated for 15 mins,2012.0
,CCNc1nc2cc(Cl)c(OC)cc2nc1NCC,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCc1c(-c2ccc(C(C)=O)cc2)[nH]c2nccnc12,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
BAY-549,Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12,Ki,1584.89,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1ccc(CNc2nc(Nc3cc(C4CC4)[nH]n3)c3sccc3n2)cc1,Ki,7.943,nM,8.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(C(=O)Nc2c(C(N)=O)sc3ccc(Cl)c(Cl)c23)cc1,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Oc1ccc(Nc2ncnc3scc(Cl)c23)cc1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,OCc1cc(-c2ccc3[nH]ncc3c2)on1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC1(C)CC2=Nc3cc(Cl)ccc3SC2=C(O)C1,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Br.COc1ccc(-c2n/c(=N\c3ccccc3)sn2-c2ccccc2)cc1,IC50,1100.0,nM,5.96,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,O=C1NC(=O)C(c2cn3c4c(cc(F)cc24)CN(C(=O)N2CCCCC2)CC3)=C1c1cn2ccccc2n1,IC50,0.9,nM,9.05,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2021.0
,COc1ccc2c(c1)c(C1=C(c3ccc4ccccc4c3)C(=O)NC1=O)cn2CCCn1ccnc1,IC50,59.0,nM,7.23,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,C=CC(=O)N1C(=O)CC(c2ccc(Br)cc2)Sc2ccccc21,IC50,6400.0,nM,5.19,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using GS-2 peptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,Clc1ccc(-n2cc(-c3ccncc3)nn2)cc1,IC50,1100.0,nM,5.96,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by colorimetric analysis,2012.0
,CN1CCN(CCCn2nc(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c3cccnc32)CC1,IC50,3340.0,nM,5.48,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,O=C1NC(=O)C(c2n[nH]c3ncccc23)=C1c1c[nH]c2ccccc12,IC50,7310.0,nM,5.14,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,O=C(Nc1ncnc2[nH]c(-c3cccc(Cl)c3)nc12)C1CC1,IC50,365.0,nM,6.44,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2010.0
,Cl.Cn1c(N2CCNC(c3ccccc3F)C2)nc(-c2ccncc2)cc1=O,IC50,11.0,nM,7.96,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cl.Cn1c(N2CCNC(c3cccc(F)c3)C2)nc(-c2ccncn2)cc1=O,IC50,12.0,nM,7.92,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,COc1cc(F)ccc1-c1ccnc2[nH]c(C3CCNCC3)cc12,IC50,1400.0,nM,5.85,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of full length human GSK3beta in the presence of ATP at Km concentration,2021.0
,C[C@@H]1CN(c2ccccc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,1.4,nM,8.85,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,O=C(NCCCn1ccnc1)c1ccc(O)c2[nH]c(-c3ccc(F)c(Cl)c3)nc12,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,O=C1NN=C(c2ccccc2)/C1=N/Nc1ccccc1,Ki,99.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1,IC50,316.0,nM,6.5,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1,Ki,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1,Ki,5010.0,nM,5.3,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3c(Br)cnn23)cc1Cl,IC50,8700.0,nM,5.06,Glycogen synthase kinase-3 beta,,,Inhibitory concentration for Glycogen synthase kinase-3 beta was determined in the presence of 10 um ATP (Km 50 uM),2005.0
,O=C(c1ccc(I)cc1)C(Br)Br,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using GS1 as substrate and [gamma-32P]ATP after 20 mins by radiometric assay,2011.0
,CC(=O)C1=C(c2cn(C)c3ccccc23)C(=O)NC1=O,IC50,890.0,nM,6.05,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide substrate after 30 mins by Glow-type luminescence assay in presence of 1 uM ATP,2011.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccccc4)ncnc32)c1,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,COc1cccc(-n2ncc3c(N/N=C(\C)c4ccncc4)ncnc32)c1,IC50,63.1,nM,7.2,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(OCc4ccccc4)cc3)ccc12,IC50,1184.0,nM,5.93,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccc(F)cc3)cc12,IC50,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,Nc1c(F)c(NCCNc2ccccn2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1,IC50,190.0,nM,6.72,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,COc1c(NCCCc2ccccc2)c(F)c(N)c2c(=O)c(C(=O)O)cn(C3CC3)c12,IC50,65.0,nM,7.19,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,COc1c(NCCNc2ccccn2)c(F)c(N)c2c(=O)c(C(=O)O)cn(C3CCCC3)c12,IC50,1500.0,nM,5.82,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,CC1(C)Cn2cc(C(=O)O)c(=O)c3c(N)c(F)c(NCCNc4ccccn4)c(c32)O1,IC50,440.0,nM,6.36,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,CC1(C)COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn(c23)C1,IC50,160.0,nM,6.8,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,c1ccc(Cn2cc(-c3ccc4nccnc4c3)nn2)cc1,IC50,9500.0,nM,5.02,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by colorimetric analysis,2012.0
,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)Cc3ccccc3)cc21,IC50,310.0,nM,6.51,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
,COc1cccc(-n2ncc3c(N/N=C/c4ccc(NC(=O)CCN(C)C)cc4)ncnc32)c1,IC50,5.012,nM,8.3,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,COc1ccc(OC)c(C2=C(c3cn(C)c4ccccc34)C(=O)NC2=O)c1,IC50,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,CC(C)[C@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,IC50,75.0,nM,7.12,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,Nc1c(F)c(NCCNc2ccccn2)c2c3c1c(=O)c(C(=O)O)cn3C1(CCC1)CO2,IC50,57.0,nM,7.24,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,Cc1noc(-c2ccc3occ(-c4ccc([S+](C)[O-])cc4)c3c2)n1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,O=C1N/C(=N/c2ccccc2)S/C1=C\c1ccc(F)cc1,IC50,40.0,nM,7.4,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK-3beta expressed in Baculovirus using Ser/Thr9 peptide as substrate by Z' LYTE assay,2016.0
,CCOc1cc(/C=C2\S/C(=N\Cc3ccccc3)NC2=O)ccc1O,IC50,51.7,nM,7.29,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK-3beta expressed in Baculovirus using Ser/Thr9 peptide as substrate by Z' LYTE assay,2016.0
,N#Cc1ccc(-c2nc(Nc3cc(C4CC4)[nH]n3)c3cc(Cl)ccc3n2)cc1,Ki,190.0,nM,6.72,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3beta (unknown origin) using HSSPHQ(Sp)EDEEE as substrate by pyruvate kinase-lactate dehydrogenase coupled assay,2017.0
,O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCCc1ccc(c(N3CCCC3)n1)CCCCn1cc2c2ccccc21,IC50,24.0,nM,7.62,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2007.0
,c1ccc(Nc2nc(-c3ccc4[nH]ncc4c3)c(-c3ccccc3)s2)cc1,Ki,5450.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,Clc1ccc(Nc2c(-c3ccc4[nH]ncc4c3)nc3ncccn23)cc1,Ki,121.0,nM,6.92,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,c1ccc(CCc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1,Ki,446.0,nM,6.35,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,CN(C)c1ccc(-c2nnc(Nc3ccccc3)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
EUTYPOID D,O=C1OCC(Cc2ccc(O)cc2)=C1c1cc(O)cc(O)c1,IC50,4080.0,nM,5.39,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by luminescent assay,2011.0
,Clc1ccc(C2(c3cc4[nH]ccnc-4n3)CC2)cc1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,Cc1ccc(-n2nc(C)c3c(=O)c4cc(Cl)ccc4n(O)c32)cc1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COCC(C)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(Nc2ncnc3ccccc23)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(Cn2ncc(NC(=O)c3cc(NC(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)ccc3C)c2N)cc1,IC50,2.73,nM,8.56,Glycogen synthase kinase-3 beta,,,inhibition of GSK3-beta,2011.0
,Cn1c(-c2ccccc2)cc(-c2ccncn2)cc1=O,IC50,894.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta expressed in baculovirus infected SF9 cells after 60 mins,2011.0
,O=C1C=CC2(C=C1)OCC(Cc1cn(-c3cccc(Cc4ccccc4)c3)nn1)C(=O)N2c1ccccc1,IC50,1530.0,nM,5.82,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2022.0
,O=C(Nc1cnccc1-c1ccc(F)cc1F)c1ccnc(NC(=O)C2CC2)c1,IC50,62.0,nM,7.21,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) assessed as decrease in tau phosphorylation by high content cell based assay,2016.0
,OCCNc1cc2cc(-c3ccsc3)ccc2cn1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CCC(N2CCCC2)CC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCN(CC)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NNC(=S)Nc1ccc(F)cc1)C(O)(c1ccccc1)c1ccccc1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(-c2nc3c(C(=O)Nc4cnccc4C)ccnc3[nH]2)c1,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,COc1ccncc1NC(=O)c1ccnc2[nH]c(-c3cccc(Cl)c3)nc12,IC50,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,COc1ccncc1NC(=O)c1ccnc2[nH]c(-c3ccncc3)nc12,IC50,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,NC(c1ccc(Cl)cc1)C1CCN(c2ccnc3[nH]ccc23)CC1,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta in human PC3M cells by ELISA,2008.0
,CC(C)[C@@H]1COCCN1c1nc(-c2ccncc2F)cc(=O)n1C,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,C[C@@H]1CN(c2ccccc2C#N)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,4.2,nM,8.38,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,C[C@@H]1CN(c2cccnc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,3.9,nM,8.41,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,C[C@@H]1CN(c2ncccn2)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,24.0,nM,7.62,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,Cl.Cn1c(N2CCNC(c3ccc(C#N)cc3)C2)nc(-c2ccncc2)cc1=O,IC50,15.0,nM,7.82,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,C[C@@H]1OCCN(c2nc(-c3ccncc3F)cc(=O)n2C)[C@@H]1C,IC50,32.0,nM,7.5,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,CC(C)OCCCNc1c(F)c(N)c2c(=O)c(C(=O)O)cn(C3CC3)c2c1F,IC50,110.0,nM,6.96,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,COc1c(NCCNc2ccccn2)c(F)c(N)c2c(=O)c(C(=O)O)c[nH]c12,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,CCCC(=O)Nc1n[nH]c2cc(-c3cccc(O)c3)ccc12,IC50,94.0,nM,7.03,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(O)cc3)c(-c3ccco3)cc12,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(O)cc3)c(-c3ccc(CC)cc3)cc12,IC50,49.0,nM,7.31,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,COc1cccc(C2=NNC(=O)/C2=N\Nc2ccncc2)c1,Ki,23.0,nM,7.64,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,O=C1NC(=O)C(n2ccc3ncccc32)=C1c1cn(CCCn2ccnc2)c2cc(Br)ccc12,IC50,950.0,nM,6.02,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-GSK3beta expressed in Escherichia coli BL21 (DE3),2009.0
,COc1cc(Nc2ncnc3ccc(-c4ccc(CN5CC6C(CO)C6C5)cc4)cc23)ccc1Oc1ccccc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(-c2cc3nc(Br)cnc3[nH]2)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOC(=O)c1nc2c(=O)[nH]c3cc([N+](=O)[O-])c(NC(C)=O)cc3n2c1C,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1c(O)ccc2c1CCCC2=NNC(=O)Cc1cccc2ccccc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Brc1ccc2cnc(Nc3ccncn3)cc2c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1C1CCOc2c(F)cccc21,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1cc(C2=C(c3nn(CCCCN4CCOCC4)c4ncccc34)C(=O)NC2=O)c2ccccc21,IC50,460.0,nM,6.34,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCN(CCO)CCOCCn1cc2c2ccccc21,IC50,40.0,nM,7.4,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta,2003.0
,CCS(=O)(=O)Nc1ccc(CCNC(=O)c2ccc(O)c3[nH]c(-c4ccc(F)cc4Cl)nc23)cc1,IC50,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,CSc1nn(-c2ccccn2)c(N)c1C(N)=O,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(-c2nn(C3CCC(N4CCN(C(C)=O)CC4)CC3)c3ncnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4c[nH]c5ccccc45)c3)cc12,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3[nH]2)cc1,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc2c(c1)c(-c1cc3nccnc3[nH]1)cn2C,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)c1ccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)cc1,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12,Ki,12.59,nM,7.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)N(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1,Ki,15.85,nM,7.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCCN(CCC#N)C(=O)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cccc(Cl)c1)Nc1nc(CCNc2ncnc3ccsc23)cs1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1cc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2CO)cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c1=O,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(Cl)cc1N1CCN(CCCNC(=O)c2nc(-c3cncnc3)no2)CC1,IC50,3480.0,nM,5.46,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as breakdown of glycogen synthase derived substrate peptide by ADP hunter assay in presence of 100 uM ATP,2008.0
,O=C(O)COc1ccc(Nc2ncc3nnn(C45CC6CC(CC(O)(C6)C4)C5)c3n2)cc1,IC50,169.0,nM,6.77,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=C(O)CCc1ccc(Nc2ncc([N+](=O)[O-])c(NC34CC5CC(CC(C5)C3)C4)n2)cc1,IC50,105.0,nM,6.98,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,O=C(O)c1ccc(Nc2ncc([N+](=O)[O-])c(NC34CC5CC(CC(C5)C3)C4)n2)cc1,IC50,26.0,nM,7.58,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,Clc1ccc(-c2[nH]c3nccnc3c2Cc2ccccc2)cc1,IC50,6800.0,nM,5.17,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,c1cc2[nH]ncc2cc1-c1cn(CC2CCOCC2)nn1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1c(NCCc2ccc(Oc3ccccc3)cc2)c(Nc2ccncc2)c1=O,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(C(CN)NC(=O)c2ccc(-c3ccncc3)cc2)c1,Ki,79.43,nM,7.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)cc1C,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOc1ccccc1C=NNC(=O)c1nnn(-c2nonc2N)c1N1CCCC1,Ki,39.81,nM,7.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Cc1ccc(Cl)cc1)Nc1[nH]nc2c1CCC2,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(C)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(C=C2C(=O)ON=C2c2ccc(Br)cc2)cc1OC,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1ccc(-c2ccnc(N)n2)cc1N1CCCCC1,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1c(-c2ccccc2)c2cc(Cl)ccc2[nH]c1=O,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)c(Cl)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
BERZOSERTIB,CNCc1ccc(-c2cc(-c3nc(-c4ccc(S(=O)(=O)C(C)C)cc4)cnc3N)on2)cc1,Ki,140.0,nM,6.85,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta,2019.0
,Nc1nonc1-n1nnc(C(=O)N/N=C/c2ccncc2)c1CN1CCCCC1,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Inhibitory activity against human glycogen synthase kinase-3beta (GSK3-beta) at 100 uM ATP,2003.0
,CCn1cc(C2=C(c3cn(CCCO)c4ncccc34)C(=O)NC2=O)c2cccnc21,IC50,65.0,nM,7.19,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against rabbit glycogen synthase kinase-3 beta using protein phosphatase inhibitor-2 as substrate,2004.0
,c1cc(-c2cnnn2C2C3CC4CC(C3)CC2C4)ccn1,IC50,2600.0,nM,5.58,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by colorimetric analysis,2012.0
,COc1ccc(C2=C(Nc3ccc(C(=O)Nc4ccc(Cl)cc4)cc3)C(=O)NC2=O)cc1,IC50,190.0,nM,6.72,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
MERIDIANIN B,Nc1nccc(-c2c[nH]c3cc(Br)cc(O)c23)n1,IC50,500.0,nM,6.3,Glycogen synthase kinase-3 beta,,,Inhibition of glycogen synthase kinase-3 beta,2004.0
DOVITINIB,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,Kd,350.0,nM,6.46,Glycogen synthase kinase-3 beta,,,Binding constant for GSK3B kinase domain,2011.0
,Cn1cc(C2=C(c3nn(CCCN4CCCCC4)c4ncccc34)C(=O)NC2=O)c2ccccc21,IC50,2660.0,nM,5.58,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,C[S+]([O-])c1ccc(-c2coc3ccc(-c4nnc(O)o4)cc23)cc1,IC50,130.0,nM,6.89,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,COc1ccc(-c2ocnc2C(=O)NCc2ccnc(C(F)(F)F)c2)cc1Cl,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Inhibition of catalytic activity of GSK3-beta by AlphaLISA assay,2012.0
,O=C(CC1CNC(=O)c2cc(-c3cn[nH]c3)cn21)NCc1cccc(F)c1,IC50,386.0,nM,6.41,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2013.0
,O=C1NC(=O)/C(=C/c2ccncc2)S1,IC50,1420.0,nM,5.85,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using GS-2 peptide substrate incubated for 30 mins by kinase-Glo luminescent assay,2018.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCC#Cc1ccc2c(c1)C(=O)N(C1CCC(=O)NC1=O)C2=O,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,CNC(=O)c1ccc(CNC(=O)c2ncoc2-c2ccc(OC)cc2)cc1,IC50,251.19,nM,6.6,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by fluorescence polarization assay,2012.0
,COc1ccc(-c2ocnc2C(=O)NCc2ccccn2)cc1,IC50,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by fluorescence polarization assay,2012.0
,NC(=O)c1cc(-c2ccncc2F)[nH]c1-c1ccccc1,IC50,100.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2010.0
,COc1ccc(CNC(=O)Nc2nc(C)c(C(C)=O)s2)cc1,IC50,600.0,nM,6.22,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta expressed in Escherichia coli using GS-1 as substrate incubated for 20 mins by gamma[32P]ATP-based scintillation counting analysis,2016.0
,COc1cc(C2=C(c3cn(CCCNC(=O)C(N)CC(C)C)c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,IC50,208.0,nM,6.68,Glycogen synthase kinase-3 beta,284791,,"Kinase Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",2015.0
RG-547,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,Kd,230.0,nM,6.64,Glycogen synthase kinase-3 beta,,,Binding constant for GSK3B kinase domain,2011.0
,Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12,Kd,350.0,nM,6.46,Glycogen synthase kinase-3 beta,,,Binding constant for GSK3B kinase domain,2011.0
,COc1cc(C(=O)N2CCCC2)ccc1-c1ccnc2[nH]c(C3CCNCC3)cc12,IC50,310.0,nM,6.51,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of full length human GSK3beta in the presence of ATP at Km concentration,2021.0
,COc1ccc2c(-c3ccnc(N)n3)c[nH]c2c1,IC50,7960.0,nM,5.1,Glycogen synthase kinase-3 beta,,,Inhibition of full-length recombinant human His-tagged GSK3B recombinant in baculovirus expression system using Alexa-Fluor tracer-236 incubated for 60 mins by TR-FRET based Lantha-screen Eu kinase assay,2017.0
,O=[N+]([O-])c1ccccc1-c1ccc(CSc2nnc(-c3ccncc3)o2)cc1,IC50,164.0,nM,6.79,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,N#Cc1cccc(-c2ccc(CSc3nnc(-c4ccncc4)o3)cc2)c1,IC50,84.0,nM,7.08,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1N1CCOCC1,IC50,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of catalytic activity of GSK3-beta by AlphaLISA assay,2012.0
,COc1ccc(-c2ocnc2C(=O)NCc2ccnc(C)c2)cc1Cl,IC50,31.62,nM,7.5,Glycogen synthase kinase-3 beta,,,Inhibition of catalytic activity of GSK3-beta by AlphaLISA assay,2012.0
,N#Cc1cccc(C(=O)c2sc3nc(N)c(C#N)c(-c4ccccc4Cl)c3c2N)c1,IC50,8100.0,nM,5.09,Glycogen synthase kinase-3 beta,,,Inhibition of human Nt-GST-tagged GSK-3beta,2013.0
,N#Cc1c(N)nc2sc(C(=O)c3cccc(Cl)c3)c(N)c2c1-c1ccccc1Br,IC50,4000.0,nM,5.4,Glycogen synthase kinase-3 beta,,,Inhibition of human Nt-GST-tagged GSK-3beta,2013.0
,COc1ccc(CNC(=O)Nc2cc(-c3cccnc3F)ccn2)cc1,IC50,98.0,nM,7.01,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta activity using Ser/Thr 9 peptide as substrate by FRET assay,2011.0
,O=C(CBr)c1ccc(-c2ccccc2)cc1,IC50,2500.0,nM,5.6,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using GS1 as substrate and [gamma-32P]ATP after 20 mins by radiometric assay,2011.0
,O=C(CI)c1ccc(Br)cc1,IC50,3000.0,nM,5.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using GS1 as substrate and [gamma-32P]ATP after 20 mins by radiometric assay,2011.0
,N#Cc1ccc(C(=O)C(Br)Br)cc1,IC50,1500.0,nM,5.82,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using GS1 as substrate and [gamma-32P]ATP after 20 mins by radiometric assay,2011.0
,N#Cc1cccc(C(=O)CBr)c1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using GS1 as substrate and [gamma-32P]ATP after 20 mins by radiometric assay,2011.0
,c1csc(-c2cc3[nH]ccnc-3n2)c1,IC50,1200.0,nM,5.92,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1,IC50,390.0,nM,6.41,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against human Glycogen synthase kinase-3,2002.0
,Cc1ccccc1-c1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1,Ki,125.89,nM,6.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1ccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)nc1,Ki,3.981,nM,8.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCCN(C)C)cc2NC3=O)ccc1O,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCN(CC)CC#Cc1ccc2c(c1)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(-c2ncnc3[nH]ccc23)ccc1F,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1nonc1-n1nnc(C(=O)NN=Cc2ccncc2)c1-c1ccccc1,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(C=C(C#N)c2nc3cc(C)ccc3[nH]2)c(Br)cc1O,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NN=Cc1cc(Br)c(O)c(Br)c1)Nc1ccccc1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1cc(C(CN)c2cncc(C=Cc3ccncc3)c2)c2ccccc21,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1[nH]c2cc(-c3ccccc3)cnc2[nH]1,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCOn1c2ccc(Cl)cc2c(=O)c2c(C)nn(C)c21,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(Cl)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(=O)NCCOCCOCCN)[nH]c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(N)=O)cc2)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccc(Cl)cc5o4)cc3)c1)CNC2=O,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4c(c3)OCO4)csc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccccc1-c1cc2[nH]ccnc-2n1,IC50,3300.0,nM,5.48,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN)cnc(N)c34)cc2)c1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1,Ki,63.1,nM,7.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCCNc1ccc2c3c(cccc13)C(=O)N(CCNCCO)C2=O,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2ccc(Cl)cc12,Ki,39.81,nM,7.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NCCc1cccs1)N1CC=C(c2c[nH]c3ncccc23)CC1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(F)ccc21,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN1CCC(C(=O)n2nc(N)c3cc(-c4cn(Cc5ccccc5)nn4)ccc32)CC1,Ki,31.62,nM,7.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1,Ki,158.49,nM,6.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(C(=O)O)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1sc2[nH]c(=O)n3nc(-c4ccncc4)nc3c2c1C,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCCC(=O)O)cc2)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)Cn1c(N)nc2c(F)cc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cccc(N2CCOCC2)n1)Nc1ccnc2c(C(F)(F)F)cccc12,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Br,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NCCCCCCNC(=O)Nc1cccnc1)Nc1cccnc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC1CCCCC1Nc1nccc(-c2c[nH]c3ncccc23)n1,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccn1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12,Ki,79.43,nM,7.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(Cl)c5o4)cc3)c3c(N)ncnc32)CC1,Ki,125.89,nM,6.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=NNC(=N)N)c1cc(NC(=O)NCCCCCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Brc1ccc2[nH]nc(-c3ccccc3)c2c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
LAUROGUADINE,CCCCCCCCCCCCOc1ccc(NC(=N)N)cc1NC(=N)N,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCCC3CCO)nc12,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COC(=O)Nc1ccc2c(c1)/C(=C/c1ccc(O)cc1)C(=O)N2,IC50,155.4,nM,6.81,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate measured after 60 mins by ADP-Glo luminescence assay,2019.0
,O=C(Nc1ccccc1)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12,IC50,270.0,nM,6.57,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as tau phosphorylation,2010.0
,O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCCc1ccc(s1)CCCn1cc2c2cccnc21,IC50,36.0,nM,7.44,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2004.0
,COCC1COc2ccc(-c3nnc(SCc4ccc(-c5ccccc5C#N)cc4)o3)cc2O1,IC50,233.0,nM,6.63,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using pIRS-1 as substrate preincubated for 15 mins,2012.0
,Cn1c(N2CCO[C@@H]3CCC[C@H]32)nc(-c2ccncc2F)cc1=O,IC50,4.2,nM,8.38,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,Cn1cc(C2=C(c3cccc(OCCN)c3)C(=O)NC2=O)c2ccccc21,IC50,70.0,nM,7.16,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta at 5 uM,2007.0
,O=C(CBr)C1=C(c2c[nH]c3ccccc23)C(=O)NC1=O,IC50,47.0,nM,7.33,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide substrate after 30 mins by Glow-type luminescence assay in presence of 1 uM ATP,2011.0
,C(=N/Nc1ncnc2c1cnn2-c1cccnc1)\c1ccncc1,IC50,31.62,nM,7.5,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,COc1cccc(-n2ncc3c(N/N=C/c4cccc(S(C)(=O)=O)c4)ncnc32)c1,IC50,3.981,nM,8.4,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,O=[N+]([O-])c1ccc(Nc2nnc(-c3ccc([N+](=O)[O-])cc3)o2)cc1,IC50,710.0,nM,6.15,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,CCS(=O)(=O)Nc1ccc(CCNC(=O)c2ccnc3[nH]c(-c4ccccc4)nc23)cc1,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,CCN(CC)c1ccc(-c2nc3c(C(=O)Nc4cnccc4C)ccnc3[nH]2)cc1,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,CNC(=O)C(C)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(C)cc5)cc4)csc23)cn1,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCCn1c(C2CCNCC2)nc(-c2ccc(Cl)c(Cl)c2)c1-c1ccnc(NC2CCCCC2)n1,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NS(=O)(=O)c1cccc(Nc2ncc3ccn(Cc4ccccc4)c3n2)c1,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(C(=O)N2c3ccccc3Sc3c(Cl)cncc32)cc1,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(-c2ccc3c(c2)Nc2ccccc2NC3=O)ccn1,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1[nH]n2ccccc2c1Br,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(Nc2ncnc(N3CCCc4cc(C)ccc43)n2)cc(OC)c1OC,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(O)ccc1-n1cc(C(=O)NN)c(=O)c2ccc(-c3ccncc3)cc21,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1nc(C(F)(F)F)c2c(=O)c3cc(Cl)ccc3n(O)c21,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cc(-c2cccc(N)c2)cc2cccnc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NNC(=S)Nc1ccc(Cl)cc1)C(O)(c1ccccc1)c1ccccc1,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(C(F)(F)F)ccc12,Ki,7.943,nM,8.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC1=NN(c2ccc(C(=O)O)cc2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1[nH]c2sc3c(c2c2nc(-c4ccncc4)nn12)CCCC3,Ki,125.89,nM,6.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC,Ki,100.0,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Clc1cc(Nc2nc(NC3CC3)c3sccc3n2)ccc1N1CCOCC1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
SB-220025,Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc2c(C)n1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NCc1ccccc1)c1c[nH]n2c(=O)cc(-c3ccncc3)nc12,Ki,2.512,nM,8.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(CNc2cc(-c3c[nH]c4ncccc34)cc(Cl)n2)c1C,Ki,25.12,nM,7.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Fc1cnc(Nc2ccccc2)nc1Nc1ccccc1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1CN=C(c2cccc(Cl)c2)c2c(sc3c2CCCC3)N1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COC(=O)c1cc2c(-c3cccc(F)c3)cncc2s1,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN1CCCC1COc1cncc(CCc2ccccc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1ccc(-c2ccnc(NC(=O)C3CC3)c2)nn1,IC50,140.0,nM,6.85,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,O=C(CCl)c1scc(Br)c1Br,IC50,500.0,nM,6.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by liquid scintillation counting,2009.0
,O=C1NN=C(c2ccccc2)/C1=N/Nc1cccc(Cl)c1,Ki,120.0,nM,6.92,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1cccc(C2=NNC(=O)/C2=N\Nc2ccc(Cl)cc2)c1,Ki,9.0,nM,8.05,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccncc1C1=NNC(=O)/C1=N\Nc1ccccc1,Ki,4.5,nM,8.35,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,O=C1NC(=O)/C(=C/c2ccc(/C=C3/NC(=O)NC3=O)cc2)N1,IC50,2810.0,nM,5.55,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,COc1ccc(Nc2nnc(-c3ccc(C(F)(F)F)cc3)o2)cc1,IC50,53.0,nM,7.28,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,Clc1cccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c1Cl,Ki,48.0,nM,7.32,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,Brc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1,IC50,251.19,nM,6.6,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,Cc1nc(-c2ccncc2)cc(=O)[nH]1,IC50,3000.0,nM,5.52,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,Cc1ccc2c(c1Br)/C(=N/NC(N)=S)C(=O)N2,IC50,2460.0,nM,5.61,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,CCCC(=O)Nc1n[nH]c2cc(-c3cccnc3)ccc12,IC50,5900.0,nM,5.23,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta by kinetic assay,2010.0
,Nc1nonc1-c1nc2ccccc2n1C1CC1,Ki,3300.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,O=S(=O)(Nc1ccc(-c2nc(-c3ccnc(Nc4ccc(OC(F)(F)F)cc4)c3)no2)cc1)c1cccc(C(F)(F)F)c1,IC50,2630.0,nM,5.58,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,COC[C@H]1COc2ccc(-c3nnc(SCc4ccc(-c5ccccc5C#N)cc4)o3)cc2O1,IC50,129.0,nM,6.89,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using pIRS-1 as substrate preincubated for 15 mins,2012.0
,O=C1NC(=O)c2c1c1cnn(-c3ccccc3)c1n1cccc21,IC50,1690.0,nM,5.77,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using (RREGGMSRPAS(p)VDG as substrate assessed as 32P[gamma-ATP] incorporation into substrate after 15 mins by autoradiography,2013.0
,Cl.NCCCCOc1ccc2c(c1)NC(=O)Cc1c-2[nH]c2ccc(Br)cc12,IC50,29.99,nM,7.52,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,COCCn1cc(-c2ccnc(Nc3ccccc3)n2)c2ccccc21,IC50,320.0,nM,6.5,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,Fc1cc(F)cc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCCO5)o3)cc2)c1,IC50,966.0,nM,6.01,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,O=C(Nc1cc(-c2ccc3ncccc3c2)ccn1)C1CC1,IC50,7.5,nM,8.12,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,O=C1NN=C(c2ccccc2)/C1=N/Nc1ccc(Cl)cc1,Ki,23.0,nM,7.64,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1cccc(C2=NNC(=O)/C2=N\Nc2ccccc2)c1,Ki,39.0,nM,7.41,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(C2=NNC(=O)/C2=N\Nc2ccncc2)cc1OC,Ki,3.5,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccncc1C1=NNC(=O)/C1=N\Nc1ccc(N2CCOCC2)cc1,Ki,50.0,nM,7.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,CCCCn1cc(C2=C(c3nnc4ccccn34)C(=O)NC2=O)c2ccccc21,IC50,69.7,nM,7.16,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay,2015.0
,CSc1ccc2[nH]c3c(c2c1)CC(=O)Nc1ccccc1-3,IC50,1200.0,nM,5.92,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2010.0
,Cn1cc(C2=C(c3nnc4ccccn34)C(=O)NC2=O)c2ccc(Br)cc21,IC50,327.4,nM,6.49,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay,2015.0
,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3c(C)[nH]nc3n2)c(OC(C)C)cc1C1CCN(C)CC1,IC50,4300.0,nM,5.37,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2016.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)CNCCNc3c4c(nc5cc(Cl)ccc35)CCCC4)c2)nc1OCC1CC1,IC50,62.6,nM,7.2,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)CNCCNc3c4c(nc5ccccc35)CCCC4)c2)nc1OCC1CCC1,IC50,130.4,nM,6.88,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCc1cn(CCNc2c3c(nc4ccccc24)CCCC3)nn1,IC50,64.3,nM,7.19,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)CNCCNc3c4c(nc5ccccc35)CCCC4)c2)nc1OCC(C)(C)C,IC50,165.3,nM,6.78,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,CS(=O)(=O)Nc1ccc(CCNC(=O)c2ccc(O)c3nc(-c4ccc(Cl)cc4Cl)[nH]c23)cc1,IC50,15.0,nM,7.82,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta at 5 uM,2007.0
,COCCn1cc(-c2ccnc(Nc3cccc(OC)c3)n2)c2ccccc21,IC50,140.0,nM,6.85,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2008.0
,Cc1nc(Nc2n[nH]c3ncc(F)cc23)cc(C2CCC(F)(F)CC2)n1,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,244252,,Inhibition Assay: Compounds are screened for their ability to inhibit the phosphorylation of tyrosine (TYR) residues through the use of western blotting of Jurkat cells dosed with the compounds. The phosphorylation of the specific TYR residues tested are GSK3α TYR 279 and GSK3β TYR 216.,2014.0
,Cc1ccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)cc1C,Ki,316.23,nM,6.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Fc1cccc(-c2c[nH]c3ncccc23)c1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(c1ccc(C(F)(F)F)cc1)C(Br)Br,IC50,5000.0,nM,5.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using GS1 as substrate and [gamma-32P]ATP after 20 mins by radiometric assay,2011.0
,Nc1c(Br)cc(C(=O)C(Br)Br)cc1Br,IC50,500.0,nM,6.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using GS1 as substrate and [gamma-32P]ATP after 20 mins by radiometric assay,2011.0
,CCc1ccc2[nH]nc(C(=O)NCC3CCN(CC(=O)O)CC3)c2c1,IC50,541.0,nM,6.27,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,CC(C)C1CN(c2nc(-c3ccncc3F)cc(=O)n2C)CCO1,IC50,17.0,nM,7.77,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,CC[C@H]1COCCN1c1nc(-c2ccncc2F)cc(=O)n1C,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,CCOC(=O)c1cn(-c2ccc(O)cc2C)c2cc(-c3ccncc3)ccc2c1=O,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CSc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,Ki,158.49,nM,6.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNc1cc(-c2ccccc2Cl)nc2c(Br)cnn12,IC50,247.0,nM,6.61,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,CCOC(=O)c1cc(NCc2cccnc2)n2ncc(Br)c2n1,IC50,790.0,nM,6.1,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,CC(O)c1cc(NCc2cccnc2)n2ncc(Br)c2n1,IC50,500.0,nM,6.3,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,Brc1cnn2c(NCc3cccnc3)cc(C3CCCNC3)nc12,IC50,180.0,nM,6.75,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,O=C(NCC1CCCO1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,IC50,55.0,nM,7.26,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human N-terminal GST-tagged GSK3beta (1 to 420 end residues) expressed in baculovirus expression system using unphosphorylated peptide as substrate incubated enzyme-substrate mixture for 90 mins in presence of ATP by LANCE assay,2020.0
,O=C1NC(=O)C(c2cn3c4c(cccc24)CN(C(=O)c2cnccn2)CC3)=C1c1coc2ccccc12,IC50,0.2,nM,9.7,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
LANGKOLIDE,CC(=O)O[C@H]1C[C@@H](O)C[C@H](O)C[C@@H](O)[C@@H]2O[C@H]2[C@@H](C)[C@@H]([C@@H](C)[C@@H](O)[C@H](C)[C@@H](O)[C@@H](C)[C@@H](C)O[C@H]2CC[C@H](O[C@@H]3CC[C@@H](OC(=O)[C@H](C)[C@@H](O)/C(C)=C/c4ccc5c(c4)C(=O)C=CC5=O)[C@H](C)O3)[C@H](C)O2)OC(=O)/C=C/[C@H](C)[C@@H](O)C[C@H](O)/C=C/CC[C@@H](C)[C@@H](O)[C@H](O)[C@@]2(O)O[C@@H](C1)C[C@@H](O)[C@@H]2O,IC50,2170.0,nM,5.66,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3beta by KinaseGlo assay,2012.0
,Cc1cc(Br)cc2c1NC(=O)/C2=N\NC(N)=S,IC50,8100.0,nM,5.09,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,Cc1ccccc1Nc1cc(-c2noc(-c3ccc(NS(=O)(=O)c4ccc(C(C)(C)C)cc4)cc3)n2)ccn1,IC50,2290.0,nM,5.64,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(-c3nc(-c4ccnc(Nc5ccc(F)c(C(F)(F)F)c5)c4)no3)cc2)cc1,IC50,3930.0,nM,5.41,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,Nc1ncc(-c2ccccc2)nc1C(=O)Nc1ccccc1N1CCC(N)CC1,IC50,1.0,nM,9.0,Glycogen synthase kinase-3 beta,438360,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,CS(=O)(=O)Nc1ccc(CCNC(=O)c2ccc(O)c3[nH]c(C4CC4)nc23)cc1,IC50,140.0,nM,6.85,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,CCS(=O)(=O)Nc1ccc(CCNC(=O)c2ccc(O)c3[nH]c(-c4ccccc4)nc23)cc1,IC50,47.0,nM,7.33,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,CCOc1ccncc1NC(=O)c1ccnc2[nH]c(-c3cccc(OC)c3)nc12,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,Br.c1ccc(-c2n/c(=N\CCN3CCOCC3)sn2-c2ccccc2)cc1,IC50,900.0,nM,6.05,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,O=C1Nc2ccc(I)cc2/C1=C1/S/C(=N/c2ccccc2)N(c2ccccc2)C1=O,IC50,1150.0,nM,5.94,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,O=S(=O)(Nc1ccc(-c2nc(-c3ccnc(Nc4ccc(OC(F)(F)F)cc4)c3)no2)cc1)c1cccs1,IC50,7630.0,nM,5.12,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,COc1ccccc1-c1ccnc(N[C@H]2CO[C@H]3[C@@H]2OC[C@@H]3NC(=O)Nc2cccc(C#N)c2)n1,IC50,6080.0,nM,5.22,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using phosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,C[C@H](CO)n1cnnc1-c1cccc(NC(=O)Nc2cc3ccccn3n2)n1,IC50,282.9,nM,6.55,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK3 beta H350L mutant using YRRAAVPPSPSLSR as substrate incubated for 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis,2020.0
,Cc1cccc(Nc2cc(-c3noc(-c4ccc(NS(=O)(=O)c5ccc(C(C)(C)C)cc5)cc4)n3)ccn2)c1,IC50,940.0,nM,6.03,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)CNCCCCCCCCNc3c4c(nc5ccccc35)CCCC4)c2)nc1OCC1CC1,IC50,62.2,nM,7.21,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,O=C(NCc1ccccc1)Nc1ccc2c(c1)OCO2,IC50,38.4,nM,7.42,Glycogen synthase kinase-3 beta,246655,,"Inhibition Assay: The GSK-3β activity was determined by incubation of a mixture of recombinant human GSK-3 enzyme, a phosphate source and GSK-3 substrate in the presence and in the absence of the corresponding test compound, and by measuring the GSK-3 activity of this mixture.Recombinant human glycogen synthase kinase 313 was assayed in MOPS 8 mM pH 7.3, EDTA 0.2 mM, MgCl2 10 mM and sodium orthovanadate 0.25 mM in the presence of 62.5 μM of Phospho-Glycogen Synthase Peptide-2 (GS-2), 0.5 μCi γ-33P-ATP and unlabelled ATP at a final concentration of 12.5 μM. The final assay volume was 20 μl. After incubation for 30 minutes at 30° C., 15 μl aliquots were spotted onto P81 phosphocellulose papers. Filters were washed four times for at least 10 minutes each and counted with 1.5 ml of scintillation cocktail in a scintillation counter.",2014.0
,Br.COc1ccc(-c2n/c(=N\CCO)sn2-c2ccccc2)cc1,IC50,1200.0,nM,5.92,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,C[C@@H]1CN(c2ccccn2)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,4.1,nM,8.39,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,Cn1c(N2CCNC(c3ccccc3Br)C2)nc(-c2ccncn2)cc1=O,IC50,4.3,nM,8.37,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,O=C1NC(=S)S/C1=C\c1cccc(OCCOc2ccccc2)c1,IC50,5540.0,nM,5.26,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,Cc1cc2c(cc1Br)NC(=O)/C2=N\NC(N)=S,IC50,5960.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,O=C1N/C(=N\c2ccccc2Cl)S/C1=C/C=C/c1ccccc1,IC50,6080.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,Nc1n[nH]c(Nc2ccccc2)c1-c1nc2ccccc2s1,IC50,6050.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,O=C(O)c1ccc(NC2=C/C(=N/S(=O)(=O)c3ccc4ccccc4c3)c3ccccc3C2=O)cc1,IC50,6030.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,CCc1ccc(Nc2cc(-c3noc(-c4ccc(NS(=O)(=O)c5ccc(C(C)(C)C)cc5)cc4)n3)ccn2)cc1,IC50,3240.0,nM,5.49,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,CCCNC(=O)c1sc(-c2ccnc(NC(=O)CNCCNc3c4c(nc5ccccc35)CCCC4)c2)nc1OCC1CC1,IC50,239.3,nM,6.62,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)CNCCNc3c4c(nc5ccccc35)CCCC4)c2)nc1OC,IC50,41.1,nM,7.39,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,COc1ccc(-c2ccnc(N[C@H]3CO[C@H]4[C@@H]3OC[C@@H]4NC(=O)Nc3ccccc3)n2)cc1,IC50,560.0,nM,6.25,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using phosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,CN(C)c1ccc(-c2ccnc(N[C@H]3CO[C@H]4[C@@H]3OC[C@@H]4NC(=O)Nc3cccc(C(F)(F)F)c3)n2)cc1,IC50,5660.0,nM,5.25,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using phosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,CCNC(=O)N[C@H]1CO[C@H]2[C@@H]1OC[C@@H]2Nc1nccc(-c2ccc(OC)cc2)n1,IC50,117.0,nM,6.93,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using phosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,COC(=O)N1CCN(c2nc(-c3ccncn3)cc(=O)n2C)[C@H](C)C1,IC50,70.0,nM,7.16,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,CCOc1ccccc1C1CN(c2nc(-c3ccncn3)cc(=O)n2C)CCN1.Cl,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,COc1cc(F)ccc1C1CN(c2nc(-c3ccncc3)cc(=O)n2C)CCN1C(C)=O,IC50,1700.0,nM,5.77,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,COc1cc(F)ccc1C1CN(c2nc(-c3ccncn3)cc(=O)n2C)CCN1C.Cl,IC50,26.0,nM,7.58,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
EUTYPOID C,O=C1OCC(Cc2ccc(O)c(O)c2)=C1c1ccc(O)cc1,IC50,670.0,nM,6.17,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by luminescent assay,2011.0
,Cn1cc(-c2ccc(-c3cncc(Cl)c3N3CCC4(CCNC4=O)CC3)cc2)cn1,IC50,690.0,nM,6.16,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2015.0
,CCCCNC(=O)c1cn(C(CC)CC)c(=O)c2cc(OC)c(OC)cc12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(CO)CCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1,Ki,31.62,nM,7.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Ki,31.62,nM,7.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(COc1cncc(-c2ccc(F)cc2)c1)Cc1c[nH]c2ccccc12,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1cccs1,Ki,158.49,nM,6.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(O)CCNc1cc(N2CCN(c3ccc(F)cc3)CC2)c2noc3c2c1C(=O)c1ccccc1-3,IC50,8000.0,nM,5.1,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) using biotin-labelled IRS-1 peptide as substrate incubated for 15 mins by ELISA based assay,2022.0
,Nc1c(F)c(NCCNc2ccccn2)c2c3c1c(=O)c(C(=O)O)cn3C1(CCC1)CCN2,IC50,550.0,nM,6.26,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta after 1 hr by KinaseGlo luciferase assay,2012.0
,Cc1cc(Nc2nc(Sc3ccc(NC(=O)OC(C)(C)C)cc3)nc3ccccc23)n[nH]1,Ki,4000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCc1cn(CCNc2c3c(nc4cc(Cl)ccc24)CCCC3)nn1,IC50,46.7,nM,7.33,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)CNCCNc3c4c(nc5ccccc35)CCCC4)c2)nc1OC(C)C,IC50,71.6,nM,7.14,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,O=C(NCC1CCOCC1)c1n[nH]c2ccc(-c3cnccc3CO)cc12,IC50,33.0,nM,7.48,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human N-terminal GST-tagged GSK3beta (1 to 420 end residues) expressed in baculovirus expression system using unphosphorylated peptide as substrate incubated enzyme-substrate mixture for 90 mins in presence of ATP by LANCE assay,2020.0
,CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(Cl)nccn23)n1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN1CCN(c2ccc(NC(=O)c3ccc4c(c3)/C(=C3/Nc5ccccc5C3=O)C(=O)N4)cc2)CC1,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as inhibition of [33Pi] incorporation after 80 mins by microplate scintillation counting,2010.0
,COc1cccc(OC)c1[C@H]1CN(c2nc(-c3ccncn3)cc(=O)n2C)CCO1,IC50,0.23,nM,9.64,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccncc2F)cc1=O,IC50,7.4,nM,8.13,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,O=C1NC(=S)S/C1=C\c1ccccc1OS(=O)(=O)c1ccccc1[N+](=O)[O-],IC50,1560.0,nM,5.81,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2008.0
,Cn1cc(C2=C(c3nnc4ccccn34)C(=O)NC2=O)c2cc(F)ccc21,IC50,188.0,nM,6.73,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay,2015.0
,Cc1ccc2c(-c3ccnc(Nc4ccc(Cl)c(C(F)(F)F)c4)n3)c(-c3cccc(C(F)(F)F)c3)nn2n1,Ki,630.0,nM,6.2,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,C=CC(=O)N1C(=O)CC(c2cccs2)Sc2ccccc21,IC50,4900.0,nM,5.31,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using GS-2 peptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,IC50,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,O=C(Nc1cncc(OCC2CCN(Cc3ccccc3)CC2)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,23.0,nM,7.64,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,C[C@H](/C=C\C(F)(F)F)Oc1cc(-c2cc(-c3cc(CN(C)C)cs3)cnc2N)ccc1C(N)=O,IC50,70.0,nM,7.16,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta incubated for 30 mins prior to substrate addition study done at apparent ATP Km for enzyme,2012.0
,C[C@H]1COc2c(NCCCc3ccccc3)c(F)c(N)c3c(=O)c(C(N)=O)cn1c23,IC50,67.0,nM,7.17,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23,IC50,0.6,nM,9.22,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,COc1ccc(-c2ccnc(N[C@H]3CO[C@H]4[C@@H]3OC[C@@H]4NC(=O)Nc3ccc(C(C)=O)cc3)n2)cc1,IC50,412.0,nM,6.38,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using phosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,O=C(Nc1cccc(C(F)(F)F)c1)O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2Nc1nccc(-c2ccc3c(c2)OCO3)n1,IC50,1080.0,nM,5.97,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using phosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,Cn1cc(-c2ccncc2)c2ccncc21,IC50,4780.0,nM,5.32,Glycogen synthase kinase-3 beta,,,Inhibition of full-length recombinant human His-tagged GSK3B recombinant in baculovirus expression system using Alexa-Fluor tracer-236 incubated for 60 mins by TR-FRET based Lantha-screen Eu kinase assay,2017.0
,Cn1c(N2CCOC(C3CCC3)C2)nc(-c2ccncc2F)cc1=O,IC50,12.0,nM,7.92,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,Cn1c(N2CCO[C@@H]3CCCC[C@H]32)nc(-c2ccncc2F)cc1=O,IC50,3.7,nM,8.43,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCC1CCN(Cc2c(F)cccc2F)CC1,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCC1CCN(Cc2cccc([N+](=O)[O-])c2)CC1,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCC1CCN(Cc2ccc(Cl)c(Cl)c2)CC1,IC50,41.0,nM,7.39,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,O=C(CCl)c1csc(C(=O)CCl)c1,IC50,1500.0,nM,5.82,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by liquid scintillation counting,2009.0
,CCCCCCCC(=O)NNC(=O)c1c(O)c2ccccc2n(CC=C(C)C)c1=O,IC50,7110.0,nM,5.15,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,CCNC(=O)c1nnn(-c2nonc2N)c1CN1CCCCC1,IC50,280.0,nM,6.55,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using YRRAAVPPSPSLSRHSSPHQS(PO4)EDEEE-NH2 as substrate after 60 mins in presence of [33gammaP]-ATP by topcount method,2018.0
,CCCCCCCC(=O)NNC(=O)c1c(O)c2ccc(Cl)cc2n(Cc2ccccc2)c1=O,IC50,5960.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,O=C1NN=C(c2ccccc2)/C1=N/Nc1ccccc1Cl,Ki,720.0,nM,6.14,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,CN(C)c1nc2ccc1CCCN1C=C(C3=C(C(=O)NC3=O)c3cn(c4ccccc34)CCC2)N2C=CC=CC12,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,Cc1c(C(=O)CCl)csc1C(=O)CCl,IC50,5000.0,nM,5.3,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 (GSK-3beta).,2003.0
,O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCn1cc2c2cccnc21,IC50,34.0,nM,7.47,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3beta (GSK3-beta),2003.0
,COc1ccc(-c2cccc3nc(NC(=O)C4CC4)nn23)cc1,IC50,7114.0,nM,5.15,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2014.0
,COc1nc(-c2ccnc(NC(=O)C3CC3)c2)sc1C(=O)NCCCNC(=O)COc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,IC50,874.3,nM,6.06,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCC#Cc1ccc2c(c1)C(=O)N(C1CCC(=O)NC1=O)C2=O,IC50,79.1,nM,7.1,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,CC(=O)Nc1cccc(S(=O)(=O)Nc2ccc(-c3nc(-c4ccnc(Nc5ccc(OC(F)(F)F)cc5)c4)no3)cc2)c1,IC50,2170.0,nM,5.66,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCOCCn1cc2c2cccnc21,IC50,138.0,nM,6.86,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3beta (GSK3-beta),2003.0
,Cc1ccc(-c2ccc3occ(-c4ccc(S(C)(=O)=O)cc4)c3c2)o1,IC50,42.0,nM,7.38,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2009.0
,Br.CCOC(=O)C/N=c1\nc(-c2ccccc2)n(-c2ccc([N+](=O)[O-])cc2)s1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,Br.O=[N+]([O-])c1ccc(-n2s/c(=N/Cc3cccnc3)nc2-c2ccccc2)cc1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,Br.N=c1nc(-c2ccccc2)n(-c2ccccc2)s1,IC50,600.0,nM,6.22,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,Br.OCC/N=c1\nc(-c2ccccc2)n(-c2ccccc2)s1,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,CCCCC/N=c1\nc(-c2ccc(OC)cc2)n(-c2ccccc2)s1.Cl,IC50,1100.0,nM,5.96,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,Br.OCC/N=c1\nc(-c2ccccc2)n(-c2cccc3ccccc23)s1,IC50,300.0,nM,6.52,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,Br.CCOC(=O)C/N=c1\nc(-c2ccc(OC)cc2)n(-c2ccccc2)s1,IC50,500.0,nM,6.3,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,O=C(NCC1CCOCC1)c1n[nH]c2ccc(-c3cncc(CO)c3)cc12,IC50,3400.0,nM,5.47,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) transfected in HEK cells co-transfected with tau assessed as reduction in tau phosphorylation incubated for 18 hrs in presence of 1ug/ml doxycycline,2020.0
,O=C(Nc1cnccc1Cl)c1ccnc(NC(=O)C2CC2)c1,IC50,260.0,nM,6.58,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) assessed as decrease in tau phosphorylation by high content cell based assay,2016.0
,O=C(Nc1cnccc1-c1ccccc1F)c1ccnc(NC(=O)C2CC2)c1,IC50,290.0,nM,6.54,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) assessed as decrease in tau phosphorylation by high content cell based assay,2016.0
,CC(C)Oc1cccc(-c2ccc3[nH]nc(C(=O)NCC4CCOCC4)c3c2)c1,IC50,4.0,nM,8.4,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2022.0
,O=C(O)CCCNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,IC50,3300.0,nM,5.48,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK-3beta using Ser/Thr 6 peptide as substrate preincubated for 60 mins followed by ATP and substrate addition and measured after 45 mins by Z'lyte assay,2021.0
,COc1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1C(N)=O,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,Br.CCCCC/N=c1\nc(-c2ccc(OC)cc2)n(-c2ccccc2)s1,IC50,300.0,nM,6.52,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,CN1CCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCN(C)CC1,IC50,33.0,nM,7.48,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta,2003.0
,CCCCCCCC(=O)NNC(=O)c1c(O)c2cc(Br)ccc2n(CC)c1=O,IC50,7340.0,nM,5.13,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,CS(=O)(=O)Nc1ccc(CCNC(=O)c2ccnc3[nH]c(-c4ccoc4)nc23)cc1,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,Br.CCOC(=O)C/N=c1\nc(-c2ccccc2)n(-c2ccccc2)s1,IC50,7000.0,nM,5.16,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,CN(C)S(=O)(=O)Nc1ccc(CCNC(=O)c2ccnc3[nH]c(-c4ccsc4)nc23)cc1,IC50,9.0,nM,8.05,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,Cc1cc(Nc2ncc(C)c(N3CCN(CC#N)C(C)C3)n2)sn1,IC50,1364.0,nM,5.87,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,Cc1cc(Nc2ncc(C)c(N3CC(CCC#N)C3)n2)sn1,IC50,1351.0,nM,5.87,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,Cc1cc(Nc2ncc(C)c(N3CC(C4CC4)C3)n2)sn1,IC50,1039.0,nM,5.98,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2ccccc2n(CC)c1=O,IC50,3010.0,nM,5.52,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta incubated for 30 mins by Kinase Glo luminescent kinase assay,2011.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCCCCOc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,IC50,71.6,nM,7.14,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCC#Cc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,IC50,49.2,nM,7.31,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,COc1cc(-c2ccnc(NC(=O)C3CC3)c2)ncc1C(N)=O,IC50,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(C(F)(F)F)cccc12,Ki,6.31,nM,8.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=O)N1CCC(Nc2nccc(-c3c(-c4ccc(F)cc4)nc4occn34)n2)CC1,Ki,79.43,nM,7.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=O)Nc1ccc(-n2nc3ccc(N)nc3n2)cc1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1Nc2ccccc2Nc2nnccc21,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Brc1cnc2[nH]cc(-c3ccccc3)c2c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1nc(-c2ccnc(NC(=O)C3CC3)c2)sc1C(N)=O,IC50,37.0,nM,7.43,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,NC(=O)c1cnc(-c2ccnc(NC(=O)C3CC3)c2)s1,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cccnc21,IC50,17.6,nM,7.75,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,COc1ccccc1N/N=C1\C(=O)NN=C1c1cnccc1OC,Ki,270.0,nM,6.57,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccncc1C1=NNC(=O)/C1=N\Nc1ccncc1,Ki,16.0,nM,7.8,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(C2=NNC(=O)/C2=N\Nc2ccc(Cl)cc2)cc1,Ki,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1cccc(N/N=C2\C(=O)NN=C2c2cnccc2OC)c1,Ki,3.7,nM,8.43,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,Cc1cncc(NC(=O)c2ccnc(NC(=O)C3CC3)c2)c1,IC50,9.5,nM,8.02,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cncc(-c2cccc(F)c2F)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,2.6,nM,8.59,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cncc(-c2cncc(Cl)c2)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,3.9,nM,8.41,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC(C)C(=O)Nc1cc(C(=O)Nc2cncc(-c3cc(F)ccc3F)c2)ccn1,IC50,4.6,nM,8.34,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC(F)C(=O)Nc1cc(C(=O)Nc2cnccc2-c2ccccc2)ccn1,IC50,49.0,nM,7.31,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CCOc1ccncc1NC(=O)c1ccnc(NC(=O)C2CCC2)c1,IC50,2.2,nM,8.66,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC1(C)CC(C(=O)Nc2cc(C(=O)Nc3cnccc3-c3ccccc3)ccn2)C1,IC50,1.7,nM,8.77,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,Oc1ccc(-c2n[nH]c3ncc(-c4ccc(O)c(O)c4)cc23)cc1,Kd,259.78,nM,6.58,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human GSK-3beta assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,2023.0
,Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)/N=C/c1cnc2ccc(Br)cn12,Kd,3.934,nM,8.4,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human GSK-3beta assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,2023.0
,C[C@@H]1CN(C(=O)c2ccccc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,21.0,nM,7.68,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,COc1ccc(-c2cc3c(NC(=O)C4CCCC4)ncnc3o2)cc1,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,COc1ccc(-c2cc3c(NC(=O)N4CCCC4)ncnc3o2)cc1,IC50,1950.0,nM,5.71,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,COc1ccc(-n2cnc3ccc(-c4n[nH]c(=S)o4)cc32)cc1,IC50,2.3,nM,8.64,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,O=C1NC(=S)S/C1=C\c1cc(/N=N/c2ccccc2)ccc1O,IC50,3960.0,nM,5.4,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,O=C(Cc1ccc([N+](=O)[O-])cc1)N/N=C1\C(=O)Nc2cc(Br)ccc21,IC50,4160.0,nM,5.38,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,Cc1cccc(OCCOc2cccc(/C=C3\SC(=S)NC3=O)c2)c1,IC50,2600.0,nM,5.58,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,CCCC(=O)Nc1n[nH]c2cc(CCc3ccccc3)ccc12,IC50,8525.0,nM,5.07,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccc(Br)cc23)=C1c1ccccc1[N+](=O)[O-],IC50,66.0,nM,7.18,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3cc(Br)ccc23)=C1c1ccc2ccccc2c1,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,Cc1cc(Nc2ncc(C)c(N3CC(CC#N)(OC4CC5(CC5)C4)C3)n2)sn1,IC50,237.0,nM,6.62,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,COc1ccc2c(C3=C(c4ccccc4F)C(=O)NC3=O)cn(CCCn3ccnc3)c2c1,IC50,11.0,nM,7.96,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,O=C1NC(Nc2ncccn2)=N/C1=C\c1ccc2ncsc2c1,IC50,7742.0,nM,5.11,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=c1[nH]nc2c(NCCc3ccncc3)cc(Cl)cn12,IC50,111.0,nM,6.96,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using GS-2 as substrate,2017.0
,CCN1CCOCCN(CC)CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCC1,IC50,31.0,nM,7.51,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta,2003.0
,Nc1c(F)c(NCCc2ccccc2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1,IC50,440.0,nM,6.36,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length GSK3-beta after 1 hrs by luminescence assay,2011.0
,COc1cccc(-c2cc3[nH]ccnc-3n2)c1,IC50,3200.0,nM,5.5,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,NC(=O)c1cc(-c2ccnc(Nc3ccccc3)n2)[nH]c1-c1ccccc1,IC50,100.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2010.0
,Br.c1ccc(Cn2s/c(=N/Cc3cccnc3)nc2-c2ccccc2)cc1,IC50,1100.0,nM,5.96,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,Br.OCC/N=c1\nc(-c2cccc3ccccc23)n(-c2ccccc2)s1,IC50,300.0,nM,6.52,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,NC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Clc1cc(-c2c[nH]c3ncccc23)cc(NCc2ccccc2)n1,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,C=CC(=O)N1C(=O)CC(c2ccc(C)cc2)Sc2ccccc21,IC50,4800.0,nM,5.32,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using GS-2 peptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,Oc1cnc2ccc(-c3ccncc3)cc2c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCN(CC)CCOc1ccc(-c2nc3c(C(N)=O)cccc3[nH]2)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNC(=O)C=Cc1cnc(N)c2c(-c3cc(F)c4[nH]c(C)cc4c3)csc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(-c2ccccc2)n(-c2cc(NN=Cc3ccco3)ncn2)n1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCN(CC)CCNC(=O)C=Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12,Ki,3162.28,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccccc1NC(=O)Nc1ccc2c(c1)CCc1sc3ncnc(N)c3c1-2,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(O)c1c2c(nc3ccccc13)C(=C1CCCC1)CC2,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,FC(F)(F)c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C(F)(F)F)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOC(=O)C1=C(N)n2c(sc(=Cc3cccs3)c2=O)=C(C(N)=O)C1c1cccs1,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1cc(-c2ccncn2)c(-c2ccc(F)cc2)n1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1ccc(-c2ccc3cn[nH]c3c2)cc1)Nc1cccc(F)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncnc2sc3c(c12)-c1ccc(NC(=O)Nc2ccccc2)cc1CC3,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)c1n[nH]c2c1C(c1ccccc1F)C(C#N)=C(N)O2,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(O)c1ccccc1Nc1ncnc(Nc2ccc(F)cc2)n1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(C)c5o4)cc3)c3c(N)ncnc32)CC1,Ki,79.43,nM,7.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)OC(=O)n1cc(-c2cncn2C2CCCCC2)c2ccccc21,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1nc2ccccc2s1)c1cccc2c1CN(c1nc(C(=O)O)c(-c3ccc(CO)cc3)s1)CC2,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl,Ki,794.33,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC1CCC(Nc2nccc(-c3c[nH]c4ncccc34)n2)CC1,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1nc(N)c(C#N)c(-c2ccc(Cl)cc2Cl)c1C#N,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1ccccc1-c1ccc(CSc2nnc(-c3ccc4c(c3)OCCO4)o2)cc1,IC50,5.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using pIRS-1 as substrate preincubated for 15 mins,2012.0
,COc1ccccc1NC(=O)c1nc(-c2ccc(S(=O)(=O)N3CCN(C)CC3)cc2)cnc1N,Ki,12.0,nM,7.92,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,CN1CCN(S(=O)(=O)c2ccc(-c3cnc(N)c(C(=O)Nc4cccnc4)n3)c(F)c2)CC1,Ki,1.3,nM,8.89,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,CC(C)(C)c1ccc(C(=O)Nc2cn3cc(-n4ccnc4)ccc3n2)cc1.Cl.Cl,IC50,832.0,nM,6.08,Glycogen synthase kinase-3 beta,,,"Selectivity interaction (Kinase panel (Invitrogen, enzymatic assay)) EUB0000623aCl GSK3B",2024.0
,CCS(=O)(=O)Nc1ccc(CCNC(=O)c2ccnc3[nH]c(-c4cccs4)nc23)cc1,IC50,12.0,nM,7.92,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1[nH]c3ccc(O)cc3c21,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NNc1cc(N2CCOCC2)nc(OCCc2ccccn2)n1,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CCN)nccn23)n1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cc(-c2cccc(O)c2)cc2[nH]ncc12)C1CC1,IC50,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) after 1 hr by fluorescence polarization assay,2017.0
,O=C(CCCNC(=S)Nc1ccc2c(c1)C(=O)NC2=O)NO,IC50,9850.0,nM,5.01,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using GSM as substrate incubated for 30 mins by luminescence based assay,2019.0
,COc1cc(C2=C(c3cn(CCCN)c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,IC50,129.0,nM,6.89,Glycogen synthase kinase-3 beta,410870,,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",2016.0
,O=C(CCCCCNC(=S)Nc1ccc2c(c1)C(=O)NC2=O)NO,IC50,2690.0,nM,5.57,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using GSM as substrate incubated for 30 mins by luminescence based assay,2019.0
,O=C(NCC1CCN(Cc2cccc(F)c2)CC1)c1cncc(NC(=O)c2ccnc(NC(=O)C3CC3)c2)c1,IC50,97.0,nM,7.01,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,O=C(Nc1cccc(OCC2CCN(Cc3ccccc3)CC2)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,9748.0,nM,5.01,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,O=C(NC1CCN(Cc2ccccc2)CC1)c1cncc(NC(=O)c2ccnc3[nH]ccc23)c1,IC50,6804.0,nM,5.17,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,Cc1ccc(-c2ccncc2NC(=O)c2ccnc(NC(=O)C3CC3)c2)cc1,IC50,120.0,nM,6.92,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) assessed as decrease in tau phosphorylation by high content cell based assay,2016.0
,Cc1ccc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)cc1Cl,IC50,1291.0,nM,5.89,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl,IC50,218.0,nM,6.66,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,COc1ccc2oc3ncc(OCc4ccccc4)c(-c4ccccc4)c3c2c1,Ki,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,Nc1ncc(-c2ccc(S(=O)(=O)N3CCOCC3)cc2)nc1C(=O)Nc1cccnc1,Ki,0.67,nM,9.17,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,CN1CCN(S(=O)(=O)c2cccc(-c3cnc(N)c(C(=O)Nc4cccnc4)n3)c2)CC1,Ki,74.0,nM,7.13,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,Cc1cc(S(=O)(=O)N2CCN(C)CC2)c(C)cc1-c1cnc(N)c(C(=O)Nc2cccnc2)n1,Ki,1.5,nM,8.82,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,COc1nc(-c2ccnc(NC(=O)C3CC3)c2)sc1C(=O)NCCCNc1c2c(nc3ccccc13)CCCC2,IC50,66.0,nM,7.18,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human full length N-terminal GST-tagged GSK-3beta expressed in Sf9 insect cells using prephosphorylated polypeptide as substrate after 30 mins by kinase-Glo reagent based luminescence assay,2018.0
,CCOC(=O)c1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,899.0,nM,6.05,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,COc1ccccc1-c1nc(C(N)=O)[nH]c1-c1ccnc(NC(=O)C2CC2)c1,IC50,265.0,nM,6.58,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,Cc1nc(-c2cccs2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,69.0,nM,7.16,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,CC(C)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3nnc(-c4ccccc4)o3)n2)cc1,Ki,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta,2019.0
,O=C(Nc1nccc2c1[nH]c1cc(-c3ccccc3)ccc12)C1CC1,IC50,6590.0,nM,5.18,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human full length GSK3beta expressed in baculovirus in Sf9 insect cells using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate by ADP-Glo kinase assay,2021.0
,NC(=O)c1ccc2c(c1)[nH]c1c(NC(=O)C3CC3)nccc12,IC50,200.0,nM,6.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human full length GSK3beta expressed in baculovirus in Sf9 insect cells using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate by ADP-Glo kinase assay,2021.0
,O=C1NC(=S)N/C1=C/c1ccc(-c2ccccc2Cl)o1,IC50,917.0,nM,6.04,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,COc1cc2oc3ncc(OCc4ccccc4)c(-c4ccccc4)c3c2c(OC)c1O,Ki,5400.0,nM,5.27,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GST-fused GSK-3beta expressed in insect Sf9 cells using RBER-CHKtide as substrate assessed as incorporation of 33Pi after 60 mins by microplate scintillation counting analysis,2012.0
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2cc(Cl)ccc2[nH]c1=O,IC50,3810.0,nM,5.42,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2ccc(Cl)cc2[nH]c1=O,IC50,3120.0,nM,5.51,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
PYRAZOLOPYRIMIDINE 1,CN(C)CCNC(=O)c1ccc(/C=N/Nc2ncnc3c2cnn3-c2cccc3[nH]cnc23)cc1,IC50,1.585,nM,8.8,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) expressed in Sf9 cells using GS1 as substrate and [gamma32]ATP after 30 min by scinitllation counting,2007.0
,Cc1sc(C(=O)N[C@@H]2[C@H](N)CCCC2(F)F)cc1-c1cnn2cc(Cl)cnc12,IC50,150.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Inhibition of full-length recombinant human His-tagged GSK3B expressed in baculovirus expression system by Z'-LYTE assay,2016.0
,O=C(NCC1CCN(CCc2ccccc2)CC1)c1n[nH]c2ccc(-c3ccccc3F)cc12,IC50,112.0,nM,6.95,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,Cc1ccc2[nH]nc(C(=O)NCC3CCN(CC(=O)Nc4ccccc4)CC3)c2c1,IC50,640.0,nM,6.19,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin),2015.0
,COc1ccc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCCO5)o3)cc2)c(C#N)c1,IC50,32.0,nM,7.5,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,O=[N+]([O-])c1ccccc1-c1ccc(CSc2nnc(-c3ccc4c(c3)OCO4)o2)cc1,IC50,27.0,nM,7.57,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,N=C1NC(=O)/C(=C\c2ccc(-c3ccc(Cl)c(Cl)c3)o2)S1,IC50,576.0,nM,6.24,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1,IC50,110.0,nM,6.96,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,O=C1NC(=S)N/C1=C/c1ccc(-c2ccc([N+](=O)[O-])cc2)o1,IC50,584.0,nM,6.23,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,CC(C)Oc1nc(-c2ccnc(NC(=O)C3CC3)c2)ncc1C(N)=O,IC50,0.83,nM,9.08,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,NC(=O)c1cnc(-c2ccnc(NC(=O)C3CC3)c2)cc1OCC(F)(F)F,IC50,6.8,nM,8.17,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,O=C1NC(=O)C(c2cn3c4c(cc(F)cc24)CN(C(=O)N2CCC(N4CCCCC4)CC2)CC3)=C1c1coc2ccccc12,IC50,0.53,nM,9.28,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,COCCn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cccnc21,IC50,58.2,nM,7.24,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,CN1CCN(S(=O)(=O)c2ccc(-c3ccc(N)c(C(=O)Nc4cccnc4)c3)cc2)CC1,Ki,120.0,nM,6.92,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,Nc1ncc(-c2ccc(OCCN3CCCCC3)cc2)nc1C(=O)Nc1cccnc1,Ki,18.0,nM,7.75,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,CCCCNC(=O)N1Cc2n[nH]c(NC(=O)[C@@H](C)c3ccc4ccccc4c3)c2C1,IC50,50.0,nM,7.3,Glycogen synthase kinase-3 beta,,,Inhibitory activity against GSK3-beta,2006.0
,N#Cc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1,IC50,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by fluorescence polarization assay,2012.0
,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1-c1ccncc1,IC50,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,,,Inhibition of catalytic activity of GSK3-beta by AlphaLISA assay,2012.0
,Cn1cc(-c2cnc3c(-c4csc(C(=O)N[C@@H]5CCCC[C@@H]5N)c4)cnn3c2)cn1,IC50,23.0,nM,7.64,Glycogen synthase kinase-3 beta,,,Inhibition of full-length recombinant human His-tagged GSK3B expressed in baculovirus expression system by Z'-LYTE assay,2016.0
,CCc1cnn2c(NCc3cccnc3)cc(-c3ccccc3)nc12,IC50,2800.0,nM,5.55,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,Cn1c(NCCc2ccccc2)cc(-c2ccncn2)cc1=O,IC50,592.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta expressed in baculovirus infected SF9 cells after 60 mins,2011.0
,Cn1cc(C2=C(c3cnc4ccccn34)C(=O)NC2=O)c2cc3c(cc21)OCO3,IC50,5.3,nM,8.28,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,COCCn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(Br)ccc21,IC50,82.3,nM,7.08,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,Cc1nc(C2CCCC2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,5460.0,nM,5.26,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,Cc1nc(-c2ccccc2)c(-c2ccnc(NC(=O)CCn3cnnn3)c2)[nH]1,IC50,4420.0,nM,5.36,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,Br.CCOC(=O)C/N=c1\nc(-c2ccccc2)n(-c2ccc(OC)cc2)s1,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,Br.c1ccc(-c2n/c(=N\C3CCCCC3)sn2-c2ccccc2)cc1,IC50,2100.0,nM,5.68,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,Br.c1ccc(-c2n/c(=N\Cc3cccnc3)sn2-c2ccccc2)cc1,IC50,1300.0,nM,5.89,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,Nc1ncc(-c2ccc(F)cc2)cc1/N=C/c1ccnc(NC(=O)C2CC2)c1,IC50,418.0,nM,6.38,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@]3(C)C(=CC[C@H]3[C@H]3COC(=O)C3)[C@@]21C,IC50,3000.0,nM,5.52,Glycogen synthase kinase-3 beta,,,Activation of GSK-3beta in HEK293 cells assessed as suppression of TCF/beta-catenin transcriptional activity after 24 hrs by SuperTOPFlash reporter gene assay,2015.0
,O=C(O)C1=CN2C3C(=C(NCCNc4ccccn4)C(F)=CC3C1=O)OCCC21CCC1,IC50,36.0,nM,7.44,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2023.0
,O=C1NC(=O)C(c2cn3c4c(cc(F)cc24)CN(C(=O)N2CCCCC2)CC3)=C1c1coc2ccccc12,IC50,1.9,nM,8.72,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,O=C1NC(=O)C(c2cn3c4c(cccc24)CNCC3)=C1c1coc2ccccc12,IC50,4.2,nM,8.38,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,O=C(NCC1CCN(CCc2ccccc2)CC1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,IC50,67.0,nM,7.17,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,CCOC(=O)c1ccc(CN2CCC(CNC(=O)c3n[nH]c4ccc(OC)cc34)CC2)o1,IC50,330.0,nM,6.48,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,CCCC(=O)NCCCN1CCC(CNC(=O)c2n[nH]c3ccc(OC)cc23)CC1,IC50,750.0,nM,6.12,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COc1ccncc1-c1ccc2[nH]nc(C(=O)NCC3CCN(CCc4ccccc4)CC3)c2c1,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,O=C1CCCc2cc(-c3ccnc(NC(=O)C4CC4)c3)ccc2N1,IC50,730.0,nM,6.14,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,COc1ccc(-c2ocnc2C(=O)NCCCNC(=O)/C=C/c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc1Cl,IC50,0.41,nM,9.39,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1,IC50,40.0,nM,7.4,Glycogen synthase kinase-3 beta,Antagonist,ANTAGONIST,Inhibition of GSK3-beta in the presence of 20uM ATP,2007.0
,O=C(NCCc1ccc(F)nc1)c1ccnc2[nH]c(-c3ccc(F)cc3)nc12,IC50,17.0,nM,7.77,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,CS(=O)(=O)Nc1ccc(CCNC(=O)c2ccnc3[nH]c(-c4cccs4)nc23)cc1,IC50,12.0,nM,7.92,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
,O=C1NC(=O)/C(=C/c2cc3ccccc3s2)S1,IC50,7470.0,nM,5.13,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using GS-2 peptide substrate incubated for 30 mins by kinase-Glo luminescent assay,2018.0
,O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1cccc(F)c1F,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CSc1c[nH]c2ncnc(NCCCO)c12,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(CNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)CNS(C)(=O)=O,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccccc1C(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12,Ki,5.012,nM,8.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(-c2cc3c(NCCN)ccc(C(N)=O)c3[nH]2)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1cnc(NC(=O)Nc2ccc3cc(C(=O)O)ccc3c2)cn1,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CCC(N2CCCC2)CC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(Nc2c(C(=O)O)n(CCCOc3cccc4ccccc34)c3cccc(-c4ccccc4C)c23)cc1,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Cc1ccccc1Cl)Nc1ccc2cn[nH]c2c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1ccc(-c2ccncc2)cc1NCc1ccccc1,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1C(=NNc2cccc3c(=O)[nH][nH]c(=O)c23)C(c2ccccc2)=NN1c1ccccc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCC(=O)Nc1ccc(C(=O)N2CCNCC2)c(O)c1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc(OCC(N)=O)cc1,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)n2)s1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(O)Cc1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1,Ki,400.0,nM,6.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2018.0
,COc1ccc(CC(=O)Nc2cc([C@@H]3CC[C@H](OC(=O)N4CCC4(C)C)C3)[nH]n2)cn1,Ki,0.95,nM,9.02,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged human recombinant GSK3beta H350L mutant expressed in baculovirus-infected Sf21 cells assessed as reduction in production of ADP using 5-FAMKRREILSRRPpSYR-COOH peptide as substrate preincubated with enzyme for 15 mins followed by further incubation with ATP for 30 mins by fluorescence-based microfluidic mobility shift assay,2020.0
,Nc1nonc1-c1nc2ccccc2n1-c1ccccc1,Ki,620.0,nM,6.21,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,Cc1cc(Nc2nc(N(C)c3ccccc3)nc3ccccc23)n[nH]1,Ki,312.0,nM,6.51,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,Cc1cc(Nc2nc(Sc3cccc(Cl)c3Cl)nc3ccccc23)n[nH]1,Ki,48.0,nM,7.32,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,CN(C)C(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCCF,IC50,148.9,nM,6.83,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2023.0
,Cc1ccncc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cnccc1C1CCCCC1)c1ccnc(NC(=O)C2CC2)c1,IC50,120.0,nM,6.92,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cnccc1N1CCCCC1)c1ccnc(NC(=O)C2CC2)c1,IC50,0.99,nM,9.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,C[C@@H]1CN(c2ccncc2NC(=O)c2ccnc(NC(=O)C3CC3)c2)CCO1,IC50,8.8,nM,8.06,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC(C)C(=O)Nc1cc(C(=O)Nc2cnccc2OCC(C)(F)F)ccn1,IC50,1.4,nM,8.85,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(NC(=O)C2CC(F)(F)C2)c1,IC50,1.9,nM,8.72,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,Nc1nonc1-n1nnc(C(=O)/N=N/Cc2ccncc2)c1CN1CCCCC1,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2021.0
ELLAGIC ACID,O=c1oc2c(O)c(O)cc3c(=O)oc4c(O)c(O)cc1c4c23,IC50,7500.0,nM,5.12,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta,2006.0
,O=S(=O)(Nc1ccc(-c2nc(-c3ccnc(Nc4ccc(OC(F)(F)F)cc4)c3)no2)cc1)c1ccc(Cl)s1,IC50,2980.0,nM,5.53,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(-c3nc(-c4ccnc(Nc5cccc(Cl)c5)c4)no3)cc2)cc1,IC50,190.0,nM,6.72,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1,IC50,1.0,nM,9.0,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCN1CCN(CCCCC(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,N#CCc1cnn2c(NCc3cccnc3)cc(-c3ccccc3)nc12,IC50,1100.0,nM,5.96,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,CC(=O)NCCSc1cnn2c(NCc3cccnc3)cc(-c3ccccc3)nc12,IC50,34.0,nM,7.47,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,COCCn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(F)ccc21,IC50,39.7,nM,7.4,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,C/C(=C\C=C\[C@@H](C)CC/C=C(\C)CC1OC(=O)C(=O)C1=O)CCCc1ccoc1,IC50,7500.0,nM,5.12,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta,2017.0
,CCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O,IC50,5754.4,nM,5.24,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using GS2 peptide as substrate and [gamma33P]-ATP after 30 mins by scintillation counting,2013.0
GW829055X,Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1,Ki,1250.0,nM,5.9,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,O=C(NCCc1ccc([N+](=O)[O-])cc1)c1ccc(O)c2[nH]c(Cc3ccccc3)nc12,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,CCN1CCN(C(=O)c2ccc(CCNC(=O)c3ccc(O)c4[nH]c(-c5cccs5)nc34)cc2)CC1,IC50,46.0,nM,7.34,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2012.0
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2cc(Br)ccc2n(CC)c1=O,IC50,2010.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O,IC50,5510.0,nM,5.26,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2ccccc2[nH]c1=O,IC50,4500.0,nM,5.35,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,CC(C)C(=O)Nc1n[nH]c2ncc(-c3ccccc3)cc12,IC50,19.0,nM,7.72,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)ccc12)C1CC1,IC50,8.0,nM,8.1,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(NCCCNc1c2c(nc3ccccc13)CCCC2)c1sc(-c2ccnc(NC(=O)C3CCC3)c2)nc1OCC1CC1,IC50,80.7,nM,7.09,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)CNCCCCNc3c4c(nc5ccccc35)CCCC4)c2)nc1OCC1CC1,IC50,41.6,nM,7.38,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
SB-202190,Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,Kd,2700.0,nM,5.57,Glycogen synthase kinase-3 beta,,,Binding constant for full-length GSK3B,2008.0
,Cc1occc1-c1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1,IC50,210.0,nM,6.68,Glycogen synthase kinase-3 beta,,,Inhibition of GSK2beta phosphorylation in human BT474 cells,2010.0
,O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1ccc(Cl)c(C(=O)O)c1,IC50,26.0,nM,7.58,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CC(C)c1cc(NCc2cccnc2)n2ncc(Br)c2n1,IC50,420.0,nM,6.38,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,NS(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3ncnn23)cc1,IC50,780.0,nM,6.11,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using 10 uM ATP,2006.0
,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1.O,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NCCOc1cncc(C=Cc2ccncc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)c(OC)c1,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(COCc1ccccc1)COc1cncc(C=Cc2ccncc2)c1,Ki,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc2[nH]c3c(c2c1)CC(=O)Nc1ccccc1-3,IC50,2197.86,nM,5.66,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,CN(c1ncnc2[nH]c3cc(-c4ccccc4)ccc3c12)C1CCCN(CCC#N)C1,IC50,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,Nc1ncnn2ccc(C(=O)Nc3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
BARASERTIB,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CC(C)(C)N)cnc(N)c34)cc2)c1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1n[nH]c2nc(-c3ccccc3O)ccc12)C1CC1,IC50,36.0,nM,7.44,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2ccccc2[N+](=O)[O-])=C1Nc1ccc(Cl)c(C(=O)O)c1,IC50,28.0,nM,7.55,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CSc1ccc(/C=C2\NC(=O)NC2=O)cc1,IC50,6900.0,nM,5.16,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta by ELISA,2009.0
,O=C(Nc1n[nH]c2cc(-c3ccc[nH]3)ccc12)C1CC1,IC50,320.0,nM,6.5,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccccc4)c(Br)cc23)CC1,IC50,383.0,nM,6.42,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCCC(=O)Nc1n[nH]c2ncc(-c3ccc4ccccc4c3)cc12,IC50,169.0,nM,6.77,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCCC(=O)Nc1n[nH]c2ncc(-c3ccccc3Cl)cc12,IC50,27.0,nM,7.57,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCCC(=O)Nc1n[nH]c2ncc(-c3cccc(F)c3)cc12,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CC(=O)Nc1n[nH]c2ncc(-c3ccccc3)cc12,IC50,291.0,nM,6.54,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCCC(=O)Nc1n[nH]c2ccc(-c3ccccc3)cc12,IC50,99.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CN(C1=C(c2cccc([N+](=O)[O-])c2)C(=O)NC1=O)c1ccccc1,IC50,1398.0,nM,5.85,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1ccccc1,IC50,141.0,nM,6.85,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CSc1ccc(NC2=C(c3cccc(Cl)c3)C(=O)NC2=O)cc1,IC50,532.0,nM,6.27,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1,IC50,94.0,nM,7.03,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1cccc(C2=C(c3c(C)n(C)c4ccccc34)C(=O)NC2=O)c1,IC50,220.0,nM,6.66,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,Cn1cc(C2=C(c3ccccc3Cl)C(=O)NC2=O)c2ccccc21,IC50,3.6,nM,8.44,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,CC1=NNC(=O)/C1=N\Nc1ccccc1Cl,Ki,460.0,nM,6.34,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,O=C(Nc1cccnc1)c1ccnc2[nH]c(-c3ccc(F)cc3)nc12,IC50,8.0,nM,8.1,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
EUTYPOID E,O=C1OCC(Cc2ccc(O)c(O)c2)=C1c1cc(O)cc(O)c1,IC50,2260.0,nM,5.65,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by luminescent assay,2011.0
,COc1ccc(C2=NNc3cccc4c(OC)ccc2c34)cc1OC,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
GW827106X,COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1,Ki,5010.0,nM,5.3,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
GW811761X,CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1,Ki,190.0,nM,6.72,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,CC(C)n1cc(-c2ccnc3[nH]c(C4CCN(CC(=O)N5CCCCC5)CC4)cc23)ccc1=O,IC50,1600.0,nM,5.8,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of full length human GSK3beta in the presence of ATP at Km concentration,2021.0
,O=C1NC(=O)/C(=C/c2cccc3c2OCO3)N1,IC50,138.0,nM,6.86,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,CN(C)c1cccc(/C=C2\SC(=O)NC2=O)c1,IC50,8540.0,nM,5.07,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using GS-2 peptide substrate incubated for 30 mins by kinase-Glo luminescent assay,2018.0
,Cn1c(NCC(=O)c2ccccc2)nc(-c2ccncc2)cc1=O,IC50,8.9,nM,8.05,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
MERIDIANIN C,Nc1nccc(-c2c[nH]c3ccc(Br)cc23)n1,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,O=C(Nc1cc(-c2[nH]c(CCc3ccccc3)nc2-c2ccc(F)cc2)ccn1)C1CC1,IC50,133.0,nM,6.88,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,O=C1NC(=O)/C(=C/c2ccc3c(c2)OCCO3)S1,IC50,7010.0,nM,5.15,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using GS-2 peptide substrate incubated for 30 mins by kinase-Glo luminescent assay,2018.0
,O=C1NC(=O)/C(=C/c2c(-c3ccccc3)[nH]c3ccccc23)S1,IC50,6030.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using GS-2 peptide substrate incubated for 30 mins by kinase-Glo luminescent assay,2018.0
,CN(C)c1ccccc1/C=C1\SC(=O)NC1=O,IC50,9220.0,nM,5.04,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using GS-2 peptide substrate incubated for 30 mins by kinase-Glo luminescent assay,2018.0
,COc1ccc(CNC(=O)Nc2nc3ccc(C(=O)CBr)cc3s2)cc1,IC50,770.0,nM,6.11,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using prephosphorylated peptide as substrate measured after 30 mins by Kinase-glo luminescence assay,2019.0
,c1cnc2nc(-c3ccc4[nH]ncc4c3)cn2c1,Ki,63.1,nM,7.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1cc(-c2c[nH]c3cnccc23)ccn1,IC50,9230.0,nM,5.04,Glycogen synthase kinase-3 beta,,,Inhibition of full-length recombinant human His-tagged GSK3B recombinant in baculovirus expression system using Alexa-Fluor tracer-236 incubated for 60 mins by TR-FRET based Lantha-screen Eu kinase assay,2017.0
ERLOTINIB,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,C#CC(=O)c1ccc2nc(NC(=O)NCc3ccc(OC)cc3)[nH]c2c1,IC50,2470.0,nM,5.61,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using prephosphorylated peptide as substrate measured after 30 mins by Kinase-glo luminescence assay,2019.0
,COc1ccc(CNC(=O)Nc2nc3ccc(C(C)=O)cc3s2)cc1,IC50,2260.0,nM,5.65,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using prephosphorylated peptide as substrate measured after 30 mins by Kinase-glo luminescence assay,2019.0
,O=C1NC(=O)C(c2cn3c4c(cccc24)CN(C(=O)Cc2ccncc2)CC3)=C1c1coc2ccccc12,IC50,0.59,nM,9.23,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
GW779439X,CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1,IC50,16.0,nM,7.8,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2008.0
,COc1ccc(-c2nnc(Nc3ccccc3)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,Oc1ccc(-c2nnc(Nc3ccc(Cl)cc3)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,COc1ccc(Nc2nnc(-c3ccc(S(C)(=O)=O)cc3)o2)cc1,IC50,314.0,nM,6.5,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,N#Cc1cc2c(NC(=O)C3CC3)n[nH]c2nc1-c1ccccc1,IC50,87.0,nM,7.06,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1ccc(C2=C(Nc3cccc(Cl)c3)C(=O)NC2=O)cc1,IC50,156.0,nM,6.81,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Cl)cc12)C1CC1,IC50,1.0,nM,9.0,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1ccc(-c2ocnc2C(=O)NCCCn2cc(CNC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)nn2)cc1Cl,IC50,1.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,COc1ccc(-c2ocnc2C(=O)NCCCCNC(=O)c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc1Cl,IC50,0.81,nM,9.09,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,CN1CCN(C)CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCN(C)CC1,IC50,43.0,nM,7.37,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta,2003.0
,Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1,IC50,30.0,nM,7.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2004.0
,COc1ccc([C@H]2CN(c3nc(-c4ccncn4)cc(=O)n3C)CCO2)cc1,IC50,2.9,nM,8.54,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,CN1CCN(S(=O)(=O)c2ccc(-c3cnc(N)c(C(=O)Nc4cccnc4)n3)c(C(F)(F)F)c2)CC1,Ki,1.1,nM,8.96,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,Cc1ccc(Nc2cc(-c3noc(-c4ccc(NS(=O)(=O)c5ccc(C(C)(C)C)cc5)cc4)n3)ccn2)cc1,IC50,4560.0,nM,5.34,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,COc1cc2c(Br)cc3c(c2cc1OC)C(=O)NC3=O,IC50,304.0,nM,6.52,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2021.0
,Cc1cc(Nc2ncc(C)c(-c3cnn(CCC#N)c3)n2)sn1,IC50,16.0,nM,7.8,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,Cc1cc(Nc2ncc(C)c(N3CCN(CC#N)[C@@H](C)C3)n2)sn1,IC50,2196.0,nM,5.66,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,Cc1cnc(Nc2cnn(C)c2)nc1N1CC2CCCC(C1)N2CCC#N,IC50,9896.0,nM,5.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,N#Cc1cccc(CSc2nnc(-c3ccncc3)o2)c1,IC50,3162.0,nM,5.5,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using pIRS-1 as substrate preincubated for 15 mins,2012.0
,N#Cc1ccc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCO5)o3)cc2)cc1,IC50,316.0,nM,6.5,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using pIRS-1 as substrate preincubated for 15 mins,2012.0
,N#Cc1cc(F)ccc1-c1ccc(CSc2nnc(-c3ccc4c(c3)OCCO4)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3 beta using Ulight-CFFKNIVTPRTPPPSQGK-amide substrate incubated for 90 mins by LANCE method relative to control,2015.0
,CCCCC(=O)Nc1ncnc2[nH]c(-c3cccc(C#N)c3)nc12,IC50,1220.0,nM,5.91,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2010.0
,Nc1nccn2c(C3CC(CN4CCCC4)C3)nc(-c3cccc(OCc4ccccc4)c3)c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCOC(=O)c1c(C)n(-c2ccc(I)cc2)c2c1cc(O)c1ccccc12,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1nn(C)c(C)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(=O)O)[nH]c12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(-n2cnc3ccc(-c4nnc(SCc5cccc(C#N)c5)o4)cc32)cc1,IC50,2.3,nM,8.64,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,O=C1NC(=O)C(n2ccc3ncccc32)=C1c1cn(CCCn2ccnc2)c2cc(F)ccc12,IC50,310.0,nM,6.51,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-GSK3beta expressed in Escherichia coli BL21 (DE3),2009.0
,N#Cc1c(Oc2ccc(F)c(NC(=O)Cc3cccc(C(F)(F)F)c3)c2)ccc2nc(NC(=O)C3CC3)sc12,IC50,500.0,nM,6.3,Glycogen synthase kinase-3 beta,,,Inhibition of C-terminal FLAG-tagged GSK3beta (unknown origin) expressed in baculovirus system after 30 mins,2013.0
,CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(Nc2ncc(C)c(N3CC(CC#N)C3)n2)sn1,IC50,665.0,nM,6.18,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,CN1C(=N)NC(=O)/C1=C\c1ccc(-c2ccc(F)cc2)o1,IC50,1895.0,nM,5.72,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
"12,13-DEHYDROMANZAMINE A",C1=C(c2nccc3c2[nH]c2ccccc23)C2CCN3CCCC/C=C\C/C=C/1[C@@H]1N4CCCC/C=C\[C@H]4C[C@]21C3,IC50,5400.0,nM,5.27,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSKbeta,2007.0
,O=C(Nc1cccc(C(=O)O)c1)Nc1nc2c(s1)CC(NC(=O)Nc1cccc(C(=O)O)c1)CC2,IC50,6000.0,nM,5.22,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human His-tagged GSK3beta expressed in baculovirus expression system using ser/thr-9 peptide as substrate measured after 1 hr by Z'-Lyte assay,2018.0
,Cn1cc(C2=C(c3cnc4ccccn34)C(=O)NC2=O)c2cc(Br)ccc21,IC50,0.87,nM,9.06,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,COc1cc2c(C3=C(c4coc5ccccc45)C(=O)NC3=O)cn(C)c2cn1,IC50,65.9,nM,7.18,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,Cn1cc(C2=C(c3cccc(NCC(O)CO)c3)C(=O)NC2=O)c2cc(F)ccc21,IC50,0.6,nM,9.22,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,O=C(CNC(=O)c1cnc2[nH]cc(-c3ccncc3)c2c1)NCCc1c[nH]c2ccccc12,IC50,994.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
Y-39983,C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1,Kd,924.0,nM,6.03,Glycogen synthase kinase-3 beta,Active,,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",2017.0
,COc1cc2c(cc1OC)-c1[nH]c3ccccc3c1CC(=O)N2,IC50,899.5,nM,6.05,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,COCCn1cc(NC(=O)c2csc(-c3nncn3C(C)C)n2)cn1,IC50,457.09,nM,6.34,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human His-tagged GSK3B expressed in baculovirus expression system,2017.0
,COc1ccc(-c2ccncc2NC(=O)c2ccnc(NC(=O)C3CC3)c2)cc1,IC50,77.0,nM,7.11,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) assessed as decrease in tau phosphorylation by high content cell based assay,2016.0
,N#Cc1ccc(-c2ccncc2NC(=O)c2ccnc(NC(=O)C3CC3)c2)cc1,IC50,96.0,nM,7.02,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) assessed as decrease in tau phosphorylation by high content cell based assay,2016.0
,O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1,IC50,520.0,nM,6.28,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2008.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(Nc2ccccc2)n1,IC50,0.43,nM,9.37,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,Cc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)CCn3cncn3)c2)[nH]1,IC50,82.0,nM,7.09,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,CCOC(=O)c1ncc(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,739.0,nM,6.13,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,NC(=O)c1ncc(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,47.0,nM,7.33,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,O=C(Nc1cc(-c2[nH]c(CO)nc2-c2ccc(F)cc2)ccn1)C1CC1,IC50,91.0,nM,7.04,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,CC(=O)Nc1cc(-c2[nH]c(C(N)=O)nc2-c2ccc(F)cc2)ccn1,IC50,47.0,nM,7.33,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,NC(=O)c1ncc(-c2cc(NC(=O)C3CC3)ncc2Br)[nH]1,IC50,354.0,nM,6.45,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
JNJ-7706621,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F,Kd,950.0,nM,6.02,Glycogen synthase kinase-3 beta,,,Binding constant for full-length GSK3B,2008.0
,COc1cc(C2=C(c3cn(CCN)c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,IC50,195.0,nM,6.71,Glycogen synthase kinase-3 beta,410869,,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",2016.0
,Nc1ncc(-c2ncccc2OC(F)(F)F)nc1C(=O)Nc1ncccc1N1CCC(N)(CO)CC1,IC50,1300.0,nM,5.89,Glycogen synthase kinase-3 beta,438375,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,CC1(N)CCN(c2cccnc2NC(=O)c2nc(-c3ncccc3OC(F)(F)F)cnc2N)CC1,IC50,2100.0,nM,5.68,Glycogen synthase kinase-3 beta,438378,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,CCCCc1c(-c2ccc(Cl)cc2)[nH]c2nccnc12,IC50,5900.0,nM,5.23,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
GW819230X,Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1,IC50,617.0,nM,6.21,Glycogen synthase kinase-3 beta,,,Inhibition of human Glycogen synthase kinase-3 beta,2004.0
,C=CC(=O)N1C(=O)CC(c2ccc(OC)cc2)Sc2ccccc21,IC50,6200.0,nM,5.21,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using GS-2 peptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,C=CC(=O)N1C(=O)CC(c2ccccc2C(F)(F)F)Sc2ccccc21,IC50,2800.0,nM,5.55,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using GS-2 peptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,C=CC(=O)N1C(=O)CC(c2ccc([N+](=O)[O-])cc2)Sc2ccccc21,IC50,7500.0,nM,5.12,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using GS-2 peptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
VANDETANIB,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,Ki,1995.26,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1cc(-n2cnc3c(NCc4nc5cc(Cl)c(Cl)cc5[nH]4)nc(N4CCOCC4)nc32)cn1,IC50,810.0,nM,6.09,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3b (unknown origin),2019.0
MIDOSTAURIN,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Kd,1800.0,nM,5.75,Glycogen synthase kinase-3 beta,,,Binding constant for GSK3B kinase domain,2011.0
,Cc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,53.0,nM,7.28,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,CC(C)(C)c1ccc(C(=O)Nc2cn3cc(-n4ccnc4)ccc3n2)cc1,IC50,831.76,nM,6.08,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human His-tagged GSK3B expressed in baculovirus expression system,2017.0
,O=C(O)c1ccc(N2CCN(c3cc(NCCP(=O)(O)O)c4c5c(onc35)-c3ccccc3C4=O)CC2)cc1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) using biotin-labelled IRS-1 peptide as substrate incubated for 15 mins by ELISA based assay,2022.0
,N=C1NC(=O)/C(=C\c2ccc(-c3cc([N+](=O)[O-])ccc3Cl)o2)S1,IC50,1758.0,nM,5.75,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,Cc1ccc(-c2ccc(/C=C3/SC(=N)NC3=O)o2)cc1Cl,IC50,1429.0,nM,5.84,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,FC(F)(F)c1ccc(/C=N/Nc2nnc3n2N=C(c2ccc(Cl)cc2)CS3)cc1,IC50,883.0,nM,6.05,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3-beta (unknown origin) by Kinase-Glo Max assay kit,2022.0
,Cn1ccc(NC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)n1,IC50,2577.0,nM,5.59,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cc1cnc(Nc2cnn(C)c2)nc1-c1cnn([C@H](CC#N)C2CCCC2)c1,IC50,395.0,nM,6.4,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,Cc1cc(Nc2ncc(C)c(N3CC4CCCC(C3)N4CC#N)n2)sn1,IC50,3242.0,nM,5.49,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,c1ccc(CSc2nnc(-c3ccncc3)o2)cc1,IC50,6700.0,nM,5.17,Glycogen synthase kinase-3 beta,,,Inhibitory concentration against human Glycogen synthase kinase-3,2002.0
,N#C/C=C/c1ccc2c(c1)-c1[nH]c3ccc(C(F)(F)F)cc3c1CC(=O)N2,IC50,399.94,nM,6.4,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1,IC50,160.0,nM,6.8,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2004.0
,N#Cc1c(N)nc2sc(C(=O)c3cccc(Cl)c3)c(N)c2c1-c1ccccc1Cl,IC50,3300.0,nM,5.48,Glycogen synthase kinase-3 beta,,,Inhibition of human Nt-GST-tagged GSK-3beta,2013.0
,O=C1Cc2c([nH]c3ccc(F)cc23)-c2ccccc2N1,IC50,79.98,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,O=C(Nc1cc(-c2cn(C3CCOCC3)c3cnccc23)ccn1)NC1CC1,IC50,5640.0,nM,5.25,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human His/GST-tagged GSK3beta (2 to 433 residues) expressed in baculovirus infected Sf9 cells using Ulight-glycogen synthase peptide as substrate incubated for 30 mins by TR-FRET LANCE method,2020.0
,Cc1nc(C2CCC2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,4110.0,nM,5.39,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,NC(=O)c1nc(C2CCCCC2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2cc(O)c(O)cc2N1,IC50,119.95,nM,6.92,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
HYMENIALDISINE 2,CC(=O)NC1=NC(=O)/C(=C2\CCNC(=O)c3c2cc(Br)n3C(C)=O)N1,IC50,128.82,nM,6.89,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) expressed in Sf9 cells using GS1 as substrate and [gamma32]ATP after 30 min by scinitllation counting,2007.0
,Oc1ccc2oc3ncc(O)c(-c4ccccc4)c3c2c1,Ki,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,Cc1c(-c2ccc(Cl)cc2)[nH]c2nccnc12,IC50,1700.0,nM,5.77,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,CN1CCN(c2cnc(NC3=N/C(=C\c4ccc5ncsc5c4)C(=O)N3)cn2)CC1,IC50,4120.0,nM,5.38,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COc1ccc(CC(=O)NNC(=O)Cn2c(C)nc3ccccc32)cc1,IC50,379.0,nM,6.42,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1Nc2ncccc2N[C@@H]1Cc1c[nH]c2ccccc12,Kd,9000.0,nM,5.05,Glycogen synthase kinase-3 beta,,,Binding affinity to GSK-3 beta (unknown origin) after 30 mins by isothermal titration calorimetry,2016.0
,COc1ccc(/C=C2\S/C(=N\Cc3ccccc3)NC2=O)cc1[N+](=O)[O-],IC50,2.1,nM,8.68,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK-3beta expressed in Baculovirus using Ser/Thr9 peptide as substrate by Z' LYTE assay,2016.0
,COc1ccc(/C=C2\SC(=N)NC2=O)cc1OC,IC50,80.5,nM,7.09,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK-3beta expressed in Baculovirus using Ser/Thr9 peptide as substrate by Z' LYTE assay,2016.0
,O=C1NC(=O)C(c2nn(CCCN3CCOCC3)c3ncccc23)=C1c1cn(Cc2ccccc2)c2ccccc12,IC50,1900.0,nM,5.72,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,CC(C)n1cc(C2=C(c3nn(CCCN4CCOCC4)c4ncccc34)C(=O)NC2=O)c2ccccc21,IC50,380.0,nM,6.42,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)NCc1ccncc1,IC50,3.59,nM,8.45,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,COc1cc2c(cc1OC)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1,IC50,498.0,nM,6.3,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
CEDIRANIB,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1nc(-c2ccco2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,99.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,Cc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)CCn3cnnn3)c2)[nH]1,IC50,72.0,nM,7.14,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,O=C1NC(=O)C(c2nnc3ccccn23)=C1c1cn(CCCO)c2ccccc12,IC50,120.6,nM,6.92,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay,2015.0
,C=CCn1cc(C2=C(c3nnc4ccccn34)C(=O)NC2=O)c2ccccc21,IC50,73.6,nM,7.13,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay,2015.0
,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccc(C)cc3)cc12,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,Cc1n[nH]c2ccc(-c3nnc(C)n3Cc3ccc(Cl)cc3)cc12,Kd,56.0,nM,7.25,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to GSK3B (unknown origin) assessed as dissociation constant by competitive binding assay,2023.0
,O=C1NC(NC2CCCCCC2)=N/C1=C\c1ccc2[nH]ncc2c1,IC50,3948.0,nM,5.4,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@@H](CO)CC2CCC2)=N/C1=C\c1ccc2ncsc2c1,IC50,2414.0,nM,5.62,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CC(C)C[C@@H](CF)NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,6288.0,nM,5.2,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@H]2C3CC4CC2C[C@](O)(C4)C3)=N/C1=C\c1ccc2ncsc2c1,IC50,5374.0,nM,5.27,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COC12CC3CC(CC(NC4=N/C(=C\c5ccc6ncsc6c5)C(=O)N4)(C3)C1)C2,IC50,455.0,nM,6.34,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COC(CNC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1)Cc1ccccc1,IC50,1552.0,nM,5.81,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(Nc2cncnc2)=N/C1=C\c1ccc2ncsc2c1,IC50,2990.0,nM,5.52,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CN(C)c1ccc(Oc2cc(O)cc(O)c2-c2cc(C(=O)NC3CCN(C4CCC5(CC4)OCCO5)CC3)no2)cc1,IC50,10.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2013.0
,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(Br)cnc21,IC50,5.3,nM,8.28,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,COCCn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2ccccc21,IC50,19.8,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,CNCCCn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(Br)ccc21,IC50,404.0,nM,6.39,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,CN(c1ncnc2[nH]c3cc(I)ccc3c12)C1CCCN(CCC#N)C1,IC50,1382.0,nM,5.86,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,Cn1c(NCC(=O)c2ccc(F)cc2)nc(-c2ccncc2)cc1=O,IC50,52.0,nM,7.28,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,N=C1NC(=O)/C(=C\c2ccc(-c3cccc(Cl)c3)o2)S1,IC50,767.0,nM,6.12,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,O=C1NC(=O)C(n2ccc3ncccc32)=C1c1cn(CCCn2ccnc2)c2ccccc12,IC50,550.0,nM,6.26,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-GSK3beta expressed in Escherichia coli BL21 (DE3),2009.0
,NC(=O)c1cnc(Nc2cccc(O)n2)cc1Nc1ccccc1Cl,IC50,2500.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3B (unknown origin),2023.0
PAULLONE,O=C1Cc2c([nH]c3ccccc23)-c2ccccc2N1,IC50,619.44,nM,6.21,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,Cn1cc(C2=C(N3CCOCC3)C(=O)NC2=O)c2ccccc21,IC50,8200.0,nM,5.09,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,Cn1cc(C2=C(Nc3ccccc3)C(=O)NC2=O)c2ccccc21,IC50,350.0,nM,6.46,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,Cn1cc(C2=C(c3cccc(NCC(O)CO)c3)C(=O)NC2=O)c2cc(Cl)ccc21,IC50,0.4,nM,9.4,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,COc1cccc(C2=C(c3cn(C)c4cc(F)ccc34)C(=O)NC2=O)c1,IC50,31.0,nM,7.51,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,CCOC(=O)C/N=c1\nc(-c2ccccc2)n(-c2ccccc2)s1,IC50,1800.0,nM,5.75,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,Br.c1ccc(-n2s/c(=N/Cc3cccnc3)nc2-c2cccc3ccccc23)cc1,IC50,2100.0,nM,5.68,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,Br.c1ccc(-c2n/c(=N\Cc3cccnc3)sn2-c2cccc3ccccc23)cc1,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,Br.COc1ccc(-n2s/c(=N/Cc3cccnc3)nc2-c2ccccc2)cc1,IC50,4100.0,nM,5.39,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,Cn1c(NCCNc2c3c(nc4ccccc24)CCCC3)nc(-c2ccncc2)cc1=O,IC50,4040.0,nM,5.39,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK-3beta using prephosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescence assay,2021.0
,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccc(N)cc3)cc12,IC50,8.0,nM,8.1,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,O=c1[nH]cc(-c2ccc(O)cc2)c2sc(-c3ccncc3)cc12,IC50,125.89,nM,6.9,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta expressed in baculovirus by fluorescence polarization assay,2011.0
,COc1cc2c(CNC3CCN(S(C)(=O)=O)CC3)cc3c(c2cc1OC)C(=O)NC3=O,IC50,360.0,nM,6.44,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,CN1C(=O)CC(c2ccccc2)N=C1SCc1cn(-c2cccc([N+](=O)[O-])c2)nn1,IC50,153.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin) after 30 mins by Kinase-Glo assay,2019.0
,CC(C)Nc1ccc(Oc2cc(O)cc(O)c2-c2cc(C(=O)NC3CCN(C)CC3)no2)cc1,IC50,10.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2013.0
,N#Cc1cccc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCCO5)o3)cc2)c1,IC50,225.0,nM,6.65,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,COc1cc2c(cc1OC)-c1[nH]c3ccc(C#N)cc3c1CC(=O)N2,IC50,18.0,nM,7.75,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta expressed in insect Sf9 cells,2010.0
,O=C(NCC1CCCOC1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human N-terminal GST-tagged GSK3beta (1 to 420 end residues) expressed in baculovirus expression system using unphosphorylated peptide as substrate incubated enzyme-substrate mixture for 90 mins in presence of ATP by LANCE assay,2020.0
,O=C(NC1CCS(=O)(=O)CC1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,IC50,39.0,nM,7.41,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human N-terminal GST-tagged GSK3beta (1 to 420 end residues) expressed in baculovirus expression system using unphosphorylated peptide as substrate incubated enzyme-substrate mixture for 90 mins in presence of ATP by LANCE assay,2020.0
,N#CCCN1CCC2CCN(c3ncnc4[nH]c5cc(Cl)ccc5c34)C2C1,IC50,130.0,nM,6.89,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2022.0
,COc1cc(F)ccc1-c1ccnc(NC(=O)[C@H]2CCC[C@@H](NC(C)=O)C2)c1,IC50,903.0,nM,6.04,Glycogen synthase kinase-3 beta,308360,,"In Vitro Kinase Inhibition Assay: In vitro kinase assay analysis may be performed using standard techniques described in the art. These techniques are also used by commercial services providers in order to offer in vitro kinase activity assay services, e.g. the assays offered by Millipore Inc. (worldwide website www(dot)millipore.com), ProQinase GmbH (worldwide website www(dot)proqinase.de) and others. All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50ul reaction volume. The reaction mixture was pipetted in four steps in the following order: 20ul of assay buffer (standard buffer),5ul of ATP solution (in H2O, 5 ul of test compound (in 10% DMSO), 10ul of substrate/10ul of enzyme solution (premixed)The assay for all enzymes contained 60 mM HEPES-NaOH (pH 7.5), 3 mM MgCl2, 3 mM MnCl2, 3uM Na-Orthovanadate, 1.2 mM DTT, 50 ug/ml PEG2000, 1 uM [33P]-ATP (approx. 5x1005 cpm per well).",2015.0
,CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NC(NC2CCCCC2)=N/C1=C\c1ccc2ncoc2c1,IC50,4089.0,nM,5.39,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC2CCCC(F)(F)C2)=N/C1=C\c1ccc2ncsc2c1,IC50,5688.0,nM,5.25,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COC(=O)[C@@H](NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1)C(C)O,IC50,6026.0,nM,5.22,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC(CF)c2ccccc2)=N/C1=C\c1ccc2ncsc2c1,IC50,947.0,nM,6.02,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CN(C)CC(NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1)c1ccccc1,IC50,6772.0,nM,5.17,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
INDIRUBIN,O=C1Nc2ccccc2/C1=C1/Nc2ccccc2C1=O,IC50,4.0,nM,8.4,Glycogen synthase kinase-3 beta,,,Competitive inhibition of glycogen synthase kinase-3 beta (unknown origin) using GS-1 as substrate after 30 mins by scintillation counting analysis in presence of [gamma-32P]-ATP,2016.0
,Cc1cccc(NC(=O)Nc2ccc(-c3cnc4c(-c5cnn(C)c5)cnn4c3N)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COC(=N)c1nc2ccc3ncnc(Nc4ccc(OC)cc4F)c3c2s1,IC50,5334.0,nM,5.27,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,2023.0
,O=C1NC(=O)C(c2cn(CCCO)c3ccc(F)cc23)=C1c1coc2ccccc12,IC50,15.0,nM,7.82,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,O=C(Nc1cnccc1OCCO)c1ccnc(NC(=O)C2CC2)c1,IC50,4.2,nM,8.38,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,O=Nc1c(-c2c(O)[nH]c3ccc(I)cc23)[nH]c2ccccc12,IC50,9.0,nM,8.05,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2009.0
,COc1cc(/C=C2/C(=O)Nc3ccc(NC(C)=O)cc32)cc(OC)c1OC,IC50,233.0,nM,6.63,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK3beta (636 to 661 residues) assessed as reduction in human muscle glycogen synthase type 1 fragment phosphorylation using YRRAAVPPSPSLSRHSSPHQ(pS)EDE as substrate in presence of ATP incubated for 60 mins by ADP-Glo kinase assay,2023.0
,Cn1c(-c2nonc2N)nc2ccccc21,Ki,7300.0,nM,5.14,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,Cc1ccccc1-n1ncc2c3c(c4cccn4c21)C(=O)NC3=O,IC50,1210.0,nM,5.92,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using (RREGGMSRPAS(p)VDG as substrate assessed as 32P[gamma-ATP] incorporation into substrate after 15 mins by autoradiography,2013.0
,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)[C@@H]3C[C@H]3c3ccccc3)c2)[nH]1,IC50,808.0,nM,6.09,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CCCO3)c2)[nH]1,IC50,527.0,nM,6.28,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CC3)c2)n1C,IC50,638.0,nM,6.2,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,C[S+]([O-])c1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CCC3)c2)[nH]1,IC50,428.0,nM,6.37,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,CCOc1ccncc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,170.0,nM,6.77,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) assessed as decrease in tau phosphorylation by high content cell based assay,2016.0
,O=C(Nc1cnccc1-c1ccc(OC(F)F)cc1)c1ccnc(NC(=O)C2CC2)c1,IC50,180.0,nM,6.75,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) assessed as decrease in tau phosphorylation by high content cell based assay,2016.0
,O=C(CSc1nnc(Cn2c(C(F)(F)F)nc3ccccc32)o1)Nc1ccc(F)cc1,IC50,200.0,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,CN1C(=O)CC(c2ccccc2)N=C1SCc1cn(-c2ccccc2)nn1,IC50,916.0,nM,6.04,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin) after 30 mins by Kinase-Glo assay,2019.0
,O=C(NCC1CCOCC1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human N-terminal GST-tagged GSK3beta (1 to 420 end residues) expressed in baculovirus expression system using unphosphorylated peptide as substrate incubated enzyme-substrate mixture for 90 mins in presence of ATP by LANCE assay,2020.0
,FC(F)(F)c1nc2ccccc2n1Cc1nnc(SCc2cn(-c3cccnc3)nn2)o1,IC50,150.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,CC(O)c1ccncc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,0.25,nM,9.6,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cncc(-c2cc(F)ccc2F)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,3.7,nM,8.43,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,COC(=O)c1ccoc1CN1CCC(CNC(=O)c2n[nH]c3ccc(OC)cc23)CC1,IC50,230.0,nM,6.64,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,CC(C)CN1CCC(C(=O)Nc2cc3cc(-c4cnn(C)c4)ccc3cn2)CC1,IC50,45.6,nM,7.34,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,2023.0
,Cc1cc(C(=O)NC2Nc3cccc(C)c3N2[C@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)ccn1,IC50,5257.0,nM,5.28,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,2023.0
,CCCCc1nc(-c2ccncc2)cc(=O)[nH]1,IC50,1300.0,nM,5.89,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,O=c1cc(-c2ccncc2)nc(CCCc2ccccc2)n1Cc1ccccc1,IC50,2200.0,nM,5.66,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,CN(c1ncnc2[nH]c3cc(F)ccc3c12)C1CCCN(CCC#N)C1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,N#Cc1ccc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCCO5)o3)cc2)cc1,IC50,1995.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,COc1ccc(-c2ocnc2C(=O)NCCCNC(=O)c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc1Cl,IC50,1.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,COc1ccc(-c2ocnc2C(=O)NCCCNC(=O)CCc2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc1I,IC50,1.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,COc1c(F)cc(-c2ocnc2C(=O)NCCCNC(=O)CCc2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc1F,IC50,1.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,COc1ccc(NC(=O)c2ccc(NC3=C(c4ccc(OC)cc4)C(=O)NC3=O)cc2)cc1,IC50,90.0,nM,7.05,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,FC(F)(F)c1nc2ccccc2n1Cc1nnc(SCc2cn(-c3ccccc3)nn2)o1,IC50,320.0,nM,6.5,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,CO[C@@H]1CCCC[C@@H](NC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)C1,IC50,4952.0,nM,5.3,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COc1ccc(/C=C/C(O)=C/C(=O)/C=C/c2ccc(OCc3ccccc3)cc2)cc1OC,IC50,900.0,nM,6.05,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,CCc1ccc(-n2cc(CSC3=NC(c4ccccc4)CC(=O)N3C)nn2)cc1,IC50,94.0,nM,7.03,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin) after 30 mins by Kinase-Glo assay,2019.0
,Fc1ccccc1-n1cc(CSc2nnc(Cn3c(C(F)(F)F)nc4ccccc43)o2)nn1,IC50,270.0,nM,6.57,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,C=CC(=O)Nc1cccc(C2=C(c3cn(C)c4ccc(F)cc34)C(=O)NC2=O)c1,IC50,150.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,C=CC(=O)Nc1cccc(C2=C(c3cn(C)c4cc(OC)ccc34)C(=O)NC2=O)c1,IC50,690.0,nM,6.16,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,Cc1ccc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)c(Br)c1,IC50,862.0,nM,6.06,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,O=C(NC1CCS(=O)(=O)C1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human N-terminal GST-tagged GSK3beta (1 to 420 end residues) expressed in baculovirus expression system using unphosphorylated peptide as substrate incubated enzyme-substrate mixture for 90 mins in presence of ATP by LANCE assay,2020.0
,COc1cc(C2=C(c3cn(CCCN(C)C)c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,410874,,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",2016.0
,COc1cc(C2=C(c3cn(CCN4CCCCC4)c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,410875,,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",2016.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCc1cn(-c2c3c(nc4ccccc24)CCCC3)nn1,IC50,6.5,nM,8.19,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)CNCCNc3c4c(nc5ccc(OC)cc35)CCCC4)c2)nc1OCC1CC1,IC50,39.3,nM,7.41,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)CNCCCCCCNc3c4c(nc5ccccc35)CCCC4)c2)nc1OCC1CC1,IC50,62.0,nM,7.21,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,COc1ccc(C2CN(c3nc(-c4ccncc4)cc(=O)n3C)CCN2)cc1OC,IC50,5.2,nM,8.28,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cn1c(N2CCNC(c3ccc(Cl)cc3)C2)nc(-c2ccncc2)cc1=O,IC50,6.6,nM,8.18,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cl.Cn1c(N2CCN[C@@H](c3ccc(Cl)cc3)C2)nc(-c2ccncn2)cc1=O,IC50,1.2,nM,8.92,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,COc1cc(F)ccc1C1CN(c2nc(-c3ccncc3)cc(=O)n2C)CCN1C.Cl,IC50,56.0,nM,7.25,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,COc1ccccc1-c1ccc2c(NC(=O)C3CC3)n[nH]c2n1,IC50,1593.0,nM,5.8,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COc1ccc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCO5)o3)cc2)cc1,IC50,75.0,nM,7.12,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,O=CN1Cc2cc(F)cc3c(C4=C(c5cnc6ccccn56)C(=O)NC4=O)cn(c23)CC1N1CCCCC1,IC50,1.1,nM,8.96,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta (unknown origin) assessed as decrease in phosphorylation of CREB at serine-129 in presence of ATP[gamma-33P] by filter binding assay,2018.0
,O=CN1Cc2cccc3c(C4=C(c5cnc6ccccn56)C(=O)NC4=O)cn(c23)CC1N1CCOCC1,IC50,1.3,nM,8.89,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta (unknown origin) assessed as decrease in phosphorylation of CREB at serine-129 in presence of ATP[gamma-33P] by filter binding assay,2018.0
,Cc1ccc2[nH]c3c(c2c1)CC(=O)Nc1ccccc1-3,IC50,130.02,nM,6.89,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,CN(C)C(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCCOCCF,IC50,426.0,nM,6.37,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2023.0
GSK-1000163A,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21,IC50,2700.0,nM,5.57,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
,CC(C)(C)c1ccc(-c2ccncc2NC(=O)c2ccnc(NC(=O)C3CC3)c2)cc1,IC50,800.0,nM,6.1,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) assessed as decrease in tau phosphorylation by high content cell based assay,2016.0
,O=C1NC(=O)C(c2cn3c4c(cc(F)cc24)CN(C(=O)N2CCOCC2)CC3)=C1c1coc2ccccc12,IC50,0.013,nM,10.89,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,Nc1nccc(C(=O)Nc2cccnc2)n1,IC50,2000.0,nM,,Glycogen synthase kinase-3 beta,,,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,COc1ccc(Nc2nccc(C(=O)Nc3cnccc3-c3ccccc3)n2)cc1F,IC50,0.18,nM,9.74,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2cc(Br)ccc2N1,IC50,799.83,nM,6.1,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,Cc1c(-c2ccc(OS(=O)(=O)N(C)C)cc2)[nH]c2nccnc12,IC50,500.0,nM,6.3,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,Cc1ccc2c(c1)c(C1=C(c3ccc4ccccc4c3)C(=O)NC1=O)cn2CCCn1ccnc1,IC50,5140.0,nM,5.29,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,COc1ccc2c(c1)c(C1=C(c3ccc(C)cc3)C(=O)NC1=O)cn2CCCn1ccnc1,IC50,99.0,nM,7.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,COc1ccc(C2=C(c3cn(CCCn4ccnc4)c4ccc(Br)cc34)C(=O)NC2=O)cc1,IC50,110.0,nM,6.96,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,Cc1cc(C)c(C2=C(c3cn(CCCn4ccnc4)c4ccc(Br)cc34)C(=O)NC2=O)c(C)c1,IC50,110.0,nM,6.96,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,COc1ccccc1C1=C(c2cn(CCCn3ccnc3)c3cc(Br)ccc23)C(=O)NC1=O,IC50,21.0,nM,7.68,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,COc1ccc(C2=C(c3cn(CCCn4ccnc4)c4cc(Br)ccc34)C(=O)NC2=O)cc1,IC50,230.0,nM,6.64,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,COc1ccc2c(c1)nc(-c1nonc1N)n2C1CCC1,Ki,460.0,nM,6.34,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,O=C1C(c2ccc(O)c(O)c2)=c2c(c3c(n2CCc2ccc(O)c(O)c2)=C(c2ccc(O)c(O)c2)C(=O)c2c-3ccc(O)c2O)-c2cc(O)c(O)cc21,IC50,500.0,nM,,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged human recombinant GSK3beta expressed in baculovirus-infected Sf21 cells incubated for 60 mins in presence of ATP by ADP-glo analysis,2023.0
,CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12,Kd,5000.0,nM,,Glycogen synthase kinase-3 beta,,,Binding affinity to full length human GSK3B (M1 to T433 residues) expressed in mammalian expression system by KINOMEscan assay,2018.0
,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccncc3)cc12,IC50,50.0,nM,7.3,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(O)cc3)c(-c3cccnc3)cc12,IC50,149.0,nM,6.83,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,O=S(=O)(Nc1ccc(-c2nc(-c3ccnc(Nc4ccc(OC(F)(F)F)cc4)c3)no2)cc1)c1ccccc1OC(F)(F)F,IC50,1210.0,nM,5.92,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
BMS-387032,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,Kd,37.0,nM,7.43,Glycogen synthase kinase-3 beta,,,Binding constant for GSK3B kinase domain,2011.0
,CNc1cncc(-c2c[nH]c(=O)c(NC(=O)c3ccc(N4CCC[C@H]4CN4CCCC4)cc3)c2)n1,Ki,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2011.0
,O=C(Nc1nccc2c1[nH]c1cc(F)ccc12)C1CC1,IC50,4800.0,nM,5.32,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human full length GSK3beta expressed in baculovirus in Sf9 insect cells using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate by ADP-Glo kinase assay,2021.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(Cc4ccc(C(=O)O)nc4)CC3)c2c1,IC50,320.0,nM,6.5,Glycogen synthase kinase-3 beta,335744,,"LanthaScreen TR-FRET Assay: Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screening assay, compounds were tested in duplicate at a concentration of 10 uM.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um). In a second assay, the same compounds were assayed at five concentrations ranging from 100 uM to 10 nM with ten-fold dilutions in duplicate.",2015.0
,O=C(Nc1cnccc1-c1ccc(Cl)cc1Cl)c1ccnc(NC(=O)C2CC2)c1,IC50,47.0,nM,7.33,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) assessed as decrease in tau phosphorylation by high content cell based assay,2016.0
,O=C(Nc1cnccc1-c1ccc(Cl)cc1F)c1ccnc(NC(=O)C2CC2)c1,IC50,75.0,nM,7.12,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) assessed as decrease in tau phosphorylation by high content cell based assay,2016.0
,N#Cc1ncccc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,51.0,nM,7.29,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,CC(C)(C)COc1ccncc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,1.0,nM,9.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,CN(c1ncnc2[nH]c3ccc(Br)cc3c12)C1CCCN(CCC#N)C1,IC50,6096.0,nM,5.21,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,CN(c1ncnc2[nH]c3cccc(Cl)c3c12)C1CCCN(CCC#N)C1,IC50,7943.28,nM,5.1,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,CC(C)Oc1ccc(F)c(-c2cnc(N)c(C(=O)Nc3cnccc3N3CCC[C@@H](C(=O)O)C3)n2)c1,Kd,0.046,nM,10.34,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human GSK-3beta assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,2023.0
,CCN1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cc(C2=C(c3cn(CCN(C)C)c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,IC50,3582.0,nM,5.45,Glycogen synthase kinase-3 beta,410873,,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",2016.0
,COc1cc(C2=C(c3cn(CCN4CCOCC4)c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,IC50,657.0,nM,6.18,Glycogen synthase kinase-3 beta,410876,,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",2016.0
,O=C(O)c1[nH]c2c(=O)oc3cc(O)c(O)cc3c2c1-c1ccc(O)c(O)c1,IC50,1600.0,nM,5.8,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged human recombinant GSK3beta expressed in baculovirus-infected Sf21 cells incubated for 60 mins in presence of ATP by ADP-glo analysis,2023.0
,COc1c(F)cc(-c2ocnc2C(=O)NCCCNC(=O)c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc1F,IC50,0.96,nM,9.02,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,COc1c(F)cc(-c2ocnc2C(=O)NCCCc2ccc(NC(=O)/C=C/c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)cc2)cc1F,IC50,0.95,nM,9.02,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,O=C(/C=C(O)/C=C/c1ccc(OCc2ccccc2)cc1)/C=C/c1ccc(OCc2ccccc2)cc1,IC50,2490.0,nM,5.6,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide as substrate incubated for 30 mins by Glo-type luminescence assay,2016.0
,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(F)ccc21,IC50,0.4,nM,9.4,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2022.0
,CC(C)n1cc(C2=C(c3cccc(NC(=O)CF)c3)C(=O)NC2=O)c2cccnc21,IC50,17.0,nM,7.77,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GST-tagged GSK3-beta incubated for 1 hr by Envision plate reader method,2022.0
,COc1ccc(-c2cc(=O)c3c(OC)c([C@@H]4O[C@H](C(=O)NC(C)C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)cc3o2)cc1OC,IC50,5000.0,nM,5.3,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) using peptide YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate incubated for 5 to 60 mins by ADP-Glo kinase assay,2022.0
,CCS(=O)(=O)Nc1ccc(CCNC(=O)c2ccnc3[nH]c(-c4ccc(F)cc4)nc23)cc1,IC50,4.0,nM,8.4,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting method,2012.0
TAE-684,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
IMATINIB,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc2[nH]nc(C(=O)NCC3CCN(Cc4ccc(O)cc4)CC3)c2c1,IC50,400.0,nM,6.4,Glycogen synthase kinase-3 beta,335721,,"LanthaScreen TR-FRET Assay: Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screening assay, compounds were tested in duplicate at a concentration of 10 uM.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um). In a second assay, the same compounds were assayed at five concentrations ranging from 100 uM to 10 nM with ten-fold dilutions in duplicate.",2015.0
,COc1ccc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCO5)o3)cc2)c(C#N)c1,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta by FRET assay,2013.0
,O=C1Nc2ccccc2Nc2ccccc21,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1C(F)(F)F,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(-c2csc3c2-n2cccc2C3=O)cc1O,IC50,1500.0,nM,5.82,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
,O=C(CCl)c1cc(Br)c(Br)s1,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by liquid scintillation counting,2009.0
,O=C(O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCNc1c2c(nc3ccccc13)CCCC2,IC50,270.0,nM,6.57,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human full length N-terminal GST-tagged GSK-3beta expressed in Sf9 insect cells using prephosphorylated polypeptide as substrate after 30 mins by kinase-Glo reagent based luminescence assay,2018.0
,Cc1ccc(-c2nnc(Nc3ccccc3)o2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,O=C(NCCC1CCN(Cc2cccc(Cl)c2)CC1)c1cncc(NC(=O)c2cccc(NC(=O)C3CC3)c2)c1,IC50,152.0,nM,6.82,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,CC(=O)Nc1cc(C(=O)Nc2cncc(OCC3CCN(Cc4ccc(F)cc4)CC3)c2)ccn1,IC50,3508.0,nM,5.46,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
TACRINE,Nc1c2c(nc3ccccc13)CCCC2,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,O=C(O)CN1CCC(CNC(=O)c2n[nH]c3ccc(-c4cccc(Cl)c4Cl)cc23)CC1,IC50,40.0,nM,7.4,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,Cc1cccc(-c2[nH]c(-c3ccnc(N)n3)cc2C(N)=O)c1C,Ki,25.12,nM,7.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(OC)c(Nc2ccc3nnc(-c4ccccc4)n3n2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,C=CC(=O)Nc1cccc(C2=C(c3cn(C)c4cc(F)ccc34)C(=O)NC2=O)c1,IC50,199.0,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(Cl)c1,IC50,195.0,nM,6.71,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,Cc1nc2ccccc2n1Cc1nnc(Nc2ccccc2)s1,IC50,157.0,nM,6.8,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,Nc1ncc(-c2ncccc2C(F)(F)F)nc1C(=O)Nc1ncccc1N1CCC(N)CC1,IC50,5500.0,nM,5.26,Glycogen synthase kinase-3 beta,438364,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,Nc1ncc(-c2ncccc2OC(F)(F)F)nc1C(=O)Nc1ncccc1N1CCC(N)CC1,IC50,2400.0,nM,5.62,Glycogen synthase kinase-3 beta,438373,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,Nc1ncc(-c2csc(N3CCOCC3)n2)nc1C(=O)Nc1ncccc1N1CCC(N)CC1,IC50,210.0,nM,6.68,Glycogen synthase kinase-3 beta,438376,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,COc1ccnc(-c2cnc(N)c(C(=O)Nc3ncccc3N3CCC(C)(N)CC3)n2)c1C(F)(F)F,IC50,2100.0,nM,5.68,Glycogen synthase kinase-3 beta,438379,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,COc1cc(CCC(=O)Nc2cc(-c3[nH]c(SC)nc3-c3ccc(F)cc3)ccn2)cc(OC)c1OC,IC50,363.0,nM,6.44,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,COc1ccc(CCC(=O)Nc2cc(-c3[nH]c(SC)nc3-c3ccc(F)cc3)ccn2)cc1,IC50,542.0,nM,6.27,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,O=C(Cc1ccc(F)cc1)Nc1cc(-c2[nH]c(SCc3ccccc3)nc2-c2ccc(F)cc2)ccn1,IC50,1499.0,nM,5.82,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,c1ccc(/N=c2\nc(-c3ccccc3)n(-c3ccccc3)s2)cc1,IC50,2800.0,nM,5.55,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta after 30 mins by luminescence assay in presence of ATP,2012.0
,C[C@@H]1CN(c2cncnc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,CCN1CCN(CCCC(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1,IC50,4.0,nM,8.4,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C1NC(NC2CCCCCC2)=N/C1=C\c1ccc2ncsc2c1,IC50,4992.0,nM,5.3,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CO[C@H]1CCC[C@H](NC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)CC1,IC50,6729.0,nM,5.17,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COC(=O)[C@H](CC(C)C)NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,4104.0,nM,5.39,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CC(=O)NC12CC3CC(C1)CC(NC1=N/C(=C\c4ccc5ncsc5c4)C(=O)N1)(C3)C2,IC50,663.0,nM,6.18,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CS(=O)(=O)NC12CC3CC(CC(NC4=N/C(=C\c5ccc6ncsc6c5)C(=O)N4)(C3)C1)C2,IC50,511.0,nM,6.29,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cc1csc(CNC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)n1,IC50,2155.0,nM,5.67,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CC(C)(C)OC(=O)N1CCC(CNC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)CC1,IC50,5272.0,nM,5.28,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(Nc2ccccc2)=N/C1=C\c1ccc2ncsc2c1,IC50,2225.0,nM,5.65,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CN1CC[C@@](C)(NC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)C1=O,IC50,1738.0,nM,5.76,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cc1ccc(C(=O)Nc2c[nH]nc2C(=O)NCCCOC(C)C)cn1,IC50,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK-3beta using peptide substrate after 45 mins in presence of ATP by Kinase-Glo luminescence assay,2016.0
GW829906X,Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1,IC50,39.81,nM,7.4,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,2020.0
,Cc1cc(Nc2n[nH]c3ncc(F)cc23)nc(-c2ccccc2Cl)c1C,IC50,200.0,nM,6.7,Glycogen synthase kinase-3 beta,251327,,"Inhibition Assay: Compounds of the present invention were screened for their ability to inhibit GSK-3β (AA 1-420) activity using a standard coupled enzyme system (Fox et al., Protein Sci. 1998, 7, 2249). Reactions were carried out in a solution containing 100 mM HEPES (pH 7.5), 10 mM MgCl2, 25 mM NaCl, 300 μM NADH, 1 mM DTT and 1.5% DMSO. Final substrate concentrations in the assay were 20 μM ATP (Sigma Chemicals, St Louis, Mo.) and 300 μM peptide (American Peptide, Sunnyvale, Calif.). Reactions were carried out at 30 C. and 20 nM GSK-3β. Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate, 300 μM NADH, 30 μg/ml pyruvate kinase and 10 μg/ml lactate dehydrogenase.",2014.0
,Clc1ccccc1-c1cc(NCc2cccnc2)n2ncc(Br)c2n1,IC50,54.0,nM,7.27,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2007.0
,CN(c1ncnc2[nH]c3cc(Br)ccc3c12)C1CCCN(CCC#N)C1,IC50,388.0,nM,6.41,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,CN(c1ncnc2[nH]c3cc(C#N)ccc3c12)C1CCCN(CCC#N)C1,IC50,1204.0,nM,5.92,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,C#Cc1ccc2c(c1)[nH]c1ncnc(N3CCC4CCN(CCC#N)CC43)c12,IC50,1.995,nM,8.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,C=CC(=O)N1C(=O)CC(c2ccc(F)cc2)Sc2ccccc21,IC50,6600.0,nM,5.18,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using GS-2 peptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
RAVOXERTINIB,Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1,Kd,599.0,nM,6.22,Glycogen synthase kinase-3 beta,Active,,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",2017.0
,Cc1nc2ccc(NS(=O)(=O)c3ccc(N)cc3)cc2nc1C,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1c(N2CCNC(c3cccc(Cl)c3)C2)nc(-c2ccncn2)cc1=O,IC50,1.1,nM,8.96,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,O=C(Nc1cnccn1)Nc1ccnc2cc(C(F)(F)F)ccc12,Ki,63.1,nM,7.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cc(C)ccc4F)cc3)csc12,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncc(-c2ccccc2)cc1/N=C/c1ccnc(NC(=O)C2CC2)c1,IC50,49.0,nM,7.31,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,NC(=O)c1nc(C2CC2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,CCC(CC)CNc1c(C(N)=O)cnc2ccc(C#N)cc12,IC50,550.0,nM,6.26,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2016.0
,COc1nc(-c2ccnc(NC(=O)C3CC3)c2)sc1C(=O)NCCNc1c2c(nc3cc(Cl)ccc13)CCCC2,IC50,63.0,nM,7.2,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human full length N-terminal GST-tagged GSK-3beta expressed in Sf9 insect cells using prephosphorylated polypeptide as substrate after 30 mins by kinase-Glo reagent based luminescence assay,2018.0
,C[C@H]1COCCN1c1nc(-c2ccncc2F)cc(=O)n1C,IC50,23.0,nM,7.64,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta assessed as inhibition of [gamma32P]ATP after 1 hr by liquid scintillation counting in presence of prephosphorylated GS1 peptide,2015.0
,COc1ccccc1-n1cc(CSC2=NC(c3ccccc3)CC(=O)N2C)nn1,IC50,1314.0,nM,5.88,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin) after 30 mins by Kinase-Glo assay,2019.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCC#Cc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,IC50,63.8,nM,7.2,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,O=C(Nc1cc(-c2[nH]c(-c3ccccc3)nc2-c2ccc(F)cc2)ccn1)C1CC1,IC50,570.0,nM,6.24,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,COc1ccc(/C=C2\S/C(=N\Cc3ccccc3)NC2=O)cc1OC,IC50,44.3,nM,7.35,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK-3beta expressed in Baculovirus using Ser/Thr9 peptide as substrate by Z' LYTE assay,2016.0
,Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(C(NC(C)(C)C)c3ccccn3)ns2)n1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3b (unknown origin),2018.0
,CC(C)C(=O)Nc1cc(C(=O)Nc2cnccc2-c2ccccc2)ccn1,IC50,1.4,nM,8.85,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cnccc1C1CCCC1)c1ccnc(NC(=O)C2CC2)c1,IC50,41.0,nM,7.39,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,COc1ccccc1C1C2=C(CC(C)(C)CC2=O)Nc2n[nH]c(C)c21,IC50,61.0,nM,7.21,Glycogen synthase kinase-3 beta,318301,,"HTS Assay: The GSK3beta primary screen was conducted in assay ready 1536 plates (Aurora 29847) that contain 2.5 mL/well of 10 mM compound. Human GSK3beta as a GST fusion expressed in baculoviral system was purchased from BPS Bioscience (San Diego, Calif.). The GSK3beta peptide substrate was from American Peptide (Sunnyvale, Calif.; Cat 311153). 1 L/well of CABPE (22.5 nM GSK3beta , 8 uM peptide in AB buffer (12.5 mM DTT, 0.25 mg/mL BSA, 0.5 unit/mL Heparin)), 0.5 L/well of 125 uM of ATP, and 1 L/well of positive control 50 uM of GW8510 (positive control) or AB (DMSO only neutral control) in respective wells according to plate design using BioRAPTR (Beckman, Brea, Calif.). Reactions were incubated at room temperature for 60 minutes. 2.5 uL/well of ADP-Glo (Promega, V9103) was added with BioRAPTR, and incubated at room temperature for 40 minutes followed by addition of 5 uL/well of ADP-Glo detection reagent (Promega, V9103) with Combi nL (Thermo, Waltham, Mass.).",2015.0
,CN1C(=O)CC(c2ccccc2)N=C1SCc1cn(-c2ccc(C(C)(C)C)cc2)nn1,IC50,1340.0,nM,5.87,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin) after 30 mins by Kinase-Glo assay,2019.0
,O=C1NC(=O)C(c2ccccc2)=C1Nc1ccc(C(=O)Nc2ccccc2)cc1,IC50,210.0,nM,6.68,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,Nc1ncnc2c1c(-c1cccc(O)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,IC50,1800.0,nM,5.75,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3B (unknown origin) in presence of [gamma33P]ATP,2016.0
,O=C1NCCc2[nH]c(-c3ccnc(C=Cc4ccccc4)c3)cc21,Ki,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(F)c2)c1,Ki,125.89,nM,6.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN1c2ccc(N)cc2C(c2ccccc2)c2cc(N)ccc21,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(CN)CNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COCCN1CCC(CNC(=O)c2n[nH]c3ccc(-c4ccccc4)cc23)CC1,IC50,200.0,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COCCN1CCC(CNC(=O)c2n[nH]c3ccc(-c4cccnc4)cc23)CC1,IC50,31.0,nM,7.51,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,COCCN1CCC(CNC(=O)c2n[nH]c3ccc(-c4ccc(C)nc4)cc23)CC1,IC50,64.0,nM,7.19,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,NC(=O)c1sc(-c2ccnc(NC(=O)CNCCNc3c4c(nc5ccccc35)CCCC4)c2)nc1OCC1CC1,IC50,42.6,nM,7.37,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,Cl.Cn1c(N2CCN[C@@H](c3ccc(Cl)cc3)C2)nc(-c2ccncc2)cc1=O,IC50,11.0,nM,7.96,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cc1cc(Nc2n[nH]c3ncc(F)cc23)nc(C2CCCCC2)n1,IC50,6.0,nM,8.22,Glycogen synthase kinase-3 beta,244256,,Inhibition Assay: Compounds are screened for their ability to inhibit the phosphorylation of tyrosine (TYR) residues through the use of western blotting of Jurkat cells dosed with the compounds. The phosphorylation of the specific TYR residues tested are GSK3α TYR 279 and GSK3β TYR 216.,2014.0
,O=C(NCC1CCN(Cc2ccccc2)CC1)c1n[nH]c2ccc(-c3cccnc3)cc12,IC50,95.0,nM,7.02,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,O=C(NCC1CCN(Cc2ccc(F)c(F)c2)CC1)c1cncc(NC(=O)c2ccnc(NC(=O)C3CC3)c2)c1,IC50,279.0,nM,6.55,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,COc1cc(NCCCN)c2nccc(C)c2c1Oc1cccc(C(F)(F)F)c1,IC50,35.0,nM,7.46,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) assessed as luminescence intensity by luminometry,2014.0
,CCCC(=O)Nc1n[nH]c2c(F)c(Cl)c(-c3ccccc3)cc12,IC50,6.0,nM,8.22,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
DINACICLIB,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,IC50,324.0,nM,6.49,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK3B using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate incubated for 2 hrs by [gamma-33P]-ATP assay,2021.0
,CS(=O)(=O)O.O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1,IC50,7.77,nM,8.11,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2012.0
,Cc1nn(-c2ccccc2Cl)c2c1c1c(c3cccn32)C(=O)NC1=O,IC50,940.0,nM,6.03,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using (RREGGMSRPAS(p)VDG as substrate assessed as 32P[gamma-ATP] incorporation into substrate after 15 mins by autoradiography,2013.0
,COc1ccccc1-n1ncc2c3c(c4cccn4c21)C(=O)NC3=O,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using (RREGGMSRPAS(p)VDG as substrate assessed as 32P[gamma-ATP] incorporation into substrate after 15 mins by autoradiography,2013.0
,O=C(/C=C/c1ccc(OCc2ccccc2)cc1)CC(=O)/C=C/c1ccc(OCc2ccccc2)cc1,IC50,5560.0,nM,5.25,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide as substrate incubated for 30 mins by Glo-type luminescence assay,2016.0
,COC(=O)c1ccc(CSc2nnc(-c3ccc4c(c3)OCCO4)o2)cc1,IC50,36.0,nM,7.44,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using pIRS-1 as substrate preincubated for 15 mins,2012.0
GW829874X,COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1,IC50,25.12,nM,7.6,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,COc1ccnc(-c2cnc(N)c(C(=O)Nc3ncccc3N3CCC(C)(N)CC3)n2)c1F,IC50,2100.0,nM,5.68,Glycogen synthase kinase-3 beta,438381,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,COc1ccnc(-c2cnc(N)c(C(=O)Nc3ncccc3N3CCC(C)(N)CC3)n2)c1C#N,IC50,2400.0,nM,5.62,Glycogen synthase kinase-3 beta,438383,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,C#CC(=O)c1ccc2nc(NC(=O)NCc3ccc(OC)cc3)sc2c1,IC50,4210.0,nM,5.38,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using prephosphorylated peptide as substrate measured after 30 mins by Kinase-glo luminescence assay,2019.0
,C=CC(=O)c1ccc2nc(NC(=O)NCc3ccc(OC)cc3)sc2c1,IC50,4050.0,nM,5.39,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using prephosphorylated peptide as substrate measured after 30 mins by Kinase-glo luminescence assay,2019.0
LORECIVIVINT,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Kd,155.07,nM,6.81,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human GSK-3beta assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,2023.0
,COc1ccc(-c2ocnc2C(=O)NCCCn2cc(CNC(=O)CCc3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)nn2)cc1Cl,IC50,0.27,nM,9.57,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,COc1ccc(-c2ocnc2C(=O)NCCCNC(=O)CCc2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc1F,IC50,1.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,COc1ccccc1CNC(=N)Nc1nccc(-c2cccs2)n1,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=S(=O)(Nc1ccc(-c2nc(-c3ccnc(Nc4ccc(OC(F)(F)F)cc4)c3)no2)cc1)c1ccc(Br)cc1,IC50,3120.0,nM,5.51,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) measured after 40 mins by ADP-Glo assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCc1cn(CCNc2c3c(nc4ccccc24)CCCC3)nn1,IC50,72.0,nM,7.14,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)CNCCNc3c4c(nc5ccccc35)CCCC4)c2)nc1OCC(C)C,IC50,132.4,nM,6.88,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,Cn1c(N2CCNC(c3ccccc3Br)C2)nc(-c2ccncc2)cc1=O,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,CN1CCN(S(=O)(=O)c2ccccc2-c2cnc(N)c(C(=O)Nc3cccnc3)n2)CC1,Ki,300.0,nM,6.52,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,C[C@@H]1CN(c2ccc(C#N)cc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,2.7,nM,8.57,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,COc1cc(-c2ccnc(NC(=O)C3CC3)c2)cnc1C(N)=O,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) activity by competitive binding assay,2015.0
,COc1cc(-c2ccc3c(c2)Nc2ccc(CCOc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1CC#N,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(Nc2nc(-c3ccncc3)nc3ccccc23)n[nH]1,Ki,73.0,nM,7.14,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2009.0
7-DEAZAXANTHINE,O=c1[nH]c(=O)c2cc[nH]c2[nH]1,IC50,700.0,nM,6.16,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using 19F peptide as substrate measured after 1.5 hrs by fluorescence method,2019.0
,N#Cc1cccc(CSc2nnc(-c3ccc4c(c3)OCO4)o2)c1,IC50,65.0,nM,7.19,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using pIRS-1 as substrate preincubated for 15 mins,2012.0
,O=c1ccc2nccc3c4ccc(O)cc4n1c23,IC50,6800.0,nM,5.17,Glycogen synthase kinase-3 beta,,,Activation of GSK-3beta in HEK293 cells assessed as suppression of TCF/beta-catenin transcriptional activity after 24 hrs by SuperTOPFlash reporter gene assay,2015.0
,Cc1ccc2[nH]nc(C(=O)NCC3CCN(C(=O)Nc4ccccc4)CC3)c2c1,IC50,640.0,nM,6.19,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,O=C(NC1CCOC1)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12,IC50,130.0,nM,6.89,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human N-terminal GST-tagged GSK3beta (1 to 420 end residues) expressed in baculovirus expression system using unphosphorylated peptide as substrate incubated enzyme-substrate mixture for 90 mins in presence of ATP by LANCE assay,2020.0
PIMODIVIR,O=C(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,Ki,1600.0,nM,5.8,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2014.0
NEFLAMAPIMOD,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2cccc(O)c2N1,IC50,4295.36,nM,5.37,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
SB-431542,NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1,Ki,50.12,nM,7.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN(C)C)cc21,IC50,375.0,nM,6.43,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccccc3Cl)ccc12,IC50,1353.0,nM,5.87,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(O)cc3)c(-c3ccoc3)cc12,IC50,98.0,nM,7.01,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccccc3)c(-c3ccccc3)cc12,IC50,1720.0,nM,5.76,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(OC(F)(F)F)cc3)ccc12,IC50,5498.0,nM,5.26,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,O=C1NN=C(c2ccncc2)/C1=N/Nc1ccccc1Cl,Ki,250.0,nM,6.6,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccccc1N/N=C1\C(=O)NN=C1c1ccccc1,Ki,4000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(N/N=C2\C(=O)NN=C2c2ccccc2)cc1,Ki,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(N/N=C2\C(=O)NN=C2c2ccccn2)cc1,Ki,640.0,nM,6.19,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(N/N=C2\C(=O)NN=C2c2ccc(OC)c(OC)c2)cc1,Ki,2.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1cccc(C2=NNC(=O)/C2=N\Nc2cccc(Cl)c2)c1,Ki,8.0,nM,8.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1cccc(N/N=C2\C(=O)NN=C2c2cccc(OC)c2)c1,Ki,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1cccc(C2=NNC(=O)/C2=N\Nc2ccc(C(=O)O)cc2)c1,Ki,6.5,nM,8.19,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(C2=NNC(=O)/C2=N\Nc2ccc(C#N)cc2)cc1OC,Ki,2.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,COc1ccc(C2=NNC(=O)/C2=N\Nc2cccnc2)cc1OC,Ki,3.5,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay,2010.0
,Nc1ccc2cc3cnccc3c([N+](=O)[O-])c2n1,IC50,418.0,nM,6.38,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK3beta expressed in baculovirus in Sf9 insect cells using YRRAAVPPSPSLSRHSSPHQSpEDEEE as substrate measured after 30 mins by ADP-Glo kinase assay,2022.0
,Cl.Cn1c(N2CCNC(c3ccccc3F)C2)nc(-c2ccncn2)cc1=O,IC50,8.2,nM,8.09,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,COc1cccc(C2CN(c3nc(-c4ccncn4)cc(=O)n3C)CCN2)c1.Cl,IC50,6.7,nM,8.17,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,COc1ccc2c(c1)[nH]c1cnc(NC(=O)C3CC3)cc12,IC50,8100.0,nM,5.09,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human full length GSK3beta expressed in baculovirus in Sf9 insect cells using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate by ADP-Glo kinase assay,2021.0
,NC(=O)c1cc2c(-c3ccc(F)cc3F)cncc2s1,Ki,199.53,nM,6.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(O)c1ccccc1Nc1ccnc(NCc2cccc(O)c2)n1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
AZD-1152-HQPA,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1,Ki,1995.26,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cc(F)ccc1F,Ki,1.995,nM,8.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1,Ki,630.96,nM,6.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1F,Ki,2511.89,nM,5.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1ncnc2c1C(=O)Nc1ccccc1N2,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cc2c(-c3ccc(Br)cc3)cncc2s1,Ki,100.0,nM,7.0,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)noc12,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC1CSc2c(C(=O)O)c(=O)c3cc(F)c(N4CCC(N)C4)c(F)c3n21,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1c1ccccc1,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,COc1ccc(C2=C(c3cn(CCCn4ccnc4)c4ccccc34)C(=O)NC2=O)cc1,IC50,40.0,nM,7.4,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1c1ccc(F)cc1,IC50,57.0,nM,7.24,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1c1ccc2ccccc2c1,IC50,9190.0,nM,5.04,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,Cc1ccccc1C1=C(c2cn(CCCn3ccnc3)c3ccc(Br)cc23)C(=O)NC1=O,IC50,87.0,nM,7.06,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,Cc1ccc2c(C3=C(c4ccccc4[N+](=O)[O-])C(=O)NC3=O)cn(CCCn3ccnc3)c2c1,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3cc(Br)ccc23)=C1c1ccc(F)cc1,IC50,720.0,nM,6.14,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,CCCCCCCCCCCC(=O)NNC(=O)c1c(O)c2cc(Br)ccc2n(C)c1=O,IC50,4280.0,nM,5.37,Glycogen synthase kinase-3 beta,,,Allosteric inhibition of human recombinant full length N-terminal GST-tagged GSK3beta expressed in fall armyworm Sf9 cells after 30 min in presence of ATP by kinase glo luminescent assay,2017.0
,CN1CCN(C(=O)c2ccc(-c3cnc(N)c(C(=O)Nc4cccnc4)n3)cc2)CC1,Ki,3.1,nM,8.51,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCC1CCN(Cc2ccc(F)cc2)CC1,IC50,38.0,nM,7.42,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCC1CCN(Cc2ccccc2)CC1,IC50,94.0,nM,7.03,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OC1CCN(Cc2ccccc2)CC1,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated polypeptide as substrate incubated for 1 min followed by substrate addition and measured after 30 mins by Kinase-Glo luminescence assay,2021.0
,Cc1cc(Nc2cc(Cl)nc(Oc3ccc([N+](=O)[O-])cc3)n2)n[nH]1,IC50,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2022.0
,Nc1cc(-c2cn(-c3ccccc3)c3cnccc23)ccn1,IC50,1950.0,nM,5.71,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human His/GST-tagged GSK3beta (2 to 433 residues) expressed in baculovirus infected Sf9 cells using Ulight-glycogen synthase peptide as substrate incubated for 30 mins by TR-FRET LANCE method,2020.0
,C=CC(=O)N1C(=O)CC(c2ccccc2)Sc2ccccc21,IC50,6600.0,nM,5.18,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using GS-2 peptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,C=CC(=O)N1C(=O)CC(c2cccc(Cl)c2)Sc2ccccc21,IC50,4000.0,nM,5.4,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using GS-2 peptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(Cc4nc(C(=O)O)cs4)CC3)c2c1,IC50,170.0,nM,6.77,Glycogen synthase kinase-3 beta,335723,,"LanthaScreen TR-FRET Assay: Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screening assay, compounds were tested in duplicate at a concentration of 10 uM.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um). In a second assay, the same compounds were assayed at five concentrations ranging from 100 uM to 10 nM with ten-fold dilutions in duplicate.",2015.0
,Cc1n[nH]c2ncc(-c3nnc4n3[C@H](c3ccc(Cl)cc3)CC4)cc12,Kd,3.8,nM,8.42,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to GSK3B (unknown origin) assessed as dissociation constant by competitive binding assay,2023.0
,Cc1cc(Nc2ncc(C)c(N3CC4CCC(C3)N4CCC#N)n2)sn1,IC50,311.0,nM,6.51,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,Cc1cc(Nc2ncc(C)c(N3CC(CC#N)(N4CCCC4)C3)n2)sn1,IC50,6975.0,nM,5.16,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(Nc2ccc(C(F)(F)F)cc2)n1,IC50,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,N#Cc1ccc(Nc2nccc(C(=O)Nc3cnccc3-c3ccccc3)n2)cc1Cl,IC50,0.24,nM,9.62,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,O=C(Nc1cccnc1)c1ccncn1,IC50,2000.0,nM,,Glycogen synthase kinase-3 beta,,,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,N#Cc1ccc(Nc2nccc(C(=O)Nc3cnccc3-c3ccccc3)n2)c(Cl)c1,IC50,3.8,nM,8.42,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,O=C(Nc1cnccc1-c1ccc(F)cc1)c1ccnc(Nc2ccc(C(F)(F)F)cc2)n1,IC50,2.1,nM,8.68,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,CC(=O)c1ccc(-c2c[nH]c3ncc(/C=C/C(=O)NCCc4ccccn4)cc23)cc1,IC50,1.37,nM,8.86,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,O=C1NC(NC2CC3CCC2C3)=N/C1=C\c1ccc2ncsc2c1,IC50,3259.0,nM,5.49,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC2CCC(F)(F)C2)=N/C1=C\c1ccc2ncsc2c1,IC50,4689.0,nM,5.33,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@@H]2CCCC[C@H]2O)=N/C1=C\c1ccc2ncsc2c1,IC50,9898.0,nM,5.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@@H]2CCCC[C@@H]2O)=N/C1=C\c1ccc2ncsc2c1,IC50,8153.0,nM,5.09,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@@H]2CCCC[C@H](O)C2)=N/C1=C\c1ccc2ncsc2c1,IC50,6041.0,nM,5.22,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CO[C@H]1CCC[C@@H]1NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,3520.0,nM,5.45,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CO[C@H]1CCCC[C@@H]1NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,8746.0,nM,5.06,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CO[C@@H]1CCCCC[C@H]1NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,5532.0,nM,5.26,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CC(C)C[C@H](COC(C)(C)C)NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,9997.0,nM,5.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CC(C)C[C@H](COCc1ccc(F)cc1)NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,4124.0,nM,5.38,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC23CC4CC(CC(F)(C4)C2)C3)=N/C1=C\c1ccc2ncsc2c1,IC50,169.0,nM,6.77,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COC(CNC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1)c1ccccc1,IC50,4314.0,nM,5.37,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@@H]2CCCOC2)=N/C1=C\c1ccc2ncsc2c1,IC50,9204.0,nM,5.04,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CC1(C)CCC(NC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)CO1,IC50,4746.0,nM,5.32,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CO[C@H]1CCCC[C@H]1NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,9540.0,nM,5.02,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COC(=O)[C@@H](CC(C)C)NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,1340.0,nM,5.87,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C(Nc1cnccc1OCC(F)(F)F)c1ccnc(NC(=O)C2CC2)c1,IC50,2.5,nM,8.6,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,CC(=O)Nc1c(C(N)=O)sc2ccc(Cl)c(Cl)c12,Ki,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1cccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)c1,Ki,501.19,nM,6.3,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(C(=O)O)ccc4F)cc3)c12,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1c(O)[nH]c(=O)c2c(=N)oc3ccc(Cl)cc3c12,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,OC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CNC(=O)c1cc2c(-c3ccccc3F)n[nH]c2s1,Ki,794.33,nM,6.1,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NCC(O)C(O)Cn1cc(I)c2c(N)ncnc21,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Oc1cccc(Nc2ncnc3scc(Cl)c23)c1,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC(=O)c1cc2c(Oc3cccc(F)c3)cncc2s1,Ki,251.19,nM,6.6,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,N#Cc1cccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)c1,Ki,3.981,nM,8.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(C)cc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)c1ccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)cc1NC(=O)c1ccccc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1cc(-c2ccccc2)c2nc(-c3ccncc3)cc(=O)n21,Ki,125.89,nM,6.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=c1[nH]cnc2c1sc1c(Cl)ccc(Cl)c12,Ki,3981.07,nM,5.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(-c2ocnc2C(=O)NCCCn2cncn2)cc1Cl,IC50,9.0,nM,8.05,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK3beta,2021.0
,O=C(Nc1cccc(C(F)(F)F)c1)N[C@H]1CO[C@H]2[C@@H]1OC[C@@H]2Nc1nccc(-c2cccs2)n1,IC50,4042.0,nM,5.39,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using phosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,N#Cc1ccc(-n2c(-c3nonc3N)nc3ccccc32)cc1,Ki,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,CC(C)n1c(-c2nonc2N)nc2ccccc21,Ki,1500.0,nM,5.82,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,Cc1ccccc1-c1cccc2c1c(Nc1ccccc1)c(C(=O)O)n2CCCOc1cccc2ccccc12,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(NCC1CCN(Cc2ccccc2F)CC1)c1n[nH]c2ccc(-c3cccnc3)cc12,IC50,79.0,nM,7.1,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,O=C(NCC1CCN(Cc2ccccc2F)CC1)c1cncc(NC(=O)c2ccnc(NC(=O)C3CC3)c2)c1,IC50,164.0,nM,6.79,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,O=C(Nc1cncc(OC2CCN(Cc3ccccc3)CC2)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,734.0,nM,6.13,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated for 30 mins in presence of ATP by Kinase-Glo reagent based luminescence assay,2021.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)NCCc1c[nH]c2ncccc12,IC50,128.0,nM,6.89,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)NCc1cccnc1,IC50,64.2,nM,7.19,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,Cc1cccc(Nc2cc(Nc3ccccc3Cl)c(C(N)=O)cn2)n1,IC50,380.0,nM,6.42,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) by caliper microfluidic mobility shift technology,2023.0
,COc1cncc(-c2ccc3[nH]nc(C(=O)NCC4CCN(CC(=O)O)CC4)c3c2)c1,IC50,18.0,nM,7.75,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
,Oc1cccc2c1[nH]c1c(C3=C[C@@]4(O)CC/C=C\CCCCN5CCC3[C@]3(C[C@@H]6/C=C\CCCCN6[C@H]34)C5)nccc12,IC50,4800.0,nM,5.32,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2021.0
,COc1cccc(N2CCN(c3nc(-c4ccncn4)cc(=O)n3C)[C@H](C)C2)c1,IC50,0.2,nM,9.7,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,CN1Cc2nn(C)c(C#N)c2-c2cnc3[nH]c(F)c(c3c2)-c2cn(nc2C(F)(F)F)CCCC1=O,Kd,935.91,nM,6.03,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human GSK-3beta assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,2023.0
,O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\O,IC50,190.0,nM,6.72,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) in presence of ATP,2021.0
,O=C(Nc1cncc(Oc2ccccc2)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,19.0,nM,7.72,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,Nc1ncc(-c2nc(N3CCOCC3)cc3ccccc23)nc1C(=O)Nc1ncccc1N1CCC(N)CC1,IC50,3400.0,nM,5.47,Glycogen synthase kinase-3 beta,438386,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,COc1cccc2c(C3=C(c4cn(C)c5cc(-c6ccc(Cl)cc6)c(F)cc45)C(=O)NC3=O)coc12,IC50,7160.0,nM,5.14,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta by scintillation counting,2009.0
,CCN1/C(=C/C(C)=O)Sc2ccc(O)cc21,Kd,1644.35,nM,5.78,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human GSK-3beta assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,2023.0
,O=[N+]([O-])c1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,IC50,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta by scintillation proximity assay,2008.0
,Cn1c(NCCCCNc2c3c(nc4ccccc24)CCCC3)nc(-c2ccncc2)cc1=O,IC50,920.0,nM,6.04,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK-3beta using prephosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescence assay,2021.0
,Cn1c(NCCCCCCCNc2c3c(nc4ccccc24)CCCC3)nc(-c2ccncc2)cc1=O,IC50,330.0,nM,6.48,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK-3beta using prephosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescence assay,2021.0
,COc1ccc2[nH]nc(C(=O)NCC3CCN(C)CC3)c2c1,IC50,1200.0,nM,5.92,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using Ulight-CFFKNIVTPRTPPPSQQGK-amide as substrate after 90 mins by LANCE assay,2015.0
QUINOXALINE1,Nc1n[nH]c2nc3ccccc3nc12,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2007.0
,O=C(Nc1n[nH]c2nc(-c3cccs3)c(Br)cc12)C1CCCC1,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(Nc1n[nH]c2nc(-c3ccc(O)c(Br)c3)ccc12)C1CC1,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3-beta,2008.0
,O=C1NC(NC23CC4CC(CC(C4)C2)C3)=N/C1=C\c1ccc2ncsc2c1,Kd,1762.17,nM,5.75,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human GSK-3beta assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,2023.0
,CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1,IC50,9410.0,nM,5.03,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3B (unknown origin) after 60 mins by TR-FRET assay,2016.0
,Cc1nc2ccccc2n1CC(=O)NNC(=O)Cc1ccccc1,IC50,105.0,nM,6.98,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,O=CN(O)C(CS(=O)(=O)c1ccc(-c2ccc(C(F)(F)F)cc2)cc1)c1ccc(O)cc1,Ki,1584.89,nM,5.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1c(N2CCNC(c3ccc(F)cc3)C2)nc(-c2ccncc2)cc1=O,IC50,18.0,nM,7.75,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cn1c(N2CCNC(c3ccc(Cl)cc3)C2)nc(-c2ccncn2)cc1=O,IC50,1.7,nM,8.77,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,O=C1Cc2c([nH]c3ccc(C(F)(F)F)cc23)-c2cc(Br)ccc2N1,IC50,1999.86,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,O=C1Cc2cc(Br)ccc2/C1=c1/[nH]c2ccccc2/c1=C\O,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2017.0
,O=C1N/C(=N/c2ccccc2)S/C1=C\c1ccc(O)cc1,IC50,27.7,nM,7.56,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK-3beta expressed in Baculovirus using Ser/Thr9 peptide as substrate by Z' LYTE assay,2016.0
,COc1ccc(-c2ocnc2C(=O)NCCCNC(=O)CCc2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc1Cl,IC50,1.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,COc1ccc(-c2ocnc2C(=O)NCCCCNC(=O)CCc2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc1Cl,IC50,0.84,nM,9.08,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,COc1ccc(-c2ocnc2C(=O)NCCCCNC(=O)CCc2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc1F,IC50,0.78,nM,9.11,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,COc1ccc(-c2ocnc2C(=O)NCCCc2ccc(NC(=O)/C=C/c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)cc2)cc1F,IC50,1.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,Cc1nc(C2CC2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,3090.0,nM,5.51,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,NC(=O)c1nc(-c2ccc(F)c(C(F)(F)F)c2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,79.0,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)NCc1nc2ccccc2[nH]1,IC50,62.1,nM,7.21,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,O=C1Nc2ccccc2/C1=C1/S/C(=N/N=C2/C(=O)Nc3ccccc32)N(c2ccc(O)cc2)C1=O,IC50,710.0,nM,6.15,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,CC(C)(O)c1ccncc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,0.1,nM,10.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,C[C@@H]1COCCN1c1ccncc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,0.49,nM,9.31,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,COc1ccc(-c2cnc(N)c(C(=O)Nc3cnccc3N3CCC(N)CC3)n2)cc1,IC50,0.2,nM,9.7,Glycogen synthase kinase-3 beta,438362,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,COc1ccc2c(c1C(C)N1CCNCC1)O/C(=C\c1n[nH]c3ncccc13)C2=O,IC50,6.1,nM,8.21,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by electrophoretic mobility shift assay,2015.0
RO-320432,CN(C)C[C@H]1CCn2c(c(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c3ccccc32)C1,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta assessed as [gamma33]ATP transfer to biotinylated CREB-peptide substrate after 1 hr by scintillation counting,2010.0
,O=C1NCCc2ccc(cc2)Nc2nccc(n2)Nc2cc1[nH]n2,IC50,2300.0,nM,5.64,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal NanoLuc-fused full length lysed GSK3B (unknown origin) transfected in HEK293T cells incubated for 2 hrs in presence of tracer K8 by NanoBRET assay,2023.0
TP-030-2,CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,GSK3beta(GS3BLGM1) Takeda global kinase panel,2021.0
INDIRUBIN 2,O=C1Nc2ccc(Br)cc2/C1=C1/Nc2ccccc2/C1=N\O,IC50,5.012,nM,8.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) expressed in Sf9 cells using GS1 as substrate and [gamma32]ATP after 30 min by scinitllation counting,2007.0
LGH-447,C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1,IC50,1300.0,nM,5.89,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2015.0
,C[C@@H]1CN(c2ccncc2NC(=O)c2ccnc(NC(=O)C3CC3)c2)C[C@H](C)O1,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C1/C(=C/c2c[nH]c3ncccc23)Oc2cc(OCc3cccc(F)c3)ccc21,IC50,450.0,nM,6.35,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant GSK-3beta (unknown origin) using GS peptide as substrate in presence of ATP incubated for 1 hrs by ADP-Glo kinase assay,2022.0
,COc1ccc(-c2ocnc2C(=O)NCCCNC(=O)c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc1F,IC50,1.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,N#Cc1cccc(-c2nc(Nc3cc(C4CC4)[nH]n3)c3cc(Cl)ccc3n2)c1,Ki,4000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3beta (unknown origin) using HSSPHQ(Sp)EDEEE as substrate by pyruvate kinase-lactate dehydrogenase coupled assay,2017.0
,Cc1nc(COc2ccccc2Cl)sc1-c1ccnc(N)n1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(Nc1cnccc1C(O)C(F)(F)F)c1ccnc(NC(=O)C2CC2)c1,IC50,3.6,nM,8.44,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,C[C@H]1COCCN1c1ccncc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,0.06,nM,10.22,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cnccc1-c1ccc(Cl)cc1)c1ccnc(NC(=O)[C@H]2C[C@H](F)C2)c1,IC50,1.7,nM,8.77,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cncc(-c2cccc(F)c2F)c1)c1ccnc(NC(=O)C2CCC(F)(F)C2)c1,IC50,2.5,nM,8.6,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(NC(=O)C2CCOCC2)c1,IC50,4.5,nM,8.35,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,COc1cc(Nc2nccc(-c3cnn4nc(OC)ccc34)n2)cc(C(F)(F)F)c1,Ki,190.0,nM,6.72,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,CC1(C)CC(=O)C2=C(C1)Nc1n[nH]c(C3CC3)c1[C@]2(C)c1ccccc1,IC50,5.0,nM,8.3,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK-3beta,2023.0
,CO[C@H]1CCC[C@H](NC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)C1,IC50,5668.0,nM,5.25,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,C[C@]12CC3CC(NC4=N/C(=C\c5ccc6ncsc6c5)C(=O)N4)(C1)C[C@@](C)(C3)C2,IC50,2787.0,nM,5.55,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Fc1ccc(-c2cc3[nH]ccnc-3n2)cc1,IC50,1900.0,nM,5.72,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(Nc2ccc(C(F)(F)F)cn2)c1,IC50,0.89,nM,9.05,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
ALOISINE,CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12,IC50,920.0,nM,6.04,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
DEFACTINIB,CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1,IC50,416.0,nM,6.38,Glycogen synthase kinase-3 beta,,,GSK3beta Invitrogen kinase activity assay,2021.0
,COc1ccc(-c2[nH]c3nccnc3c2C(C)C)cc1,IC50,500.0,nM,6.3,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
GW807982X,CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1,Ki,3160.0,nM,5.5,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
GF-109203,CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21,IC50,190.0,nM,6.72,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2004.0
,CC(C)N1CCN(c2nc(-c3ccncn3)cc(=O)n2C)[C@H](C)C1,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,C[C@H]1CNCCN1c1nc(-c2ccncc2)cc(=O)n1C,IC50,920.0,nM,6.04,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,C[C@@H]1CN(S(C)(=O)=O)CCN1c1nc(-c2ccncn2)cc(=O)n1C,IC50,46.0,nM,7.34,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,COc1ccc(N2CCN(c3nc(-c4ccncn4)cc(=O)n3C)[C@H](C)C2)cc1,IC50,0.1,nM,10.0,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using prephosphorylated-GS1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric analysis,2017.0
,COc1ccccc1C1CN(c2nc(-c3ccncc3)cc(=O)n2C)CCN1.Cl,IC50,1.8,nM,8.74,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cl.Cn1c(N2CCN[C@H](c3ccc(Cl)cc3)C2)nc(-c2ccncn2)cc1=O,IC50,26.0,nM,7.58,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,COc1ccc(C2CN(c3nc(-c4ccncn4)cc(=O)n3C)CCN2)cc1OC,IC50,7.8,nM,8.11,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,COc1cccc(C2CN(c3nc(-c4ccncc4)cc(=O)n3C)CCN2)c1.Cl,IC50,11.0,nM,7.96,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,Cc1cc(F)ccc1C1CN(c2nc(-c3ccncc3)cc(=O)n2C)CCN1.Cl,IC50,24.0,nM,7.62,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using prephosphorylated GS-1 peptide as substrate after 1 hr in presence of [gamma-32P]ATP by liquid scintillation spectrometric method,2017.0
,COc1ccc(-c2[nH]c3nccnc3c2CCCCl)cc1,IC50,2500.0,nM,5.6,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,O=C1NC(=O)C(c2nn(CCCN3CCOCC3)c3ncccc23)=C1c1cn(CCCN2CCOCC2)c2ccccc12,IC50,1290.0,nM,5.89,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,Cc1cc(Nc2ncc(C)c(N3CCN(CC#N)CC3)n2)sn1,IC50,1624.0,nM,5.79,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3B (unknown origin) incubated for 45 to 120 mins in presence of ATP by Kinase-Glo luminescent assay,2023.0
,N#CCn1c2ccc(O)cc2c2c3c(n4cccc4c21)C(=O)NC3=O,IC50,420.0,nM,6.38,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2021.0
,N#Cc1ccc(N2CC[C@@H](Nc3c(C(N)=O)cnc4[nH]ccc34)[C@@H](F)C2)nc1,IC50,980.0,nM,6.01,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2015.0
,CC1(C)C(=O)N([C@H]2CCc3c(O)cccc32)c2nc(Nc3ccccc3)ncc21,IC50,2988.0,nM,5.53,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant full length His-tagged GSK3B expressed in baculovirus expression system,2017.0
AZD-5438,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,Kd,62.0,nM,7.21,Glycogen synthase kinase-3 beta,Active,,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",2017.0
,O=C(Nc1cnccc1N1CCOCC1)c1ccnc(NC(=O)C2CC2)c1,IC50,1.0,nM,9.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,COC[C@H](NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1)c1ccccc1,IC50,5168.0,nM,5.29,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cl.Cl.NCC(NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1)c1ccccc1,IC50,616.0,nM,6.21,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CN1CCN(c2cnc(NCCNc3ccc([N+](=O)[O-])c(N)n3)nc2-c2ccc(Cl)cc2Cl)C(=O)C1,IC50,3.981,nM,8.4,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) expressed in Sf9 cells using GS1 as substrate and [gamma32]ATP after 30 min by scinitllation counting,2007.0
KADSURANIN,COc1cc2c(c(OC)c1OC)-c1c(cc3c(c1OC)OCO3)C[C@@H](C)[C@@H](C)C2,IC50,81.0,nM,7.09,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK3-beta,2022.0
,Cc1nc(-c2ccc3c(c2)OCO3)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,IC50,467.0,nM,6.33,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) by ADP-Glo assay,2019.0
GW809885X,COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1,IC50,6309.57,nM,5.2,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
PYRAZOLOPYRIDAZINE 1,COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccc([N+](=O)[O-])cc3)cc12,IC50,18.0,nM,7.75,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccc(Br)cc23)=C1c1cc(F)c(F)cc1F,IC50,120.0,nM,6.92,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,COc1ccc(C2=C(c3cn(CCCn4ccnc4)c4ccc(Br)cc34)C(=O)NC2=O)cc1OC,IC50,51.0,nM,7.29,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccc(Br)cc23)=C1c1ccc2c(c1)OCO2,IC50,44.0,nM,7.36,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,COC(=O)[C@H](C)NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,5142.0,nM,5.29,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COC(=O)C1(NC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)C2CC3CC(C2)CC1C3,IC50,659.0,nM,6.18,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC23CC4CC(CC(NC(=O)C5CC5)(C4)C2)C3)=N/C1=C\c1ccc2ncsc2c1,IC50,366.0,nM,6.44,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NCCCn2ccnc2)=N/C1=C\c1ccc2ncsc2c1,IC50,6192.0,nM,5.21,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(Nc2cccc(OC(F)F)c2)=N/C1=C\c1ccc2ncsc2c1,IC50,3681.0,nM,5.43,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cn1ncc2cccc(NC3=N/C(=C\c4ccc5ncsc5c4)C(=O)N3)c21,IC50,3683.0,nM,5.43,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CN1CCN(c2ccc(NC3=N/C(=C\c4ccc5c(c4)OCCO5)C(=O)N3)cc2)CC1,IC50,120.0,nM,6.92,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC2COC2)=N/C1=C\c1ccc2ncsc2c1,IC50,5917.0,nM,5.23,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC2CC2)=N/C1=C\c1ccc2ncsc2c1,IC50,5898.0,nM,5.23,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cc1ccc2c(c1)c(C1=C(c3ccccc3C)C(=O)NC1=O)cn2CCCn1ccnc1,IC50,73.0,nM,7.14,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,COc1ccc(C2=C(c3cn(CCCn4ccnc4)c4ccc(OC)cc34)C(=O)NC2=O)cc1,IC50,14.0,nM,7.85,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,Cc1c(-c2ccc(/C=C3/SC(=N)NC3=O)o2)ccc([N+](=O)[O-])c1C,IC50,571.0,nM,6.24,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,Cc1nc(N)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,Ki,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2007.0
,O=C1Nc2ccc(S(=O)(=O)O)cc2/C1=C1/Nc2ccccc2/C1=N\O,IC50,80.0,nM,7.1,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2007.0
MERIDIANIN D,Nc1nccc(-c2c[nH]c3cc(Br)ccc23)n1,IC50,2500.0,nM,5.6,Glycogen synthase kinase-3 beta,,,Inhibition of glycogen synthase kinase-3 beta,2004.0
,O=C1N/C(=N/Cc2ccccc2)S/C1=C\c1ccc(Cl)c([N+](=O)[O-])c1,IC50,24.0,nM,7.62,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK-3beta expressed in Baculovirus using Ser/Thr9 peptide as substrate by Z' LYTE assay,2016.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)NCCc1c[nH]cn1,IC50,49.0,nM,7.31,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate in presence of gamma-33P-ATP,2016.0
,CCOC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCF,IC50,68.1,nM,7.17,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2023.0
,COc1ccc2c(c1)/C(=C1/Nc3ccccc3/C1=N\O)C(=O)N2,IC50,90.0,nM,7.05,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3beta (unknown origin) after 10 mins in presence of [gamma32P]ATP by beta counting method,2017.0
,CC(C)C[C@H](CF)NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,1559.0,nM,5.81,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CN(C)c1nc2ccc1CCCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CCC2,IC50,3.0,nM,8.52,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,CC1CN(c2ccncc2NC(=O)c2ccnn3cc(-c4ccccc4)nc23)CCO1,IC50,0.2,nM,9.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2021.0
,O=C1N/C(=N\c2ccc(O)cc2)S/C1=C1\C(=O)Nc2ccc(Br)cc21,IC50,1440.0,nM,5.84,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
NINTEDANIB,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,Kd,83.0,nM,7.08,Glycogen synthase kinase-3 beta,,,Binding constant for GSK3B kinase domain,2011.0
,CC(=O)Nc1cc(-c2nc(OCC3CC3)c(C(=O)NCCCNc3c4c(nc5ccccc35)CCCC4)s2)ccn1,IC50,92.8,nM,7.03,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,Nc1ncc(-c2ccccc2F)nc1C(=O)Nc1cnccc1N1CCC(N)CC1,IC50,0.1,nM,10.0,Glycogen synthase kinase-3 beta,438359,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
DAROVASERTIB,CC1(N)CCN(c2cccnc2NC(=O)c2nc(-c3ncccc3C(F)(F)F)cnc2N)CC1,IC50,3100.0,nM,5.51,Glycogen synthase kinase-3 beta,438377,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,CCCNc1ccc2ncc(-c3ccc4[nH]ncc4c3)n2n1,IC50,53.0,nM,7.28,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK3beta expressed in baculovirus in Sf9 insect cells using YRRAAVPPSPSLSRHSSPHQSpEDEEE as substrate measured after 30 mins by ADP-Glo kinase assay,2022.0
,Cc1nnc(-c2ccc3occ(-c4ccc([S@+](C)[O-])cc4)c3c2)o1,IC50,53.0,nM,7.28,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(Nc2ccc(Cl)cn2)c1,IC50,0.9,nM,9.05,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,COc1ccc(Nc2nccc(C(=O)Nc3cnccc3-c3ccccc3)n2)cc1,IC50,0.45,nM,9.35,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(Nc2c(F)cc(Cl)cc2F)n1,IC50,3.9,nM,8.41,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,CS(=O)(=O)c1ccc(Nc2nccc(C(=O)Nc3cnccc3-c3ccccc3)n2)cc1,IC50,0.25,nM,9.6,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,N#Cc1ccc(Nc2nccc(C(=O)Nc3cnccc3-c3ccccc3)n2)cc1,IC50,0.15,nM,9.82,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,N#Cc1ccc(Nc2nccc(C(=O)Nc3cncnc3OCC(F)(F)F)n2)cc1,IC50,0.74,nM,9.13,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,O=C(Nc1cnccc1OCC(F)(F)F)c1ccnc(Nc2ccc(C(F)(F)F)cc2)c1,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,Cc1nnc(-c2ccc3occ(-c4ccc([S+](C)[O-])cc4)c3c2)o1,IC50,53.0,nM,7.28,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3-beta (unknown origin),2023.0
,COc1cc(C2CN(C(=O)c3cc(COC[C@@H](O)CO)ccn3)C2)ccc1OCc1ccc(C2CC2)cc1,IC50,1000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 insect cells using phosphoglycogen synthase peptide-2 as substrate,2019.0
,O=C1Nc2ccc(NC(=O)c3ccccc3)cc2/C1=C/c1ccc(O)cc1,IC50,4343.0,nM,5.36,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate measured after 60 mins by ADP-Glo luminescence assay,2019.0
,O=C(Nc1n[nH]c2cc(-c3ccsc3)ccc12)C1CC1,IC50,329.0,nM,6.48,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCCC(=O)Nc1n[nH]c2ncccc12,IC50,2343.0,nM,5.63,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1,IC50,0.8,nM,9.1,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
PF-03758309,Cc1nc(Nc2n[nH]c3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1,Kd,667.0,nM,6.18,Glycogen synthase kinase-3 beta,Active,,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",2017.0
,Cn1cc(C2=C(c3nn(CCCn4ccnc4)c4ncccc34)C(=O)NC2=O)c2ccccc21,IC50,4890.0,nM,5.31,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,O=C1NC(Nc2ccccc2)=N/C1=C\c1ccc2c(c1)OCO2,IC50,380.0,nM,6.42,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta expressed in insect cells using YRRAAVPPSPSLSRHSSPHQ-phosphoS-EDEEE as substrate and [gamma33P]ATP after 30 mins by scintillation counting,2012.0
,Cc1n[nH]cc1/C=C1/C(=O)Nc2ccccc21,IC50,5680.0,nM,5.25,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK3beta (636 to 661 residues) assessed as reduction in human muscle glycogen synthase type 1 fragment phosphorylation using YRRAAVPPSPSLSRHSSPHQ(pS)EDE as substrate in presence of ATP incubated for 60 mins by ADP-Glo kinase assay,2023.0
,COc1ccncc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,3.4,nM,8.47,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,COc1cc(C2=C(c3cn(CCCN4CCN(C)CC4)c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,IC50,3238.0,nM,5.49,Glycogen synthase kinase-3 beta,410877,,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",2016.0
,COCCn1cc(-c2ccncc2)c2ccncc21,IC50,3000.0,nM,5.52,Glycogen synthase kinase-3 beta,,,Inhibition of full-length recombinant human His-tagged GSK3B recombinant in baculovirus expression system using Alexa-Fluor tracer-236 incubated for 60 mins by TR-FRET based Lantha-screen Eu kinase assay,2017.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(Nc2ccc(Cl)cc2)c1,IC50,13.0,nM,7.89,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,Cc1ccc(Nc2nccc(C(=O)Nc3cnccc3-c3ccccc3)n2)cc1,IC50,0.31,nM,9.51,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,O=C(Nc1cnccc1-c1ccc(F)cc1)c1ccnc(Nc2ccc(Cl)cc2)n1,IC50,1.1,nM,8.96,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,N#Cc1ccc(Nc2nccc(C(=O)Nc3cnccc3OCC(F)(F)F)n2)cc1,IC50,0.07,nM,10.15,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,O=C1NC(N[C@@H]2CCC[C@@H](O)C2)=N/C1=C\c1ccc2ncsc2c1,IC50,7600.0,nM,5.12,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
GW549034X,CCn1c(-c2nonc2N)nc2ccccc21,Ki,700.0,nM,6.16,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta assessed as decrease in NADH absorbance at 340 nm in the presence of,2009.0
,O=C1NC(N[C@H]2CCC[C@H](O)CC2)=N/C1=C\c1ccc2ncsc2c1,IC50,6733.0,nM,5.17,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cl.Cl.NC[C@@H](NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1)c1ccccc1,IC50,102.0,nM,6.99,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CCOC(=O)c1cccc(NC(=O)Nc2nc3c(s2)CC(N2C(=O)c4ccccc4C2=O)CC3)c1,IC50,5300.0,nM,5.28,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human His-tagged GSK3beta expressed in baculovirus expression system using ser/thr-9 peptide as substrate measured after 1 hr by Z'-Lyte assay,2018.0
GW819077X,FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1,Ki,150.0,nM,6.82,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,O=C(Nc1nccc2c1[nH]c1cc(OC(F)(F)F)ccc12)C1CC1,IC50,7620.0,nM,5.12,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human full length GSK3beta expressed in baculovirus in Sf9 insect cells using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate by ADP-Glo kinase assay,2021.0
,Cc1cnccc1-c1cc(=O)n(C)c(N2CCO[C@@H](c3ccc(F)cc3)C2)n1,IC50,2466.0,nM,5.61,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK-3beta using prephosphorylated GS1 peptide and [gamma-32P]ATP as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,O=C1NC(=O)C(c2cn3c4c(cc(Br)cc24)CNCC3)=C1c1coc2ccccc12,IC50,11.5,nM,7.94,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta-mediated YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE phosphorylation,2013.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCCOCCOCCn1cc(COc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)nn1,IC50,79.5,nM,7.1,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCCOCCOCCOc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,IC50,73.2,nM,7.13,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged recombinant human GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescent assay,2021.0
,CC(C)(C#N)c1cccc(-c2ccnc3[nH]ccc23)n1,Ki,210.0,nM,6.68,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using HSSPHQS(PO3H2)EDEEE peptide as substrate measured after 15 mins in presence of ATP by spectrophotometric analysis,2019.0
,COc1ccc(-c2ocnc2C(=O)NCCCCNC(=O)c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc1F,IC50,0.62,nM,9.21,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,COc1ccc(-c2c[nH]c3ncc(/C=C/C(=O)NCc4ccncc4)cc23)cc1,IC50,0.508,nM,9.29,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
RGB-286638,COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1,Kd,8.0,nM,8.1,Glycogen synthase kinase-3 beta,Active,,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",2017.0
,CN1CC=C(c2c(O)cc(O)c3c(=O)cc(-c4ccc(Sc5nc6ccccc6n5C)cc4)oc23)CC1,IC50,160.0,nM,6.8,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK3beta in presence of ATP by ADP-glo luminescent assay,2020.0
,O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1,IC50,220.0,nM,6.66,Glycogen synthase kinase-3 beta,,,Inhibition of full-length recombinant human His-tagged GSK3B expressed in baculovirus expression system by Z'-LYTE assay,2016.0
,O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCC(O)CO,IC50,110.0,nM,6.96,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3beta (unknown origin) after 10 mins in presence of [gamma32P]ATP by beta counting method,2017.0
,C=CC(=O)N1C(=O)CC(c2ccccc2Cl)Sc2ccccc21,IC50,2500.0,nM,5.6,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using GS-2 peptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,Nc1ncc(-c2ccccc2F)nc1C(=O)Nc1cnccc1N1CCNCC1,IC50,0.2,nM,9.7,Glycogen synthase kinase-3 beta,438363,,"GSKbeta Assay: Types of GSK-3 assay used to test the selectivity/off target potential compounds of the invention with respect to PKC Î±/Î¸ inhibition activity includes the following: Type 1: The GSK-3 specific peptide used in this assay was derived from the phosphorylation site of glycogen synthase and its sequence is: YRRAAVPPSPSLSRHSSPHQ(S)EDEEE (SEQ ID NO: 1). (S) is pre-phosphorylated as is glycogen synthase in vivo and the three consensus sites for GSK-3 specific phosphorylation are underlined. The buffer used to make up the glycogen synthase peptide and [γ-33P] ATP consisted of MOPS 25 mM, EDTA 0.2 mM, magnesium acetate 10 mM, Tween-20 0.01% and mercaptoethanol 7.5 mM at pH 7.00. The compounds were dissolved in dimethyl sulphoxide (DMSO) to a final concentration of 100 mM. Various concentrations were made up in DMSO and mixed with the substrate (GSK-3 peptide) solution (to a final concentration 20 uM) described in the above section along with rabbit or human GSK-3α and GSK-3β (final concentration 0.5 uM/mL enzyme). The reactions were initiated with the addition of [γ-33P] ATP (500 cpm/pmole) spiked into a mixture of ATP (final concentration of 10 uM). After 30 minutes at room temperature the reaction was terminated by the addition of 10 uL of H3PO4/O.OP/0 Tween-20 (2.5%). A volume (10 uL) of the mixture was spotted onto P-30 phosphocellulose paper (Wallac & Berthold, EG&G Instruments Ltd, Milton Keynes). The paper was washed four times in H3PO4 (0.5%), 2 minutes for each wash, air dried and the radioactive phosphate incorporated into the synthetic glycogen synthase peptide, which binds to the P-30 phosphocellulose paper, was counted in a Wallac microbeta scintillation counter Analysis of Data: Values for IC50 for each inhibitor were calculated by fitting a four-parameter logistic curve to the model: cpm=lower+(upper-lower)/(I+(concentration IC50)).",2016.0
,O=C1NC(NCc2cccnc2)=N/C1=C\c1ccc2ncsc2c1,IC50,2839.0,nM,5.55,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(Nc2nncs2)=N/C1=C\c1ccc2ncsc2c1,IC50,6102.0,nM,5.21,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
GW827099X,Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1,Ki,10.0,nM,8.0,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,Cc1n[nH]c2ccc(-c3nnc4n3[C@H](c3ccc(Cl)cc3)CC4)nc12,Kd,39.0,nM,7.41,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to GSK3B (unknown origin) assessed as dissociation constant by competitive binding assay,2023.0
,O=C(Nc1cnccc1C1CCC1)c1ccnc(NC(=O)C2CC2)c1,IC50,7.5,nM,8.12,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cnccc1N1CCC(F)(F)CC1)c1ccnc(NC(=O)C2CC2)c1,IC50,0.19,nM,9.72,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC1(C)COCCN1c1ccncc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,0.15,nM,9.82,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cncc(C2CCC2)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,1.0,nM,9.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC(C)C(=O)Nc1cc(C(=O)Nc2cnccc2OCC(F)(F)F)ccn1,IC50,0.72,nM,9.14,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cnccc1N1CCC(F)(F)CC1)c1ccnc(NC(=O)[C@H]2C[C@H](Cl)C2)c1,IC50,0.37,nM,9.43,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CCOc1ccncc1NC(=O)c1ccnc(NC(=O)C2CCCC2)c1,IC50,0.62,nM,9.21,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(NC(=O)C2CCCC2)c1,IC50,2.1,nM,8.68,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cncc(-c2ccccc2)c1)c1ccnc(NC(=O)C2CCCC2)c1,IC50,1.2,nM,8.92,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(NC(=O)[C@@H]2CC[C@@H](O)C2)c1,IC50,2.5,nM,8.6,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cnccc1-c1ccc(Cl)cc1)c1ccnc(NC(=O)C2CCC(F)(F)C2)c1,IC50,0.46,nM,9.34,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(Nc1cncc(-c2ccccc2F)c1)c1ccnc(NC(=O)C2CCC(F)(F)C2)c1,IC50,1.4,nM,8.85,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,Cc1[nH]nc2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12,IC50,500.0,nM,6.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2010.0
,Cc1ccc2c(C3=C(c4ccc5ccccc5c4)C(=O)NC3=O)cn(CCCn3ccnc3)c2c1,IC50,140.0,nM,6.85,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,CCOC(=O)C1Cc2nc(-c3ccc(Cl)c(Cl)c3)n(-c3ccnc(N[C@@H]4CCCN(C(=O)C5CC5)C4)n3)c2C1,IC50,194.8,nM,6.71,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) incubated for 20 mins in presence of 33P-ATP,2023.0
,CN(C)C(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCF,IC50,151.6,nM,6.82,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2023.0
,O=C1NC(NC2CCC2)=N/C1=C\c1ccc2ncsc2c1,IC50,6483.0,nM,5.19,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@H]2CCCCC[C@@H]2O)=N/C1=C\c1ccc2ncsc2c1,IC50,6011.0,nM,5.22,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@@H]2CCCC[C@@H](O)C2)=N/C1=C\c1ccc2ncsc2c1,IC50,4368.0,nM,5.36,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CO[C@H]1CCC[C@@H](NC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)CC1,IC50,9256.0,nM,5.03,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC2C3CC4CC(C3)CC2C4)=N/C1=C\c1ccc2ncsc2c1,IC50,4759.0,nM,5.32,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COc1ccc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(OC)cc2)cc1,IC50,530.0,nM,6.28,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide as substrate incubated for 30 mins by Glo-type luminescence assay,2016.0
,COc1ccc(-c2c3c(nc4nc(SCCc5ccccc5)nc(N)c24)CCCC3)cc1OC,IC50,4700.0,nM,5.33,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)sc1C(=O)c1ccccc1[N+](=O)[O-],IC50,107.0,nM,6.97,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin)-mediated phosphorylation of peptide substrate incubated for 15 mins prior to substrate addition measured after 90 mins by P33-radiolabeled assay,2013.0
,COc1ccc(-c2cc(=O)c3c(OC)c([C@H]4O[C@H](C(=O)N[C@@H](C)C(F)(F)F)[C@@H](O)[C@H](O)[C@H]4O)c(OC)cc3o2)cc1OC,IC50,590.0,nM,6.23,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta in human SH-SY5Y cells after 2 hrs by ELISA,2019.0
,CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
DACTOLISIB,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,Ki,3162.28,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(NC(=O)CCNC(=O)Nc2nc(C)c(-c3ccc(-n4cccn4)cc3)s2)no1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)CCc3ccc(C(F)(F)F)cc3)c2)[nH]1,IC50,956.0,nM,6.02,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,CSc1nc(-c2ccnc(NC(=O)C3CC3)c2)c(-c2ccc(F)cc2)n1C,IC50,1780.0,nM,5.75,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,O=C(Nc1cc(-c2[nH]c(SCc3ccccc3)nc2-c2ccc(F)cc2)ccn1)C1CC1,IC50,229.0,nM,6.64,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,O=C(Nc1cc(-c2[nH]c(SCc3ccccc3)nc2-c2ccc(F)cc2)ccn1)C1CCCC1,IC50,663.0,nM,6.18,Glycogen synthase kinase-3 beta,,,Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 mins followed by substrate and 25 uM ATP addition measured after 60 mins by ADP-Glo luminescence assay,2019.0
,O=C(CBr)c1ccc(C(F)(F)F)cc1,IC50,5000.0,nM,5.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta using GS1 as substrate and [gamma-32P]ATP after 20 mins by radiometric assay,2011.0
,CO[C@H]1CCCCC[C@H]1NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,2994.0,nM,5.52,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NCc2ccccc2)=N/C1=C\c1ccc2ncsc2c1,IC50,2147.0,nM,5.67,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NCC(O)Cc2ccccc2)=N/C1=C\c1ccc2ncsc2c1,IC50,4814.0,nM,5.32,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CNCC(NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1)c1ccccc1.Cl.Cl,IC50,227.0,nM,6.64,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COc1ccc(-c2ocnc2C(=O)NCCCNC(=O)c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc1I,IC50,0.48,nM,9.32,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,COc1ccc(-c2ocnc2C(=O)NCCCn2cc(CNC(=O)/C=C/c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)nn2)cc1I,IC50,0.33,nM,9.48,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,COc1ccc(-c2ocnc2C(=O)NCCCNC(=O)/C=C/c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc1I,IC50,1.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,CCOC(=O)C1Cc2nc(-c3ccc(Cl)c(Cl)c3)n(-c3ccnc(N[C@H]4CCCN(C(=O)C5CC5)C4)n3)c2C1,IC50,4861.0,nM,5.31,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) incubated for 20 mins in presence of 33P-ATP,2023.0
,C[C@@H](NC(=O)/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)[C@@H](O)c1ccccc1,IC50,180.0,nM,6.75,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate in presence of gamma-33P-ATP,2016.0
,CO[C@H]1CCC[C@@H](NC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)C1,IC50,8850.0,nM,5.05,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COC[C@@H](NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1)c1ccccc1,IC50,5596.0,nM,5.25,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cc1ccc(CNC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)o1,IC50,2813.0,nM,5.55,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(-c2cc3nccn3c(Nc3ncccc3C(N)=O)n2)cc1OC,Ki,19.95,nM,7.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,ON=C(c1nc2ccccc2[nH]1)c1nc2ccccc2[nH]1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
MLN-8054,O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cn1c(NCCNc2c3c(nc4ccc(Cl)cc24)CCCC3)nc(-c2ccncc2F)cc1=O,IC50,8130.0,nM,5.09,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK-3beta using prephosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescence assay,2021.0
,O=C1NC(=S)S/C1=C\c1ccccc1OCOc1ccccc1/C=C1/SC(=S)NC1=O,IC50,8750.0,nM,5.06,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,O=C(Nc1cnccc1-c1ccccc1Cl)c1ccnc(NC(=O)C2CC2)c1,IC50,3.7,nM,8.43,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,C[C@H]1CN(c2ccncc2NC(=O)c2ccnc(NC(=O)C3CC3)c2)CCO1,IC50,0.99,nM,9.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC(C)C(=O)Nc1cc(C(=O)Nc2cnccc2-c2ccc(Cl)cc2)ccn1,IC50,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC(C)C(=O)Nc1cc(C(=O)Nc2cncc(-c3ccccc3F)c2)ccn1,IC50,5.6,nM,8.25,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC(C)n1cc(-c2ccnc3[nH]c(C4CCN(CC(=O)N5CCCC5)CC4)cc23)ccc1=O,IC50,1500.0,nM,5.82,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of full length human GSK3beta in the presence of ATP at Km concentration,2021.0
,Cn1c(NCCNc2c3c(nc4ccccc24)CCCC3)nc(-c2ccncc2F)cc1=O,IC50,1180.0,nM,5.93,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK-3beta using prephosphorylated polypeptide as substrate incubated for 30 mins in presence of ATP by Kinase-Glo luminescence assay,2021.0
,C=CC(=O)N1C(=O)CC(c2ccc(-c3ccccc3)cc2)Sc2ccccc21,IC50,5800.0,nM,5.24,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using GS-2 peptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2021.0
,O=C1NC(=O)C(c2cn(CCC3N=CC=N3)c3ccccc23)=C1c1noc2ccccc12,IC50,0.73,nM,9.14,Glycogen synthase kinase-3 beta,,,Inhibition of full length recombinant human His-tagged GSK3beta expressed in baculovirus expression system using Ser/Thr 9 peptide substrate by Z'-LYTE assay,2017.0
,O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1,IC50,2500.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2018.0
LUTEOLIN,O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,IC50,1500.0,nM,5.82,Glycogen synthase kinase-3 beta,,,Inhibition of Homo sapiens (human) recombinant GSK3beta after 30 min by Kinase-Glo assay,2013.0
,CCCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl,IC50,405.0,nM,6.39,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta H350L mutant (2 to end residues) at 10 uM using phospho GS2 peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay,2019.0
,O=C(Nc1cncc(N2CCCCC2)c1)c1ccnc(NC(=O)C2CC2)c1,IC50,130.0,nM,6.89,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC(C)C(=O)Nc1cc(C(=O)Nc2cnccc2OCCN2CCOCC2)ccn1,IC50,2.3,nM,8.64,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC(C)C(=O)Nc1cc(C(=O)Nc2cnccc2OCCC(C)(C)O)ccn1,IC50,2.8,nM,8.55,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,COc1ccccc1C1=C(Nc2cccc(C#N)c2)C(=O)NC1=O,IC50,36.0,nM,7.44,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) assessed as transfer of radiolabelled phosphate group from ATP by reaction biology method,2021.0
,Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12,Ki,265.0,nM,6.58,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta after 1 hr,2011.0
,O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1,IC50,141.0,nM,6.85,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,Cc1n[nH]c2ccc(-c3nnc(C)n3Cc3ccc(C(F)(F)F)cc3)cc12,Kd,210.0,nM,6.68,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to GSK3B (unknown origin) assessed as dissociation constant by competitive binding assay,2023.0
,O=C1NC(N[C@H]2CCOC2)=N/C1=C\c1ccc2ncsc2c1,IC50,6566.0,nM,5.18,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC2CCCCOC2)=N/C1=C\c1ccc2ncsc2c1,IC50,2771.0,nM,5.56,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC2CCCSC2)=N/C1=C\c1ccc2ncsc2c1,IC50,7223.0,nM,5.14,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C(Nc1cncnc1OCC(F)(F)F)c1ccnc(Nc2ccccc2)n1,IC50,1.1,nM,8.96,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,O=C(Nc1cnccc1-c1ccc(F)cc1)c1ccnc(Nc2ccc(F)cc2)n1,IC50,0.56,nM,9.25,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,O=C(Nc1cnccc1OCC(F)(F)F)c1ccnc(Nc2ccc(C(F)(F)F)cc2)n1,IC50,0.28,nM,9.55,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,COC(=O)Nc1ccc2c(c1)C(=Cc1ccc(O)cc1)C(=O)N2,IC50,155.0,nM,6.81,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human recombinant GSK-3 beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate incubated for 60 mins in presence of ATP by luminescence based analysis,2022.0
ISOGRANULATIMIDE,O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21,IC50,500.0,nM,6.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2007.0
,CC(=O)Nc1ccc2ccn(-c3cc(NCCCN(C)C)n4ncc(C#N)c4n3)c2c1,IC50,2600.0,nM,5.58,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCc1cn(CCNc2c3c(nc4ccccc24)CCCC3)nn1,IC50,20.8,nM,7.68,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12,IC50,754.0,nM,6.12,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2007.0
,CCNC1=NC(c2ccc(F)cc2)NC(=O)N1,IC50,7110.0,nM,5.15,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2022.0
,Cc1nc2ccccc2n1CC(=O)NNC(=O)c1c[nH]c2ccccc12,IC50,148.0,nM,6.83,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,COc1ccccc1Nc1nnc(Cn2c(C)nc3ccccc32)s1,IC50,184.0,nM,6.74,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay,2016.0
,O=S(=O)(c1ccccc1)N1CC(c2cccc3ccccc23)Oc2ccccc21,IC50,4100.0,nM,5.39,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human His-tagged GSK3beta using GS-2 peptide as substrate in presence of [33P]gamma-ATP after 15 mins by microbeta counting method,2017.0
R-1487,Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,COc1ccc(-c2ocnc2C(=O)NCCCn2cc(CNC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)nn2)cc1I,IC50,0.31,nM,9.51,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
,COc1ccc(-c2ocnc2C(=O)NCCCc2ccc(NC(=O)CCc3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)cc2)cc1Cl,IC50,1.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK-3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEE as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by Kinase-Glo luminescent kinase assay,2023.0
BMS-863233,O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12,Kd,8793.0,nM,5.06,Glycogen synthase kinase-3 beta,Uncertain,,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",2017.0
,COc1ccc2c(c1)c(C1=C(c3ccc(F)cc3)C(=O)NC1=O)cn2CCCn1ccnc1,IC50,150.0,nM,6.82,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccc(Br)cc23)=C1c1cccs1,IC50,90.0,nM,7.05,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,O=C1NC(=O)C(c2nn(CCCN3CCOCC3)c3ncccc23)=C1c1c[nH]c2ccccc12,IC50,830.0,nM,6.08,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB,2013.0
,CCOC[C@@H](CC(C)C)NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,2685.0,nM,5.57,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NC23CC4(F)CC(F)(CC(F)(C4)C2)C3)=N/C1=C\c1ccc2ncsc2c1,IC50,94.0,nM,7.03,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NCc2ccccn2)=N/C1=C\c1ccc2ncsc2c1,IC50,8311.0,nM,5.08,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@@H]2CCCCC[C@H]2O)=N/C1=C\c1ccc2ncsc2c1,IC50,6978.0,nM,5.16,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@@H]2CCC[C@H](O)CC2)=N/C1=C\c1ccc2ncsc2c1,IC50,9328.0,nM,5.03,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(Nc2ccccn2)=N/C1=C\c1ccc2ncsc2c1,IC50,1660.0,nM,5.78,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CCNC(=O)c1sc(-c2ccnc(NC(=O)CNCCNc3c4c(nc5ccccc35)CCCC4)c2)nc1OCC1CC1,IC50,114.4,nM,6.94,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay,2020.0
,CN1CCN(S(=O)(=O)c2ccc(-c3cnc(N)c(C(=O)Nc4cccnc4)n3)cc2F)CC1,Ki,9.0,nM,8.05,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using biotin- AAEELDSRAGS(PO3H2)PQL as substrate and [gamma32P]ATP after 20 mins by scintillation proximity assay,2012.0
CHLOROLITHIUM,[Cl-].[Li+],IC50,6530.0,nM,5.18,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3beta using prephosphorylated GS1 peptide as substrate after 1 hr by liquid scintillation spectrometry,2013.0
,CN1CC=C(c2c(O)cc(O)c3c(=O)cc(-c4ccc(Sc5nc6ccccc6[nH]5)cc4)oc23)CC1,IC50,117.0,nM,6.93,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK3beta in presence of ATP by ADP-glo luminescent assay,2020.0
,CN1CCN(c2ccc(Nc3nccc(-c4ccccc4)n3)cc2C(F)(F)F)CC1,Kd,2800.0,nM,5.55,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human full length GSK-3 beta (M1 to T433 residues) expressed in mammalian expression system by KdELECT kinase assay,2021.0
SILMITASERTIB,O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12,IC50,190.0,nM,6.72,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human C-terminal his tagged GSK3beta (26 to 383 residues) expressed in Escherichia coli using GYSI(YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE) as peptide substrate incubated for 1 hr in presence of ATP by cook activity assay,2023.0
GW817394X,COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1,IC50,7.943,nM,8.1,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
TP-008,Cc1cnc(-c2cc(Cl)ccc2F)cc1-n1c(=O)n(CC(N)=O)c2cnccc21,IC50,5000.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2016.0
,COc1ccc(CCN2COc3c([C@@H](C)CCC=C(C)C)ccc(C)c3C2)cc1OC,IC50,1270.0,nM,5.9,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,CC(=O)N(C)c1ccc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1,IC50,1400.0,nM,5.85,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,O=C(NCCC1CCN(Cc2ccccc2F)CC1)c1ccc2c(c1)[nH]c1c(NC(=O)C3CC3)nccc12,IC50,6780.0,nM,5.17,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3-beta (unknown origin) incubated for 60 mins by ATP-Glo luminescent assay,2022.0
,COc1ccc(C2=C(c3cn(CCCn4ccnc4)c4cc(C)ccc34)C(=O)NC2=O)cc1,IC50,97.0,nM,7.01,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) activity assessed as fluorescence intensity by ADP-Glo Kinase Assay,2023.0
,CC(=O)Nc1ccc2cnn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1,IC50,700.0,nM,6.16,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,COc1cccc(OCc2cc(C)ccn2)c1-c1ccc2c(c1)CCNCC2,IC50,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2018.0
,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(C)c(C=C2C(=O)Nc3ccccc32)[nH]1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,C[C@@H](c1ccc(F)cc1)n1nnc2cnc3ccc(-c4ccc5ocnc5c4)cc3c21,IC50,1594.0,nM,5.8,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant human GSK3beta expressed in fall armyworm sf21 cells using Phospho-glycogen synthase peptide-2 as substrate in presence of [gamma-32]-ATP,2017.0
GW827396X,COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1,Ki,7940.0,nM,5.1,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
,NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1,IC50,481.0,nM,6.32,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(Nc1n[nH]c2nc(-c3ccccc3)c(-c3ccccc3)cc12)C1CC1,IC50,415.0,nM,6.38,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
TP-030-1,CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21,IC50,1000.0,nM,6.0,Glycogen synthase kinase-3 beta,,,GSK3beta(GS3BLGM1) Takeda global kinase panel,2021.0
,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(S(N)(=O)=O)cc3)o2)S1,IC50,250.0,nM,6.6,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta,2007.0
,COc1ccc(-c2cc(=O)c3c(OC)c([C@@H]4O[C@H](C(=O)N[C@@H](C)C(F)(F)F)[C@@H](O)[C@H](O)[C@H]4O)c(OC)cc3o2)cc1OC,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) using peptide YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate incubated for 5 to 60 mins by ADP-Glo kinase assay,2022.0
,COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)C[C@H](COC1CC1)NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,3600.0,nM,5.44,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
VATALANIB,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NC(NCC(O)C2CCCCC2)=N/C1=C\c1ccc2ncsc2c1,IC50,3078.0,nM,5.51,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
GW843682X,COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC,Ki,1995.26,nM,5.7,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3ccccc3)cc12,IC50,22.0,nM,7.66,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,COC(=O)Nc1ccc2c(c1)/C(=C\c1ccc(O)cc1)C(=O)N2,IC50,155.0,nM,6.81,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK3beta (636 to 661 residues) assessed as reduction in human muscle glycogen synthase type 1 fragment phosphorylation using YRRAAVPPSPSLSRHSSPHQ(pS)EDE as substrate in presence of ATP incubated for 60 mins by ADP-Glo kinase assay,2023.0
,O=C1Nc2ccc(NC(=O)c3ccccc3)cc2/C1=C\c1ccc(O)cc1,IC50,4343.0,nM,5.36,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK3beta (636 to 661 residues) assessed as reduction in human muscle glycogen synthase type 1 fragment phosphorylation using YRRAAVPPSPSLSRHSSPHQ(pS)EDE as substrate in presence of ATP incubated for 60 mins by ADP-Glo kinase assay,2023.0
,COCC(=O)c1[nH]ncc1/C=C1\C(=O)Nc2ccccc21,IC50,6720.0,nM,5.17,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK3beta (636 to 661 residues) assessed as reduction in human muscle glycogen synthase type 1 fragment phosphorylation using YRRAAVPPSPSLSRHSSPHQ(pS)EDE as substrate in presence of ATP incubated for 60 mins by ADP-Glo kinase assay,2023.0
,O=C(Nc1ccccc1)Nc1[nH]nc2nnc(-c3ccccc3)c(-c3ccccc3)c12,IC50,7360.0,nM,5.13,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method,2018.0
,N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)cn1,Ki,5011.87,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,NC1=NONC1N1N=NC(C(=O)N/N=C/c2ccncc2)C1CN1CCCCC1,IC50,100.0,nM,7.0,Glycogen synthase kinase-3 beta,,,Inhibitory activity against GSK3-beta,2005.0
,CCc1cccc2c3c([nH]c12)-c1ccccc1NC(=O)C3,IC50,699.84,nM,6.16,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
,CC(=O)Nc1ccc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1,IC50,130.0,nM,6.89,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
SB-242235,COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1,IC50,374.0,nM,6.43,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
LAPATINIB,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
LESTAURTINIB,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,Kd,1300.0,nM,5.89,Glycogen synthase kinase-3 beta,,,Binding constant for GSK3B kinase domain,2011.0
,CC(C)Oc1ccncc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,1.9,nM,8.72,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GST tagged GSK-3beta (unknown origin) incubated for 1 hrs by HTRF assay,2016.0
,O=C1Cc2c([nH]c3ccc(C(F)(F)F)cc23)-c2cc(C#CC3(O)CCCCC3)ccc2N1,IC50,1999.86,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
GW833373X,Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1,Ki,20.0,nM,7.7,Glycogen synthase kinase-3 beta,,,Binding affinity for human glycogen synthase kinase 3 beta,2004.0
(RS)-ROSCOVITINE,CCC(CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
RUCAPARIB,CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,c1cnc2[nH]cc(-c3ccnc(NCC4CCCCC4)n3)c2c1,Ki,125.89,nM,6.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NCCc2[nH]c(-c3ccnc(-c4cnc5ccccc5c4)c3)cc21,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=O)c1ccncc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,0.85,nM,9.07,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,N=C1NC(=O)C(=C2CCNC(=O)c3[nH]c(Br)cc32)N1,IC50,70.0,nM,7.16,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2023.0
GSK-938890A,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21,IC50,1040.0,nM,5.98,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
GSK-943949A,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21,IC50,1110.0,nM,5.96,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3-beta phosphorylation in human BT474 cells,2009.0
,COc1cc2c(cc1O)CCn1c-2c(-c2ccc(O)c(O)c2)c2c3cc(O)c(OC)cc3oc(=O)c21,IC50,3000.0,nM,5.52,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged human recombinant GSK3beta expressed in baculovirus-infected Sf21 cells incubated for 60 mins in presence of ATP by ADP-glo analysis,2023.0
,O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(-c3ccccc3)cc12)C1CC1,IC50,24.0,nM,7.62,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=C(Nc1n[nH]c2nc(-c3ccc(O)c(Cl)c3)ccc12)C1CC1,IC50,7.0,nM,8.15,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,O=c1oc2cc(O)c(O)cc2c2c(-c3ccc(O)c(O)c3)cn(CCc3ccc(O)c(O)c3)c12,IC50,800.0,nM,6.1,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged human recombinant GSK3beta expressed in baculovirus-infected Sf21 cells incubated for 60 mins in presence of ATP by ADP-glo analysis,2023.0
,Nc1n[nH]c2ncc(-c3ccccc3)cc12,IC50,430.0,nM,6.37,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,CCN1CCN(CCCC(=O)Nc2n[nH]c3nc(-c4cccc(O)c4)ccc23)CC1,IC50,21.0,nM,7.68,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
,Cc1ccc(-c2ccnc(N)c2/N=C/c2ccnc(NC(=O)C3CC3)c2)cc1,IC50,1252.0,nM,5.9,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,Nc1ncccc1/N=C/c1ccnc(NC(=O)C2CC2)c1,IC50,71.0,nM,7.15,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,Nc1ncc(-c2ccc(F)cc2)cc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,240.0,nM,6.62,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,Nc1ncc(-c2ccncc2)cc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,199.0,nM,6.7,Glycogen synthase kinase-3 beta,,,Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay,2019.0
,CO[C@@H]1CCC[C@H]1NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,3560.0,nM,5.45,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@@H](CO)CC2CCCC2)=N/C1=C\c1ccc2ncsc2c1,IC50,2872.0,nM,5.54,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NCc2nc3ccccc3s2)=N/C1=C\c1ccc2ncsc2c1,IC50,9026.0,nM,5.04,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COCCNC(=O)c1nc(-c2ccc(S(=O)(=O)N3C=CN(C)CC3)cc2)cnc1N,Ki,90.0,nM,7.05,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to full length GST-tagged human recombinant GSK-3beta (1 to 420 residues) expressed in Escherichia coli assessed as inhibition constant,2023.0
,CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl,Kd,2722.0,nM,5.57,Glycogen synthase kinase-3 beta,Active,,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",2017.0
ZOTIRACICLIB,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,Kd,447.0,nM,6.35,Glycogen synthase kinase-3 beta,Active,,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",2017.0
,CCOC(=O)c1cccc(NC(=O)Nc2nc3c(s2)CC(NC(=O)Nc2cccc(C(=O)OCC)c2)CC3)c1,IC50,2500.0,nM,5.6,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant full length human His-tagged GSK3beta expressed in baculovirus expression system using ser/thr-9 peptide as substrate measured after 1 hr by Z'-Lyte assay,2018.0
,O=C1NC(NC2CCCCCC2)=N/C1=C\c1ccc2ncoc2c1,IC50,3019.0,nM,5.52,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cn1cnc2ccc(/C=C3\N=C(NC45CC6CC(CC(C6)C4)C5)NC3=O)cc21,IC50,1541.0,nM,5.81,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COC(=O)[C@@H](NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1)C(C)C,IC50,8236.0,nM,5.08,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@@H](CO)Cc2ccccc2)=N/C1=C\c1ccc2ncsc2c1,IC50,2743.0,nM,5.56,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COc1ccc(/C=C2\N=C(Nc3ccc(N4CCN(C)CC4)cc3)NC2=O)cc1O,IC50,200.0,nM,6.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COc1nc(C)ccc1NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,8972.0,nM,5.05,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cc1n[nH]c2ccc(-c3nnc4n3[C@H](c3ccc(Cl)cc3)CC4)cc12,Kd,2.2,nM,8.66,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to GSK3B (unknown origin) assessed as dissociation constant by competitive binding assay,2023.0
,O=C(Nc1cnccc1N1CCC(F)(F)CC1)c1ccncn1,IC50,260.0,nM,6.58,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,O=C(Nc1cnccc1-c1ccc(F)cc1)c1ccnc(Nc2ccccc2)n1,IC50,0.25,nM,9.6,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,N#Cc1ccc(Nc2nccc(C(=O)Nc3cnccc3-c3ccc(F)cc3)n2)cc1,IC50,0.35,nM,9.46,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(Nc2cccnc2)n1,IC50,1.2,nM,8.92,Glycogen synthase kinase-3 beta,,INHIBITOR,Displacement of FL-KRREILSRRP[ps]ERYR-NH2 from human recombinant N-terminal His6-tagged GSK-3-beta (14 to 306 residues) H355L mutant expressed in baculovirus-infected Sf21 cells incubated for 20 hrs by fluorescence based analysis,2023.0
LINIFANIB,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1,Ki,1258.93,nM,5.9,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C(O)CCN(CCC(=O)O)c1ccc(/C=C2\SC(=S)NC2=O)cc1,IC50,263.0,nM,6.58,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,2010.0
,CC(=O)c1ccc(-c2c[nH]c3ncc(/C=C/C(=O)NCc4ccncc4)cc23)cc1,IC50,1.42,nM,8.85,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,O=C(C/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)NCCc1c[nH]c2ccccc12,IC50,3760.0,nM,5.42,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
ERKi,C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1,IC50,540.0,nM,6.27,Glycogen synthase kinase-3 beta,Not Active,,Invitrogen kinase screen (GSK3B),2021.0
,CC(N)C1CCC(C(=O)Nc2ccncc2)CC1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(C)Oc1cc(Nc2nc(NC(C)c3ccc(F)cn3)ncc2Cl)n[nH]1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1Nc2ccccc2/C1=C1/Nc2cc(Br)ccc2C1=O,IC50,4.0,nM,8.4,Glycogen synthase kinase-3 beta,,,Competitive inhibition of glycogen synthase kinase-3 beta (unknown origin) using GS-1 as substrate after 30 mins by scintillation counting analysis in presence of [gamma-32P]-ATP,2016.0
,CS(=O)(=O)c1ccc(-c2c[nH]c3ncc(/C=C/C(=O)NCc4ccncc4)cc23)cc1,IC50,220.0,nM,6.66,Glycogen synthase kinase-3 beta,,,Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay,2016.0
,CC(C)C[C@@H](CO)NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,9375.0,nM,5.03,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,COc1ccc(C2=C(Nc3ccc(C(=O)Nc4ccccc4)cc3)C(=O)NC2=O)cc1,IC50,170.0,nM,6.77,Glycogen synthase kinase-3 beta,,,Inhibition of Glycogen synthase kinase-3 beta (unknown origin),2019.0
,C[C@@H]1CCCC[C@H]1NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,8364.0,nM,5.08,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CC(C)(C)OC[C@H](NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1)c1ccccc1,IC50,9974.0,nM,5.0,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
GO-6976,Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O,Ki,15.85,nM,7.8,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,C=C(C)c1ccncc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,IC50,4.4,nM,8.36,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,Cc1ccc(-c2cncc(NC(=O)c3ccnc(NC(=O)C4CC4)c3)c2)cn1,IC50,2.5,nM,8.6,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC(C)OCCCC(=O)c1n[nH]cc1NC(=O)c1ccccc1,IC50,2.0,nM,8.7,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3-beta (unknown origin),2023.0
,CC1(C)CN(c2ccncc2NC(=O)c2ccnc(NC(=O)C3CC3)c2)CCO1,IC50,0.79,nM,9.1,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,CC(C)(C)C(=O)Nc1cc(C(=O)Nc2cncc(-c3cccc(F)c3F)c2)ccn1,IC50,24.0,nM,7.62,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin) incubated for 1 hr by HTRF assay,2023.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)N[C@@H](CO)Cc1ccccc1,IC50,752.0,nM,6.12,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate in presence of gamma-33P-ATP,2016.0
,O=C(/C=C/c1cnc2[nH]cc(-c3ccccc3)c2c1)NCCc1cccnc1,IC50,32.0,nM,7.5,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate in presence of gamma-33P-ATP,2016.0
,COc1cnc(-c2cnc3ccccc3c2)nc1-c1cc2c([nH]1)CCNC2=O,IC50,1.491,nM,8.83,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta,2012.0
,Cc1cccc2c3c([nH]c12)-c1ccccc1NC(=O)C3,IC50,500.03,nM,6.3,Glycogen synthase kinase-3 beta,,,Inhibitory activity against glycogen synthase kinase-3 beta purified from insect sf9 cells,2004.0
AZD-4573,CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1,IC50,247.0,nM,6.61,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin) in presence of 5 mM ATP,2020.0
,O=C1NC(NC2CCCCC2)=N/C1=C\c1ccc2ncsc2c1,IC50,7056.0,nM,5.15,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(N[C@@H]2CCC[C@@H](O)CC2)=N/C1=C\c1ccc2ncsc2c1,IC50,6374.0,nM,5.2,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CC(C)C[C@H](COCc1ccccc1)NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,5193.0,nM,5.29,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1NC(NCc2ccccc2C(F)(F)F)=N/C1=C\c1ccc2ncsc2c1,IC50,6918.0,nM,5.16,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,Cc1cnc(CNC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)cn1,IC50,9033.0,nM,5.04,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
QUERCETIN,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,,Inhibition of Homo sapiens (human) recombinant GSK3beta after 30 min by Kinase-Glo assay,2013.0
,CN1CCN(c2ccc(Nc3nccc(-c4cccc([N+](=O)[O-])c4)n3)cc2C(F)(F)F)CC1,Kd,3800.0,nM,5.42,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human full length GSK-3 beta (M1 to T433 residues) expressed in mammalian expression system by KdELECT kinase assay,2021.0
,CCOC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCCOCCF,IC50,344.8,nM,6.46,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2023.0
,O=C(NCCF)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCC1CC1,IC50,18.2,nM,7.74,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2023.0
,O=C1NCCCCCNc2nccc(n2)Nc2cc1[nH]n2,IC50,3500.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of N-terminal NanoLuc-fused full length lysed GSK3B (unknown origin) transfected in HEK293T cells incubated for 2 hrs in presence of tracer K8 by NanoBRET assay,2023.0
,O=C(/C=C(O)/C=C/c1ccc(O)cc1)/C=C/c1ccc(O)cc1,IC50,8390.0,nM,5.08,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using prephosphorylated polypeptide as substrate incubated for 30 mins by Glo-type luminescence assay,2016.0
,CN1CCN(c2cc(C(=O)Nc3cc4cc(-c5cnn(C)c5)ccc4cn3)ccn2)CC1,Kd,1183.0,nM,5.93,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human GSK-3beta assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,2023.0
GW578748X,COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O,IC50,3162.28,nM,5.5,Glycogen synthase kinase-3 beta,,,"Ability to inhibit 50% glycogen synthase kinase-3 beta of recombinant human, expressed as log of concentration",2004.0
,O=C1NC(N[C@@H](CO)CC2CC2)=N/C1=C\c1ccc2ncsc2c1,IC50,4391.0,nM,5.36,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,O=C1CC[C@H](NC2=N/C(=C\c3ccc4ncsc4c3)C(=O)N2)CN1,IC50,8184.0,nM,5.09,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
PAZOPANIB,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1,IC50,93.0,nM,7.03,Glycogen synthase kinase-3 beta,,,Inhibition of recombinant GSK3-beta,2008.0
APIGENIN,O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,IC50,1900.0,nM,5.72,Glycogen synthase kinase-3 beta,,,Inhibition of Homo sapiens (human) recombinant GSK3beta after 30 min by Kinase-Glo assay,2013.0
,O=C1C(c2ccc(O)c(O)c2)=c2c(c3c(n2CCc2ccc(O)c(O)c2)=C(c2ccc(O)c(O)c2)C(=O)c2cc(O)c(O)cc2-3)-c2cc(O)c(O)cc21,IC50,200.0,nM,,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal His6-tagged human recombinant GSK3beta expressed in baculovirus-infected Sf21 cells incubated for 60 mins in presence of ATP by ADP-glo analysis,2023.0
,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(O)cc3)ccc12,IC50,44.0,nM,7.36,Glycogen synthase kinase-3 beta,,,Inhibition of human recombinant GSK3-beta using gamma[33P]-ATP after 30 mins by scintillation proximity assay,2010.0
,COc1ccc(-c2[nH]c3nccnc3c2C)cc1OC,IC50,2000.0,nM,5.7,Glycogen synthase kinase-3 beta,,,"Inhibition of glycogen synthase kinase-3 beta, purified from porcine brain or expressed in and purified from insect Sf9 cells",2003.0
,Cc1cnc(Nc2ccnn2C)nc1-c1cc2n(c1)C(=O)N([C@H](CO)c1cccc(Cl)c1)C2,IC50,64.3,nM,7.19,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2022.0
,CCOC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCOCCF,IC50,421.8,nM,6.38,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2023.0
,CN(c1ncnc2[nH]c3cc(-c4ccco4)ccc3c12)C1CCCN(CCC#N)C1,IC50,5011.87,nM,5.3,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3-beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP Glo kinase assay,2022.0
,Cc1ccccc1-n1nnc(C(=O)Nc2ccc3ccccc3n2)c1C,Kd,4300.0,nM,5.37,Glycogen synthase kinase-3 beta,,,Binding affinity to recombinant full length human N-terminal GST-tagged GSK3beta expressed in sf9 cells by SPR analysis,2019.0
PF-04217903,OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
FASUDIL,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,Ki,2511.89,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
SP-600125,Oc1c2ccccc2c2c3c(cccc13)N=N2,Ki,316.23,nM,6.5,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
GSK-269962A,CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21,Ki,63.1,nM,7.2,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12,Ki,398.11,nM,6.4,Glycogen synthase kinase-3 beta,active,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CN1CCN(c2ccc(NCCNc3ccc([N+](=O)[O-])c(N)n3)nc2-c2ccc(Cl)cc2Cl)C(=O)C1,IC50,8.0,nM,8.1,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2023.0
,O=C1Nc2ccccc2/C1=C1\Nc2ccccc2\C1=N/O,IC50,55.0,nM,7.26,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2021.0
HARMINE,COc1ccc2c(c1)[nH]c1c(C)nccc12,IC50,350.0,nM,6.46,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK-3beta (unknown origin),2021.0
6BIO,O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O,IC50,1500.0,nM,5.82,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2017.0
,O=C1N=C(Nc2c(Cl)cccc2Cl)S/C1=C\c1ccc2nccnc2c1,Kd,938.72,nM,6.03,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human GSK-3beta assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,2023.0
,O=C1NC(=O)/C(=C/c2cccnc2)S1,IC50,8750.0,nM,5.06,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin) using GS-2 peptide substrate incubated for 30 mins by kinase-Glo luminescent assay,2018.0
,COc1ccc(-n2c(C)c([N+](=O)[O-])c3ccc(O)cc32)cc1,IC50,7488.0,nM,5.13,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,2023.0
SULFURETIN,O=C1/C(=C/c2ccc(O)c(O)c2)Oc2cc(O)ccc21,IC50,1950.0,nM,5.71,Glycogen synthase kinase-3 beta,,,Inhibition of human GSK3beta,2017.0
,Cc1cc(OCc2ccc(Cl)c(Cl)c2)ccc1CN1CC(C(=O)O)C1,Ki,3981.07,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
,CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1,Ki,6309.57,nM,,Glycogen synthase kinase-3 beta,inactive,,PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: GSK3B,
HYPOTHEMYCIN,COc1cc(O)c2c(c1)[C@H]1O[C@@H]1C[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O,IC50,663.0,nM,6.18,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK-3beta preincubated for 3 hrs followed by ATP and substrate addition measured by serial dilution assay,2021.0
EPALRESTAT,CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1,IC50,21.0,nM,7.68,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of human GSK-3beta,2023.0
,O=C(Nc1cccnc1)c1ccnn2cc(-c3ccccc3)nc12,IC50,17.1,nM,7.77,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of GSK3beta (unknown origin),2021.0
TAK-901,CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1,Kd,6168.0,nM,5.21,Glycogen synthase kinase-3 beta,Active,,"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",2017.0
EPIGALOCATECHIN GALLATE,O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1,IC50,6269.0,nM,5.2,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of recombinant human GSK-3beta expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,2023.0
,COc1ccc2nc3ccc(OC)cc3c(SCCCN)c2c1,Kd,2705.19,nM,5.57,Glycogen synthase kinase-3 beta,,INHIBITOR,Binding affinity to human GSK-3beta assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,2023.0
,CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc([N+](=O)[O-])cc3)on2)CC1,IC50,10.0,nM,,Glycogen synthase kinase-3 beta,,,Inhibition of GSK3beta (unknown origin),2013.0
,COC[C@H](CC(C)C)NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,4694.0,nM,5.33,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
,CC(C)C[C@H](CO)NC1=N/C(=C\c2ccc3ncsc3c2)C(=O)N1,IC50,2519.0,nM,5.6,Glycogen synthase kinase-3 beta,,INHIBITOR,Inhibition of N-terminal GST/His6-fused human full length GSK-3-beta (1 to 420 residues) expressed in Sf9 cells using RBERCHKtide and [gamma33P]ATP as substrate incubated for 60 mins by radiometric 33PanQinase assay,2023.0
